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ABSTRACT 
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Abstract 
Soft tissue sarcomas (STS) are a group of malignant tumours that arise in mesenchymal tissues.  
Their exact cause remains unknown but the strongest associations are inherited cancer susceptibility 
and radiation exposure.  They are very diverse, comprising over 50 clinico-biologic subtypes based 
on phenotypic and genetic information. The majority of STS subtypes however still have no known 
specific diagnostic markers and fewer still possess therapeutic targets.  This is in spite of pervasive 
chromosomal instability evidenced by multiple seemingly random somatic copy number aberrations 
(SCNA).     
One aim of this study was the utilisation of microarray-based comparative genomic hybridisation 
(aCGH) for high resolution mapping of genome-wide SCNA in order to identify patterns that are 
specific for three STS subtypes - Leiomyosarcoma (LMS), Undifferentiated Pleomorphic Sarcoma 
(UPS) and Gastrointestinal Stromal Tumours (GIST).  A total of seventy-four cases were analysed 
and frequent and/or subtype-specific SCNA with pathogenetic potential were identified using multiple 
statistical methods and biologic context correlation.  Secondly, the study aimed to develop a suitable 
disease model for functional studies to confirm the pathogenetic implication of identified candidate 
genes.  Primary tissue cultures were therefore set up from 47 tumours. 
Over 20 candidate pathogenetic genes and molecular pathways were identified among the three 
STS subtypes with potential roles in cancer hallmark acquisition, genomic instability and 
mesenchymal lineage differentiation.  Confluent cell cultures were established for more than half of 
primary tumours, including 7 stable long-term cultures (15% of cases).  One candidate gene with a 
potential role in tumour progression, TRIO was frequently amplified in UPS.  The pattern of 
amplification was confirmed using fluorescence in situ hybridisation (FISH) on primary tumour 
metaphases and its over-expression confirmed by Immunohistochemistry.  Finally, preliminary 
studies using small molecule targeted inhibition of the TRIO gene product showed significant 
inhibition of in vitro proliferation and invasion of primary UPS cells.  
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           CHAPTER ONE 
INTRODUCTION 
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1.1 SOFT TISSUES OF THE BODY AND SARCOMA 
Human body tissues may be divided into four main groups – epithelial tissues (parenchyma), which 
comprise specialised organ-specific functional cells; the mesenchyme, which provides functional and 
structural support for the epithelial tissues in various organ systems; the haemato-lymphoid, and the 
nervous systems (Knowles and Selby 2006).  The mesenchyme is derived from the embryological 
mesoderm and neuro-ectoderm and includes connective tissue (fibroblasts and extracellular matrix), 
adipose tissue, bone, cartilage, muscle, lymphatic and blood vessels (Figure 1.1).  With the 
exception of bone, these are referred to as the soft tissues of the body (Knowles and Selby 2006).   
Sarcomas are described as malignant neoplasms that arise in these mesenchymal tissues (Knowles 
and Selby 2006).  They constitute a genetically, pathologically and clinically diverse group of tumour 
with grave life- and/or limb-threatening consequences (Thway 2009).   Since all organs have a 
specialised epithelium as well as supporting mesenchymal tissue, soft tissue sarcomas (STS) can in 
theory arise in virtually any organ of the body.  They however occur most frequently in the 
extremities (up to 75%) followed by the trunk (10%) and retroperitoneum (10%) (Fletcher, Bridge et 
al. 2013, Francis, Dennis et al. 2013).   
1.2 EPIDEMIOLOGY 
Compared with carcinomas that characteristically arise in parenchymal tissues, soft tissue sarcomas 
are relatively rare and constitute only about 1% of adult cancers and 1% of all soft tissue neoplasms 
(Toro, Travis et al. 2006, Fletcher, Bridge et al. 2013, Francis, Dennis et al. 2013).   However, up to 
15% of these tumours occur in children and adolescents, with specific subtypes e.g. embryonal 
rhabdomyosarcoma, occurring almost exclusively in this age group (Thway 2009, Fletcher, Bridge et 
al. 2013). 
The World Health Organization (WHO) estimates the worldwide annual incidence of STS at around 
50 cases per million population with no evidence of significant geographical variation (Fletcher, 
Bridge et al. 2013).  In the United Kingdom, annual incidence estimates are in keeping with 
worldwide figures with approximately 3300 new cases diagnosed in 2010 (Francis, Dennis et al. 
2013).  Like most other malignancies the frequency of STS increases with age, with incidence rising 
up to 230 cases per million among men aged >85 years.   Overall, the median age at diagnosis is 
around 65 years with a slight male preponderance (Fletcher, Bridge et al. 2013).  However, the 
gender distribution varies with age group.  While the male-female ratio at age >85 is approximately 
1.9:1 in the UK, there is a female preponderance among individuals aged 45 – 59 years attributed to 
an increased number of gynaecological tract sarcomas (Francis, Dennis et al. 2013).    
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Figure 1.1: Illustration of the Embryological Origin of Mesenchymal Tissues 
Mesenchymal stem cells derived from the mesoderm and neuro-ectoderm differentiate into various adult mesenchymal cell lineages.  With the exception of bone, these are 
collectively referred to as soft tissues. 
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1.3 AETIOLOGY AND PREDISPOSING FACTORS 
Like most other cancers, the exact cause of STS is unknown.  While most arise sporadically, several 
inheritable cancer-predisposing syndromes, as well as environmental factors have been implicated. 
1.3.1 Familial Cancer-predisposing Syndromes 
Increased risk of sarcoma development has been identified among individuals with certain familial 
cancer syndromes, all of which result from autosomal recessive mutations in (or deletion of) tumour 
suppressor genes.  Some of these inheritable mutations have also been demonstrated in tumour 
cells from sporadic cases of STS and even in tumour cells in other cancers (Malkin, Li et al. 1990).   
1.3.1.1 Li Fraumeni Syndrome 
First described in a retrospective study of families with a high incidence of childhood 
rhabdomyosarcoma, a follow-up study found that STS were the second commonest tumours among 
members of the index four families (Li and Fraumeni 1982).  The syndrome is characterized by a 
germ-line mutation in the TP53 tumour-suppressor gene that causes an increased lifetime risk of 
developing malignant tumours of a wide variety, at a young age and at multiple primary sites.  In 
decreasing order of frequency, other cancers observed in the syndrome include pre-menopausal 
breast cancer, osteosarcoma, brain tumours, adrenocortical tumours, lung cancer, leukaemia, 
lymphoma, renal cancer, colorectal cancer and gonadal germ cell tumours (Bougeard, Sesboue et 
al. 2008).   
1.3.1.2 Neurofibromatosis Type I  
Another heritable disease, neurofibromatosis Type I is caused by an autosomal dominant mutation of 
the tumour-suppressor gene, NF1 and characterized by the development of skin lesions, skeletal 
dysplasia, and benign neurofibromas.  Neurofibromatosis patients however have a higher frequency 
of development of malignant peripheral nerve sheath tumour (MPNST) subtype of STS than the 
normal population such that it is regarded as a hallmark complication of the disease (Korf 2000).  
Patients have been noted to occasionally develop other STS subtypes, Gastrointestinal stromal 
tumours, leukaemias and phaeochromocytomas (King, Debaun et al. 2000).   
1.3.1.3 Familial Retinoblastoma 
Characterised by the development of malignant tumours of the retina in infancy or early childhood, 
familial retinoblastoma patients carry a germ-line mutation in one copy of the tumour suppressor RB1 
gene.  Damage to the other normal allele of the gene (‘a second hit’) has been implicated in tumour 
development (Knudson 1971, Wong, Boice et al. 1997).  Several years (10 or more) after 
radiotherapy for their ocular tumours, these patients have a 20-fold increased risk compared to the 
normal population, of developing second malignant tumours the most common of which are bone 
and soft tissue sarcomas (Marees, Moll et al. 2008).  The second tumours occur with a frequency 
higher than that for patients with sporadic retinoblastoma and while the majority occur within the 
radiation field, up to a quarter arise outside the field suggesting a radiation-independent aetiology 
(Kleinerman, Schonfeld et al. 2012).  
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1.3.2 Viral Infections 
1.3.2.1 Kaposi Sarcoma-associated Herpes Virus (KSHV) 
Formerly referred to as the Human Herpes Virus Type 8 (HHV8), this virus was initially identified in 
AIDS-related form of Kaposi sarcoma (Chang, Cesarman et al. 1994).  It was also detected in all 
other forms of Kaposi sarcoma and follow-up studies showed that antibodies to KSHV were present 
in blood even before development of tumour (Weiss, Whitby et al. 1998), suggesting that HHV-8 
plays a role in the pathogenesis of Kaposi sarcoma, while immunosuppression determines its clinical 
course (Fletcher, Unni et al. 2002).   
1.3.2.2 Ebstein-Barr Virus 
Similarly, leiomyosarcomas are rare in immunocompetent children, but significantly more common 
among HIV-positive ones.  Detection of Epstein Barr Virus (EBV) in leiomyomas and 
leiomyosarcomas from HIV-positive children, but not HIV-negative ones led researchers to conclude 
that EBV infection of smooth muscle in AIDS patients contributes to the pathogenesis of benign and 
malignant tumours in these patients (McClain, Leach et al. 1995).   Further, EBV infection in a small 
percentage (<1%) of post-transplant immunosuppressed patients results in mesenchymal tumours 
that arise in vascular smooth muscle (Jonigk, Laenger et al. 2012). 
1.3.3 Ionizing Radiation 
Following radiation exposure, usually as adjuvant therapy for cancer e.g. retinoblastoma or breast 
cancer, a significantly higher than normal frequency of occurrence of sarcomas has been noted 
(Warren and Sommer 1936, Robinson, Neugut et al. 1988).  The majority of the recorded tumours 
are un-differentiated pleomorphic sarcomas and the relative risk increases with the dose of radiation 
the patients were exposed to (Sheppard and Libshitz 2001).  Comprising 3 - 5% of all STS, radiation-
related sarcomas were found to carry a poor prognosis (Hazard ratio 1.7) compared to other STS 
(Gladdy, Qin et al. 2010, Bjerkehagen, Smastuen et al. 2012). 
1.3.4 Chronic Lymphoedema 
Stewart-Treves syndrome was first described in 1948 after women who had chronic lymphoedema 
as a complication of axillary lymph node surgery were noted to develop lymphangiosarcoma (Stewart 
and Treves 1948).  Similar tumours have subsequently been described in patients with patients with 
lymphoedema from other causes, but rare in patients without lymphoedema (Sordillo, Chapman et 
al. 1981).  Some authors have attributed this STS development to regional immunosuppression in 
the limbs of these patients (Schreiber, Barry et al. 1979). 
1.3.5 Other Environmental Factors  
Exposure to certain chemicals such as vinyl chloride and thorotrast has been associated with 
development of hepatic angiosarcoma (Makk, Creech et al. 1974, Kaick, Dalheimer et al. 1999).  Yet 
other STS subtypes have been linked (with limited evidence) to occupational exposure to chemicals 
including dioxin (Fingerhut, Halperin et al. 1991), phenoxyherbicides and chlorophenols (Hoppin, 
Tolbert et al. 1998).   
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1.4 DIAGNOSIS 
Soft tissue sarcomas most commonly present as painless lumps, the size of which generally 
depends on the anatomic location.  While superficial tumours and those in the distal extremities or 
head/neck are often discovered early and at a small size; deep-seated (e.g. retroperitoneal) tumours 
or those in proximal extremities may grow to a large size, or occasionally become symptomatic (due 
to compression of nerves, vessels or other organs) before they are discovered (Cormier and Pollock 
2004, Clark, Fisher et al. 2005).  Many tumours are discovered after trauma to nearby structures, 
and this leads to initial misdiagnosis as benign trauma-related pathology e.g. haematoma or fat 
necrosis.  In order to prevent late diagnoses, current guidelines by the British Sarcoma Group 
recommend the investigation by a specialist sarcoma centre, of any soft tissue mass that is 
increasing in size, greater than 5cm in diameter, or deep to the fascia (Grimer, Judson et al. 2010).  
Radiological imaging by Ultrasonography, Plain radiography, Computed Tomography, Magnetic 
Resonance Imaging, is typically the first modality of investigation of soft tissue masses.  In 
experienced hands, radiologic features are able to rule out malignancy in the majority of cases.  
Imaging is often necessary to guide biopsy for histological diagnosis as well as determination of 
tumour size and extent for staging the disease and for determination of appropriate treatment 
modalities.  It is also necessary for follow-up; early identification of recurrence or metastasis, and 
prognostication (Cormier and Pollock 2004).   
While initial histological characterisation of sarcomas is usually by cellular morphology with most 
tumours composed of spindle cells, epitheloid cells, pleomorphic cells or small round cells, accurate 
diagnosis typically requires the employment of ancillary methods such as immunohistochemistry, 
cytogenetic and molecular genetic techniques (Thway 2009).  Being rare as well as very 
morphologically diverse  (with >100 histological subtypes), soft tissue tumours tend to constitute a 
significant diagnostic challenge for many pathologists (Bovée and Hogendoorn 2009).  In addition, it 
is now known that STS with similar morphologic appearance may actually represent distinct 
pathologic entities with different clinical course and response to treatment.   
The major subtypes of malignant soft tissue tumours according to the 2013 WHO classification are 
summarized in Table 1.1.  While the current classification retains the traditional broad tumour 
classes that are based upon the adult mesenchymal tissues that they resemble the most, the WHO 
Working Group for soft tissue tumour classification have since 2002 incorporated the molecular and 
genetic features of these tumours in addition to histopathology (Fletcher, Unni et al. 2002, Fletcher, 
Bridge et al. 2013). This is because molecular and genetic information has vastly increased the 
understanding of the biology of these tumours leading to improved classification and more accurate 
prediction of their clinical course (Fletcher, Bridge et al. 2013, Fletcher 2014).  
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Table 1.1: Major Subtypes of Soft Tissue Sarcomas  
Adipocytic Tumours 
Intermediate (locally aggressive) 
 Atypical lipomatous tumour / Well differentiated liposarcoma 
Malignant 
 Dedifferentiated liposarcoma 
 Myxoid liposarcoma 
 Pleomorphic liposarcoma 
 Liposarcoma, not otherwise specified 
 
Fibroblastic / Myofibroblastic 
Tumours 
Intermediate (rarely metastasizing) 
 Dermatofibrosarcoma protuberans 
 Solitary fibrous tumour (malignant)  
 Inflammatory myofibroblastic tumour 
 Myxoinflammatory fibroblastic sarcoma 
 Infantile fibrosarcoma 
Malignant 
 Adult fibrosarcoma 
 Myxofibrosarcoma 
 Low grade fibromyxoid sarcoma 
 Sclerosing epithelioid fibrosarcoma 
Smooth Muscle Tumours 
Malignant 
 Leiomyosarcoma 
 
Skeletal Muscle Tumours 
Malignant 
 Embryonal rhabdomyosarcoma  
 Alveolar rhabdomyosarcoma  
 Pleomorphic Rhabdomyosarcoma 
 Spindle Cell/Sclerosing Rhabdomyosarcoma 
 
Vascular Tumours 
Intermediate (rarely metastasizing) 
 Kaposi sarcoma 
Malignant 
 Epithelioid haemangioendothelioma 
 Angiosarcoma of soft tissue 
 
Chondro-osseous Tumours 
Malignant 
 Extraskeletal mesenchymal Chondrosarcoma 
 Extraskeletal osteosarcoma 
 
Gastrointestinal Stromal Tumours 
Malignant 
 Malignant Gastrointestinal Stromal Tumour 
 
Nerve Sheath Tumours 
Malignant 
 Malignant Peripheral Nerve Sheath Tumour 
 Epitheloid malignant Peripheral Nerve Sheath Tumour 
 Malignant Triton Tumour 
 Malignant Granular Cell Tumour 
 Ectomesenchymoma 
 
Tumours of uncertain differentiation 
Intermediate (rarely metastasising) 
 Angiomatoid fibrous histiocytoma 
Malignant 
 Synovial sarcoma 
 Epithelioid sarcoma 
 Alveolar soft part sarcoma 
 Clear cell sarcoma of soft tissue 
 Extraskeletal myxoid chondrosarcoma  
 Malignant mesenchymoma 
 Desmoplastic small round cell tumour 
 Extrarenal rhabdoid tumour 
 Neoplasms with perivascular epithelioid cell differentiation (PEComa) 
 Intimal sarcoma 
Undifferentiated/Unclassified 
Sarcomas 
Malignant 
 Undifferentiated spindle Cell Sarcoma 
 Undifferentiated Pleomorphic Sarcoma 
 Undifferentiated round cell sarcoma 
 Undifferentiated epitheloid sarcoma 
 Undifferentiated sarcoma NOS 
Subtype classification is based on 2013 WHO Classification of Bone and Soft Tissue Tumours (Fletcher, Bridge 
et al., 2013).  Only non-benign soft tissue sarcoma subtypes are shown. 
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1.5 PROGNOSIS AND TREATMENT 
Histologic diagnosis by itself may not be sufficient to predict the clinical course in most STS 
(Fletcher, Bridge et al. 2013).  Other than histology, factors that have been shown to influence 
prognosis include the tumour grade, depth, size and patient’s age (Grobmyer and Brennan 2003).   
1.5.1 Tumour Grading 
Tumour histopathologic grade is generally regarded as the most important factor for prediction of 
distant metastasis in soft tissue sarcomas (Coindre 2006, Thway 2009) and the most widely-
accepted STS grading system as noted in the 2013 WHO classification was developed by the 
Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) and based on the Trojani 
system (Trojani, Contesso et al. 1984), a name by which it is still commonly referred.  As 
summarised in Tables 1.2, it totals scores assigned to three independent prognostic factors including 
- histological subtype/degree of differentiation (Table 1.3); extent of tumour necrosis; and mitotic 
index (Coindre, Terrier et al. 1996).   
Table 1.2: Grading System for Soft Tissue Sarcomas 
Histological Parameter  Definition 
1.  Tumour differentiation 
Score 1 
Sarcomas closely resembling normal adult mesenchymal tissue 
(e.g. well-differentiated liposarcoma, well-differentiated 
leiomyosarcoma) 
Score 2 
Sarcomas for which histological typing is certain (e.g., myxoid 
Liposarcoma, myxofibrosarcoma). 
Score 3 
Embryonal and undifferentiated sarcomas, sarcomas of doubtful 
type, synovial sarcomas. 
2.  Mitotic count 
Score 1 0-9 mitoses per 10 HPF* 
Score 2 10-19 mitoses per 10 HPF 
Score 3 20 mitoses per 10 HPF 
3.  Tumour necrosis 
Score 0 No necrosis 
Score 1 <50% tumour necrosis 
Score 2 50% tumour necrosis 
Histological grade 
Grade 1 Total score 2,3 
Grade 2 Total score 4,5 
Grade 3 Total score 6, 7, 8 
* HPF – High Powered Field 
Grading System was developed by the Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) 
and based on the Trojani system (Table adapted from Coindre 2006). 
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Table 1.3: Differentiation Scores for Soft Tissue Sarcoma Subtypes in the FNCLCC grading 
system 
Histological Type Differentiation Score 
Well-differentiated liposarcoma 
1 
Well-differentiated leiomyosarcoma  
Malignant Neurofibroma 
Well-differentiated fibrosarcoma  
Myxoid Liposarcoma  
2 
Conventional leiomyosarcoma  
Conventional MPNST 
Conventional fibrosarcoma 
Myxofibrosarcoma  
Myxoid Chondrosarcoma 
Conventional angiosarcoma  
*High-grade Myxoid (Round Cell) Liposarcoma 
3 
Pleomorphic liposarcoma  
*Dedifferentiated Liposarcoma 
*Embryonal/alveolar/pleomorphic rhabdomyosarcoma  
Poorly-differentiated/pleomorphic leiomyosarcoma 
Poorly-differentiated/epithelioid angiosarcoma  
Poorly-differentiated MPNST  
Malignant triton tumour  
Synovial Sarcoma 
Extraskeletal Osteosarcoma 
*Extraskeletal Ewing Sarcoma 
Mesenchymal chondrosarcoma  
*Clear cell sarcoma  
*Epithelioid sarcoma  
*Alveolar Soft Part Sarcoma 
Malignant Rhabdoid Tumour 
Undifferentiated (spindle cell and pleomorphic) sarcoma 
Grading System was developed by the Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) 
and based on the Trojani system (Table adapted from Coindre 2006). 
The FNCLCC (Trojani) system is however of very limited use in determining likelihood of local 
tumour recurrence, which is believed to depend mainly on surgical resection margins (discussed in 
detail below.  It is therefore not recommended for use in tumours that rarely metastasize, as well as 
specific STS subtypes including dedifferentiated and round cell liposarcoma, Rhabdomyosarcoma, 
Epitheloid sarcoma, Ewing sarcoma, Alveolar soft part Sarcoma and clear cell sarcoma where 
histologic type alone is more predictive of metastatic potential.  
1.5.2 Tumour Staging 
While tumours that arise in superficial tissues such as atypical lipomatous tumours in subcutaneous 
tissue, are generally considered to be less aggressive since they rarely metastasize, deep-seated 
tumours tend to follow a more aggressive clinical course (Billing, Mertens et al. 2008, Thway 2009).  
Metastasis in majority of STS is via the haematogenous route and unlike carcinoma, lymph node 
spread is rare (<5%), with few exceptions including epitheloid sarcomas, synovial sarcomas, 
embryonal rhabdomyosarcoma, clear cell sarcoma and angiosarcoma (Fong, Coit et al. 1993).   
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In common clinical use for prognostication is the TNM staging system that combines systems 
developed by the UICC and AJCC and incorporates tumour size, depth, nodal and distant 
metastases with tumour grade.  The features of this system are summarised in Table 1.4. 
Table 1.4: TNM Staging System for of Soft Tissue Sarcomas 
Parameter Definition 
Primary tumour (T)
1
 
 
Tx Primary tumour cannot be assessed  
T0 No evidence of primary tumour 
T1 
Tumour < 5cm in greatest dimension 
T1a: superficial tumour 
T1b: deep tumour 
T2 
Tumour > 5cm in greatest dimension 
T2a: superficial tumour  
T2b: deep tumour 
Regional lymph nodes (N)
2
 
 
Nx Regional lymph nodes cannot be assessed 
N0 
No regional lymph node metastasis 
 
N1 
Regional lymph node metastasis 
 
Distant metastasis (M) 
M0 No distant metastasis 
M1 
Distant metastasis 
 
Grading 
 
Low Grade FNCLCC Grade 1 
High Grade FNCLCC Grade 2 and 3 
 
TNM Stage 
Stage IA 
T1a N0, Nx M0 Low grade 
T1b N0, Nx M0 Low grade 
Stage IB 
T2a N0, Nx M0 Low grade 
T2b N0, Nx M0 Low grade 
Stage IIA 
T1a N0, Nx M0 High grade 
T1b N0, Nx M0 High grade 
Stage IIB T2a N0, Nx M0 High grade 
Stage III T2b N0, Nx M0 High grade 
Stage IV 
Any T N1 M0 Any grade 
Any T Any N M1 Any grade 
1 – Superficial and deep tumours are exclusively superficial and deep to the deep fascia, respectively and 
tumours that are retroperitoneal, mediastinal and pelvic in location are regarded as deep tumours 
2 – Since regional node involvement is rare, N0 instead of NX or pNX is assigned in cases where nodal status 
is not assessed either clinically or pathologically  
Table adapted from 2013 WHO Classification of Bone and Soft Tissue Tumours (Fletcher, Bridge et al., 2013) 
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1.5.3 Treatment Strategy 
Due to differences in sensitivity to various therapeutic modalities, accurate histological diagnosis, 
grading and staging are essential for determining appropriate regimes.  However, wide surgical 
resection of the primary tumour remains the mainstay of treatment for the majority of localised STS 
in adults in the UK (Grimer, Judson et al. 2010).  Histological assessment of resection margins is 
then carried out as this has been found to be the best parameter for assessing the likelihood of local 
recurrence and probably influences overall survival (Novais, Demiralp et al. 2010).  In general, 
excision with a normal soft tissue margin of 1cm or equivalent (e.g. normal fascia) is desirable and in 
appropriate cases, further excision may be carried out in order to achieve the desired safe margin.  
Surgical excision may be also considered as a palliative procedure in some cases of metastatic 
disease or as a definitive procedure for solitary or few metastatic tumour deposits (Grimer, Judson et 
al. 2010).   
Post-operative radiotherapy is the standard adjuvant modality for intermediate and high-grade 
tumours, although pre-operative radiotherapy may be used especially in radio-sensitive subtypes 
such as myxoid liposarcoma (de Vreeze, de Jong et al. 2008) to reduce tumour size (down-stage) 
and increase the probability of achieving safe surgical margins.  Chemotherapy has not been shown 
to be effective in the adjuvant setting, but neoadjuvant chemotherapy is integral to treatment of 
certain STS subtypes such as Ewing’s tumours, alveolar and embryonal Rhabdomyosarcoma and 
may be used for down staging in selected cases.  For the majority of sarcomas, chemotherapy is 
reserved as palliation for advanced metastatic disease.  Targeted molecular therapies are in use for 
specific STS subtypes e.g. Imatinib for Gastrointestinal Stromal Tumours and Dermatofibrosarcoma 
protuberans (discussed later). 
1.5.4 Follow-up and Survival 
High grade STS tend to relapse within 2 – 3 years, while low-grade tumours relapse later if at all 
(Casali, Jost et al. 2008).   For intermediate and high grade therefore, current UK and European 
guidelines recommend 3 - 4 monthly follow-up with clinical examination and appropriate imaging for 
the first 2 – 3 years; bi-annual follow up till 5 years and subsequent annual follow up.  While in 
patients with low-grade tumours, 4-6 monthly follow up for 3 – 5 years and subsequent yearly follow 
up is regarded as sufficient (Casali, Jost et al. 2008, Grimer, Judson et al. 2010). 
Average 5-year survival for STS ranges between 50 and 65% and one third to half of patients 
develop lung metastases and/or local tumour recurrence despite the current standard of therapy 
(Grimer, Judson et al. 2010, Fletcher, Bridge et al. 2013, Francis, Dennis et al. 2013).  There is 
therefore an urgent need for development of effective targeted therapies for use in metastatic 
disease and like for most cancers, the key to this is believed to lie in the genetic and molecular 
mechanisms that drive these tumours. 
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1.6 A GENETIC BASIS FOR CANCER 
Initial proposals for genomic abnormalities being responsible for cancer were made in the early 
twentieth century by Boveri following observations of abnormal chromosomes in malignant cells that 
were published in 1914 and recently translated and reviewed by Henry Harris (Boveri 1914, Boveri 
2008).   With the establishment of DNA as the hereditary material of cells and developments in 
cytogenetics, specific chromosomal aberrations in many malignant tumours, particularly in 
haematological malignancies and certain mesenchymal tumours were demonstrated (Mertens, 
Panagopoulos et al. 2009). Further evidence was provided by the demonstration of oncogenic 
transformation of normal mouse fibroblast cells by transfection with total genomic DNA from cancer 
cell lines (Krontiris and Cooper 1981).   
It is now generally accepted that while certain germ-line mutations are responsible for familial 
predisposition to cancer, acquired changes in the genome of cancer cells are responsible for the 
causation and pathogenesis of cancer (Weir, Zhao et al. 2004, Stratton, Campbell et al. 2009).  
Various changes have been described at different levels within the genome of cancer cells, ranging 
from loss/gain of entire chromosomes to subtle nucleotide base mutations.  These changes generally 
lead to alterations to the normal expression of genes that regulate cell proliferation and differentiation 
and result in the malignant phenotype of cancer cells.   While some of these changes are believed 
play a role in the initiation of tumourigenesis (‘drivers’), others (‘passengers’) are acquired as 
tumours progress and do not necessarily contribute to pathogenesis (Stratton, Campbell et al. 2009).   
DNA sequence mutations involving one or a few nucleotides in the coding region of oncogenes or 
tumour suppressor genes have been associated with many cancers (Stratton, Campbell et al. 2009). 
These base substitutions, deletions or insertions can be ‘mis-sense’ or ‘non-sense’ mutations and 
disrupt the function of the products of these oncogenes or tumour-suppressor genes resulting in 
uncontrolled cell proliferation.  Typical examples include k-RAS mutations in pancreatic cancer, c-
KIT mutations in gastrointestinal tumours and p53 mutations in a wide range of cancers (Lengauer, 
Kinzler et al. 1998, Stratton, Campbell et al. 2009).   
Numerical alterations in the normal diploid chromosome complement (aneuploidy) due to gains or 
losses in whole chromosomes are a feature of most human cancers (Lengauer, Kinzler et al. 1998).  
Chromosome numbers between 60 and 90 are common among cancer cells with significant intra-
tumour heterogeneity as well as structural abnormalities such as inversions, deletions and 
duplications (Rajagopalan and Lengauer 2004).  Structural rearrangements in chromosomal DNA 
such as translocations are also notable in cancer pathogenesis.  They can be balanced, in which the 
rearrangement changes the gene order, but does not duplicate or delete any part of the DNA; or 
unbalanced, where there is an associated loss or gain of chromosomal DNA.   
Balanced translocations have been described in most types of tumours (Lengauer, Kinzler et al. 
1998, Mitelman, Johansson et al. 2003).  Many of these are associated with, and even occasionally 
are pathognomonic of specific tumour types.  They also correlate with clinical course and are of 
prognostic significance, in some tumours (Mitelman, Johansson et al. 2007).  The molecular 
consequence of most recurrent, specific balanced translocations is the rearrangement of genetic 
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sequences and formation of fused genes, which results in either altered expression of the involved 
genes or formation of abnormal proteins.  In addition, in vivo experimental studies of these gene 
fusion constructs in transgenic animals results in neoplasia (Heisterkamp, Jenster et al. 1990, Perez-
Losada, Pintado et al. 2000), while silencing of the fusion transcripts in in vitro systems reverses 
their neoplastic characteristics (Thomas, Gessner et al. 2005, Thomas, Greil et al. 2006).  The sum 
total of this evidence overwhelmingly suggests that gene rearrangements are not only 
pathogenetically significant, but probably represent important events in tumour initiation.   
Somatic copy number aberrations (SCNA), in which restricted regions of chromosomes are either 
lost (deletions) or gained (amplifications), with consequent alteration in the expression of oncogenes 
and tumour suppressor genes are another feature of many tumour genomes (Albertson, Collins et al. 
2003).  They differ from copy number variations (CNV), which are variations in DNA copy number 
seen in the germ-line DNA of different individuals and are of no pathological significance (Beroukhim, 
Mermel et al. 2010).  They can be detected by molecular cytogenetic methods e.g. Fluorescence-in-
situ-Hybridization (FISH) and comparative genomic hybridization (CGH) and have led to the 
identification of cancer-related genes and potential therapeutic targets (Zender, Spector et al. 2006, 
Lahortiga, De Keersmaecker et al. 2007, The Cancer Genome Atlas Research Network 2008).  
1.7 GENETICS OF SOFT TISSUE SARCOMAS 
Genomic alterations ranging from subtle sequence changes to possession of multiples of the normal 
chromosome complement have been described among STS.  Significant correlation between 
molecular and genetic features of these tumours and their clinico-biologic properties have led to 
better classification, clinical management and identification of potential therapeutic targets (Mertens, 
Panagopoulos et al. 2009).  On the basis of their known genetic changes, most STS may be 
allocated four main groups as discussed in the following sections. 
1.7.1 Sarcomas with Specific Oncogenic Mutations 
Gene sequence mutations have been found to be specific to certain sarcoma subtypes, most notably 
the Gastro-Intestinal Stromal Tumours (GIST).  Originally classified histologically as smooth muscle 
tumours and then immunophenotypically as neural tumours (Fletcher, Berman et al. 2002), the 
discovery of these gene mutations and their consequent molecular alterations have not only provided 
further insight to the cells of origin and pathogenesis of these tumours, but been translated into 
actual and clinically-effective molecular therapy.  Hirota et al, in 1998 published a study in which they 
demonstrated that GISTs carried a specific sequence mutation in the cKIT gene, which leads to its 
constitutional activation, independent of its ligand (Hirota, Isozaki et al. 1998).  Subsequent studies 
showed that in a subset of GISTs that were negative for the KIT mutation, mutations with similar 
consequences in another tyrosine kinase, platelet-derived growth factor receptor gene, PDGFRA 
were present (Heinrich, Corless et al. 2003).   
The demonstration of KIT by immunohistochemistry (positive in up to 95% of cases) has proven to 
be a sensitive diagnostic tool for this previously poorly categorized tumour.  Furthermore and in 
concordance with the pathogenetic evidence, the clinical use of tyrosine kinase inhibitor treatments – 
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Imatinib and Sunitinib as first and second-line therapies has led to clinical response in patients with 
metastatic and inoperable disease and greatly improved what used to be a dire prognosis (Liegl-
Atzwanger, Fletcher et al. 2010).   
1.7.2 Sarcomas with Characteristic Translocations and Fusion Genes 
This group, which constitutes approximately 20% of cases of STS, are characterized by specific 
chromosomal aberrations, mostly balanced translocations, some of which are even considered to be 
pathognomonic (Mitelman, Johansson et al. 2007, Mertens, Panagopoulos et al. 2009).  Most of 
these gene fusions and other molecular consequences are believed to be important steps in 
tumorigenesis.  At present, this group includes more than a dozen sarcoma sub-types and about 30 
known translocations, most of which result in fusion genes as summarised in Table 1.5.    
Based on the current understanding of genomics in tumour development, the specificity of fusion 
genes for sarcoma subtypes makes it likely that they are ‘driver’ aberrations.  This is because they 
are consistently found in these sarcomas wherein they frequently are the sole karyotypic 
abnormality.  It is therefore presumable that they are important in tumour initiation and promote cell 
proliferation with accumulation of further ‘passenger’ mutations that confer more malignant 
characteristics as the tumour progresses (Mitelman, Johansson et al. 2007).  This concept is further 
given credence by the results of studies that show that like in other cancers, expression of these 
fusion gene constructs in vitro and in experimental animals leads to the development of tumours e.g. 
leukaemia, liposarcoma that have the phenotypic characteristics of the human tumours (Daley, Van 
Etten et al. 1990, Perez-Losada, Pintado et al. 2000).  In addition, the clinical success of therapies 
that specifically target fusion transcripts or their molecular effects, as demonstrated in Philadelphia 
chromosome-positive Chronic Myeloid Leukaemia make them potential targets for future therapies 
(Deininger, Buchdunger et al. 2005). 
The observation that sarcomas may arise following relatively few specific genetic events may 
partially explain why sarcomas in children and young patients tend to belong to this group, while 
sarcomas without characteristic translocations appear to require the accumulation of genetic 
alterations over time and are thus mostly seen in older patients (Thway 2009, Ordonez, Osuna et al. 
2010).  The molecular effects of fusion genes that elucidate how they contribute to pathogenesis has 
been demonstrated in many STS subtypes and on this basis, translocation sarcomas may be 
categorized based on the molecular alterations that result from their characteristic fusion genes.  
These will now be discussed using relevant examples. 
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Table 1.5: Characteristic chromosomal translocations and fusion genes in Soft Tissue Sarcoma 
Subtypes 
Sarcoma Subtype Genomic Aberration Genetic Consequence 
Fusion Genes resulting in Aberrant Transcription Factors 
    Ewing’s’/PNET 
t(11;22)(q24;q12) 
t(21;22)(q22;q12) 
t(7;22)(p22;q12) 
t(17;22)(q12;q12) 
t(2;22)(q33;q12) 
t(16;21)(p11;q22) 
t(2;16) 
inv (22) 
EWSR1-FLI1 
EWSR1-ERG 
EWSR1-ETV1 
EWSR1-ETV4 
EWSR1-FEV 
FUS-ERG 
FUS-FEV 
EWSR1-ZSG 
    Myxoid/round cell liposarcoma 
t(12;16)(q13;p11) 
t(12;22)(q13;q12) 
FUS–DDIT3 
EWSR1–DDIT3 
    Desmoplastic small round cell tumour t(11;22)(p13;q12) EWSR1–WT1 
    Clear cell sarcoma 
t(2;22)(q33;q12) 
t(12;22)(q13;q12) 
EWSR1–CREB1 
FUS–ATF1 
EWSR1–ATF1 
    Angiomatoid fibrous histiocytoma 
t(2;22)(q33;q12) 
t(12;16)(q13;p11) 
t(12;22)(q13;q12) 
EWSR1–CREB1 
FUS–ATF1 
EWSR1–ATF1 
    Extraskeletal myxoid chondrosarcoma 
t(3;9)(q12;q22) 
t(9;15)(q22;q21) 
t(9;17)(q22;q11) 
t(9;22)(q22;q12) 
TFG–NR4A3 
TCF12–NR4A3 
TAF15–NR4A3 
EWSR1–NR4A3 
    Low-grade fibromyxoid sarcoma 
t(7;16)(q33-34;p11) 
t(11;16)(p11;p11) 
FUS–CREB3L2 
FUS–CREB3L1 
    Alveolar soft part sarcoma t(X;17)(p11;q25) ASPSCR1–TFE3 
    Alveolar rhabdomyosarcoma 
t(1;13)(p36;q14) 
t(2;2)(p23;q36) 
t(2;13)(q36;q14) 
t(X;2)(q13;q36) 
PAX7–FOXO1A 
PAX3–NCOA1 
PAX3–FOXO1A 
PAX3–FOXO4 
    Solitary fibrous tumour inv (12)(q13q13) NAB2-STAT6 
    Epitheloid Haemangioepithelioma t(1;3)(p36.3;q25) WWTR1-CAMTA1 
    Mesenchymal chondrosarcoma t(8;8)(q21.1;q13.3) HEY1-NCOA2 
Fusion Genes resulting in Dysregulated tyrosine Kinase Genes 
    Infantile fibrosarcoma t(12;15)(p13;q25) ETV6–NTRK3 
    Inflammatory myofibroblastic tumour 
t(1;2)(q21;p23) 
inv(2)(p23q35) 
t(2;2)(p23;q13) 
t(2;4)(p23;q21) 
t(2;11)(p23;p15) 
t(2;17)(p23;q23) 
t(2;19)(p23;p13) 
TPM3–ALK 
ATIC–ALK 
RANBP2–ALK 
SEC31A–ALK 
CARS–ALK 
CLTC–ALK 
TPM4–ALK 
Fusion Genes involving Chromatin Remodelling Genes 
    Synovial sarcoma 
 
t(X;18)(p11;q11) 
t(X;20)(p11;q13) 
SS18–SSX1, 
SS18–SSX2 
SS18L1–SSX1 
SS18–SSX4 
Fusion Genes resulting in Growth Factor Dysregulation 
    Dermatofibrosarcoma protuberans 
Ring chromosome, 
t(17;22)(q21;q13), 
der(22)t(17;22) 
COL1A1–PDGFB 
Subtypes and genetic data are based on 2013 WHO Classification of Bone and Soft Tissue Tumours (Fletcher, 
Bridge et al., 2013).  Only non-benign soft tissue sarcoma subtypes are shown. 
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1.7.2.1 Fusions Resulting In Aberrant Transcription Factors 
About half of the fusion proteins that have been demonstrated in STS so far involve products of 
genes that encode transcription factors (Jain, Xu et al. 2010).   Most important among these genes 
are those that encode the TET family of transcription proteins that include the Translocated in 
Liposarcoma gene TLS (also known as FUS); Ewing’s’ Sarcoma gene EWSR1; and TATA-binding 
Associated Factor gene TAFII68 (also known as TAF15).  The members of this family display 
considerable redundancy in their pathogenetic roles in various STS subtypes (Jain, Xu et al. 2010).  
Apart from the TET family, other transcription factor genes are also involved in the fusion genes 
specific for some sarcoma subtypes (Table 1.5). 
The fusion gene products typically consist of the replacement of the RNA-binding domain of one 
transcription factor with the DNA-binding domain of its fusion partner and this is believed to result in 
alterations in specificity and transcription activity of the target gene.  Resultant effects that have been 
demonstrated with some of these fusion transcripts include increased cell proliferation, improved cell 
survival, reduced apoptosis, induction of angiogenesis, invasion and metastases (Bovée and 
Hogendoorn 2009).    
Examples of STS subtypes with fusion genes that have been demonstrated to have this 
pathogenetic mechanism are shown on Table 1.5.   Interestingly, some of these fusion genes are 
shared by STS subtypes e.g. the t (12;16)(q13;p11) that fuses EWRS1 with ATF1 that is 
characteristic in both Clear Cell Sarcoma and Angiomatoid Fibrous Histiocytoma.  This observation 
of identical genetic defects in morphologically and clinically distinct tumours has led authors to 
suggest that these gene fusions play an early role in sarcomagenesis by inducing transformation in 
mesenchymal progenitor cells, which then go on to differentiate along distinct pathways (Antonescu, 
Dal Cin et al. 2007, Iwasaki, Nabeshima et al. 2009).  
1.7.2.2 Fusion Genes Resulting In Deregulated Receptor Tyrosine Kinases 
Fusion genes have been described in STS that result in constitutive activation of receptor tyrosine 
kinases in a manner analogous to the BCR- ABL fusion of Chronic Myeloid Leukaemia.  Examples of 
these STS include congenital fibrosarcomas (Knezevich, McFadden et al. 1998, Krishnan, Khanna et 
al. 2008) and Inflammatory Myofibroblastic Tumour (IMT) (Lawrence, Perez-Atayde et al. 2000, 
Patel, Murphy et al. 2007, Mertens, Panagopoulos et al. 2009).  
1.7.2.3  Fusion Genes Involving Chromatin Remodelling Genes 
In synovial sarcomas, the SS18 (SYT) gene located at 18q11 and one of three SSX genes in the 
Xp11 band forms one of three fusion genes – SS18-SSX1 (Clark, Rocques et al. 1994); SS18-SSX2 
(de Leeuw, Balemans et al. 1995); or SS18-SSX4 (Skytting, Nilsson et al. 1999).  The SSX genes 
which are believed to regulate transcription via epigenetic mechanisms (histone modification and 
DNA methylation) are juxtaposed to form a dysfunctional chimeric gene (de Bruijn, Nap et al. 2007).    
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1.7.2.5 Fusion Genes Resulting in Growth Factor Dysregulation 
Dermatofibrosarcoma protuberans is characterized by the fusion of the platelet-derived growth factor 
β gene (PDGFB) at 22q13 and the α1 chain of type 1 collagen gene (COL1A1) at 17q22, which 
results in dysregulation of autocrine growth signalling by PDGFB (Simon, Pedeutour et al. 1997).  
The COL1A1-PDGFB chimeric gene is the result of either ring chromosomes that contain low-level 
amplified sequences from 17q and 22q (Minoletti, Miozzo et al. 1995, Naeem, Lux et al. 1995, Kiuru-
Kuhlefelt, El-Rifai et al. 2001), or an unbalanced translocation (17;22)(q22;q13) (Pedeutour, Lacour 
et al. 1996, Dobin, Diaz et al. 1999). 
As would be expected with this pathogenetic mechanism,  tumours carrying the COL1A1-PDGFB 
fusion genes show clinical response to tyrosine kinase inhibitors e.g. imatinib mesylate (McArthur, 
Demetri et al. 2005).  Copy number gains of this fusion gene have also been described in the rare 
transformation of DFSP into high-grade fibrosarcoma (Abbott, Erickson-Johnson et al. 2006).   
1.7.3 Sarcomas with Characteristic Somatic Copy Number Changes  
Somatic copy number abnormalities (SCNA), mostly amplifications have been detected in most soft 
tissue sarcomas (Myllykangas, Böhling et al. 2007).  Some amplifications are seen with such high 
frequency in certain sarcoma subtypes, that they are regarded as characteristic.  While they are not 
in principle specific, because they are also seen with significantly high frequency in other distinct 
sarcoma subtypes, they can play a valuable role in achieving correct diagnosis, particularly in cases 
where morphological characteristics are equivocal (Bovée and Hogendoorn 2009).  In addition, these 
amplifications are believed to harbour clues to the pathogenesis of the sarcomas and thus potential 
therapeutic targets (Coindre, Pedeutour et al. 2009). 
Atypical Lipomatous Tumour (ALT)/Well-differentiated Liposarcomas (WDLPS) and Dedifferentiated 
Liposarcomas (DDLPS), which constitute 20-25% of all sarcomas, represent the most important 
example of sarcomas in this category.  The presence of a supernumerary ring/giant ‘marker’ 
chromosome that always contains amplified sequences from the long arm of chromosome 12 
(12q14-15) is characteristic of these tumours.  While this usually represents the sole karyotypic 
aberration in ALT/WDLPS, secondary aberrations such as double minute chromosomes and multiple 
copies of the marker chromosome with significant intratumour heterogeneity are sometimes 
observed in DDLPS (Pedeutour, Suijkerbuijk et al. 1994, Italiano, Bianchini et al. 2009). 
Among important target genes in the amplified regions is MDM2 located at 12q15, which is over-
expressed in up to 100% of tumours and whose product inhibits p53 thus promoting cell survival.  
Other important potential oncogenes include CDK4, which is involved in the G1-S phase cell cycle 
checkpoint and HMG, which is involved in chromatin organization during transcription (Iwasaki, 
Nabeshima et al. 2009).  Amplifications of the 1p32 and 6q23 bands in DDLPS lead to the 
amplification of JUN and ASK1, respectively.  These genes are also amplified in mouse models of 
liposarcoma.  Both gene products inhibit peroxisome proliferator-activated receptor gamma (PPAR-
), a major player in adipocytic differentiation and may thus play a role in the dedifferentiation of 
liposarcomas and represent potential therapeutic targets (Mertens, Panagopoulos et al. 2009).   
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Despite the fact that they are not exactly tumour specific, identification of these karyotypic changes 
or gene amplifications (MDM2 and CDK4) is playing an increasing role in diagnosis of these tumours 
(Mertens, Panagopoulos et al. 2009). They may be used to differentiate ALT/WDLPS from 
morphologically similar, but benign adipocytic tumours or for the establishment of a lipogenic origin 
for dedifferentiated sarcomas.  It has been suggested that majority of pleomorphic sarcomas that 
arise in the retroperitonum are dedifferentiated liposarcomas, since they carry these gene 
amplifications (Coindre, Mariani et al. 2003). 
Another STS with a characteristic copy number change is the Embryonal Rhabdomyosarcoma, in 
which 70-100% of cases have allele loss at 11p15.5.  Other characteristic changes include trisomy of 
chromosomes 2 and 8 (Anderson, Gordon et al. 1999, Mertens, Panagopoulos et al. 2009).  This 
copy number alteration is also seen among Wilms’ tumours and hepatoblastoma and though it may 
not be important from a diagnostic point of view, it is believed to be the site of pathogenetically 
important genomic change, since it is consistently detected (Anderson, Gordon et al. 1999, Xia, 
Pressey et al. 2002).  Molecular studies have identified a number of cell cycle related genes in the 
region as candidates.  They include H19, IGF2, CDKN1C and BWR1A, but whether or not they are 
actually involved in tumour pathogenesis is yet to be fully elucidated (Anderson, Gordon et al. 1999).   
1.7.4 Sarcomas with Complex Karyotypic Aberrations 
This group comprises the majority of STS (about 50%) and includes most adult tumours that exhibit 
spindle cell and pleomorphic morphology.  Highly complex karyotypes with multiple numerical and 
structural aberrations are characteristic and marked intra-tumour heterogeneity is seen in these 
tumours with metaphase aberrations observed in virtually all cells and no two cells with an identical 
chromosome complement in many cases.  In addition, all these tumours possess numerous 
recurrent and non-random somatic copy number alterations that have been reported to involve 
virtually every chromosome in the genome (Mandahl, Mertens et al. 2004).   
Tumours that belong to this group include leiomyosarcoma (LMS); myxofibrosarcoma (MFS); 
pleomorphic subtypes of liposarcoma (PLPS) and rhabdomyosarcoma (PRMS); undifferentiated 
pleomorphic sarcomas (UPS or pleomorphic sarcoma UPS – not otherwise specified).    Others are 
Malignant Peripheral Nerve Sheath Tumours and relatively rare and less well-studied STS like adult 
fibrosarcoma, angiosarcoma and extraskeletal osteosarcoma (Guillou and Aurias 2009). 
Typically there is no known correlation between the chromosome breakpoints and clinico-
pathological subtypes (Guillou and Aurias 2009, Iwasaki, Nabeshima et al. 2009).  There is however, 
considerable overlap in the chromosomal aberration patterns across the tumour subtypes (Mertens, 
Panagopoulos et al. 2009).  Both conventional and array CGH analyses of these tumours showed 
that LMS and UPS share a similar genomic profile  (up to 80% similarity) of frequently amplified/lost 
sequences, some of which even have prognostic significance (Larramendy, Gentile et al. 2008, 
Carneiro, Francis et al. 2009).  Similarly, MFS and PLPS are reported to show very similar genomic 
aberrations that are distinct from those in LMS.  However, frequent copy number changes in certain 
regions are common to all four STS subtypes, including deletion in 10q and 13q, as well as 
amplifications in the short arm of chromosome 5 (Idbaih, Coindre et al. 2004). 
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Generally, it is believed that these genomic regions are amplified and deleted frequently because 
they contain oncogenes and tumour suppressor genes, respectively that are involved in tumour 
pathogenesis (Helman and Meltzer 2003).  In a few regions, molecular pathogenetic consequences 
of the copy number changes have been demonstrated, but many marker chromosomes and their 
target genes remain elusive because of dearth of investigated cases and the karyotypic complexity.  
Some of these as yet unidentified unbalanced chromosomal aberrations may even include 
pathogenetically-important gene fusions (Mertens, Panagopoulos et al. 2009). 
1.8 CELLULAR ORIGIN OF SARCOMAS 
The exact cell from which sarcomas originate remains unknown.  Despite nomenclature that is based 
on morphological resemblance to adult mesenchymal cell lineages, a step-wise progression model 
from normal cell through dysplasia to malignancy (as established in carcinomas) does not appear to 
apply to sarcomas (Thway 2009).  STS that exhibit features of specific mesenchymal lineage 
differentiation such as Rhabdomyosarcoma are known to arise in areas of the body where skeletal 
muscle tissue is sparse or even absent (Thway 2009) and many STS with similar histologic 
appearance have been shown to represent distinct clinic-biologic and molecular genetic entities 
(Fletcher, Bridge et al. 2013) 
A concept of differentiation is therefore proposed for sarcomagenesis whereby malignant 
transformation occurs in mesenchymal stem cells which retain a limited capacity for differentiation 
into the various lineages (Xiao, Mohseny et al. 2013).  The main problem with this concept however 
is that the identity of human mesenchymal stem cells remains controversial and as yet, they have not 
been categorically characterised or isolated with most preparation being a heterogenous mixture of 
cells, some of which express putative stem cell markers (Lin, Wang et al. 2011).  However, ectopic 
expression of the EWS/FLI1 chimeric protein in human bone marrow derived mesenchymal 
progenitor cells reportedly led to their transformation with immunophenotypic and transcriptomic 
characteristics that closely resembled Ewing’s tumours (Miyagawa, Okita et al. 2008).   
Recent studies in transgenic mice where mesenchymal stem cells are better characterised, showed 
that myogenic progenitor cells were able to give rise to both myogenic and non-myogenic sarcomas 
depending on which genes were disrupted (Blum, Ano et al. 2013).  These studies support the 
differentiation theory for sarcomagenesis but also raise the question of a possible role for specific 
genomic aberrations in the determination of the mesenchymal lineage differentiation of STS 
subtypes.  
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1.9 GENOMIC INSTABILITY IN SOFT TISSUE SARCOMAS 
Genomic instability has been described as an enabling characteristic that facilitates the acquisition of 
the hallmarks of malignancy (Hanahan and Weinberg 2011).  It is believed to account for the 
progressive accumulation of mutations in the cancer cell genome with the resultant effect that many 
tumour cells are characterised by multiple genomic changes at various levels and there is significant 
intra-tumour heterogeneity (Negrini, Gorgoulis et al. 2010).  Instability has been described at the 
level of nucleotide sequences and microsatellites, where they are believed to be due to defects in 
Nucleotide Exchange Repair (NER) and Mismatch Repair (MMR) mechanisms for DNA damage 
during replication, respectively.  Nucleotide Instability (NIN), in particular can result in drastic 
phenotypic changes, but these forms of instability, are mostly seen in hereditary forms of cancer and 
are thus relatively rare (Lengauer, Kinzler et al. 1998).  Microsatellite instability (MIN) with associated 
mismatch repair defects has been well characterised in a subset of colorectal cancers and detected 
in up to 40% of STS in some studies (Martin, Grear Hurt et al. 1998, Boland and Goel 2010, 
Monument, Lessnick et al. 2012). 
Chromosomal instability (CIN) in which cells accumulate chromosomal abnormalities (whole and/or 
segmental amplifications and deletions) at a higher than normal rate is however the major form of 
genomic instability in sporadic cancers (Negrini, Gorgoulis et al. 2010).  In various cancers, CIN has 
been quantified using the number of SCNA present in the genome; the proportion of the genome 
affected; or the rate of Loss of Heterozygosity (LOH) and studies showed that it is a prominent 
feature of many STS, particularly among those without characteristic chromosomal abnormalities 
(Johnson, Gettings et al. 2007, Barretina, Taylor et al. 2010, Beroukhim, Mermel et al. 2010). 
Although the exact mechanisms of chromosomal instability are still far from being full understood, 
two main theories – the mutator hypothesis and oncogene-induced DNA replication stress model are 
well-established (Negrini, Gorgoulis et al. 2010). 
DNA damage in the form of Double Strand Breaks (DSBs) occurs frequently (up to 10 events per day 
in normal cells) from a variety of intrinsic and extrinsic causes (Lieber 2010).  In the normal cell, 
intact cell cycle checkpoints and DNA repair pathways are required to stop the mitotic cell cycle and 
repair the damage (or failing this, eliminate the damaged cell by initiating apoptosis) thus maintaining 
the integrity of the genome and preventing the transmission of this damage in mitosis.  This involves 
a very complex interplay between proteins coded for by genes known collectively as ‘caretaker 
genes’ including prominent examples such as TP53, BRCA1, BRCA2, CDNK2A and ATM 
(Lengauer, Kinzler et al. 1998, Negrini, Gorgoulis et al. 2010).  The mutator hypothesis states that 
mutations that lead to inactivation of the ‘caretaker’ genes result in accumulation of replication errors 
and further driver and passenger mutations.   
While the mutator hypothesis is well established with regard to hereditary cancers such as those 
seen in Li-Fraumeni syndrome and Ataxia Telangiectasia that are characterised by germ-line 
mutations of TP53 and ATM respectively, observations in sporadic cancers that only a third of 
tumours that exhibit CIN possess caretaker gene mutations suggest it may not be solely responsible 
for their CIN.  Other mechanisms of caretaker gene inactivation such as copy number deletion or 
 21 
 
epigenetic regulation may however play a role in these sporadic cancers (Negrini, Gorgoulis et al. 
2010).  Mutations and/or altered gene expression involving the TP53 gene have been shown in 
numerous genetic and expression studies to be common among soft tissue sarcomas with complex 
genomic profiles (Toguchida and Nakayama 2009, Barretina, Taylor et al. 2010). Zhang et al 
demonstrated frequent association between ATM defects and rhabdomyosarcomas (Zhang, Bhakta 
et al. 2003) and previous study carried out in the Rare Tumour Research Group revealed frequent 
copy number losses involving the ATM gene in both GIST and leiomyosarcoma (Ul-Hassan, Sisley et 
al. 2009).   
Reviewed by Halzonetis et al, the second model used to explain CIN is derived from evidence in 
cancerous and precancerous lesions and proposes that abnormal proliferation driven by activated 
oncogenes deregulates the entry of tumour cells into the mitotic cycle resulting in DNA replication 
stress and accumulation of double strand breaks at specific genomic sites called “common fragile 
sites” (Halazonetis, Gorgoulis et al. 2008).  In both models, the genomic instability leads to the 
disruption of more caretaker genes that exacerbates the genomic instability and sets up a vicious 
cycle of progressive accumulation of genomic abnormalities. 
More recently, whole genome sequencing studies in cancer have led to the description of a 
phenomenon in which a cancer cell undergoes a single ‘cataclysmic’ genomic event termed 
chromothripsis that results in a large number of genomic rearrangements (Kloosterman, Hoogstraat 
et al. 2011, Stephens, Greenman et al. 2011).   This mechanism for chromosomal instability and 
possibly even tumour initiation is believed to occur in around 2 – 3% of cancers in general, but bone 
sarcomas in particular (Stephens, Greenman et al. 2011).   Another study suggested that a subset of 
malignant melanomas that showed complex genomic rearrangements suggestive of chromothripsis 
were associated with a poor prognosis (Hirsch, Kemmerling et al. 2013).  
Telomere dysfunction is another mechanism that has been demonstrated in cancers and believed to 
contribute to CIN in conjunction with the two models described above (Murnane 2012).  In normal 
cells, telomeres are short repeat sequences with associated proteins present at the ends of 
chromosomes to prevent them from being seen by the DNA repair mechanisms as Double Strand 
Breaks (DSBs).  They also participate in cellular aging as their progressive shortening and attrition 
eventually leads to senescence (Jefford and Irminger-Finger 2006).  As demonstrated in STS, 
telomere loss leads to erroneous chromosomal end joining and a series of bridge–fusion-breakage 
cycles (Figure 1.2) that result in aneuploidy, chromosomal translocations, amplifications or deletions 
(Artandi, Chang et al. 2000, Artandi and DePinho 2000, Gisselsson, Pettersson et al. 2000, Murnane 
2012).   While telomere loss promotes the initiation of genomic instability, tumour cells have been 
shown to subsequently activate telomerase maintenance mechanisms such as telomerase and 
alternative lengthening of telomeres in order to remain immortal (Begus-Nahrmann, Hartmann et al. 
2012).  Abnormal maintenance of telomere length has been demonstrated in various STS subtypes 
(Montgomery, Argani et al. 2004, Johnson, Gettings et al. 2007, Heaphy, Subhawong et al. 2011) 
and clinical trials evaluating telomere maintenance as a therapeutic target in cancer are on-going 
(Xu, Li et al. 2013). 
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 Figure 1.2: Illustration of Breakage–Fusion–Bridge (BFB) Cycle contribution to Chromosomal 
Instability 
Telomere Dysfunction and Defective Cell Cycle Checkpoint Responses in tumour cells lead to erroneous fusion 
of chromosome ends that form a bridge between chromatid ends during anaphase with subsequent breakage of 
one of the chromatids in telophase.  Following cytokinesis, one daughter cell contains an extra copy of the 
affected chromosome segment (amplification) with a corresponding deletion in the other daughter cell .  The 
ends of the abnormal chromosomal appear as double strand breaks (DSBs), which may become fused and 
enter another BFB cycle.     
1.10 COPY NUMBER MAPPING IN CANCER 
Copy number aberrations are an important pathogenetic mechanism in cancer and understanding 
their patterns can lead to identification of therapeutic targets (Taylor, Barretina et al. 2008).   High-
resolution mapping of copy number aberrations in cancer genomes is a valuable way of identifying 
recurrent genomic changes.  Coupled with epigenetic, expression and functional data, this can 
further our understanding of the molecular basis of cancers and markers can be identified that can 
be targeted for tumour diagnosis, prognostic sub-classification or pharmacologic/biologic therapy 
(Taylor, Barretina et al. 2011).  To this end, large-scale projects to catalogue genomic copy number 
aberrations in large cohorts of specific cancers e.g. the Cancer Genome Atlas Project have been 
established and over time have yielded important insights in a number of cancers, including 
glioblastoma multiforme and ovarian carcinoma (The Cancer Genome Atlas Research Network 2008, 
Mankoo, Shen et al. 2011, The Cancer Genome Atlas Research Network 2011).   
Oligonucleotide micro-array based comparative genomic hybridization (array CGH or aCGH) is a 
high-resolution technique that is commonly utilised for the simultaneous detection of all SCNA across 
the entire genome.   It is therefore highly suited for the study of certain STS subtypes, which are 
characterised by multiple complex SCNA as it allows the detection, accurate mapping and 
subsequent analysis of aberrations with a view to identification of pathogenetic abnormalities.  
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1.11 HYPOTHESIS AND STUDY AIMS 
A large proportion of STS are characterised by genomic instability that is evidenced by pervasive, 
multiple seemingly random genomic copy number aberrations.  Aberrations that occur with a higher 
frequency than can be explained by random chance is likely to have been specifically targeted by 
tumours for a survival benefit.  The following hypothesis was therefore developed for this PhD 
project: 
“Soft Tissue Sarcomas that are characterized by complex karyotypes bear genomic 
abnormalities that are subtype-specific, but as yet unidentified” 
Further, strong associations exist between STS and DNA-damaging ionising radiation and inheritable 
conditions where DNA-repair mechanisms are defective.  It is therefore plausible that defects in cell 
cycle regulatory and DNA repair genes are important in STS pathogenesis. 
This PhD Project therefore specifically aims: 
1. To carry out high-throughput genome-wide mapping of somatic copy number aberrations 
(SCNA) in primary soft tissue sarcomas using Oligonucleotide Array Comparative Genomic 
Hybridisation  
 
2. To identify patterns of SCNA that are specific for STS subtypes as well as those involved in 
DNA Repair and Cell Cycle Regulation and Mesenchymal Cell Differentiation 
 
 
3. To develop a suitable disease model for the functional study of candidate pathogenetic SCNA 
and affected genes 
 
4. To further characterise candidate pathogenetic SCNA and affected genes in terms of protein 
expression and functional consequences 
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CHAPTER TWO 
MATERIALS AND METHODS 
2  
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2.1 PATIENTS AND TUMOUR SAMPLES 
2.1.1 Ethics Statement 
National Research Ethics Committee approval was obtained for the collection and use of fresh and 
archival tissue samples (reference numbers 09/H1313/52 and 09/H1313/30, respectively).  Patients 
gave written informed consent prior to the collection of fresh tissue samples and all data from 
archival samples was analysed anonymously.  Tumour and normal tissue was collected and stored 
according to the principles of the Declaration of Helsinki and the use of tissue was in compliance with 
the Human Tissue Act, 2004.  
2.1.2 Tumour Samples 
Tumour samples were collected as fresh specimens and/or archival FFPE blocks from STS cases 
collected between 1994 and 2012 at the Histopathology Department of the Royal Hallamshire 
Hospital, Sheffield, UK.  Details of all 88 STS cases included in this study are summarised in 
Appendix 1. 
2.1.2.1 Fresh Tumour Samples 
Fresh tumour samples were obtained from patients receiving surgical treatment for STS at Sheffield 
Teaching Hospitals within 30 minutes of resection.  STS cases comprised various subtypes and 
tumours were macroscopically sampled by an experienced sarcoma pathologist prior to fixing in 10% 
neutral-buffered formalin (NBF).  Samples for tissue culture were collected in sterile phosphate-
buffered saline (PBS) and additional tumour samples were snap-frozen and stored in liquid nitrogen 
or at -80ºC until DNA extraction or other molecular analysis.  Normal tissue where available, was 
obtained from tumour-free margins of excised specimens and snap-frozen in liquid nitrogen. 
2.1.2.2 FFPE Samples 
Representative FFPE tumour sections stained by routine haematoxylin and eosin (H+E) were 
examined by an experienced sarcoma pathologist and areas comprised of >70% tumour cells were 
outlined.  Where necessary, the outlined areas were then scraped off subsequent 20µm sections for 
DNA extraction, or specifically targeted on 5µm sections for Fluorescence In-situ Hybridisation 
and/or immunohistochemistry. 
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2.2 MATERIALS 
2.2.1 General Laboratory Reagents and Equipment 
General laboratory reagents and equipment used in this study are summarised in Appendix 2.  
Method-specific reagents are described in subsequent sections. 
2.2.2 Tissue Culture and Chromosome Preparation 
Culture Medium:  Primary STS tumour cells were maintained in RPMI 1640 culture medium (Lonza), 
supplemented as outlined in table 2.1 below: 
Table 2.1:  Tissue culture medium supplements 
Supplement %( v/v) 
Fetal Calf Serum (Lonza) 20% 
L-Glutamine (200mM in 0.85% NaCl; Lonza) 1% 
Amphotericin B (Lonza) 1% 
Penicillin/Streptomycin (10kU/ml; Lonza) 1% 
D+ glucose (45% solution, Sigma)  0.4% 
Media was then stored at 4
o
C and warmed to 37
o
C prior to use. 
Trypsin-EDTA:  0.4% Trypsin-EDTA solution (Lonza-BioWhitaker) was stored at -20
o
C in 50ml 
aliquots then thawed gently in a 37
o
C incubator prior to use. 
Phosphate-buffered Saline:  Sterile Dulbecco’s Phosphate Buffered Saline (Lonza-BioWhitaker) 
containing 0.0095M PO4 without Ca
2+
 or Mg
2+
 was stored at room temperature.  
Colcemid:   10µg/ml KaryoMAX
®
 Colcemid (Gibco), was stored at 4ºC 
Hypotonic Solution:  0.075M potassium chloride (KCl) was prepared by dissolving 2.235mg KCl in 
400ml dH2O, autoclaved then stored at 4ºC and warmed to 37ºC prior to use. 
Fixative Solution:  A mixture of methanol and glacial acetic acid in a ratio of 3:1 respectively was 
prepared and used within 30 minutes. 
2.2.3 Giemsa Banding 
Sorenson’s Buffer:  9.47g of disodium hydrogen orthophosphate (Na2HPO4) and 9.08g potassium di-
hydrogen orthophosphate (KH2PO4) made up to 1000ml with ddH2O and stored at room temperature 
for up to one month. 
Banding Trypsin:  0.6g of Trypsin 1:250 powder (Difco) in 250ml of Sorensen’s buffer then stored in 
10ml aliquots at -20ºC.    
Gurr’s Buffer:   One Gurr’s buffer tablet (BDH) was dissolved in 1000ml dH2O and adjusted to pH 6.8 
then stored at room temperature. 
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Giemsa (Leishman) Stain:  Leishman’s Stain (BDH) and Gurr’s buffer were mixed in a 1:5 ratio and 
used within 15 minutes of preparation 
2.2.4 DNA Extraction 
Sodium thiocyanate:  1M NaSCN (Sigma)
 
was prepared by dissolving 12.3g NaSCN powder in 
distilled water (dH2O) and stored at room temperature for up to one month 
DNA Extraction Kit: DNeasy
®
 Blood and Tissue Kit (Qiagen) comprising  
 Proteinase K 
 Tissue Lysis Buffer (Buffer ATL),  
 Lysis Buffer (Buffer AL),  
 Wash Buffers (Buffers AW1 and AW2), 
 Elution Buffer (Buffer AE) 
 DNeasy
®
 mini spin columns and collection tubes.  
2.2.5 Agarose Gel Electrophoresis 
Agarose:  Agarose powder (Fisher) was stored at room temperature and gels were prepared just 
before use. 
Running Buffer:  1X TAE (Tris-Acetate-EDTA) was diluted from 50X stock solution prior to use.  
Stock solution comprised 242g Tris base; 57.1ml Glacial Acetic Acid and 18.6g EDTA dissolved in 
1000ml dH2O and stored at room temperature.  
Electrophoresis Unit:  Multi sub choice electrophoresis unit (Geneflow), comprises 
 Gel casting tray (15 × 7cm) 
 Sample comb (for 20 samples) 
 Electrophoresis tank 
Power Source:  Power-Pac 3000 basic power supply for electrophoresis (BioRad) 
Ethidium bromide:  10mg/ml Ethidium bromide prepared by dissolving 1g ethidium bromide in 100ml 
dH2O and stored at 4ºC 
DNA Ladder:  1kB DNA ladder (Promega) stored at 4ºC 
Loading Buffer:  6X Loading buffer - 0.25% (w/v) bromophenol blue and 30% (v/v) glycerol prepared 
by adding 25mg bromophenol blue to 3ml glycerol and making up to 10ml with dH2O then stored at 
4ºC  
2.2.6 Array Comparative Genomic Hybridisation 
Restriction Digestion Enzymes:  Restriction enzymes and other reagents (Promega)  
 Alu 1 (10 U/μl)  
 Rsa 1 (10 U/μl)  
 10X Buffer C  
 Acetylated Bovine Serum Albumin (10μg/ml)  
All stored at -20
o
C.  
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Random Priming with Exo-Klenow Labelling Kit:  Agilent Genomic DNA Enzymatic Labelling Kit 
(Agilent) comprising  
 Random Primers,  
 5X Buffer,  
 10X dNTP,  
 Cyanine 3-dUTP (1.0 mM),  
 Cyanine 5-dUTP (1.0 mM), and 
 Exo-Klenow Fragment 
All stored at -20ºC. 
Labelled DNA Purification:  Amicon
®
 Ultra 0.5ml 30kDA filters and 1.5ml microfuge collection tubes 
(Millipore)  
ULS Labelling Kit:  Agilent ULS Labelling Kit (Agilent) stored at 4ºC comprising 
 ULS-Cy 3 reagent 
 ULS-Cy 5 reagent 
 10X Labelling solution 
 Agilent-KREApure
®
 purification columns with collection tubes 
Cot-1 DNA:  1mg/ml Cot-1 DNA Pre-Hybridisation (Invitrogen) stored at -20ºC 
Hybridisation Kit: Oligo aCGH Hybridisation Kit (Agilent) comprising  
 2X Oligo aCGH Hybridisation solution 
 10X Blocking Agent 
Stored at room temperature. 
Blocking Solution: CGHblock
®
 (Agilent) stored at -20ºC 
Hybridisation Assembly:  Microarray hybridisation assembly comprising 
 SurePrint
®
 G3 Human CGH Microarray Slide - 4 × 180K   
 Hybridisation Gasket Slide  
 Hybridisation Chamber Kit - SureHyb
®
 enabled, Stainless Steel 
All obtained from Agilent, Stockport, UK.  
Hybridisation Oven: Microarray Hybridisation Oven (Agilent) equipped with removable rotator rack 
Wash Buffer Kit:  Oligo aCGH/ChIP-on chip Wash Buffer Kit comprising 
 Oligo aCGH Wash Buffer 1, and  
 Oligo aCGH Wash Buffer 2  
Scanner:  SureScan High-Resolution Microarray Scanner (Agilent) 
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2.2.7 Fluorescence In-situ Hybridisation 
Commercial Probes:  Commercial FISH probes (Vysis) were stored at -20°C in the dark.  The 
commercial probes used in this study are summarised in Table 2.2 below. 
Table 2.2:  Commercial FISH Probes used in this study 
Probe Name Target Locus Fluorophore 
Volume for 5 slides 
(Efficiency)* 
Vysis LSI ATM ATM 11q22.3 SpectrumOrange
®
 1.5µl 
Vysis LSI 13 (RB1) RB1 13q14 SpectrumGreen
®
 1.5µl 
CEP 3 Chr 3 Centromere 3p11.1-q11.1 SpectrumOrange
®
 1.0µl 
CEP 8 Chr 8 Centromere 8p11.1-q11.1 SpectrumOrange
®
 1.0µl 
CEP 11 Chr 11 Centromere 11p11.11-q11 SpectrumGreen
®
 1.0µl 
* - based on user experience within the Rare Tumour Research Group  
 
Bacterial Artificial Chromosome (BAC) Clones:  Clones were obtained from two BAC libraries 
(Invitrogen) as E. coli bacterial glycerol stocks and stored at -80ºC.  Their characteristics are 
summarised on Table 2.3 below. 
Table 2.3:  BAC Clones used in this study 
Clone ID Target Locus Library Size Vector Host 
RP11-586K23 TRIO (5’ end) 5p15.2 RPCI-11 219kB pBACe3.6 DH10B E. coli 
CTD-2505B6 TRIO (3’ end) 5p15.2 CITB-Human D1 183kB pBeloBAC11 HS996 E.coli 
 
Bacterial Culture Media:  Luria-Bertani (LB) media (Sigma) was prepared as solid media or broth 
according to manufacturers’ instructions and stored at room temperature 
Selection Antibiotic:  Chloramphenicol (Sigma) stored in stock concentration of 20mg/ml at 4ºC in the 
dark and added to LB media at a working concentration of 12.5µg/ml.  
Solution P1:  prepared as outlined below, filter-sterilized and stored at 4°C 
 50mM Tris, pH 8 
 10mM EDTA 
 100µg/ml RNase A 
Solution P2:  prepared as outlined below, filter sterilized and stored at room temperature 
 0.2N NaOH 
 1% SDS 
Solution P3:  3M Potassium Acetate (KOAc) at pH 5.5; autoclaved and then stored at 4°C. 
BAC DNA Labelling Kit:  Nick Translation Kit (Abbott Molecular) stored at -20°C, comprising 
 Nick translation enzyme mix  
 10X nick translation buffer  
 dATP, dCTP, dGTP, and dTTP solutions  
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 Nuclease-free water  
Labelled Nucleotides:  1mM SpectrumGreen-labelled dUTP (Abbott Molecular) diluted to 0.2mM with 
nuclease-free water and stored in 10µl aliquots at -20ºC in the dark. 
Hybridisation buffers:  LSI/WCP and CEP Hybridisation buffers (AbbottMolecular) stored at -20ºC 
Tissue Pre-treatment:  Zymed ‘Spotlight’ Tissue Pretreatment Kit (Invitrogen) stored at 4ºC, 
comprising 
 Pretreatment solution (pH 7.0), and  
 Enzyme reagent  
Counterstain:  VECTASTAIN
®
 mounting medium with DAPI (4’, 6-diamidino-2-phenylindole) obtained 
from Abbott Molecular and stored in the dark at 4°C 
SSC Buffer:  20X Saline Sodium Citrate (SSC) stock prepared as from components outlined below in 
1L dH2O, adjusted to pH 7.0 and stored at room temperature 
 3M NaCl 
 300mM NaHCO3 
SSCT1 - 0.4xSSC/0.3% Tween 20 (200ml 2XSSC + 1.5ml Tween 20 made up to 500ml with 
deionised water) 
SSCT2 - 2XSSC/0.1% Tween 20 (500ml 2XSSC + 0.5ml Tween 20)    
PBS with MgCl2 - PBS + 50mM MgCl2 (50ml 1M MgCl2 + 950ml PBS) stored at room temperature 
for up to one month 
Pepsin – Pepsin (Sigma) stored at -20ºC in 25µl aliquots at 100mg/ml stock concentration and 
diluted 1:2000 in 0.01N HCl for working concentration. 
Fixative Solution – 37% Formaldehyde (Sigma) stored at room temperature in the dark and diluted to 
1% in PBS/MgCl2 as working solution 
2.2.8 Immunochemistry 
Peroxidase Quenching Solution:  0.3% Hydrogen peroxide (H2O2) freshly prepared by diluting stock 
30% H2O2 stock solution (Sigma) in 100% methanol. 
Blocking Serum:  Normal horse serum (Vector) was stored at 4°C and diluted in PBS to give a 
10%working concentration 
Tris-EDTA Buffer: 1.21g Tris base and 0.37g EDTA in 1L dH2O, adjusted to pH 9.0 + 0.5ml Tween 
20 
Citrate Buffer:  1.92g anhydrous citric acid dissolved in 1L dH2O adjusted to pH 6.0 + 0.5ml Tween 
20 
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Primary Antibodies:  Primary antibodies were stored at 4°C and diluted in 2% normal serum (diluted 
in PBS).  The various antibodies used in this study are summarised in Table 2.4 below. 
Table 2.4:  A summary of primary antibodies used in this study and the corresponding reagents 
Antigen (Ag) 
Target 
Manufacturer Source Type Class Working 
Dilution 
Blocking 
Serum 
Ag Retrieval 
Buffer 
Trio 
Santa Cruz 
Sigma 
Goat 
Rabbit 
Polyclonal 
Polyclonal 
IgG 
IgG 
1:150 
1:50 
Horse 
Tris-EDTA  
(pH 9.0) 
cKIT Dako  Mouse Monoclonal IgG 1:200 Horse 
Citrate 
(pH 6.0) 
α-smooth 
muscle actin 
Dako Mouse Monoclonal IgG 1:100 Horse N/A 
Secondary Antibodies:  Secondary antibodies (Vector) were stored at 4°C and diluted 1:200 in 2% 
blocking serum to give working solution. 
Avidin/Biotin Peroxidase Kit:  VECTASTAIN Elite ABC Kit (Vector) stored at 4ºC and used according 
to manufacturers’ instructions 
Peroxidase Substrate Kit:  DAB Peroxidase Substrate Kit (Vector) stored at 4ºC and used according 
to manufacturers’ instructions 
DePex:  DPX mountant (Sigma) stored at room temperature and used in a fume hood 
2.2.9 Cell Proliferation Assay 
Protein Inhibitor:  ITX3 (Sigma), a specific inhibitor of the n-terminal domain of the Trio RhoGEF 
protein dissolved to 1mM stock concentration in DMSO and stored at room temperature. 
Tetrazolium reagent:  3- (4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) obtained 
from Sigma was dissolved to 1mg/ml stock concentration in sterile PBS and stored at 4ºC. 
2.2.10 Cell Migration/Invasion Assay 
Boyden Chamber:  48-well micro chemotaxis chamber AP-48 (Neuroprobe)  
Filter Membrane:  Polycarbonate track etch membrane with 8µm pore size (Neuroprobe) was used 
for all cell lines 
Extracellular Matrix Mix:  Extracellular matrix (ECM) components were diluted and stored at 4ºC.   
The ECM mix was freshly prepared just before use as summarised in Table 2.5 below. 
Table 2.5:  Extracellular Matrix Mix Components 
ECM 
Protein 
Source Manufacturer Stock Concentration 
Working Concentration 
(diluted in PBS) 
Collagen 
Human 
Placenta 
Sigma 
2.0mg/ml (in 0.5M Acetic Acid) 
15µg/ml Fibronectin 
Human 
Fibroblasts 
2.0mg/ml (in sterile dH2O) 
Laminin 
Human 
Fibroblasts 
1.0 mg/ml (in sterile PBS) 
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2.3 METHODS 
2.3.1 Tissue Culture 
2.3.1.1 Fresh Tumour Processing 
STS tumour specimens were obtained as described in Section 2.1.2.  A small fresh tissue sample 
(typically around 10mm × 10mm × 5mm) was placed in a sterile petri dish with a few drops of culture 
media and minced with a sterile scalpel until very fine.  An additional 10ml culture media was then 
added and the suspended tissue was transferred to a 25ml universal tube and centrifuged at 
1000rpm for 5 minutes at room temperature.  The supernatant was then removed, the tissue re-
suspended in fresh media and transferred to T25 flasks and 1ml slopes, which were subsequently 
placed in a 5% CO2 incubator at 37
o
C in 95% humidified air (37°C/5%CO2 incubator).  Media in the 
flasks and slopes was changed as required. 
2.3.1.2 Sub-cultures 
Washes were set up when it appeared that some viable cells remained unattached to the flask or 
slope.  The media in the culture was transferred to a 25ml universal tube, and replaced with warm 
fresh media.  The tube was then centrifuged at 1000rpm for 5 minutes and the supernatant removed.  
The pellet was re-suspended in warm fresh media and transferred to a sterile T25 flask, which was 
placed in the incubator.  
Cells were generally sub-cultured when they reached 80 – 90% confluence to provide room for 
further growth.  For a T25 flask, the media was removed and the cells rinsed twice with sterile PBS.  
Trypsin (2.5mls) was then added and the cells incubated at 37
o
C and monitored on the inverted 
microscope until dissociated.  Trypsinisation was then halted by adding 2.5ml of fresh culture media.  
The cells (now suspended) were transferred to a 25ml universal tube and centrifuged at 1000rpm for 
5 minutes at room temperature.  The supernatant was removed, the cell pellet re-suspended in fresh 
media and split among the appropriate number of flasks, where the media was made up to 5mls 
before being placed in the incubator.  For cells that were dividing faster, cultures were transferred to 
T75 flasks and sub-cultured as described using twice as much media and trypsin at each step. 
2.3.2 DNA Extraction 
Qiagen DNeasy
®
 Blood and Tissue Kit was used to extract DNA from tissues and cultured cells. 
Briefly, the kit works on the principles of alkaline lysis, binding, washing and elution.  The cells or 
tissues are lysed then loaded onto a silica-based membrane, which selectively adsorbs DNA in the 
presence of high concentrations of chaotropic salts.  Centrifugation and two wash steps serve to 
remove contaminants and the pure DNA is then eluted. 
2.3.2.1 Cell/Tissue Preparation and Lysis 
FFPE Tissue 
Tissue was macro-dissected where necessary as described in Section 2.1.2.2.  Approximately 4mm
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of tissue (the equivalent of two 20µm-thick sections measuring 10mm × 10mm)  was placed in a 
1.5ml microfuge tube , then 480µl PBS and 20µl 10% Tween 20 (diluted in nuclease free water) were 
added.  The tube was then placed on a heat block at 90ºC for ten minutes to de-paraffinise the tissue.  
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This was followed by centrifugation at 10,000 × g for 15 minutes at room temperature and immediate 
transfer to ice for 2 minutes.  The wax disc formed on the surface was carefully removed with 
tweezers and the supernatant discarded without disturbing the pellet.  Absolute ethanol (1ml) was 
added followed by centrifugation at 10,000 × g for 5 minutes at room temperature.  The ethanol was 
removed and the lid left open to allow the pellet allowed to air-dry completely.   
Cross-links (DNA:DNA and DNA:protein) were then broken by adding 1M NaSCN (400µl) to each 
sample tube and overnight incubation at 37°C.  Samples were then centrifuged at 10,000 × g for 20 
minutes at room temperature and the supernatant carefully removed.  PBS (400µl) was added 
followed by centrifugation at 10,000 × g for a further 20 minutes at room temperature and removal of 
the supernatant.   Buffer ATL (360µl) and Proteinase K (40µl) were then added and the sample 
incubated on a heat block at 56
o
C for at least 24 hours, with periodic vortexing and addition of fresh 
proteinase K every 6 to 8 hours until the tissue was completely dissolved.   
The sample was then allowed to cool to room temperature and RNase A (8µl) was added and briefly 
vortexed then incubated at room temperature for 2 minutes.  Buffer AL (400µl) was added and the 
tube incubated on a hot block at 70C for 10 minutes.  Absolute ethanol (440µl) was then added to 
the tube and its contents transferred to 2 separate labelled DNeasy
®
 mini spin columns (about 660µl 
each). 
Fresh Frozen Tissue 
Frozen Tissue (10 – 20mg) was transferred to a clean nuclease-free 1.5ml microfuge tube and 
Proteinase K (20µl) and Tissue Lysis Buffer ATL (180µl) added and mixed by vortexing.    The tube 
was then incubated on a heat block at 56
o
C for up to 24 hours with periodic vortexing and addition of 
fresh Proteinase K every 6-8 hours until the tissue was completely dissolved.  A mixture of Buffer AL 
(200 µl) and absolute ethanol (200µl) was then added to each sample tube, immediately vortexed 
and the sample transferred to a single labelled DNeasy
®
 mini spin column. 
Cultured Cells  
Cultured cells were dissociated with trypsin and centrifuged as described in Section 2.3.1.2.  The 
cells were then re-suspended in PBS at a density of approximately 2 × 10
7
cells/ml.  200µl of the cell 
suspension was then transferred to a 1.5ml microfuge tube.  Proteinase K (20µl) and Buffer AL 
(200µl) were added, the mixture vortexed and incubated at 56
o
C on a heat block until the tissue was 
completely dissolved (usually within 30 minutes).  Absolute ethanol (200µl) was then added to each 
sample tube, vortexed and the contents transferred to a single labelled DNeasy
®
 mini spin column. 
2.3.2.2 DNA Adsorption 
The DNeasy
®
 mini spin column loaded with lysate (FFPE tissue, fresh tissue or cultured cells) was 
then placed in a collection tube and centrifuged at 6,000 × g for 1 minute.  The collection tube and 
contents were discarded and the spin column placed in a fresh collection tube. 
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2.3.2.3 Washing 
Buffer AW1 (500µl) was added to the each spin column and centrifuged at 6,000 × g for 1 min.  The 
flow-through and collection tube were again discarded and the spin column transferred to a fresh 
collection tube.   
The subsequent wash step depended on the source of DNA.  For fresh frozen tissue or cultured 
cells, buffer AW2 (500µl) was added, while for FFPE samples it was substituted with an equivalent 
volume of 80% ethanol.  Samples were then centrifuged at 16,000 × g for 3 minutes.   
2.3.2.4 DNA Elution 
DNA from fresh frozen tissue or cultured cells was eluted in Buffer AE or 1X TE, while that from 
FFPE tissue was eluted in nuclease-free water.  The volume of eluent used depended on the desired 
DNA yield and concentration.  In general, smaller eluent volumes gave higher eluate DNA 
concentrations, but lower overall DNA yields and vice versa.  Eluent volumes therefore ranged 
between 50µl (for FFPE samples) and 200µl (for cultured cells). 
Following the second wash step, spin columns were placed in a fresh, labelled 1.5ml microfuge tube.  
An appropriate volume of eluent was added and then incubated upright for 1 minute at room 
temperature followed by centrifugation at 6,000 × g for 1 minute.  The elution was repeated in the 
same or a fresh microfuge tube if an even larger overall DNA yield was required.  The spin column 
was then discarded and the microfuge tube containing eluted DNA stored at 4C (in Buffer AE or 1X 
TE) or -20C (in nuclease free water).  
2.3.3 DNA Quantification and Purity Assessment 
DNA was quantified and assessed for purity by UV-VIS Spectrophotometry using the NanoDrop
®
 
ND-1000 (ThermoScientific) instrument set-up for measurement of double-stranded DNA.   The 
instrument automatically calculates DNA concentration from small sample volumes (as little as 1µl) 
using a modified Beer-Lambert equation:  
         ⁄  
Where,   is DNA concentration in ng/μl;   is absorbance at 260nm,   is the wavelength-dependent 
absorbance coefficient (50ng·cm/µl for double-stranded DNA) and   is the path length in cm.  The 
ratios of absorbance at 260nm vs. 280nm (A260/A280) and 260nm vs. 230nm (A260/A230) were used to 
assess DNA purity.  Generally, A260/A280values between 1.80 and 2.00 indicated the absence of 
protein contamination, while A260/A230 values greater than 1.90 indicated the absence of 
contamination by other organic compounds. 
Briefly, the optical surfaces of the Nanodrop
®
 instrument were cleaned with lint-free wipes and 1 - 2µl 
of nuclease-free water loaded to initialize the instrument.  Similar volumes of DNA eluent and 
samples were then loaded to serve as a blank and for measurement respectively, cleaning the 
optical surfaces between samples.  DNA samples that were of low concentration were vacuum-
centrifuged to the desired concentration, while those samples with low A260/A230 were re-precipitated 
for purification (Section 2.3.4) 
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2.3.4 DNA Precipitation 
Sodium Acetate-Ethanol precipitation was used to purify DNA samples that had low A260/A230 values 
indicative of contamination with organic substances such as guanidine or ethanol that could 
potentially inhibit DNA labelling reactions.  Precipitation was also used to clean labelled BAC DNA 
for FISH experiments (Section 2.3.8.4). 
The DNA sample was placed in a 1.5ml microfuge tube and 3M sodium acetate (0.1 volumes) added, 
followed by absolute ethanol (2.5 volumes). The reaction was then mixed well by pipetting up and 
down and incubated at -80ºC for 30 minutes. The sample was then centrifuged at 12,000 × g for 30 
minutes at -4ºC. The supernatant was carefully removed leaving the DNA pellet intact and 70% 
ethanol (200μl) carefully added and then removed to wash the pellet (this step was omitted for BAC 
DNA).   The tube was then left open under a laminar flow hood to allow residual ethanol to evaporate 
completely at room temperature.  The precipitated DNA was then reconstituted with 50μl of 1X TE 
and its concentration and purity re-assessed as described (Section 2.3.3). 
2.3.5 Agarose Gel Electrophoresis 
Agarose gels used in this study were prepared in 1% concentration by dissolving agarose (1g) in 1X 
TAE (100ml) in a conical flask and heating until fully dissolved in a microwave oven.  The solution 
was t allowed to cool for about 3 minutes before addition of Ethidium bromide (5μl), pouring into the 
gel-casting tray with combs in position and then left to set as it cools. The comb was subsequently 
removed and the gel submerged in an electrophoresis tank containing 1X TAE as running buffer. 
Each DNA sample (5µl) was mixed with 6x loading buffer (1µl) and then loaded into a single noted 
well of the agarose gel.  Standard 1kB DNA ladder (5µl) was also loaded into a separate well for 
DNA fragment size determination.  Electrophoresis was carried out at 90V for 90 minutes and bands 
were visualized using a UV trans-illuminator and photographed.     
2.3.6 Array-based Comparative Genomic Hybridisation 
Oligonucleotide Array-based Comparative Genomic Hybridisation was used to detect copy number 
aberrations in tumour DNA.  Briefly, tumour and matched reference gDNA were labelled with 
different fluorescent dyes and co-hybridised to an array of 180,000 oligonucleotide probes covering 
the entire genome at high resolution.  The array was then washed and scanned, the differential 
intensity of the fluorescent dyes at each probe serving as a surrogate for the ratio of copy numbers 
of probe sequence in the tumour vs. reference genome.  The main steps of this method are shown 
schematically in Figure 2.1.  
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Figure 2.1:  Schematic Representation of Oligonucleotide Microarray-based Genomic Hybridisation 
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2.3.6.1 DNA Labelling (Random Priming with Exo-Klenow) 
Whole genomic DNA obtained from fresh frozen tissue, cultured cells or commercially available 
reference DNA was labelled by random priming with Exo-Klenow (enzymatic method) carried out 
according to manufacturers’ instructions.  Briefly, genomic DNA is digested at specific restriction 
sites, denatured and then using random primers, a DNA polymerase (Exo-Klenow fragment of E. coli 
DNA polymerase) is used to amplify the DNA while fluorophore-labelled dUTP nucleotides are 
simultaneously incorporated at the 3’ ends of newly-synthesized DNA fragments.  Any 
unincorporated fluorescent nucleotides are then removed from the system in order to minimise 
background fluorescent signal in array experiments.  
For a typical aCGH experiment, 0.5 - 1µg of each DNA sample was labelled.  Samples of tumour 
DNA were matched with equivalent amounts of normal DNA (either extracted from normal tissue 
from the same patient or commercial reference DNA) and labelled simultaneously in separate 
reactions.  Prior to labelling, the concentration and purity of DNA samples were determined as 
described in Section 2.3.3. 
Restriction Digestion 
For each 4 × 180K microarray, 8 DNA samples (4 tumour and 4 matched normal) of volumes 
equivalent to the starting amount of DNA were placed in clean 0.2ml thin-walled PCR tubes and 
made up to 20.2µl with nuclease free water, where necessary.   
A Digestion Master Mix, sufficient for 10 reactions was then made up as outlined on Table 2.6 below.  
Table 2.6:  Restriction Digestion Master Mix Components 
 Per tube (µl) *For 10 tubes (µl) 
Nuclease-free Water 2.0 20 
10X buffer 2.6 26 
Acetylated BSA (10µg/µl) 0.2 2 
Alu-1 (10µg/µl) 0.5 5 
Rsa-1 (10µg/µl) 0.5 5 
Total 5.8 58 
 
To each reaction tube, Digestion Master Mix (5.8µl) was then added, making the volume up to 26µl 
and the tubes transferred to a thermocycler with a heated lid, programmed for incubation at 37ºC for 
2 hours for the digestion reaction, followed by 65ºC for 20 minutes to kill the enzymes.  The reaction 
tubes were then held at 4ºC until ready for labelling.   
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Enzymatic Labelling Reaction  
Random Primers (5µl) were added to each reaction tube (containing restriction digested DNA), 
making the volume up to 31µl and incubated at 95ºC for 3 minutes, then held at 4ºC for at least 5 
minutes.   
During this incubation step, Labelling Master Mixes were prepared using Cy3-dUTP and Cy5-dUTP 
in separate tubes, on ice and in dim conditions, as outlined on Table 2.7 below.  Generally, tumour 
DNA was labelled with Cy5 while normal DNA was labelled with Cy3.  However, fluorophores may be 
swapped provided tumour and normal DNA are differentially labelled and the fluorophore used for 
each is noted. 
Table 2.7:  Exo-Klenow Labelling Master Mix Components 
 Per tube (µl) *For 5 tubes (µl) 
5X buffer 10.0 50 
10X dNTP 5.0 25 
Cy3-dUTP or Cy5-dUTP 3.0 15 
Exo-klenow fragment 1.0 5 
Total 19.0 95 
The reaction tubes were briefly centrifuged and the appropriate labelling master mix (19µl) was 
added to each tube to make a total volume of 50µl and mixed well by pipetting up and down.  The 
tubes were then transferred to the thermocycler where they were incubated at 37ºC for 2 hours for 
the labelling reaction then 65ºC for 10 minutes to inactivate the enzyme.  Samples were then held at 
4ºC until clean up. 
Clean-up of Exo-Klenow Labelled DNA 
Unincorporated fluorophore-labelled nucleotides and other reaction components were removed using 
Amicon
®
 30kDa filters, which trap the labelled genomic DNA fragments on the basis of their large 
size.  Each labelling reaction was mixed with 1X TE (430µl) and transferred to a labelled Amicon
®
 
filter placed in a collection tube and centrifuged at 14, 000 x g for 10 minutes at room temperature.  
The flow-through was removed and discarded and further 1X TE (480µl) was added to each filter 
followed by a second centrifugation at 14, 000 x g for 10 minutes.  The flow-through and collection 
tube were discarded and the filters inverted into fresh collection tubes.    
The inverted filters were centrifuged at 1, 000 x g for 1 minute at room temperature to yield a flow-
through volume of approximately 21µl clean labelled DNA.  When necessary, sample volumes were 
adjusted to 21µl by addition of 1X TE or vacuum centrifugation).  
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2.3.6.2 DNA Labelling (Universal Linkage System) 
The Universal Linkage System (ULS) is a chemical reaction, which directly incorporates platinum-
conjugated fluorescent dyes into DNA molecules.  Optimised for use in FFPE DNA, it was used to 
label tumour and matched normal DNA for array CGH.  Starting amounts of tumour DNA ranged 
between 0.5 and 1µg (usually 0.8µg), depending on the amount of DNA available and this was 
matched with equivalent amounts of normal DNA (as with Exo-Klenow labelling).  
Heat Fragmentation 
All DNA samples were visualised on agarose gels (Section 2.3.5) to determine average fragment 
size.  For samples with relatively large DNA fragments e.g. commercial reference DNA or some 
FFPE DNA samples, heat fragmentation was required prior to labelling.   
For a single 4 × 180K array experiment, the corresponding volumes of eight DNA samples were 
placed in thin-walled 0.2ml PCR tubes and made up to 8µl with nuclease-free water. Fragmentation 
was then carried out at 95ºC and the duration of incubation depended on the average DNA fragment 
size, as summarised on Table 2.8 below.  Incubation was carried out on a thermocycler with a 
heated lid and the reaction tubes were subsequently held at 4ºC until ready for labelling.  
Table 2.8:  Duration for Heat Fragmentation by DNA source and Fragment size 
 
 
ULS Labelling Reaction 
During the heat fragmentation step, ULS-Cy3 and ULS-Cy5 dye master mixes were prepared on ice 
and in dim conditions.  The volume of dye used per reaction depended on the amount of DNA in the 
reaction.  For most experiments, about 1µl dye and 0.8µg of DNA, corresponding to a ratio of 
1.25µl/µg was used, as shown on Table 2.9 below. 
Table 2.9:  ULS Labelling Master Mix Components 
Component Per tube (µl) *For 4 tubes (µl) 
10X Labelling solution 1.0 4.5 
ULS-Cy3 or ULS-Cy5 1.0* 4.5 
Total 2.0 9.0 
* - the volume of dye used depends on the amount of DNA used.  A typical ratio was 1µl dye for 
0.8µg DNA (1.25:1µl/µg).  When smaller volumes of dye were required, the total volume per 
reaction was made up with nuclease- free water. 
Average DNA 
Fragment Size (Kb) 
DNA source 
Incubation Time 
(at 95ºC) 
>10.0  Commercial DNA 
Fresh frozen tissue 
10 minutes 
7.0 – 10.0 Some FFPE tissues 5 minutes 
<7.0  Most FFPE tissues No fragmentation 
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Following a pulse centrifugation to drive the contents of the reaction tube to its bottom, appropriate 
dye master mix (2µl) was added to each tube to make the reaction volume up to 10µl, and mixed 
well by pipetting up and down. The tubes were then placed in a thermocycler with a heated lid 
programmed for incubation at 85ºC for 30 minutes for the labelling reaction and then held at 4ºC until 
ready for clean-up. 
ULS Clean-up  
Unreacted dye can lead to excess background fluorescence and this was removed using 
KREApure
®
 filters (Agilent).  Towards the end of the labelling reaction, one KREApure
®
 filter per 
reaction was briefly vortexed, placed in a collection tube and centrifuged at 17, 000 × g for 1 minute 
at room temperature.  The flow-through and lid were then discarded and 300µl of nuclease-free 
water applied to each filter.  A further centrifugation step at 17, 000 × g for 1 minute was then carried 
out and the collection tubes and flow-through discarded.  The filters were then transferred to clean 
labelled 1.5ml microfuge tubes. 
As soon as labelling was completed, the reaction tubes were pulse centrifuged to drive contents to 
the bottom and 10µl of nuclease-free water added, making the volume up to 20µl in each.  Each total 
reaction was then transferred to a KREApure
®
 filter placed in the corresponding labelled microfuge 
tube and centrifuged at 17, 000 × g for 1 minute at room temperature.  The filters were then 
discarded and clean ULS-labelled DNA samples collected in the microfuge tube were stored at 4ºC 
in the dark until required. 
2.3.6.3 Measurement of DNA Labelling Efficiency 
UV-VIS Spectrophotometry was used to determine the fluorescent activity of labelled DNA using the 
NanoDrop
® 
ND-1000.  The procedure used was similar to that described for DNA quantification (in 
Section 2.3.3) and the instrument simultaneously calculates the concentration of DNA, Cy3- and 
Cy5-dyes based on absorbance measurements at wavelengths 260, 550 and 650nm, respectively.  
The absorbance coefficient was set for double-stranded DNA at 50ng·cm/µl and appropriate blank 
solutions were used (1X TE and 1X labelling solution for Exo-Klenow and ULS labelled samples, 
respectively).  From each labelled DNA sample, 1.5µl was taken for spectrophotometry. 
Exo-klenow labelling reactions involve amplification of the DNA while ULS labelling reactions do not.  
The two methods therefore had different parameters for evaluating the efficiency of labelling.   For 
Exo-Klenow labelled samples, the final DNA yield and the amount of dye per microgram of DNA 
(Specific Activity) were used.  ULS labelling efficiency was assessed using the number of molecules 
of dye per molecule of DNA (Degree of labelling) expressed as a percentage.  The calculation 
methods for these parameters are shown below with optimal values summarised in Table 2.10. 
                             ⁄    
                           ⁄
                       ⁄  
 
                                  ⁄               
                        
                              ⁄  
                        ⁄
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Table 2.10:  Expected Values for DNA labelling efficiency parameters  
 Exo-Klenow ULS 
 Cy3 Cy5 Cy3 Cy5 
Dye Specific Activity (pmol/µg) 25 - 55 20 - 40 - - 
Degree of Labelling (%) - - 1.75 - 3.50 0.75 – 2.50 
DNA Yield (µg) 5 - 10 Same as input amount* 
Values are based on starting amounts of DNA between 0.5 and 1.0µg 
* - ULS labelling reactions do not amplify input DNA 
 
If labelling was optimal, tumour and matched normal DNA samples (19.5µl each for enzymatic 
labelling and 18.5µl each for ULS labelling) were then combined.  For ULS-labelled samples, the 
combined volume was reduced from 37µl to 22µl by vacuum centrifugation in the dark and then 
prepared for hybridisation.  Enzymatic labelled samples (combined volume of 39µl) were stored in 
the dark at -20ºC until ready for hybridisation.   
2.3.6.4 Pre-hybridisation Blocking 
Repetitive DNA sequences were blocked with COT-1 DNA prior to hybridisation using the Agilent 
Oligo aCGH Hybridisation Kit, according to manufacturers’ instructions.   
Enzymatic-Labelled Samples 
Combined matched samples were transferred to pre-labelled 0.2ml thin-walled PCR tubes.   A 
hybridisation master mix was prepared as outlined on Table 2.11.   71µl of the hybridisation master 
mix was added to each sample tube making the total volume up to 110µl and mixed well by pipetting 
up and down.  They were then pulse centrifuged and transferred to a thermocycler programmed for 
incubation at 95ºC for 3 minutes, followed by 37ºC for 30 minutes and then held at 37ºC until ready 
for hybridisation assembly. 
Table 2.11:  Hybridisation Master Mix Components for Enzymatic-Labelled Samples 
 Per tube (µl) *For 5 tubes (µl) 
Human COT-1 DNA 5 25 
10X Blocking Agent 11 55 
2X RPM Buffer 55 275 
Total 71 355 
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ULS-labelled Samples 
Pre-hybridisation blocking reaction was made up by adding 61µl of a hybridisation master mix 
(prepared as summarised in Table 2.12) to each sample tube, making the volume up to 83µl.  The 
reaction was mixed well by pipetting up and down and pulse centrifuged. It was then incubated on a 
thermocycler programmed as for enzymatic-labelled samples.  The tubes were then pulse 
centrifuged and 27µl of CGHblock
®
 (pre-equilibrated to room temperature) was added, to bring the 
total reaction volume to 110µl and mixed well by pipetting up and down. 
Table 2.12:  Hybridisation Master Mix Components for ULS-Labelled Samples 
 Per tube (µl) *For 5 tubes (µl) 
Human COT-1 DNA 5 25 
100X Blocking Agent 11 55 
2X RPM Buffer 55 275 
Total 61 355 
2.3.6.5 Hybridisation Assembly 
One clean 4X microarray gasket slide was loaded into the SureHyb
®
 chamber base with the gasket 
label facing up and aligned with the rectangular section of the chamber base.  Noting the position of 
the gaskets relative to the barcode, 100µl of each sample (Exo-Klenow or ULS-labelled) was slowly 
dispensed into a gasket in a ‘drag and dispense’ manner.   
A microarray slide was then carefully placed, active “Agilent- labelled” side down, onto the gasket 
slide and the SureHyb
®
 chamber cover put in place over the sandwiched slides.  The clamp was 
then slid gently onto both pieces and tightened to complete the assembly.  The assembly was 
rotated vertically to wet the microarray slide and ensure that trapped air bubbles are freely mobile.    
The chamber assembly was then placed in the rotator rack of the microarray hybridisation oven set 
to 65ºC and set to rotate at 20 rpm for exactly 24 hours (for fresh frozen samples) or 40 hours (for 
FFPE samples). 
2.3.6.6 Post-Hybridisation Washing and Scanning 
Two wash conditions were set up before the hybridisation assembly was removed from the 
incubator.  The first wash setup consisted of a glass dish with slide rack filled with aCGH Wash 
Buffer 1 and placed on a magnetic stirrer with a rotating stir bar in place.  The second wash setup 
involved filling a glass dish with aCGH Wash Buffer 2 pre-warmed to 37
o
C and maintained on a 
heated magnetic stirrer with a rotating stir bar in place. 
The SureHyb
®
 chamber assembly was taken out of the Hybridisation Oven at the end of 24 hours 
and assessed to ensure that all bubbles were still mobile.  It was then laid on a horizontal surface 
and the clamp unscrewed and gently slid off.  The chamber cover was then carefully lifted off the 
slide sandwich, which is removed intact from the chamber and transferred in the same plane 
(horizontal with microarray slide on top) to a third glass dish containing Wash Buffer 1. 
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Keeping the sandwich submerged in Wash Buffer 1, the slides were then gently pried apart with 
plastic forceps and the gasket slide allowed to drop to the bottom of the glass dish.  The microarray 
slide was then immediately transferred to the slide rack in the first wash setup and washed for 5 
minutes at room temperature.  Quickly, so that the slide is not allowed to dry, the slide rack was then 
transferred to the second wash setup and the slide washed for exactly 1 minute at 37ºC.  The slide 
rack was then removed slowly to minimize the formation of droplets on the slide, which is then 
placed in a slide holder for immediate scanning. 
Slides were scanned using the Agilent Surescan
® 
microarray scanner with control software v8.3 
(Agilent) configured as recommended by manufacturers.  The scanned images were saved in 
Tagged Image File Format (.TIFF), which were examined for hybridisation artefacts or microarray 
damage.   
2.3.6.7 Microarray Data Processing 
Array Quality Assessment and Feature Extraction 
Scanned images were analysed using Feature Extraction software v10.7.3 (Agilent).  The software 
normalises the fluorescent intensity of both dyes at each probe and calculates their ratio, expressed 
on a logarithmic scale (probe log2-ratio).   Log2-ratios for all 180,000 probes were then exported as 
Feature Extraction files in Tab Delimited Text (.txt) format. 
The feature extraction software generates in addition, a Quality Control (QC) report that includes 
statistical metrics used to assess the reproducibility and reliability of results in each microarray 
experiment.   Average background noise and signal-to-noise ratio for each dye were determined by 
calculating the mean green and red signal intensities at all genomic probes compared to non-
hybridising control probes.  A Derivative Log Ratio Spread (DLRS), an important parameter for 
determining reliability of array CGH was also calculated by measuring variation in the difference 
between log2 ratios of consecutive oligonucleotide probes.  Threshold values used for acceptance of 
array CGH data as valid based on these metrics are summarised in Table 2.13 below. 
Table 2.13:  QC metric thresholds for Array CGH Experiments by Labelling Method and DNA source 
Threshold values are based on manufacturers’ recommendations 
 
  
 Exo-Klenow Labelling ULS Labelling 
 Fresh Tissue/Cells Fresh Tissue/Cells FFPE Tissue 
Signal Intensity 
(Red or Green) 
>90 >90 >90 
Signal to Noise Ratio  
(Red or green) 
>30 >20 >20 
Derivative Log Ratio Spread  <0.3 <0.3 <0.4 
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Aberration Detection 
For individual arrays, genomic copy number aberrations were identified using the FASST2 (Fast 
Adaptive States Segmentation Technique 2) algorithm in Nexus Copy Number Software v6.1 
(Biodiscovery).  The algorithm uses a Hidden Markov Model (HMM) - based approach that does not 
aim to estimate the copy number state at each probe but uses many states to cover more 
possibilities, such as mosaic events. These state values are then used to make calls based on a 
specified log2 ratio threshold.   
Log2 ratio threshold values of +0.25 and -0.3 were used to identify single copy number gains and 
losses respectively, and threshold values for gains and losses of two or more copies were set at 
+1.14 and -1.1 respectively.  Significance threshold p-value was set at a minimum of 5.0 × 10
-6
, 
requiring at least three contiguous probes for aberration calls.  All threshold values were based on 
analysis software manufacturers’ recommendations.  Aberrations were presented on graphical 
genomic plots called ideograms, which could be viewed at whole genome, chromosome and single 
gene/exon levels to permit easy visual analysis (Figure 2.1). 
 
2.3.7 Chromosome Spread Preparation  
2.3.7.1 Chromosome harvesting 
Cells were cultured in flasks until they were 60 – 80% confluent.  Colcemid 0.05µg/ml (around 7 
drops added to 5ml of media) was then added using a 1ml syringe and the cells incubated for a 
further 2 - 4 hours.  The media was then transferred to a 15ml universal tube (harvesting tube) and 
pre-warmed trypsin-EDTA at 37ºC used to dissociate the cells.  The cell suspension was then added 
to the same harvesting tube and centrifuged at 1500rpm for 5 minutes at room temperature.   
The supernatant was removed, save 0.5ml in which the pellet was gently re-suspended.  Hypotonic 
(0.075M) potassium chloride (approximately 5ml) was then added drop-wise while gently agitating 
the cell suspension and the harvesting tube transferred to the 37ºC/5%CO2 incubator for 30-45 
minutes to allow the cells to swell.  They were then centrifuged at 1000rpm for 10 minutes and the 
supernatant removed leaving approximately 0.5ml in which the pellet was gently re-suspended.  
Freshly prepared methanol – acetic acid fixative solution (approximately 2ml) was then added in 
drops while gently agitating the cells.  This was followed by a repeat of the centrifugation, re-
suspension and fixative steps.  The harvesting tubes were then stored upright at -20ºC until ready for 
slide preparation. 
2.3.7.2 Slide Preparation 
Metaphase chromosome spreads were prepared on clean glass slides using the method originally 
described by Hsu and Pomerat (Hsu and Pomerat 1953).  Briefly, cells that had been incubated in 
hypotonic solution and then fixed were dropped onto slides from a variable height and where 
necessary, a few drops of fixative solution added to improve chromosome spreading.  Slides were 
then left to dry in air and stored for up to one week at room temperature or at -20ºC for longer. 
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2.3.8 Giemsa Banding 
Giemsa banding (G-banding) was carried out on metaphase chromosome spreads prepared as 
described in Section 2.3.7.2 and aged by air-drying for one week.   Banding was done in humid 
condition, on a slide rack over a sink half-filled with warm water.  Slides were first covered with 
banding trypsin and incubated for at least 90 seconds (depending on metaphase spread quality) 
after which they were rinsed off with Sorenson’s buffer.  They were then stained with Giemsa 
solution for at least 30 seconds, rinsed off with Gurr’s buffer, blotted with filter paper and allowed to 
air-dry.   Slides were then analysed under an Olympus
®
 BH-2 light microscope attached to a 
software-controlled Cohu
®
 high performance Charge-Coupled Device camera (Applied Imaging
®
). 
Duration of trypsin treatment and Giemsa staining varied depending on metaphase spread quality 
and experiments typically involved multiple attempts using increasing durations, until staining was 
optimised and clear banding patterns could be seen.   Images were captured and the total number of 
chromosomes per metaphase was recorded from a minimum of 30 metaphase spreads.  
Chromosomal G-banding pattern analysis was carried out by experienced Cytogeneticist, Dr Karen 
Sisley. 
2.3.9 Fluorescence in situ Hybridisation 
Fluorescence in situ hybridisation (FISH) was used to visually confirm copy number aberrations and 
obtain ploidy information, using interphase nuclei and/or metaphase chromosome spreads harvested 
from cultured STS cells (as described in Section 2.3.7) or on FFPE tissue sections.  Where available, 
commercial probes were used for FISH.  Otherwise, target-specific DNA fragments cloned into 
Bacterial Artificial Chromosome (BAC clones) vectors were used to prepare customised probes.   
2.3.9.1 Preparation of Bacterial Artificial Chromosome DNA 
BAC clones were supplied in transformed E.coli, which was first cultured to amplify the cloned 
human DNA sequences followed by bacterial lysis and purification.  E.coli glycerol stocks were 
streaked on selective LB agar plates containing chloramphenicol (12.5µg/ml) and then incubated 
overnight at 37°C.  Single colonies were then transferred into 15ml polypropylene tubes containing 
2ml selective LB broth (containing 12.5µg/ml with chloramphenicol) and incubated overnight at 37ºC 
on a shaker at 300rpm.   
The now-turbid culture broth was then transferred to a fixed-angle centrifuge and spun at 3000rpm 
for 10 minutes at room temperature.  The supernatants were carefully removed and each pellet re-
suspended in 0.3ml of Solution P1.   An equivalent volume of Solution P2 was then added to each 
tube, gently shaken to mix its contents and allowed to sit upright for 5 minutes at room temperature, 
during which the sample changed from turbid to translucent.  Solution P3 (0.3ml) was then added 
slowly, while gently agitating the tube allowing a white precipitate of proteins and bacterial DNA to 
form.  The tubes were again placed on ice for 5 minutes and subsequently centrifuged at 10,000rpm 
for 10 minutes at 4ºC on the fixed angle centrifuge. 
Careful to avoid the white precipitate at the bottom, the supernatant that contained only human DNA 
sequences was then transferred to a 2ml microfuge tube containing 800µl of ice-cold isopropanol.  
The mixture was inverted a few times to mix and then incubated on ice for 5 minutes, followed by 
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centrifugation at 16,000 × g for 15 minutes at 4ºC.  The supernatant was removed and 500µl of 70% 
ethanol was added, the tube quickly inverted a few times to wash the pellet and then centrifuged at 
16,000 × g for 5 minutes at 4ºC.  The ethanol was then removed and the tube left open to allow the 
pellet to air-dry completely before it was re-suspended in 1X TE buffer (40µl).  DNA yield and sample 
purity was checked using the Nanodrop as described in Section 2.3.3. 
2.3.9.2 BAC DNA Labelling (Nick Translation) 
Nick translation as described by Rigby et al, was used to label BAC DNA (Rigby, Dieckmann et al. 
1977).   Briefly, DNAse 1 was used to form single-strand breaks (nicks) in the BAC DNA, which were 
used as starting points by E. coli DNA polymerase (holoenzyme) for degradation by 5’ – 3’ 
exonuclease activity followed by replacement of the nucleotides by its DNA polymerase activity, 
simultaneously incorporating fluorophore-labelled nucleotides (that were supplied in high 
concentration) every 20-25 nucleotides. 
A nick translation reaction was prepared in a thin-walled 0.2ml PCR tube on ice.  Reaction 
components were added in the order outlined on Table 2.14 and mixed well by pipetting up and 
down. The reaction tube was then transferred to a thermocycler programmed for incubation at 15°C 
for 8 hours and then at 70°C for 10 minutes to stop to the reaction, after which the tubes were held at 
4°C.   
Table 2.14:  Components of Nick Translation Reaction 
Component Volume (µl) 
Nuclease-free water 17.5     
1µg BAC DNA   
0.2mM Labelled dUTP 2.5 
0.1mM dTTP 5 
0.1mM dNTP mix 10 
10X Nick Translation Buffer 5 
Nick Translation Enzyme 10 
Total 50 
Agarose gel electrophoresis (as described in Section 2.3.4) was used to visualise the labelled DNA 
and carried out using 5µl of the sample.  The remainder was stored in 15µl aliquots at -20ºC in the 
dark.  
2.3.9.3 Pre-treatment of FISH Slides 
FFPE tissue Sections 
Tissue sections (5µm thick) on glass slides were incubated on a heat block at 58ºC for 3 minutes 
and then de-paraffinised by two consecutive incubations in xylene for 5 minutes each under a fume 
hood.  This was followed by dehydration in absolute ethanol for 5 minutes at room temperature, after 
which the slides were transferred to a coplin jar containing 0.2N HCl (50ml) and incubated for 
between 20 and 23 minutes.  They were subsequently washed for 2 minutes in distilled de-ionised 
water (ddH2O) on a shaker with gentle agitation.    
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The slides were then transferred to a coplin jar containing Zymed pre-treatment solution (40-50ml) 
held at 95ºC in a water-bath and incubated for 2 – 3 hours, after which they were washed twice in 
ddH2O for 3 minutes each at room temperature with gentle agitation.  Enzyme reagent was pre-
warmed to room temperature and 100µl applied to 22 × 50mm coverslips, which were used to cover 
each tissue section.  The sections were then placed in a humid chamber and incubated at room 
temperature for 2 – 3 hours, refreshing the enzyme after every 60 minutes.  The coverslips were 
then removed and the slides washed thrice in ddH2O for 2 minutes each at room temperature with 
gentle agitation.  They were then incubated through a series of 70%, 95% and 100% ethanol for 3 
minutes each to dehydrate, and allowed to dry completed in room air. 
Fixed Cells and Metaphase Chromosome Spreads 
Slides were treated with RNAse A (125µl) loaded onto 22 × 50mm coverslips, and incubated in a 
humid chamber at 37°C for 1 hour.  They were then washed thrice in 2X SSC for 5 minutes each 
with gentle agitation.  Next, the slides were immersed in a coplin jar containing pre-warmed Pepsin-
HCl solution held at 37°C on a water bath and incubated for exactly 10 minutes.  This was followed 
by two washes in PBS for 5 minutes each and a further wash in PBS-MgCl2 for 5 minutes at room 
temperature with gentle agitation. The slides were then incubated in 37% formaldehyde solution to 
fix for 10 minutes at room temperature and washed again in PBS for 5 minutes with gentle agitation.  
They were then dehydrated by immersion in a series of 70%, 95% and 100% ethanol for 3 minutes 
each and air-dried. 
2.3.9.4 Preparation and Application of FISH Probes  
During the pre-treatment of target slides, labelled BAC probe was precipitated using the sodium 
acetate – ethanol precipitation method described in Section 2.3.4.  COT1 DNA (1µg) and normal 
human genomic DNA (2µg) were added to each 100ng of BAC probe DNA as carriers to facilitate 
precipitation. The precipitated DNA pellet was re-suspended in LSI/WCP hybridisation buffer (7µl per 
slide).  Where commercial probes were to be simultaneously applied to the target sample, an 
appropriate volume (based on probe efficiency shown on Table 2.2) of commercial probe was added 
to the re-suspended BAC probe.  This probe master mix volume was then made up to 10µl per slide 
using nuclease-free water.  Similarly, for samples where a combination of commercial probes were 
to be applied, the appropriate volumes of each probe were added to 7µl hybridisation buffer per slide, 
and the mixture made up to 10µl per slide with nuclease-free water.  The LSI/WCP hybridisation 
buffer was used, except in cases where both probes were centromeric (CEP probes), in which the 
higher stringency CEP hybridisation buffer was used to prevent non-specific hybridisation.  
Probe DNA was denatured by placing the master mix on a heat block at 80°C for 10 minutes.  It was 
then pulse centrifuged and 10µl was loaded onto individual 22 × 22mm coverslips over which each 
pre-treated target slide was firmly placed and sealed with vulcanising rubber solution.  The slides 
were then placed on the heat block at 80ºC for 2 minutes to denature target DNA, after which they 
were transferred to a dark, humid chamber and incubated at 37ºC for 16 -18 hours for hybridisation.  
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2.3.9.5 Post-Hybridisation Washes and Counterstaining 
Post-hybridisation washing and subsequent steps were carried out under dim conditions.  Coverslips 
were removed using tweezers and the slides transferred to a coplin jar filled with SSCT-1 at 73ºC on 
a water bath where they were incubated for exactly 2 minutes.  They were then transferred to SSCT-
2 for a 1-minute wash at room temperature with gentle agitation. This was followed by dehydration 
through a series of 70%, 95% and 100% ethanol for 2 minutes each and drying in air. 
DAPI counterstain solution was then placed in two 10µl drops on a 22 × 50mm coverslip over which 
each slide was firmly placed facedown and sealed with nail varnish.  Slides were then stored at 4ºC 
for at least 2 hours to allow counterstaining before analysis on a fluorescent microscope.  FISH 
probe signals were scored from 100-200 non-overlapping intact nuclei or metaphase spreads in each 
case and images were captured using Cytovision
®
 software.   
2.3.10 Immunochemistry  
Cultured cells fixed on glass slides were used for immunocytochemistry while FFPE sections (4µm-
thickness) were used for immunohistochemistry by the modified Avidin-Biotin-Peroxidase Complex 
(ABC) method described by Hsu et al (Hsu, Raine et al. 1981).  Briefly, samples were pre-treated as 
required to expose relevant epitopes and block non-specific antibody binding.  They were then 
incubated with a specific primary antibody, washed and then a biotin-conjugated secondary antibody, 
which binds to the FC portion of any bound primary antibody, is added.  Samples are washed again 
and bound secondary antibody forms complexes with added avidin molecules linked to an enzyme 
reporter system that leads to a colorimetric reaction that is used to detect the presence of the target 
antigen in the sample.  Negative controls slides in which samples were incubated with either 
antibody diluent or immunoglobulin fraction in place of primary antibody were included in every 
experiment and where available, positive control samples were also included. 
2.3.10.1 Slide Preparation for Immunocytochemistry 
Glass slides were cleaned by immersion in methanol for 10 minutes at room temperature.  They 
were then left to dry under a laminar flow hood and arranged in a single layer in a sterile 20mm petri 
dish. Primary sarcoma cells cultured in flasks until they were 60 – 80% confluent were trypsinised as 
described in Section 2.3.1 and counted.  Approximately 20,000 cells, re-suspended in 0.5ml of 
culture media were then transferred to each slide.  The petri dish was placed in the 37C/5%CO2 
incubator for 4 hours to allow the cells to attach to slides and then a further 10ml of culture media 
was added to the petri dish and incubated overnight. 
The media was then removed and the slides washed twice with sterile PBS.  The slides were then 
placed on a rack and incubated in an ice-cold fixative solution made up of methanol and acetone in a 
1:1 mixture for 10 minutes.  The slides were then dried under the laminar flow hood and used for 
immunocytochemistry or stored at -20ºC until needed. 
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2.3.10.2 Tissue Preparation and Epitope Retrieval for Immunohistochemistry 
Tissue sections were de-paraffinised by two consecutive 10-minute incubations in xylene and then 
dehydrated by 5-minute serial incubations in 70%, 95% and 100% Ethanol.  They were then 
incubated in 1% H2O2 for 30 minutes at 37ºC to quench peroxidase activity and subsequently 
washed in PBS for 5 minutes.  Heat-induced epitope retrieval (HIER) was carried out by immersing 
the tissue sections in an appropriate buffer (Table 2.4) then heating in a microwave set at 900W for 8 
minutes.  They were allowed to cool in the same buffer for at least 15 minutes and then washed in 
PBS for 5 minutes.   
2.3.10.3 Blocking and Primary Antibody Incubation 
Relevant areas of tissue sections and fixed cells were outlined on the slides using a wax pen and 
washed for 5 minutes in PBS.   Appropriate 10%blocking serum (Table 2.4) was then applied and 
incubated for one hour at room temperature.  The blocking serum was then tipped off and primary 
antibody (diluted in 2% blocking serum) was applied to test and positive control slides.  To negative 
control slides, either 2% blocking serum (without antibody) or relevant immunoglobulin fraction (also 
diluted in 2% blocking serum) was applied.  Slides were then incubated for 1-2 hours at room 
temperature or overnight at 4ºC. 
2.3.10.4 Secondary Antibody Incubation and Immunoreactivity 
Slides were washed twice in PBS for 5 minutes each and the appropriate biotinylated secondary 
antibody (also diluted in 2% blocking serum) was applied to all slides and incubated for 30 minutes at 
room temperature.  ABC reagent was prepared immediately and allowed to stand during secondary 
antibody incubation.  The slides were then washed twice in PBS for 5 minutes each and ABC 
reagent applied and incubated for 30 minutes at room temperature.  This was followed by two 5-
minute washes in PBS after which freshly-prepared peroxidase substrate solution (DAB) was applied 
and incubated at room temperature until the desired brown stain intensity developed (up to 10 
minutes).   
2.3.10.5 Counterstaining and Mounting 
The slides were rinsed in tap water and counterstained for 60 seconds in Gill’s haematoxylin then 
washed in running tap water.  Slides were transferred to Scott’s water substitute for 10 seconds and 
washed further in running tap water until the water was clear.   
The sections were then dehydrated by serial 3-minute incubations in 70%, 95% and 100% ethanol 
and de-waxed by two consecutive incubations in xylene for 3 minutes each under a fume hood.  
While still wet with xylene, the sections were then covered with 22 × 40mm coverslips using DePex 
and allowed to dry.  Slides were then examined using a light microscope at the appropriate 
magnification. 
2.3.11 Cell Proliferation Assay 
The MTT ((4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to assess 
proliferation in cultured cells treated with the Trio RhoGEF inhibitor, ITX3.  It is based on the principle 
that only viable cells are able to metabolize tetrazolium salts to form blue formazan crystals.  Briefly, 
equal numbers of cells were cultured in 96-well plates in the presence of ITX3 or DMSO vehicle.  
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MTT was then added to the cultures and any formazan crystals formed were dissolved.  Compared 
with appropriate controls, the optical density of the resulting solution was used as a surrogate for the 
number of viable cells remaining in culture.  
Cells were seeded at a density of 2,000 – 10,000 cells in 100µl of media in each well of a 96-well 
plate and incubated in a 37
o
C/5%CO2 incubator for 4 hours to allow cells to settle.  The media in 
each well was then removed and replaced with culture media containing 1% DMSO (v/v) with or 
without incremental concentrations of ITX3 (50µM - 1mM) in triplicate.  The cells were then returned 
to the incubator and cultured for 7-10 days.  Exactly 100µl MTT (1mg/ml dissolved in PBS) was then 
added to each well and the culture plates were then returned to the incubator for up to 4 hours, 
monitoring the control wells (without ITX3) for the formation of blue formazan crystals.  The media in 
the wells was then removed completed by pipette aspiration and replaced with exactly 100µl DMSO.  
They were then incubated for at least 30 minutes in the dark with gentle agitation.  Optical density 
absorbance in each well was then measured at 570nm on a spectrophotometer.  The ratio of 
absorbance in the test wells to control wells was calculated as relative MTT activity.  Average MTT 
activity from five replicate wells was plotted against ITX concentration and statistical significance (p < 
0.05) judged by two-way ANOVA with Bonferroni post hoc correction, using GraphPad Prism
®
 
software v6.0.   
2.3.12 Micro-chemotaxis/Invasion Assay 
A 48-well micro-chemotaxis chamber was used to assess the effect of Trio RhoGEF inhibitor 
treatment on invasive and chemotactic activity of primary sarcoma cells.  A modification of the 
method described by Albini et al (Albini, Iwamoto et al. 1987) was used in which a porous 
polycarbonate membrane was coated with an artificial extracellular matrix composed of collagen, 
laminin and fibronectiin in equal concentration (Table 2.5) and foetal bovine serum used as chemo-
attractant. 
Briefly, cells were cultured in full culture media (RPMI 1640 supplemented with 20% serum) in 6-well 
plates until they were 60 – 80% confluent.  The media was then replaced with serum-free media 
(RPMI 1640 containing 0.1% Bovine Serum Albumin) and returned to the incubator.   After 4 hours, 
DMSO (1% v/v) with or without incremental concentrations of ITX3 was added to the media in test 
and control wells, respectively.  An additional control well did not have any DMSO or inhibitor added. 
The cells were then cultured for a further 2 hours before they were trypsinised, counted and re-
suspended in serum-free media containing the same DMSO/inhibitor concentration. 
During inhibitor pre-treatment, polycarbonate membranes were coated on their underside with 
artificial extracellular matrix (ECM) solution for 45 minutes then allowed to dry in a laminar flow hood.   
A minimum of 3 replicates of control and test wells were set up in each experiment.  Lower wells of 
the Boyden chamber were filled with 27-28µl full culture media and the coated membrane carefully 
placed over them.  The silicone gasket and upper chamber were then carefully placed over the 
membrane and assembly screws applied and tightened.   A 50µl volume of the cell suspension 
containing approximately 1 × 10
4 
cells was then added to noted wells of the upper chamber and the 
assembly placed in the 37°C/5%CO2 incubator for 16 – 24 hours.   
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The chamber was then disassembled and any cells on the top surface of the membrane gently 
removed by scraping over a plastic wiper.  The underside of the membrane was then washed for 5 
minutes in PBS and the cells fixed by washing in 100% methanol for 5 minutes.  Any cells remaining 
on the underside of the membrane were then stained with 4% Gill’s Haematoxylin for 5 minutes and 
excess stain removed by washing in dH2O for another 5 minutes.  The membrane was then mounted 
on a glass slide with DePex.   
Cell present on the underside of the membrane were photographed using a light microscope at × 
200 magnification. For each well, cells in 5 random fields were counted and averages taken over 
three replicate wells.  Using GraphPad Prism
®
 software v6.0, average cell counts were then plotted 
against inhibitor concentration and compared with controls, using the one-way ANOVA test with 
Bonferroni’s post hoc correction for statistical significance (when p < 0.05).    
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CHAPTER THREE 
RESULTS:  OPTIMISATION OF ARRAY CGH 
3  
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3.1 INTRODUCTION 
Array CGH involves co-hybridising fragments of test and reference genomic DNA that have been 
differentially labelled with fluorescent dyes to a set of mapped and annotated DNA sequences 
(probes) on a microarray.  By measuring the ratio of fluorescence at each probe, it is possible to 
detect copy number differences between the test (tumour) and reference (normal) DNA at that 
genomic location such that genome-wide copy number aberrations can be accurately mapped. 
Target probes may be cDNA sequences, Bacterial Artificial Chromosomes (BACs) or 
oligonucleotides and depending on the size, type and number of probes on the array, somatic copy 
number aberrations (SCNAs) can be detected at the level of single genes and even specific exons 
(Barrett, Scheffer et al. 2004). The highest resolution aCGH methods available are the 
oligonucleotide (60mers) arrays and with up to a million probes on an array, SCNAs may be detected 
with a resolution as high as 1-2 Kilobase pairs (kb).  Commercially available oligonucleotide CGH 
arrays have an added advantage of being customisable by user-friendly in silico design that can 
focus on specific areas of the genome at no additional cost (Tan, Lambros et al. 2007).  
In order to generate reproducible aCGH results, pure high molecular weight DNA (usually obtained 
from fresh frozen tissue, blood or cultured cells) has traditionally been used.  Availability of fresh 
tissue is however limited, particularly in rare tumours like STS and most tumour tissue available for 
research is formalin-fixed and paraffin-embedded (FFPE) in order to preserve the tissue structure for 
histology.  DNA isolated from such tissues is typically of low quality (low yield and highly fragmented) 
due to the degradative effects of formalin (Srinivasan, Sedmak et al. 2002) and studies comparing 
the aCGH performance of high and low quality DNA showed that fragment sizes < 200 base pairs 
(typical of FFPE DNA) produced noisy and irreproducible results (van Beers, Joosse et al. 2006, Mc 
Sherry, Mc Goldrick et al. 2007).  Another major limitation to the use of FFPE DNA for high-
resolution oligonucleotide aCGH is technical difficulty in labelling fragmented DNA. Traditional 
enzymatic methods for labelling DNA (Nick translation or Random priming) involve a fragmentation 
step with DNase or restriction digestion respectively, which in the case of FFPE DNA further 
fragments the DNA.  An alternative to enzymatic labelling is the Universal Linkage System (ULS), 
which directly labels the DNA by a chemical reaction that incorporates platinum-conjugated 
fluorophores into DNA without the need for fragmentation, making it suitable for low quality 
fragmented DNA such as that from FFPE tissue (Alers, Rochat et al. 1999).  
Recent efforts have been made to optimise the utility of archived FFPE tissues for array CGH after 
labelling by enzymatic (Hostetter, Kim et al. 2010) and ULS methods (Szponar, Yusenko et al. 2010, 
Braggio, McPhail et al. 2011, Chen, Liu et al. 2011, Oikawa, Yoshiura et al. 2011, Rossi, Klersy et al. 
2011).  Nevertheless, the use of FFPE DNA for aCGH is still regarded as technically challenging and 
limited to very small-scale studies, which have reported variable data quality.   Previous work using 
the lower resolution chromosome CGH identified common aberrations that were subsequently 
confirmed by FISH (Ul-Hassan, Sisley et al. 2009).   Optimisation of the ULS labelling protocol and 
subsequent high-resolution oligonucleotide array CGH analysis (Agilent
®
 180K platform) was thus 
done using archival FFPE leiomyosarcoma tissue and the results are presented in this chapter.   
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3.2 RESULTS 
3.2.1 Tumour Samples 
Twenty-two FFPE tumours diagnosed as LMS obtained from the Sheffield archive were analysed by 
aCGH.  Their ages (archival storage time) at the time of analysis ranged from 1 - 17 years, eight 
cases being over 10 years old  (Table 3.1).  Two cases, LMS 20 and 21 had been initially processed 
in a different Pathology laboratory.   Fresh frozen (FF) samples from three of the cases, LMS 8, 9 
and 10 were also analysed.  The quality of the DNA obtained from the FF samples and subsequent 
array CGH results were compared with those of the corresponding FFPE tumours.  FISH was used 
to verify some of the consistent copy number changes. 
 
Table 3.1:  Characteristics of Archival FFPE LMS cases included in this study.   
Case Anatomical Site 
Tumour Sampling 
Date 
Age of Sample at Analysis 
(Years) 
LMS 1 Bowel 2010 1 
LMS 2 Lower Limb 2011 1 
LMS 3 Lower Limb 2011 1 
LMS 4 Bladder 2011 1 
LMS 5 Stomach 2011 1 
LMS 6 Stomach 1994 17 
LMS 7 Lower Limb 1999 12 
LMS 8 Bladder 1998 13 
LMS 9
§
 Vagina 2011 1 
LMS 10
§
 Retroperitoneum 2011 1 
LMS 11
§
 Pelvis 2011 1 
LMS 12 Stomach 2011 1 
LMS 13 Uterus 2004 8 
LMS 14 Bowel 1995 17 
LMS 15 Uterus 1997 15 
LMS 16 Uterus 1997 15 
LMS 17 Nose 1998 14 
LMS 18 Pelvis 2004 8 
LMS 19 Retroperitoneum 2003 9 
LMS 20* Uterus 2008 4 
LMS 21* Uterus 2011 1 
LMS 22 Lower Limb 2000 12 
§ - 
Additional fresh samples obtained and frozen before fixing in formalin 
* - Initially processed in a different institution 
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3.2.2 DNA Yield and Quality  
The DNA yield was generally good, exceeding 10µg in most cases.  In two cases however, the yield 
was low and vacuum centrifugation was used to bring DNA concentration to optimal values.  Another 
FFPE DNA sample had A260/230 < 1.50 and the DNA was re-purified by sodium acetate-isopropanol 
precipitation before labelling.   
When visualized on agarose gels against a 1kb ladder, DNA from the FF samples and commercial 
pooled genomic DNA showed relatively distinct bands of high molecular weight DNA, while that from 
FFPE tumours showed a range of fragment sizes that varied from less than 1.0kb on average, to as 
high as 8.0kb.  The degree of fragmentation appeared to be worse in FFPE samples that were older 
when compared with the more recent tumours (Figure 3.1).  The tumour samples included in this part 
of the study were chosen to reflect a wide range of both sample age and degree to DNA degradation 
as visualised on agarose gels.  
Figure 3.1:  Agarose gel images illustrating the degree of fragmentation of DNA samples obtained 
from FFPE tissue compared with those from fresh tissue. 
Panel A:  DNA extracted from FFPE leiomyosarcoma samples of different ages (shown in brackets) showing degradation to 
varied degrees , compared with commercial pooled female genomic DNA with a clear band of large DNA fragments.   
Panel B:  Comparison of DNA extracted from paired FF and FFPE leiomyosarcoma tissue (LMS 9, 10 and 11).  FF samples 
show relatively distinct bands of high molecular weight DNA, while corresponding FFPE samples show low molecular weight 
fragments in a wide range of sizes. 
All DNA samples are compared against a 1Kb DNA ladder.  DNA Electrophoresis was done on 1.0 % agarose gels were pre-
stained with Ethidium Bromide and examined under UV light.  
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3.2.3 Optimisation of DNA Labelling 
Initial attempts at DNA labelling by the ULS method produced a variable degree of labelling.  The 
results showed that when labelling reactions were carried out on heat blocks or water baths, the 
degree of labelling was consistently low.  In addition, for cases where post-labelling DNA quantitation 
showed that there was a higher amount of DNA in the reaction than initially estimated, the degree of 
labelling was either variable or arrays failed due to signal intensities that were below recommended 
thresholds.   
Since the ULS system does not amplify the DNA, this suggested that the ratio of DNA to ULS Cy-dye 
in the reaction was high, resulting in an inefficient labelling reaction.  The protocol was therefore 
modified to use excess ULS fluorophore relative to the amount of DNA (about 0.8 µg of DNA to 1ml 
of fluorophore).  Reactions were also carried out in thin-walled tubes on a thermal cycler to ensure 
uniform optimal temperature throughout the reactions.  All FFPE samples that were labelled in this 
way had consistently good degree of labelling. Results of experiments carried out before and after 
optimisation of the labelling protocol are summarised in Table 3.2. 
Using this optimised labelling method, aCGH experiments were carried out using DNA from a total of 
42 FFPE tumours (including the 22 LMS presented in this chapter). Quality control metrics of these 
array experiments were compared to those from experiments done with high quality DNA labelled 
using the enzymatic method (Table 3.3).   In concordance with their recommended degrees of 
labelling (described in Section 2.3.6.3), the average signal intensities of Cy3-labelled DNA (green) 
were higher than those of Cy5-labelled DNA (red).  The signal intensities for both fluorophores 
however were generally higher than the manufacturer-recommended threshold regardless of tissue 
sample type and labelling method. Similarly, signal-to-noise ratio was optimal in all FFPE samples 
labelled by the optimised protocol.  Although samples ULS-labelled FFPE samples showed lower 
signal to noise-ratio values compared with enzymatically labelled ones, this was expected based on 
their recommended optimal thresholds of > 10 and > 20 respectively (Table 3.3). 
The Derivative Log Ratio Spread (DLRS) is widely regarded as a robust parameter for measurement 
of the quality of microarray experiments. It represents the ‘noisiness’ of array data and a low DLRS 
value means that the data has small probe-to-probe variability and better ability to array to identify 
small aberrations and vice versa.  Manufacturer-recommended thresholds for DLRS when using 
FFPE DNA is < 0.4, a value above which array data may be compromised.  With the exception of 
two cases, DLRS values for all the array experiments were < 0.4 (Table 3.3) with majority of the 
FFPE samples having DLRS < 0.3 (Figure 3.2).  Mean DLRS value was approximately of 0.24 for 
both FF and FFPE tissue samples types.   
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Table 3.2:  Optimization of DNA Labelling Protocol 
Sample 
Tissue 
Type 
Amount of DNA 
Used (µg) 
ULS-Dye 
Used 
DNA to dye 
ratio (µg/µl) 
Post Labelling 
DNA Yield (µg) 
Degree of 
Labelling 
(%) 
Labelling 
Pass/Fail 
Dye Signal 
Intensity on 
Array 
A - Labelling reactions carried out using hot blocks and water baths 
1 FFPE 0.5 Cy5 1.0 0.49 0.4 Fail *NP 
2 FFPE 0.5 Cy5 1.0 0.5 0.2 Fail *NP 
3 FFPE 0.5 Cy5 1.0 0.5 0.23 Fail *NP 
4 FFPE 0.5 Cy5 1.0 0.66 0.36 Fail *NP 
5 Control DNA 0.5 Cy3 1.0 0.45 0.45 Fail *NP 
6 Control DNA 0.5 Cy3 1.0 0.45 0.45 Fail *NP 
7 Control DNA 0.5 Cy3 1.0 0.39 0.39 Fail *NP 
8 Control DNA 0.5 Cy3 1.0 0.56 0.56 Fail *NP 
B - Labelling reactions carried out using thermo-cycler 
9 FF  0.5 Cy5 1.0 0.89 2.01 Pass 99 
10 FFPE  0.5 Cy5 1.0 0.72 2.39 Pass 94 
11 FFPE  0.5 Cy5 1.0 0.59 3.27 Pass 79 
12 Control DNA 0.5 Cy3 1.0 0.73 1.08 Fail *NP 
13 Control DNA 0.5 Cy3 1.0 0.68 1.15 Fail *NP 
14 Control DNA 0.5 Cy3 1.0 0.88 0.97 Fail *NP 
15 Control DNA 0.5 Cy3 1.0 0.83 2.15 Pass 153 
16 Control DNA 0.5 Cy3 1.0 0.78 2.19 Pass 148 
17 Control DNA 0.5 Cy3 1.0 0.82 2.19 Pass 103 
C - Labelling reactions carried out using thermo-cycler and excess dye 
18 FFPE 0.8 Cy5 0.8 0.8 2.24 Pass 307 
19 FFPE 0.8 Cy5 0.8 0.6 2.32 Pass 245 
20 FFPE 0.8 Cy5 0.8 0.64 1.56 Pass 275 
21 FFPE 0.8 Cy3 0.8 0.91 2.04 Pass 383 
22 Control DNA 0.8 Cy3 0.8 0.95 3.08 Pass 1503 
23 Control DNA 0.8 Cy3 0.8 0.81 3.07 Pass 1251 
24 Control DNA 0.8 Cy3 0.8 0.76 3.1 Pass 1228 
25 Control DNA 0.8 Cy3 0.8 0.87 3.11 Pass 
1403 
*NP – Array CGH not performed on sample (if sample failed on spectrophotometry).  Spectrophotometry for 
DNA concentration and Degree of Labelling (DoL) done using Nanodrop
®
 ND-2000 and optimal DoL = 0.75 – 
2.5% (for ULS- Cy5); or 1.75 – 3.5% (for ULS Cy3).  Dye Signal Intensity calculated as part of Quality Control 
Metrics by Agilent Feature Extraction Software (v10.7.3).  
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Table 3.3:  Comparison of array CGH quality control metrics for ULS-labelled and Enzymatic-
labelled samples 
 Enzymatic labelling (n=32) ULS labelling (n=42) 
 Threshold Mean Range Threshold Mean Range 
Cy3 Signal Intensity (Green) >90 758 (170 – 4204) >90 1334 (749 – 2145) 
Signal-to-noise ratio (Green) >20 63.4 (14.2 – 118.7) >10 43.7 (25.1 – 79.7) 
Cy5 signal Intensity (Red) >90 603 (73 – 2167) >90 517 (117 – 1266) 
Signal-to-noise ratio (Red) >20 54.8 (24.9  - 90.3) >10 28.2 (10.5 – 51.0) 
Derivative Log Ratio Spread 
(DLRS) 
<0.3 0.24 (0.12 – 0.51) <0.4 0.24 (0.17 – 0.40) 
Array CGH quality control metrics were calculated using Agilent
®
 Feature Extraction software and thresholds 
are recommended by microarray platform manufacturer. 
 
 
 
 
Figure 3.2:  Derivative Log Ratio Spread (DLRS) Values of Array CGH Experiments  
Tumour sample types are shown on the X-axis.  DLRS values for individual microarray experiments are plotted 
as dots while means and standard errors for each sample type are shown as long and short horizontal lines, 
respectively plotted against the y-axis.   
 
DLRS values were calculated using Agilent feature Extraction software. 
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3.2.4 Comparison of Paired Fresh Frozen vs. FFPE Tumour DNA 
In three LMS cases (LMS 9, 10 and 11), paired samples of macroscopically sampled fresh tumour 
and macro-dissected FFPE tumour were obtained.  High molecular weight DNA from the fresh frozen 
(FF) tissue was labelled by the enzymatic method, while fragmented FFPE DNA from the same 
tumours was labelled using the one-step ULS method. There was good correlation between paired 
FF and FFPE samples in two out of the three cases.  The Pearson correlation coefficients (r) of 
overall probe log2-ratios were 0.58 (p < 0.0001) and 0.54 (p < 0.0001) for LMS 9 and LMS 10 
respectively (Table 3.4).   
 
Table 3.4:  Correlation of Probe log2 ratios of paired FF and FFPE LMS samples  
Correlation LMS 9 LMS 10 LMS 11 
Number of Probes 180,880 180,880 180,880 
Pearson Coefficient, r 0.59 0.54 −0.02 
95% Confidence Interval 0.5830 to 0.5891 0.5365 to 0.5431 −0.03 to −0.021 
Pearson’s Correlation, r of log2 ratio values of all probes on tumour DNA samples was calculated using 
GraphPad
®
 Prism software and statistically significant (p < 0.0001). 
 
Genomic profiles of detected SCNAs in both sample types were also very similar in both LMS cases 
with most chromosomes showing near identical loss and gain patterns (Figures 3.3 and 3.4).    One 
of the most significant differences in SCNAs was seen in LMS 9, where a low level amplification 
detected on chromosome 4 in the macro-dissected FFPE sample was not seen in FF sample (Figure 
3.3C).  Similar moving average patterns of higher amplitude were however retained at the telomeric 
ends of 4q in both sample types.  In both LMS 9 and 10, on most chromosomes where the 
aberrations detected by the calling algorithm were dissimilar, closer examination showed that the 
moving average pattern of probe log2 ratios remained similar with amplitude close to the threshold 
set in the algorithm for SCNA detection.  An example is shown in Figure 3.4C. 
The third case (LMS 11) compared in this way however, showed poor overall probe log2 ratio 
correlation (r = −0.02).  Although a few small aberrations were seen in both sample types, most of 
the SCNAs detected in the macro-dissected FFPE tissue were not detected in FF tissue (Figure 3.5).  
Histological examination showed that unlike the other two cases, the LMS 11 sample was composed 
of less than 50% tumour cells with a significant ad-mixture of normal cells.  
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Figure 3.3:  Comparison of Array CGH results in paired Fresh Frozen and Formalin-fixed Paraffin -Embedded samples from LMS 9 
Panel A:  Graphical whole-genome views of copy number aberrations (SCNAs) identified in both sample types showing close similarities on most 
chromosomes.  Panel B:  Higher resolution graphical views of Chromosome 11 showing the close similarity in gain and loss patterns detected in both sample 
types.  Panel C: High-resolution views showing the most dissimilar SCNA pattern detected between both sample types on chromosome 4.     
On Panel A, aberrations called by FASST2 algorithm are represented by blue triangles to the right (amplifications) and red triangles to the left (deletions) of corresponding 
chromosomes. Double blue and red triangles/lines represent high-level amplifications and two-copy deletions, respectively.  On Panels B and C, dots represent individual probe 
log2 ratios plotted as a function of their chromosomal position with a moving average of probe log2 ratios (wavy dark blue line).  Horizontal blue lines above zero line represent log 
ratio detection thresholds for single copy and high level amplifications and horizontal red lines below zero line represent log ratio detection thresholds for single and two-copy 
deletions.  Aberration calls are represented by thick black lines with corresponding shaded blue areas above (amplifications) and red areas below (deletions) the zero line.  
 61 
 
Figure 3.4:  Comparison of Array CGH results in paired Fresh Frozen and Formalin-fixed Paraffin -Embedded samples from LMS 10 
Panel A:  Graphical whole-genome views of copy number aberrations (SCNAs) identified in both sample types showing close similarities on most 
chromosomes.  Panel B:  Higher resolution graphical views of Chromosome 13 showing the close similarity in gain and loss patterns detected in both sample 
types.  Panel C: High-resolution views showing that even though the SCNAs identified by the calling algorithm on chromosome 9 are not identical, the moving 
averages of probe log2 ratios in both sample types remain similar.      
On Panel A, aberrations called by FASST2 algorithm are represented by blue triangles to the right (amplifications) and red triangles to the left (deletions) of the chromosomes. 
Double blue and red triangles/lines represent high-level amplifications and two-copy deletion, respectively.  On Panels B and C, dots represent individual probe log2 ratios plotted 
as a function of their chromosomal position with a moving average of probe log2 ratios (wavy dark blue line).   Horizontal blue lines above zero line represent log ratio detection 
thresholds for single copy and high level amplifications and horizontal red lines below zero line represent log ratio detection thresholds for single and two-copy deletions.  
Aberration calls are represented by thick black lines with corresponding shaded blue areas above (amplifications) and red areas below (deletions) the zero line. 
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Figure 3.5:  Comparison of Array CGH results in paired Fresh Frozen and Formalin-fixed Paraffin -Embedded samples from LMS 11 
Panel A:  Graphical whole-genome views of both sample types showing that majority of the copy number aberrations (SCNAs) identified in the macro-dissected 
FFPE sample were not detected in the FF sample.  Deletions on the long arms of chromosomes 9, 14 and 15 as well as the short arm of chromosome 16 were 
the called on both sample types.  Panel B:  High resolution graphical views of a 6Mb region along on Chromosome 14 (14q24.1) showing a group of probes with 
an average log2 ratio of approximately 0.6 and the corresponding single copy amplification detected in the FFPE sample but no aberrations detected in the FF 
sample.  Panel C: High-resolution graphical views showing a closely similar copy number aberration detected on Chromosome 15 (15q11.2) in both sample 
types with similar probe log2 ratios.      
On Panel A, aberrations called by FASST2 algorithm are represented by blue triangles to the right (amplifications) and red triangles to the left (deletions) of the chromosomes. 
Double blue and red triangles/lines represent high-level amplifications and two-copy deletion, respectively.  On Panels B and C, dots represent individual probe log2 ratios plotted 
as a function of their chromosomal position with a moving average of probe log2 ratios (wavy dark blue line).   Horizontal blue lines above zero line represent log ratio detection 
thresholds for single copy and high level amplifications and horizontal red lines below zero line represent log ratio detection thresholds for single and two-copy deletions.  
Aberration calls are represented by thick black lines with corresponding shaded blue areas above (amplifications) and red areas below (deletions) the zero line. 
 63 
 
3.2.5 Common Aberrations 
Common aberration analysis of the 22 FFPE LMS cases was carried out to identify candidate driver 
SCNA.  Overall, deletions were more common than amplifications.  Statistical significance of 
common aberrations was determined using the GISTIC algorithm with recommended thresholds of 
G-score > 1.0 and q-bounds < 0.05 (discussed in detail in Chapter 4). 
Five significant amplifications and five deletions were detected; involving around 500 genes in total 
were identified.  Significant deletions involved important tumour suppressor genes like PTEN, RB1 
and TP53.  Among important genes affected by the significant amplifications was MYOCD, a gene 
that is involved in smooth muscle differentiation.  These significant SCNA confirm results of multiple 
previous array CGH studies in LMS and are summarised in Figure 3.6.  Detailed results of other 
SCNA detected and candidate genes are presented in chapter 4. 
 
Figure 3.6:  Statistically-Significant Common Genomic Copy Number Aberrations among 22 FFPE 
Leiomyosarcomas 
Statistically significance of common aberrations was determined using the GISTIC algorithm.  
Commonly aberrant regions are plotted along the x-axis as a function of their chromosomal position 
and their q-values are plotted on the y-axis on a negative log
10
 scale so that the highest bars 
represent most significant genomic regions.  Blue bars represent commonly amplified regions and 
red bars represent commonly deleted regions. Genomic regions with G-score > 10 and q-values < 
0.05 are considered significant (shaded grey) and important candidate genes in these regions e.g. 
RB1, MYOCD are shown in black. 
 
Aberrations in individual samples were called using FASST2 Algorithm. 
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3.3 DISCUSSION 
Traditional large-scale projects for the evaluation of genome wide copy number aberrations in cancer 
were designed as prospective studies, which exclusively utilised fresh frozen tumour tissue.  This 
was due to a perceived requirement of high quality DNA for the microarray-based methods that are 
typically utilised.  Prospective study design is a problem when studying rare cancers such as LMS 
because it would take many years to accumulate large enough numbers for meaningful analysis.  
Tissue fixation in formalin is the standard procedure in most institutions and over many years, large 
FFPE tissue archives have been accumulated.  Such archives are an essential source of tumour 
tissue for research and they come complete with associated clinical data such as disease 
progression, outcome and therapeutic responses, which can readily be correlated with molecular 
genetic data.  
Formalin fixation, which is aimed primarily at preserving tissue protein structure for histopathological 
studies results in the formation of inter- and intra-strand cross-links between DNA molecules that 
produces low yields of highly fragmented nucleic acids (Srinivasan, Sedmak et al. 2002).  Other 
effects, such as strand cleavage and base modifications make PCR amplification of whole genome 
DNA prone to bias and errors.  As expected, DNA from the FFPE LMS tumours in this study showed 
varying degrees of fragmentation compared to that from FF tissues and the degree of degradation 
appeared to be worse with older samples (Figure 3.1).  However, factors such as pre-fixation and 
intra-fixation durations and tissue penetration are known to influence the degree of formalin effects 
on tissue DNA (Srinivasan, Sedmak et al. 2002).  Some of the more degraded samples in this study 
were fixed before standardized protocols for tissue fixation, to preserve their suitability for molecular 
studies, were widely-established.  Two other LMS cases (among five such cases in the entire study) 
were initially processed in a different Pathology laboratory. 
Initial attempts to label FFPE DNA using standard ULS protocols were not consistently successful.  
The use of a thermocycler with a heated lid gave higher degrees of labelling than heat blocks or 
circulating water baths for incubations during labelling, presumably because the temperature is more 
uniformly maintained throughout the labelling reaction.   Insufficient dye amounts relative to DNA 
were also found to lead to variable or poor ULS labelling, and even small errors (from user or 
equipment) that caused underestimation of DNA concentration gave poor labelling results. Using an 
excess of dye relative to DNA in labelling reactions gave consistent good degree of labelling and 
successful arrays (Table 3.2).  This is in keeping with results published in a recent study that showed 
that estimation of DNA concentration is critical to sample assessment for labelling (de Jong, Verbeke 
et al. 2011).   
Regardless of sample age or fixation protocol, all aCGH experiments utilising FFPE tissue in this 
study showed good DLRS values when labelling was done using the modified protocols (Figure 3.2).  
A review of relevant literature did not reveal any studies that reported such consistent good DLRS 
values from ULS-labelled archival FFPE tumour DNA.  A number of recent studies using FFPE 
tissues of similar age have reported variable DLRS values, the majority of cases reported having 
DLRS values between 0.3 and 0.5, with some as high as 1.0 (Braggio, McPhail et al. 2011, Oikawa, 
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Yoshiura et al. 2011, Hirsch, Camps et al. 2012).  The reliability of results were further strengthened 
by the observation that when FFPE samples from female patients were hybridised against sex-
mismatched DNA, the expected X-chromosome gain or loss detected had probe log2 ratios near the 
expected values, even in cases where there were few other SCNA detected (details are shown in 
Section 4.3.6). 
Two out of three paired FF and FFPE samples from identical tumours that were compared showed 
good overall probe log2-ratio correlation with Pearson’s coefficients similar to those reported from a 
similar study (de Jong, Verbeke et al. 2011).  In these two cases, shown in figures 3.3 and 3.4, the 
SCNAs detected across the entire genome in the compared FF and corresponding FFPE samples 
were also similar.  For a few chromosomes where the SCNAs detected by the calling algorithm were 
dissimilar, visual examination at a higher resolution showed that in most cases a similar moving 
average pattern was retained and the amplitude of average probe log2 ratios was close to the set 
thresholds for low-level (single copy) aberration detection, thus explaining why aberrations were 
differentially called in the two sample types.  The calling algorithm thresholds set for analysis of array 
CGH data in this study were chosen based on previous studies in literature and regarded as valid as 
they enabled the detection of common aberrations among the LMS cases that concur with previous 
studies (discussed later in this section).    
The third case (LMS 11) showed poor statistical correlation of the overall probe log2-ratios from both 
sample types and the results showed that although a few common SCNAs were seen, the majority of 
SCNAs detected in the FFPE sample were not detected in the FF one.  A minority of the genomic 
regions in LMS 9 and 10 also showed significant difference in the probe moving average pattern in 
addition to SCNA detected.  This prompted a revisit of the histology of all three tumours, which 
showed that LMS 11 was very heterogenous and contained large areas of haematoma and normal 
cells (not shown), while the former two were composed relatively homogenously of tumour cells.  In 
any whole genome nucleic acid isolation, the presence of germ-line DNA from normal cells 
‘contaminating’ a tumour sample can potentially mask genomic aberrations. The ability to macro-
dissect tumour cells from the FFPE tissues apparently helps to reduce the masking of genomic copy 
number aberrations   (Hostetter, Kim et al. 2010, Yau, Mouradov et al. 2010).  One oligonucleotide 
array CGH study modelled mosaicism using leucocytes from patients with trisomy 21 diluted with 
those from normal patients.  It was demonstrated that CNA would only be readily detected if present 
in around 30% of cells in a mosaic population with an average log ratio of around 0.21, and that this 
log ratio would reduce to 0.08 if only 10% of cell carried the aberration (Neill, Torchia et al. 2010).  
Another study utilising SNP arrays estimated the minimum percentage of aberrant cells at 25% 
(Gondek, Tiu et al. 2008).   Heterogeneity of tumour cell populations between the two areas of the 
whole tumour that were sampled independently and represented by the FF and FFPE samples could 
potentially account for some of the low level differential aberrations detected in these paired samples 
in the cases that looked more homogenous on histological examination. 
Common aberration analysis was carried out among the 22 FFPE LMS cases in this study.  Frequent 
common aberrations detected were in concordance with those reported in previous studies.  
Deletions on 10q and 13q have been reported as frequent among LMS in numerous studies (Derre, 
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Lagace et al. 2001, Hu, Rao et al. 2005, Larramendy, Kaur et al. 2006, Ylipaa, Hunt et al. 2011).  
Previous work in the Rare Tumour Research Group (RTRG) demonstrated a frequent loss on 11q 
that involves the locus of the ATM gene (Ul-Hassan, Sisley et al. 2009) that is mirrored in the current 
study and subsequently confirmed by FISH.  Focal genomic regions with statistically high frequency 
of copy number aberrations over the “background” aberration were identified.  The results are very 
similar to those reported by Barretina et al, who showed deletions on 10p, 10q, 13q, 17p and an 
amplification on 17p as the most statistically significant common aberrations from data obtained from 
fresh frozen tumour samples (Barretina, Taylor et al. 2010).  The regions identified contain loci for 
well-established tumour suppressor and cell cycle regulatory genes such as PTEN, RB1 and TP53.  
A frequent focal amplification detected on 17p among the LMS cases in this study specifically 
covered the MYOCD gene locus.  The same region was recently shown to be frequently amplified 
and over-expressed in at least one subset of LMS and is now widely considered to be a likely driver 
SCNA for well-differentiated LMS (Perot, Derre et al. 2009, Taylor, Barretina et al. 2011).  Over a 
quarter of the cases presented in this study showed SCNAs on genomic regions that involve loci for 
at least three of the five genes mentioned above, and may well represent a subset of LMS, although 
the small number of cases does not allow any correlation with clinical data to have sufficient 
statistical power.  The potential for expanding such a retrospective study to improve its statistical 
power cannot however, be overemphasized. 
At present, the cost per sample of labelling DNA by the ULS method is less than that of the 
enzymatic method and labelling and clean-up is complete within one hour, compared with the 
enzymatic methods that require at least five times that duration.  Most importantly however, in a 24-
month period that has seen only three operable LMS cases treated in this centre with the possibility 
of obtaining fresh tissue, access to the FFPE archives has permitted the analysis of more than 
twenty cases for which progression and survival data is available.   
In summary, this optimised protocol makes ULS-labelling a very reliable, cheap, fast method that 
provides access to long-term archival samples prepared using even non-standard protocols, and has 
proven to be applicable to samples processed in other laboratories.  The results generated from this 
archival tissue are in close concordance with those from multiple previous studies that utilized fresh 
tumour tissue, adding to the data validity and it is now possible to carry out retrospective studies in 
LMS and other rare STS subtypes utilising high-resolution genomic copy number mapping, 
maximising its potential to unravel pathogenetic mechanisms. 
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CHAPTER FOUR 
RESULTS:  ARRAY CGH  
4  
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4.1 INTRODUCTION 
Elucidation of their molecular genetic characteristics has played an important role in the current 
understanding of the pathology of many STS subtypes and led to advances in their classification, 
diagnosis and even treatment (Taylor, Barretina et al. 2011, Fletcher, Bridge et al. 2013). However, 
the majority of STS subtypes are characterised by genetic instability as evidenced by pervasive 
genomic abnormalities, which appear to be random and as yet have not been useful in tumour 
characterisation (Barretina, Taylor et al. 2010).   There is a strong association between exposure to 
ionising radiation and the development STS as well as a higher incidence of these tumours in 
individuals who carry inherited, inactivating mutations of DNA damage response genes.  It is 
therefore likely that genomic copy number aberrations that lead to inactivation of pathways involved 
in cellular response of DNA damage are not only an important mechanism leading to genomic 
instability, they are strongly linked to the cancer phenotype (Davoli and de Lange 2011, Lord and 
Ashworth 2012).   
Among cancers in general, certain aberrations have been shown to be recurrent and preserved even 
as the tumours evolve and accumulating evidence has led to the current view that genetic instability 
is an enabling characteristic that leads to the cancer phenotype and that the resulting recurrent 
somatic copy number aberrations (SCNA) are an important clue to pathogenetic mechanisms 
(Hanahan and Weinberg 2011, Taylor, Barretina et al. 2011).  Analysis of recurrent SCNA has led to 
the identification of genes with roles in tumour induction and/or progression and even suggested 
novel therapeutic approaches in various cancers including lung cancer (Weir, Woo et al. 2007, 
Chitale, Gong et al. 2009), ovarian cancer (Eder, Sui et al. 2005, The Cancer Genome Atlas 
Research Network 2011), acute lymphoblastic leukaemia  (Lahortiga, De Keersmaecker et al. 2007, 
Mullighan, Goorha et al. 2007), hepatocellular cancer (Zender, Spector et al. 2006), glioblastoma 
(The Cancer Genome Atlas Research Network 2008, Wiedemeyer, Brennan et al. 2008) and even 
STS (Taylor, Barretina et al. 2008, Barretina, Taylor et al. 2010). 
In an integrative study of over 3000 cancer genomes, Beroukhim and colleagues found that in almost 
all cancer types the most frequent SCNA involved either short genomic regions (focal SCNA) or 
whole chromosome arms (gains or losses).  Around 10% of the cancer genome on average is 
affected by focal SCNA, the frequency of which showed an inverse relationship with genomic region 
size.  Focal SCNA were also far more likely to occur with high amplitude (many more copies or 
homozygous deletion), compared with whole-arm events (Beroukhim, Mermel et al. 2010).  Focal 
SCNA are therefore statistically more likely to target specific genes and from a research point of view, 
the smaller genomic regions affected make target gene identification more feasible. On a 
background of overall genetic instability as seen in STS, the focal SCNA are likely to be numerous 
with the majority being random so-called ‘passenger’ aberrations that have no functional role.  The 
challenge is to differentiate these from ‘driver’ SCNA that have consequences that contribute to the 
cancer phenotype (Beroukhim, Mermel et al. 2010).   
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High-resolution oligonucleotide array CGH is elegantly designed to address the problem of 
identification of recurrent focal SCNA, particularly those of such small size that they might have been 
missed by previous studies that utilised lower resolution methods such as spectral karyotyping, 
chromosomal CGH or even BAC arrays.  It is also particularly suitable for the analysis of tumours 
such as STS where the majority of subtypes have characteristically complex karyotypes. This 
chapter details the results of copy number analysis and the shortlisting process for candidate ‘driver’ 
SCNA and affected genes in three STS subtypes comprising leiomyosarcoma (LMS), 
Gastrointestinal Stromal tumours (GIST) and Undifferentiated Pleomorphic Sarcoma (UPS).    
A combination of approaches was used to assess statistical likelihood that SCNA were non-random 
events.  Genes affected by these non-random SCNA represented a shortlist of candidate ‘driver’ 
genes that were examined individually in terms of the biological consequences of their aberrations.  
Evidence that deletion or amplification of potential candidate genes could contribute to the 
acquisition of any of the hallmarks of cancer (reviewed by Hanahan and Weinberg in 2011) meant 
that they were added to a final list of candidate genes.  In addition, specific attention was paid to 
deletion of individual genes and pathways that play a role in DNA damage responses and 
maintenance of genomic integrity, as these could provide insights into the mechanisms for genomic 
instability of STS.  Aberrations involving genes relevant to differentiation in cells of mesenchymal 
origin was an additional criterion that was used in selection of candidate genes, as these may 
provide clues to the biological origin of STS subtypes.    
The overall strategy used for candidate gene identification in this study is summarised in Figure 4.1 
and discussed in detail in subsequent sections. Array CGH analysis and aberration calling have 
previously been discussed in Chapter 3. 
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Figure 4.1: Overview of Work-flow for Array CGH Data Analysis and Candidate Gene identification 
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4.2 ARRAY CGH DATA ANALYSIS WORK-FLOW 
4.2.1 Common Focal SCNA identification 
For ease of reference, the strategy of Beroukhim and colleagues was adopted such that SCNA of a 
size larger than 5Mb (e.g. whole-arm events) were generally described as gains or losses to 
differentiate them from smaller focal SCNAs which were referred to as amplification or deletions 
(Beroukhim, Mermel et al. 2010).   Using a stacking algorithm, all SCNA identified within specific 
genomic regions in a relevant set of STS cases were ‘stacked’ over one another and a frequency 
plot generated, as shown in Figure 4.2.   
Common focal SCNA were identified as the minimal common region (MCR) of overlap among the 
SCNAs covering that locus (Figure 4.2).  This region is generally regarded as being most likely 
statistically, to contain a targeted gene (Beroukhim, Mermel et al. 2010).  The threshold frequency for 
common focal SCNA was set at 20% in order to increase the sensitivity of the data analysis.   
Figure 4.2: Frequency Plot and Stacked SCNA from Individual STS Cases showing an example of a 
Minimal Common Region (MCR) 
Top panel shows the chromosomal region (9p21) and its approximate size.  Middle panel shows the 
corresponding frequency plot of aberrations for all 8 LMS cases (bottom panel) plotted as percentages along the 
y-axis. Blue shading above zero line represent amplification frequency and red shading below zero line 
represents deletion frequency. Horizontal lines in bottom panel represent individual samples as shown on the 
left.  Grey segments have normal copy number; blue segments above represent amplifications; while red 
segments below represent deletions.   
The MCR (solid double arrow) is the smallest region that is aberrant in all the affected samples.  It differs from 
the whole region of common aberration (indicated by the dotted double arrow) that is aberrant with a frequency 
higher than the threshold of 20% (indicated by the yellow arrows).    
All SCNAs are detected using the FASST2 algorithm  
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4.2.2 Exclusion Criteria for Focal SCNA 
4.2.2.1 Germ-line Copy Number Variations  
Copy number variations (CNV) refer to DNA sequences that are found at different copy numbers in 
the germ-line DNA of two different individuals.  They are generally defined as a form of structural 
variation in the human genome with a size > 0.5 to 1 kilobase (Valsesia, Mace et al. 2013).  Although 
they are believed to have no direct pathological consequence, associations with complex genetic 
traits (multifactorial disorders) have been described (Conrad, Pinto et al. 2010).  To differentiate then 
from common focal SCNAs therefore, comparisons were made between all SCNA identified and 
known CNVs from the Toronto Database of Genomic Variants (Iafrate, Feuk et al. 2004).   
All common focal SCNAs that had 100% overlap with known CNVs were further examined at high 
resolution for the type and frequency of aberration, as well as SCNA breakpoints.  Among this subset 
with 100% CNV overlap, SCNAs were concluded to be likely CNVs and excluded from subsequent 
analysis only if: 
 they contained no known genes (unlikely to have functional consequences), or 
 they showed within an identical pair of breakpoints, amplification in some samples and 
deletion in others  (normal population variation), and/or 
 both their 5’ and 3’ breakpoints coincided exactly with those of the known CNVs  
 
Figure 4.3 shows an example of a SCNA identified at 1p31.1 among 16 pleomorphic sarcoma cases 
that was chosen for exclusion. 
 
4.2.2.2 Sex Chromosomes 
Reference DNA used for array CGH experiments on archival FFPE tissue was not matched for 
gender because the samples were initially anonymised.  Overall, samples from seven female and six 
male patients were found to have been sex-mismatched.   
In all the sex-mismatched cases where male reference DNA was used, the expected results of a 
single copy gain of the X chromosome and homozygous loss of the Y chromosome was confirmed 
by array CGH.  An example is shown in Figure 4.4A, where apart from the sex chromosomes, no 
other genomic copy number aberrations were detected.  The reverse (i.e. single copy loss of 
chromosome X and high level amplification of chromosome Y) was seen when female reference 
DNA was used (Figure 4.4B).  These cases therefore served as positive control experiments.  
However, copy number data from sex chromosomes had to be excluded from subsequent common 
aberration analyses. 
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Figure 4.3: Frequency Plot and Individual Samples showing an example of an Aberrant Region that 
represents a Copy Number Variation (CNV) 
The region below the vertical lines lies completely with in a known CNV region (purple track), shows variable 
aberration in different cases with identical breakpoints, and contains no gene loci.  It was therefore concluded to 
be a likely CNV and excluded from further analysis.  Top shows the chromosomal region, its approximate size 
and corresponding frequency plot of aberrations for all 16 UPS cases, plotted as percentages along the y-axis. 
Blue shading above zero line represent amplification frequency and red shading below zero line represents 
deletion frequency.  Horizontal lines below represent individual samples arranged in decreasing order of SCNA 
log ratio with their identities shown on the left.  Grey segments have normal copy number, blue segments 
represent gains and red segments represent losses. Vertical lines show exact alignment of SCNA breakpoints. 
All SCNAs are detected using the FASST2 algorithm; known CNV region is from the Toronto Database of Genomic Variants 
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Figure 4.4:  Genome View Ideograms of aCGH experiments using sex-mismatched reference DNA 
Panel A – whole genome view of SCNA detected in tumour DNA from a female that was matched with male 
reference DNA showing the expected single copy gain of the X chromosome and homozygous loss of the Y 
chromosome.  Panel B – shows a sex mismatched scenario opposite to that in Panel A and the expected 
SCNAs.  Aberrant regions are shown as coloured shading on the chromosome (blue represents amplification 
and red represents deletion).   Dots represent individual probes.  Black vertical lines represent mean log ratio for 
the corresponding region on the chromosome.  Horizontal distance to the right (amplification) or left (deletion) of 
the vertical capped zero line represents the amplitude of log ratio.   
All SCNAs are detected using the FASST2 algorithm  
 
GIST 04:  Female Patient vs. Male Reference DNA 
GIST 06:  Male Patient vs. Female Reference DNA 
 
A 
B 
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4.2.3 Significance Testing of Common Focal SCNA 
4.2.3.1 Common Aberration Analyses 
Two validated methods, STAC and GISTIC (see below) were used for statistical analysis of common 
focal SCNA to identify potential driver aberrations based primarily on their frequency of occurrence.   
Both tools are built into Nexus Software (Biodiscovery
®
) and utilise SCNAs that have already been 
identified using the FASST2 calling algorithm, as described in Chapter 3.  They however apply 
different statistical approaches to significance testing (as summarised in Table 4.1), an overall 
strategy that makes the data analysis more robust (Rueda and Diaz-Uriarte 2010).  
Significance Testing for Aberrant Copy Number (STAC)  
Introduced by Diskin et al in 2006, STAC uses a global frequency statistic approach to attempt to 
identify a set of aberrations that are stacked on top of one another such that it would not occur 
randomly. It uses permutations of the SCNA in each arm of the chromosome to see how likely it is 
for a SCNA to occur at any location with a particular frequency.  Using a p-value cut-off of 0.05, it 
then highlights the regions of common aberration that have a frequency that is higher than would be 
accounted for by random chance (Diskin, Eck et al. 2006).   
Genomic Identification of Significant Targets in Cancer (GISTIC)  
GISTIC incorporates in addition to aberration frequency, the amplitude of SCNA (log ratio values) for 
assignment of G-scores to each region.  It then determines the probability of a score occurring by 
chance against a genome-wide random distribution of aberrations (Beroukhim, Getz et al. 2007) and 
applies a False Detection Rate correction for multiple sample testing with which it determines a q-
value for that region.   The program also identifies within these regions, ‘peak’ regions that have the 
highest statistical likelihood of containing affected genes (maximal G-score and minimal q-value).  
 
Table 4.1:  Differences between the STAC and GISTIC algorithms 
 STAC GISTIC 
Criteria or Region Selection 
Frequency of Aberrations 
Only 
Both Frequency and 
Amplitude of aberration 
Null model 
(for statistical significance) 
Permutation of regions 
within a chromosome arm 
Permutation of probes over 
the entire genome 
Correction for 
Multiple Sample Testing 
Does not require 
correction 
Requires correction 
(FDR) 
Peak Region identification No Yes 
FDR – False Discovery Rate Correction 
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4.2.3.2 Enrichment Analysis of Affected Genes 
Enrichment is a statistical approach that is used for the functional analysis of the long lists of genes, 
such as those affected by common focal SCNA (Huang da, Sherman et al. 2009).  Based on their 
biological function, the affected genes were systematically mapped to their associated 
biological/molecular pathways.  Statistical analysis was then carried out to identify pathways that 
were significantly over-represented (enriched) among the aberrant genes.  In this study, the publicly 
available Database for Annotation, Visualisation, and Integrated Discovery (DAVID) Bioinformatics 
Tool v6.7 (http://david.abcc.ncifcrf.gov, accessed March 2013) was used for enrichment analysis.   
The tool is able to handle gene lists with as many as 3000 annotated genes and determines the 
proportion of genes on the list that are involved in a particular molecular pathway (pathway mapping).  
It then compares this to the proportion of genes in the entire genome (population background) that 
are involved in the same pathway and uses a modified Fisher’s Exact test (EASE score) to 
determine significance.  
 A simple ratio of these proportions known as Fold Enrichment is also calculated as a measure of the 
magnitude of pathway enrichment.  This provides an idea of the gene distribution of the enriched 
pathways and fold enrichment values above 1.5 are generally considered to be ‘interesting’.  This is 
not a strict cut-off, however and fold enrichment is typically taken together with EASE score for a 
robust assessment of the statistical relevance of these pathways.   For example, if 10% of genes on 
a list are involved in apoptosis versus only 1% of genes in the genome, the EASE score (p-value) is 
< 0.05 with a ten-fold enrichment and therefore the apoptotic pathway is considered to be very 
significant. (Huang da, Sherman et al. 2009).    
Genes involved in amplified and deleted focal SCNA were analysed separately to facilitate biological 
interpretation of results.  The affected genes were mapped to gene lists from curated pathways in the 
well-known and validated Kyoto Encyclopaedia of Genes and Genomes (KEGG) and Biocarta
®
 
databases, which include a wide range of molecular signalling pathways, including those with 
specific relevance to cancer.   In addition to EASE score and fold enrichment, output from the DAVID 
tool also includes graphical representations of the significant pathways, highlighting all affected 
genes on the list submitted (as shown in Figures 4.7 - 9 and, 4.13 - 15). 
4.2.3.3 Differential Aberration Analysis 
Differential aberration analysis was used in an attempt to identify ‘driver’ genes that are specific for 
certain STS subtypes. Hypothetically, subtype-specific ‘drivers’ would be selected for in that STS 
subtype and the aberrations would occur at a higher frequency in that subtype relative to others.  All 
the common focal SCNA identified in each STS subtype examined were therefore compared with 
those identified in a set of other STS subtypes.   
Subtypes with few or no SCNA were excluded from the control group in order to add an additional 
level of stringency to the differential aberration analysis.  Control groups for differential aberration 
analysis in this study therefore included STS that are known to have complex karyotypes as defined 
by Guillou and Aurias in their review (Guillou and Aurias 2009) and included leiomyosarcoma, 
undifferentiated pleomorphic sarcoma, myxofibrosarcoma, dedifferentiated and pleomorphic 
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liposarcoma, malignant peripheral nerve sheath tumours, pleomorphic rhabdomyosarcoma and 
angiosarcoma. Comparison of genomic regions with SCNA that were detected with a differential 
frequency (test subtype minus control group frequency) above a 40% threshold was carried out 
using a tool built into the Nexus
®
 Copy Number Software.  Fisher’s exact test was used to assess the 
statistical significance of the difference in aberration frequency with p < 0.05 set as a cut-off. 
4.2.4 Assessment of Shortlisted Candidate Genes 
The statistical approaches above described generated more manageable shortlists of potential 
candidate genes (those involved in the statistically significant common SCNA, differential SCNA and 
enriched pathways).  These genes were then individually examined in terms of biological function 
and reported involvement in cancer using the Atlas of Genetics and Cytogenetics in Oncology and 
Haematology (http://AtlasGeneticsOncology.org) as a starting point.  A free, online database, the 
atlas contains detailed and curated information on genes, cytogenetics, and clinical entities in cancer, 
and cancer-prone diseases with PubMed links to relevant peer-reviewed articles and other resources 
(Huret, Ahmad et al. 2013).  A final list of candidate genes was then compiled for each STS subtype 
based on the potential functional implications of the amplification or deletion in which they are 
involved, as well as reported abnormalities in various cancers with particular attention paid to STS.  
As previously discussed, functional assessment of the shortlisted candidate genes was based on 
known role in acquisition of cancer hallmarks as well as genome maintenance and mesenchymal cell 
lineage differentiation (Figure 4.1). 
4.3 STS SUBTYPES AND GENERAL ARRAY CGH PROFILE FEATURES 
Array CGH was initially adapted to fresh tissue samples regardless of subtype and DNA from fresh 
frozen tissue samples from 32 cases was analysed.  Following the optimisation of ULS labelling 
method, STS subtypes known to have complex karyotypes but no specific markers, including LMS 
and UPS were chosen for more extensive analysis.   GISTs were chosen as a third subtype for 
analysis in order to follow up on previous work in the research group that suggested the presence of 
a shared genetic abnormality with LMS (Ul-Hassan, Sisley et al. 2009). DNA from archival FFPE 
samples for 45 cases were chosen for analysis.  Three cases had both fresh and FFPE samples 
analysed and used for comparison and optimisation as described in Section 3.2.  In total therefore, 
74 separate STS cases, comprising 15 different clinico-biologic subtypes were analysed using array 
CGH as summarised on Table 4.2.   
After exclusion of CNVs and sex chromosomes, featureless (flat) arrays were seen in one GIST 
(shown in Figure 4.4A), one WDLPS and 9 other cases including all three angiosarcomas, both 
ASPS, the synovial sarcoma, the EMCS, the SFT and Ewings’ sarcoma.   With the exception of the 
angiosarcomas and SFT, all the other STS subtypes where all cases had featureless arrays are 
known to have characteristic chromosomal translocations (Table 1.2).  All of the 63 other cases had 
aberrations detected on at least one autosome.  Eight out of the twelve liposarcoma cases (all 3 
subtypes) showed the characteristic amplification on 12q13-15 involving the MDM2 and CDK4 genes 
(data not shown) and in some of these cases, this was the only aberration detected across the entire 
genome.  Complex karyotypes with aberrations involving up to half of the autosomes were seen in 
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the MPNST, the PRMS and all 3 MFS cases.  Detailed features of the GIST, LMS and UPS (48 
cases in total) are discussed in subsequent sections of this chapter. 
Table 4.2:  Summary of Soft Tissue Sarcoma subtypes analysed by array CGH 
STS Subtype 
No. of FFPE 
Samples 
No. of Fresh 
Samples 
Number 
of Cases 
Undifferentiated Pleomorphic Sarcoma (UPS) 12 4 16 
Leiomyosarcoma (LMS) 21 3§ 21 
Gastrointestinal Stromal Tumour (GIST) 11 0 11 
Pleomorphic Liposarcoma (PLPS) 1 3 4 
De-differentiated Liposarcoma (DDLPS) 0 4 4 
Well-differentiated Liposarcoma (WDLPS) 0 4 4 
Myxofibrosarcoma (MFS) 0 3 3 
Angiosarcoma  0 3 3 
Alveolar Soft Part Sarcoma (ASPS) 0 2 2 
Malignant Peripheral Nerve Sheath Tumour (MPNST) 0 1 1 
Extraskeletal Myxoid Chondrosarcoma (EMCS) 0 1 1 
Pleomorphic Rhabdomyosarcoma (PRMS) 0 1 1 
Synovial Sarcoma 0 1 1 
Ewing’s Sarcoma 0 1 1 
Solitary Fibrous Tumour (SFT) 0 1 1 
Total 45 32 74 
§
 - Cases analysed as both Fresh and FFPE samples 
4.4 ARRAY CGH DATA ANALYSIS BY SUBTYPE  
Two out of fifteen STS subtypes (LMS and UPS) comprised half of the total 74 cases analyses by 
array CGH (Table 4.2), reflecting an intentional bias in sampling that favoured STS subtypes with 
complex and unbalanced karyotypes.  Not only are these STS subtypes the best suited for analysis 
by array CGH, a method that only detects unbalanced genomic abnormalities, they constitute the 
majority of STS that lack defining genomic abnormalities.   
Not surprisingly, the bias was also reflected in the results of common aberration analysis of all 74 
cases.  Using the GISTIC and STAC tools, the majority of significant common focal SCNA detected 
among the entire set were the same as those detected in the over-represented subtypes.  The 
GISTIC algorithm detected in addition, aberrations that recurred in relatively few cases but with very 
large amplitude such as the high-level 12q14 amplifications that are characteristic of liposarcomas. 
The results (common aberration analysis only) were therefore unlikely to be useful for identification 
of novel common aberrations among STS in general and are not presented within this chapter, but 
available in Appendix 3. 
Detailed analyses of SCNA detected among 3 STS subtypes including 21 LMS, 16 UPS and 11 
GIST cases were carried out using the approach described above and summarised in Figure 4.1. 
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4.4.1 Copy Number Aberrations among Leiomyosarcomas  
4.4.1.1 Leiomyosarcoma Cases 
Although 22 cases, diagnosed as LMS were analysed by array CGH, only 21 of these were included 
for identification of common focal SCNA. The remaining case was excluded because it was re-
classified as a GIST based on its genomic profile and confirmation by immunohistochemistry 
(discussed in detail in Section 4.5).  In three of the cases LMS 08, 09 and 10 both fresh and FFPE 
samples were analysed by array CGH.  However, only data from FFPE samples (for all 21 cases) 
was used for common aberration and subsequent analyses. 
The tumour samples were obtained from patients aged between 39 and 82 (mean = 59) years at the 
time of diagnosis.  There was a female predominance with 16 out of the 21 patients being female but 
only six tumours arose in the female genital tract even though most tumours occurred within in the 
abdominal or pelvic cavities.  The majority (18 out of 22) were high grade (Trojani grade 3) with no 
obvious relationship to site or size.   The features of all the LMS tumours analysed are summarised 
in Table 4.3. 
Table 4.3:  Summary of LMS Cases used for Identification of Common Focal SCNA  
Case 
Sampling 
Date 
Gender 
Age (years)  
at Diagnosis 
Site Size Grade 
LMS 01 2010 Female 63 Bowel 210 3 
LMS 02 2011 Female 38 Lower Limb 60 3 
LMS 03 2011 Female 47 Lower Limb 50 3 
LMS 04 2011 Male 67 Bladder 85 3 
LMS 05 2011 Female 63 Stomach 50 2 
LMS 06 1999 Female 82 Lower Limb 60 3 
LMS 07 1998 Male 37 Bladder 50 3 
LMS 08 2011 Female 63 Vagina 50 3 
LMS 09 2011 Male 39 Retroperitoneum 95 3 
LMS 10 2011 Female 49 Pelvis 85 1 
LMS 11 2011 Female 80 Stomach 60 3 
LMS 12 2004 Female 58 Uterus 85 3 
LMS 13 1995 Female 76 Bowel 40 3 
LMS 14 1997 Male 77 Uterus 130 3 
LMS 15 1997 Male 54 Uterus 160 3 
LMS 16 1998 Female 69 Nose 50  2 
LMS 17 2004 Female 54 Pelvis 15 3 
LMS 18 2003 Female 49 Retroperitoneum 180 3 
LMS 19 2008 Female 52 Uterus  3 
LMS 20 2011 Female 69 Uterus 82 3 
LMS 21 2000 Female 49 Lower Limb 35 1 
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4.4.1.2 Recurrent Gains and Losses 
Only general observations were made with respect to gains and losses, because the focus of the 
study was on focal SCNA.  Most LMS cases showed complex genomic profiles (with SCNAs 
detected on ten or more chromosomes).  Only three cases (LMS 07, 12 and 20) had relatively simple 
genomic profiles. For all the LMS cases, copy number losses were more common than gains across 
the entire genome.  The most frequent deletions (seen in > 40% of cases) include whole or near-
whole arm deletion in 10p, 10q, 13q, 16q, and 11q as well as Amplifications on 1q and 17p.  A 
penetrance plot summarising the frequency of chromosomal gains and losses is shown in Figure 4.5 
below. 
 
Figure 4.5:  Frequency Plot of Common Genomic Copy Number Aberrations among 21 FFPE 
Leiomyosarcomas 
Commonly aberrant regions are plotted as a function of their chromosomal position.  Red bars to the left of the 
chromosome represent frequency of deletions and blue bars to the right of the chromosome represent 
amplifications.  The heights of the bars correspond to the frequency of aberrations among the cases. 
All SCNAs are detected using the FASST2 algorithm  
 
 81 
 
4.4.1.3 Common Focal SCNA 
A total of 1253 common focal SCNAs were detected among LMS with a minimum frequency of 20%.  
Covering approximately 20% of the genome, they ranged in size from 2kb to 7.3 Mb (mean = 317kB, 
median= 206kB).  Of these, 96 regions contained no genes while another 18 represented CNVs and 
so were excluded from further analysis.  Of the remaining, 720 regions had copy number 
amplifications (involving a total of 2031 gene loci) while 419 regions (involving 1842 gene loci) had 
copy number deletions.    Deletion in 13q14.2 – q14.3 was one of the most frequent focal aberrations 
detected, present in 14 of the 21 LMS cases (67%).  The 11q22.3 region covering the locus of the 
ATM gene was also frequently deleted (in approximately 43% of cases).  A candidate gene identified 
in a previous study in our laboratory (Ul-Hassan, Sisley et al. 2009), the ATM gene locus deletion 
was confirmed using Fluorescence in situ Hybridisation (FISH) on two LMS cases, FFPE sections of 
LMS 13 (not shown) and in cells cultured from the primary tumour in LMS 08 (Figure 4.6). 
Figure 4.6:  Two-colour Interphase Fluorescence in situ Hybridisation (FISH) images of nuclei of 
cultured leiomyosarcoma cells. 
A – Metaphase and interphase nucleus derived from normal lymphocytes showing expected diploid complement 
with 2 copies each of the chromosome 11 centromere (green) and ATM locus (red).  B - Cells were derived from 
culture of fresh tissue from LMS 08.  Most cells have polysomy 11 (five or more green chromosome 11 
centromere signals), but relatively few copies of the red ATM gene locus signal at 11q22 representing an overall 
copy number deletion.   Nuclei are counter-stained with DAPI (blue).  
Images were captured using x63 magnification objective  
4.4.1.4 Significance Testing of Common Focal SCNA 
STAC 
Using  the STAC approach, 38 common focal amplifications in LMS were found  to be statistically 
significant (frequency ≥ 20%, p < 0.05).  All but one genomic region involved at least one gene and 
the amplifications covered loci for a total of  165 genes.  Table A1 in Appendix 4 lists all the genes 
affected by significant amplifications identified by STAC among LMS. Nine of these genes have been 
implicated with gain in copy number and/or function abnormalities in various cancers (highlighted in 
Table 4.4).  Only one of these ARHGEF2, a putative oncogene which encodes a rho-guanine 
nucleotide GTPase exchange factor (rhoGEF) has previoulsy been implicated in STS (Frolov, 
Chahwan et al. 2003, Brecht, Steenvoorden et al. 2005).  Another, PIK3R1 that encodes the p85a 
regulatory subunit of phophatidyl inotisol-3-kinase (PIK3) has oncogenic properties but has also 
been reported as down-regulated, in a number of cancers (Taniguchi, Winnay et al. 2010).  More 
recent findings in endometrial carcinomas however clearly demonstrate gain of function mutations in 
this gene (Cheung, Hennessy et al. 2011) that correlate with its amplification being a driver 
aberration.
A BA BA B 
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Table 4.4:  Significant Common Focal Amplifications among LMS (STAC) 
 Cytoband Region 
Length 
(Mb) 
Frequency 
(%) 
P-Value Genes 
Cancer 
Genes 
Chr 1 
p12 - p11.2 120,563,106-120,756,223 0.19 48 0.000 1 NOTCH2 
q21.1 144,009,907-144,995,110 0.99 71 0.000 8 PDE4DIP 
q21.1 145,112,508-145,278,200 0.17 76 0.000 2 - 
q21.2 149,311,087-149,596,705 0.29 62 0.016 6 - 
q21.2 149,818,426-149,873,111 0.05 62 0.016 11 - 
q21.3 154,899,255-154,958,577 0.06 62 0.016 6 
CKS1B 
SHC1 
q22 155,177,125-155,253,539 0.08 62 0.016 8 - 
q22 155,894,065-156,045,700 0.15 62 0.016 8 ARHGEF2 
q24.2 168,235,779-168,258,696 0.02 62 0.016 1 - 
Chr 2 
q22.3 145,162,871-145,304,149 0.14 29 0.016 1 - 
p22.2 37,823,758-38,245,167 0.42 33 0.009 2 - 
q11.2 97,527,264-97,623,299 0.01 38 0.000 2 - 
q13.13 48,766,079-49,005,661 0.24 52 0.000 3 - 
Chr 3 q26.31 71,958,976-172,051,964 0.09 52 0.003 1 - 
Chr 5 
q32 148,717,819-148,929,994 0.21 43 0.043 5 - 
p13.2 37,012,156-37,067,386 0.06 52 0.015 1 - 
q11.2 54,728,700-54,928,310 0.20 43 0.043 3 - 
q12.3 64,264,133-64,412,850 0.15 43 0.043 1 - 
q13.1 67,067,899-67,548,574 0.48 43 0.043 1 PIK3R1 
q13.2 71,430,376-71,606,831 0.18 48 0.001 2 - 
q14.3 90,402,321-90,686,262 0.28 48 0.001 2 - 
Chr 6 p22.2 26,124,423-26,259,251 0.13 38 0.007 17 - 
Chr 9 
p22.1 19,095,812-19,317,927 0.22 29 0.033 3 - 
q22.31 94,034,499-94,186,403 0.15 38 0.012 2 - 
Chr 11 
p13 35,110,040-35,316,017 0.20 29 0.006 2 CD44 
q12.3 62,314,338-62,641,063 0.33 24 0.003 35 - 
Chr 12 q24.11 109,123,797-109,147,883 0.02 33 0.004 1 - 
Chr 13 q34 110,918,305-111,046,505 0.13 43 0.000 2 - 
Chr 14 
q22.1 51,964,027-52,127,715 0.16 57 0.002 1 - 
q24.1 69,144,273-69,519,867 0.38 57 0.002 3 - 
Chr 16 
q22.1 69,228,790-69,753,047 0.52 29 0.043 10 NQ01 
q22.3 72,964,471-73,143,118 0.18 33 0.001 2 - 
q24.1 84,963,962-85,068,069 0.10 33 0.001 1 - 
Chr 17 
q22 55,948,928-56,056,018 0.11 38 0.023 2 - 
q23.1 57,816,707-57,935,524 0.12 38 0.023 1 - 
Chr 19 p13.11 18,429,433-18,583,639 0.15 48 0.003 7 
ELL 
GDF15 
Chr 22 q12.3 36,665,486-36,786,805 0.12 48 0.013 1 MYH9 
      165 11 
Genomic regions shown have amplification frequency ≥ 20% and p < 0.05 as judged by the STAC algorithm.  
Only regions that involve at least one known gene locus are listed and only the affected genes that have been 
implicated in cancer are shown.  Genes with reported gain of copy number and/or function abnormalities in 
cancer (candidate driver genes) are in shown in red while those that have been described with the opposite 
abnormalities in cancer are shown in grey (likely passengers).  Genes that have been implicated in STS are 
highlighted in bold red text.   
STAC analysis was carried out using Nexus
®
 Copy Number Software and gene function information was 
obtained from Atlas of Genetics and Oncology and PubMed literature reviews.    
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There were 31 significant common focal deletions identified among LMS  (Frequency ≥ 20%, p < 
0.05).  Thirty of these involve one or more gene locus with 113 genes affected in total (listed on 
Table A2 in Appendix 4). Only four of the affected genes have been implicated in cancer and none of 
them have specifically associated identified in STS (Table 4.5).  With the exception of PRDM16, 
whose knockdown has been shown to be involved in myogenic differentiation (Seale, Bjork et al. 
2008), the remaining three genes have reported reduction in copy number or expression in various 
cancers.   
Table 4.5:  Significant Common Focal Deletions among LMS (STAC) 
 Cytoband Region 
Length 
(Mb) 
Frequency 
(%) 
P-Value Genes 
Cancer 
Genes 
Chr 1 
p36.33 1,075,323-1,151,667 0.08 62 0.000 3 - 
p36.33 1,870,020-2,195,283 0.03 38 0.009 3 - 
p36.32 2,472,466-2,539,213 0.07 52 0.000 3 TNFRSF14 
q44 248,983,071-249,250,621 0.27 33 0.000 4 - 
p36.32 3,184,391-3,448,830 0.26 48 0.000 3 PRDM16
‡
 
p36.32 4,793,782-5,354,520 0.56 38 0.009 1 - 
Chr 2 
q36.3 229,013,827-229,907,621 0.89 48 0.024 2 - 
q36.3 230,795,681-230,895,774 0.10 48 0.024 1 - 
q37.1 233,213,865-233,427,159 0.21 52 0.001 10 - 
q37.1 233,903,041-234,336,019 0.43 48 0.024 6 - 
q37.1 234,507,893-235,056,307 0.55 48 0.024 14 - 
q37.2 235,880,185-236,368,103 0.49 52 0.001 1 - 
q37.3 241,538,072-241,782,200 0.24 57 0.000 5 - 
q37.3 242,503,450-242,825,417 0.32 57 0.000 10 BOK 
Chr 4 p16.1 8,771,782-8,886,137 0.11 33 0.002 1 - 
Chr 6 p25.3 1,696,679-1,919,998 0.22 38 0.019 1 - 
Chr 8 q24.3 143,656,045-144,082,427 0.43 33 0.019 12 - 
Chr 9 
q34.11 - q34.12 133,145,616-133,553,257 0.41 43 0.038 3 - 
q34.3 137,870,941-138,031,761 0.16 48 0.002 1 - 
q34.3 140,630,365-140,833,019 0.20 57 0.000 2 - 
Chr 11 p15.5 975,029-1,093,963 0.12 43 0.003 3 MUC2 
Chr 12 p13.31 7,796,205-7,921,641 0.13 38 0.026 5 - 
Chr 14 q32.33 104,561,057-104,763,502 0.20 33 0.002 2 - 
Chr 19 p13.3 0-307,937 0.31 29 0.002 6 -- 
Chr 20 
q13.33 60,072,327-60,546,948 0.47 29 0.000 1 - 
q13.33 61,064,386-61,378,893 0.31 24 0.023 2 - 
q13.33 61,638,941-61,818,375 0.18 24 0.023 2 - 
q13.33 62,844,161-63,025,520 0.18 33 0.000 2 - 
Chr 21 q22.3 45,818,895-45,951,075 0.13 33 0.000 3 - 
Chr 22 q13.32 49,017,773-49,105,738 0.09 52 0.000 1 - 
      113 4 
Genomic regions shown have deletion frequency ≥ 20% and p < 0.05 as judged by the STAC algorithm.  Only 
regions that involve at least one known gene locus are listed and only the affected genes that have been 
implicated in cancer are shown.  Genes with reported loss of copy number and/or function abnormalities in 
cancer (candidate driver genes) are in shown in red.  Genes that have been implicated in STS are highlighted in 
bold red text.  
‡ 
- gene with role in mesenchymal lineage differentiation  
STAC analysis was carried out using Nexus
®
 Copy Number Software and gene function information was 
obtained from Atlas of Genetics and Oncology and PubMed literature reviews.    
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It was notable that so few candidate genes were identified among the deleted focal SCNA in LMS 
compared to the amplifications.  The STAC algorithm assesses significance of focal SCNA against 
the background aberration in chromosome arm on which it is located; and whole arm losses were 
more common than gains among LMS (Figure 4.5). It is therefore presumable that the high 
frequency of losses (copy number loss > 5Mb in size) made some of the deletions less significant 
based on the algorithm’s criteria.  This adds further justification to the use of more than one statistical 
approach to determination of focal SCNA significance. 
GISTIC 
The GISTIC algorithm determined a total of 5 amplifications and 5 deletions to be significant in LMS 
(G-score >1.0, q-bound <0.05).  The significant focal SCNA ranged in size from 0.5 to 18.6Mb and 
had peak regions of between 53 and 498kb in size (summarised on Tables 4.6 and 4.7).  The 
significantly amplified focal SCNAs occurred with a higher frequency in general (median frequency = 
67%) compared with the significant deletions (median frequency = 52%) but had lower G-scores 
(mean amplification score 7.1 vs. mean deletion score 12.1).    
The significant amplifications involved loci for a total of 135 genes (listed in Table B1 of Appendix 4).  
Five of these genes have been implicated in cancer, but PDE4DIP and MYOCD have been reported 
with the appropriate abnormalities to qualify them as candidate drivers in LMS.  MYOCD is 
particularly notable because it is involved in smooth muscle differentiation and was shown to be 
amplified and over-expressed in a subset of LMS (Perot, Derre et al. 2009).  It was also the only 
gene located in the peak region of its amplicon (Table 4.6). 
Table 4.6:  Significant Common Focal Amplifications among LMS (GISTIC) 
 Cytoband Region 
Length 
(Mb) 
Frequency 
(%) 
G-
Score 
Q-
Bound 
No. of 
Genes 
Genes 
in Peak 
Cancer 
Genes 
Chr 1 
1q21.1 
144,009,907-
145,492,482 
1.5 81 6.85 0.03 15 
SEC22B 
NOTCH2NL 
PDE4DIP 
1q42 
228,255,947-
231,657,562 
3.4 24 6.49 0.05 36 GALNT2 - 
Chr 3 3q25.1-26.1 
150,855,624-
165,822,232 
15 67 7.41 0.02 55 - 
GMPS 
MLF1 
Chr 14 14q11.2 
22,394,168-
23,535,702 
1.1 76 6.64 0.04 16 - - 
Chr 17 17p12 
11,235,749-
14,746,194 
3.5 43 8.08 0.02 13 MYOCD 
MAP2K4 
MYOCD 
       135 4 5 
Genomic regions shown have amplification G-score ≥ 1.0 and q < 0.05 as judged by the GISTIC algorithm.  Only 
affected genes that have been implicated in cancer are shown in the last column.  Genes with reported gain of 
copy number and/or function abnormalities in cancer (candidate driver genes) are in shown in red while those 
that have been described with the opposite abnormalities in cancer are shown in grey (likely passengers).  
Cancer-implicated genes with as yet undetermined or inconsistent functional status are shown in black.  Genes 
that have been implicated in STS are highlighted in bold red text.   
GISTIC analysis was carried out using Nexus
®
 Copy Number software and gene function information was 
obtained from Atlas of Genetics and Oncology and PubMed literature reviews.    
 85 
 
Like the large genomic region losses, the significant focal deletions identified by GISTIC covered 
larger regions of the genome than amplifications and involved nearly 350 genes (summarised in 
Table B2 of Appendix 4).  Twenty-five of these genes have reported functions that led to their 
selection as candidate drivers.  Two of these - PRDM16 and CEP55 were selected because of their 
involvement in mesenchymal cell differentiation and maintenance of genome integrity, respectively 
(Table 4.7)  
Fourteen of the deleted genes were present within peak regions of the significant SCNA.  Five of 
these were identified candidate genes by functional assessment.   Notable genes located in the peak 
regions include the well-known tumour suppressor genes PTEN and TP53 (both deleted in 52% of 
cases).  Other notable tumour suppressor genes identified as candidates (but not located in peak 
regions) include RB1 and FAS (Table 4.7). 
 
Table 4.7:  Significant Common Focal Deletions among LMS (GISTIC) 
 Cytoband Region 
Length  
(Mb) 
Frequency 
(%) 
G-
Score 
Q-
Bound 
No. of 
Genes 
Genes 
in Peak 
Genes in 
Atlas 
Chr 1 1p36 
2,285,830-
4,637,196 
2.4 48 9.69 0.00 23 
PRDM16 
ARHGEF16 
TNFRSF14 
DFFB 
PRDM16
‡
 
Chr 2 2q37 
233,732,597-
243,199,373 
9.4 67 13.59 0.00 88 - 
BOK 
ING5 
INPP5D 
Chr 10 10q22.3-24.2 
81,212,702-
99,855,478 
18.6 52 7.97 0.03 133 
ATAD1 
CFL1P1 
KLLN 
PTEN 
RNLS 
BMPR1A 
LGI1 
RBP4 
TNKS2 
KLLN 
PTEN 
FAS 
CEP55* 
Chr 13 13q14 
46,723,507-
53,957,341 
7.2 67 18.78 0.00 53 
CDADC1 
CAB39L 
SETDB2 
PHF11 
RB1 
ARL11 
INTS6 
PHF11 
RCBTB1 
RCBTB2 
Chr 17 17p13.1 
7,111,674-
7,650,119 
0.5 52 11.18 0.00 47 
TP53 
WRAP53 
EFNB3 
TP53 
CLDN7 
DLG4 
KCTD11 
TNFSF12 
       344 14 25 
Genomic regions shown have deletion G-score ≥ 1.0 and q < 0.05 as judged by the GISTIC algorithm.  Only 
affected genes that have been implicated in cancer are shown in the last column.  Genes with reported loss of 
copy number and/or function abnormalities in cancer (candidate driver genes) are in shown in red.   Genes that 
have been implicated in STS are highlighted in bold red text. 
* - gene with potential role in maintenance of genome integrity 
‡ 
- gene with role in mesenchymal lineage differentiation  
GISTIC analysis was carried out using Nexus
®
 Copy Number software and gene function information was 
obtained from Atlas of Genetics and Oncology and PubMed literature reviews.    
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4.4.1.5 Enrichment Analysis of Affected Genes 
Amplified Genes 
Enrichment analysis of the 2383 genes involved in common focal amplifications in LMS (Section 
4.4.1.3) identified a total of 29 molecular pathways with genes that were significantly over-
represented (EASE p-value < 0.05) as summarised in Table C1 of Appendix 4.  Detailed examination 
of the over-represented pathways showed that nine of them have functions that are directly related to 
the cancer phenotype (presented in Table 4.8).  Among these were three pathways relevant to 
specific cancers, including chronic myeloid leukaemia, small cell and non-small cell lung cancer.  
Signalling pathways relevant to these and various other cancers including the Epidermal Growth 
Factor and Mitogen-activated protein kinase pathways (shown in Figure 4.7) were also over-
represented.  The Focal adhesion and Rho signalling pathways may be important for cell motility and 
cell-matrix interaction involved in tumour progression. 
Figure 4.7:  Graphic output showing enrichment of members of the Biocarta® Mitogen-activated 
Protein Kinase (MAPK) Signalling pathway among genes frequently amplified in LMS 
All genes involved in amplified focal SCNA with a frequency ≥ 20% among LMS were submitted and the MAPK 
Signalling was significantly enriched (EASE p-value <0.05).  Yellow arrows represent activation.  Pathway 
members coded for by genes deleted in LMS are highlighted by red stars.   
Pathway and highlighted genes are graphical results automatically generated following enrichment analysis by 
the DAVID analysis tool (http://david.abcc.ncifcrf.gov, accessed March 2013).  Pathway information is based on 
Biocarta
®
 database (http://www.biocarta.com/pathfiles/h_mapkpathway.asp, accessed March 2013).   
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Table 4.8:  Cancer-related Molecular Pathways significantly over-represented in commonly amplified 
focal SCNA among LMS 
Pathway ID Term 
Gene 
Count 
Fisher 
p-value 
EASE 
P-Value 
Genes Involved 
Fold 
Enrichment 
BIOCARTA 
h_ptenPathway 
PTEN-dependent Cell 
Cycle Arrest and 
Apoptosis 
7 4.6E-3 0.0181 
MAPK1 
BCAR1 
SHC1 
PIK3CA 
FOXO3B 
GRB2 
PIK3R1 
3.13 
BIOCARTA 
h_rhoPathway 
Rho cell motility 
signalling pathway 
7 1.2E-2 0.0276 
DIAPH1 
SRC 
ARHGEF11 
PIP5K1B 
ROCK1 
ARHGAP5 
MYLK 
2.87 
BIOCARTA 
h_egfPathway 
EGF signaling pathway 7 1.3E-2 0.0399 
JUN 
SHC1 
PIK3CA 
GRB2 
FOS 
SRF 
PIK3R1 
2.65 
BIOCARTA 
h_integrinPathway 
Integrin Signaling 
Pathway 
9 5.4E-3 0.0171 
MAPK1 
ROCK1 
GRB2 
FYN 
JUN 
BCAR1 
RAP1A 
SHC1 
SRC 
2.60 
KEGG:   
hsa05222 
Small cell Lung Cancer 21 9.9E-5 0.0003 
BCL2 
LAMC2 
TRAF4 
MYC 
LAMC1 
E2F2 
CCNE1 
IKBKB 
FHIT 
PIK3R1 
PIK3CA 
LAMA3 
LAMA4 
NFKBIA 
PTGS2 
CKS1B 
BCL2L1 
RARB 
RXRB 
COL4A2 
COL4A1 
2.39 
KEGG:   
hsa05220 
Chronic Myeloid 
Leukaemia 
16 3.9E-3 0.0093 
SHC4 
MYC 
E2F2 
IKBKB 
GRB2 
PIK3R1 
MAPK1 
SMAD3 
SHC1 
PIK3CA 
SOS2 
SHC3 
NFKBIA 
TGFBR2 
BCL2L1 
CBLB 
2.04 
KEGG  
hsa05223 
Non-small cell lung 
cancer 
11 2.2E-2 0.0495 
MAPK1 
SOS2 
RASSF1 
PIK3CA 
FOXO3B 
E2F2 
GRB2 
RARB 
FHIT 
RXRB 
PIK3R1 
1.95 
KEGG 
hsa04510: 
Focal adhesion 40 3.4E-5 0.0001 
CAV2 
DIAPH1 
GRB2 
BCAR1 
COL3A1 
ITGA11 
ITGB5 
SRC 
ARHGAP5 
TNR 
BCL2 
SOS2 
COL6A2 
PIK3CA 
COL6A1 
SHC1 
SHC3 
THBS2 
THBS3 
PIK3R1 
SHC4 
THBS4 
COL4A2 
COL4A1 
VAV3 
ROCK1 
MYLPF 
ACTN1 
COL5A2 
MAPK1 
ITGA9 
LAMA4 
LAMA3 
FYN 
ITGA5 
JUN 
RAP1A 
LAMC2 
LAMC1 
MYLK 
1.90 
BIOCARTA 
h_mapkPathway 
MAP kinase signalling 
pathway 
15 7.9E-3 0.0249 
JUN 
MAP2K3 
MAP3K4 
MAPK6 
IKBKB 
GRB2 
MAPKAPK2 
MAPK1 
SHC1 
DAXX 
NFKBIA 
MAP4K5 
MAPK7 
FOS 
RPS6KA5 
1.85 
All genes involved in amplified focal SCNA with a frequency ≥ 20% among LMS were submitted for enrichment 
analysis.  Only cancer-related pathways with EASE p-value < 0.05 are shown (in decreasing order of fold 
enrichment).  All affected genes are listed with genes with gain of copy number and/or function abnormalities in 
cancer (candidate driver genes) shown red.  Genes that have been described with deletion or loss of function in 
cancer are shown in grey (likely passengers).   
Enrichment analysis was carried out using DAVID Bioinformatics tool (http://david.abcc.ncifcrf.gov, accessed March 2013) 
based on information from Biocarta
® 
(http://www.biocarta.com/genes/index.asp, accessed March 2013) and KEGG
®
 
(http://www.genome.jp/kegg/pathway.html, accessed March 2013) databases. 
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Surprisingly, the PTEN dependent cell cycle arrest and apoptosis pathway was identified as being 
over-represented among the amplified genes in LMS with the highest enrichment score.  
Amplifications leading to increased overall activity of this pathway (i.e. cell cycle arrest and 
apoptosis) would not be in keeping with a malignant phenotype.  However, functional examination of 
the 7 genes on the pathway that were actually amplified in LMS showed that they play a negative 
regulatory role to - or are inhibited by the PTEN tumour–suppressor (Figure 4.8).  Most notable 
among these are PIK3CA and PIK3R1 that encode the 110α and 85α- subunits respectively, of 
phosphatidyl inositol–3-kinase (PIK3), which functions in signal transduction following activation by 
growth factor receptor tyrosine kinases and is antagonised by the PTEN product.   PIK3 activity is 
frequently deregulated in cancer it is considered an important druggable target (Willems, Tamburini 
et al. 2012).  
Figure 4.8:  Graphic output showing enrichment of members of the Biocarta® PTEN-dependent cell 
cycle arrest and apoptosis pathway among genes frequently amplified in LMS. 
All genes involved in amplified focal SCNA with a frequency ≥ 20% among LMS were submitted for enrichment 
analysis and the pathway was significantly enriched (EASE p-value <0.05).  Yellow arrows represent activation 
while red lines represent inhibition.  Pathway members coded for by genes amplified in LMS are highlighted by 
red stars.  Although the pathway is named for the role of the PTEN tumour suppressor, the members of the 
pathway affected by amplifications in LMS (with the exception of FKHRL1) function to increase cell survival, 
cause cell migration and inhibit apoptosis.   Within the pathway, they are directly or indirectly negatively 
regulated by the PTEN tumour suppressor.  The affected genes are listed in Table 4.8.  PI3K subunits p85 and 
p110 are coded for by PIK3R1 and PIK3CA respectively.  SHC, GRB2, P130Cas and ERK2 are encoded by 
SHC1, GRB2, BCAR1 and MAPK1 respectively.  FOXO3B is a pseudogene of FOXO3A, a known tumour 
suppressor that encodes FKHRL1.  
Pathway and highlighted genes are graphical results automatically generated following enrichment analysis by 
the DAVID analysis tool (http://david.abcc.ncifcrf.gov, accessed March 2013).  Pathway information is based on 
Biocarta
®
 database (http://www.biocarta.com/pathfiles/h_ptenpathway.asp, accessed March 2013).   
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Deleted Genes 
A total of eight pathways were found to be significant (EASE p-value < 0.05) among 2219 commonly-
deleted genes in LMS (summarised in Table C2 in Appendix 4).   Only one, the regulation of 
transcriptional activity by PML is relevant to cancer pathogenesis.  The key member of the PML 
pathway (shown graphically in Figure 4.9) is encoded by the pro-myelocytic leukaemia gene, PML 
and forms large protein complex known as the PML nuclear bodies (PML–NB).  One of the 
frequently deleted genes among LMS, SUMO1 encodes small ubiquitin-like modifier (SUMO) 
proteins, which are involved in post-translational modification of the PML protein that is required for 
interaction with other nuclear proteins such as p53, RB and DAXX.  De-acetylation of p53 mediated 
by SIRT1 (whose encoding gene SIRT1 was also commonly deleted gene in LMS) facilitates its 
interaction with the PML-NB (Appella and Anderson 2001, Lallemand-Breitenbach and de Thé 2010).   
The interactions of the PML-NB with p53 and RB1 have a positive regulatory effect on their 
transcriptional activation and both encoding tumour-suppressor genes, were frequently deleted in 
LMS.  DAXX on the other hand causes transcriptional repression, which is abrogated by interaction 
with PML-NB.  This PML-DAXX interaction is one of the mechanisms of Fas-mediated apoptosis 
(Lallemand-Breitenbach and de Thé 2010) and Fas was found to be frequently deleted among LMS.  
Overall, the biologic function of the PML pathway members involved in common deletions in LMS 
thus suggest that disruption of this pathway may play an important role in tumour pathogenesis 
(Figure 4.9).      
Figure 4.9:  Graphic output showing enrichment of members of the Biocarta® Regulation of 
Transcriptional Activity by PML pathway among genes frequently deleted in LMS 
All genes involved in deleted focal SCNA with a frequency ≥ 20% among LMS were submitted and the PML 
pathway was significantly enriched (EASE p-value <0.05).  Yellow arrows represent activation while red lines 
represent inhibition.  Pathway members coded for by genes deleted in LMS are highlighted by red stars.   
Pathway and highlighted genes are graphical results automatically generated following enrichment analysis by 
the DAVID analysis tool (http://david.abcc.ncifcrf.gov, accessed March 2013).  Pathway information is based on 
Biocarta
®
 database (http://www.biocarta.com/pathfiles/h_ptenpathway.asp, accessed March 2013).   
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4.4.1.6 Differential Aberration Analysis 
Differential aberration analysis was carried out to compare common focal SCNA in LMS to identical 
regions on other STS.  The control group was comprised of 32 STS cases of various subtypes 
known to have complex genomic profiles (discussed in Section 4.2.3.3).  Using a threshold of at least 
40% differential frequency, four common focal amplifications and five focal deletions were found to 
be significant (p-value < 0.05).  A complete list of genes affected by the significant differential 
amplifications and deletions among LMS is available in Appendix 4 (Tables D1and D2). 
The significant differential amplifications involved only around 0.45Mb in total and covered loci for six 
genes, among which two were chosen as candidate drivers (summarised in Table 4.9).  One of the 
genes MYH11, encodes a definitive marker of smooth muscle differentiation (Tamama, Sen et al. 
2008, Kurpinski, Lam et al. 2010) and was chosen based on a potential role in mesenchymal lineage 
differentiation of these tumours.  The other ACTN1 encodes α-actinin, an actin filament that has 
been found to be over-expressed in various cancers with functional implications (Quick and Skalli 
2010).  It was also identified by enrichment analysis as a candidate amplified driver gene based on 
its function in the KEGG
®
 focal adhesion pathway (Section 4.5.1.5 and Table 4.8).   Neither had 
previously been implicated in STS. 
Table 4.9:  Differential Amplifications in LMS 
 Region Cytoband Count 
Region 
Length (Mb) 
Freq. in 
LMS (%) 
Freq. in 
Others (%) 
p-value q-bound 
Genes 
in Atlas 
Chr 1 
203,369,354-203,514,881 q32.1 2 0.15 52.4 9.4 0.0010 0.21 - 
183,311,689-183,353,653 q25.3 1 0.04 57.1 15.6 0.0025 0.25 - 
Chr 14 69,333,317-69,519,867 q24.1 2 0.19 57.1 9.4 0.0003 0.18 ACTN1 
Chr 16 15,891,532-15,957,512 p13.11 1 0.07 52.4 6.3 0.0002 0.15 MYH11* 
   6      2 
Genomic regions shown have a differential frequency of amplification > 40% in LMS (compared with average of 
other STS subtypes with complex karyotypes) and p < 0.05 as judged by the Fisher’s exact test.  Only affected 
genes that have been implicated in cancer are shown in the last column.  Genes with reported gain of copy 
number and/or function abnormalities in cancer (candidate driver genes) are in shown in red. 
* - gene possibly involved in differentiation 
Differential aberration analysis was carried out using Nexus
®
 Copy Number software and gene function 
information was obtained from Atlas of Genetics and Oncology and PubMed literature reviews.    
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The five regions with significant differential copy number deletions in LMS involved around 0.77Mb in 
total and covered the loci for seven genes.  Only two of the seven genes have been implicated in 
cancer (Table 4.10).  One of these was the PRDM16 gene, which was involved in a focal deletion at 
1p36.32 that was identified as significant using both the STAC and GISTIC algorithms and whose 
deletion would prevent differentiation into an adipocytic lineage in favour of smooth muscle (Section 
4.4.1.4).    
The other gene BTRC encodes a member of the F-box proteins called βTrCP1 that plays positive 
and negative regulatory roles in the NF-κB and Wnt signalling pathways, respectively (Koch, Waha 
et al. 2005, Müerköster, Arlt et al. 2005).  It has been found to be over-expressed in breast (Bhatia, 
Herter et al. 2002), pancreatic (Müerköster, Arlt et al. 2005), colorectal (Ougolkov, Zhang et al. 2004) 
and hepatocellular carcinoma (Koch, Waha et al. 2005) .   Its reported functions therefore did not 
support a driver role in LMS. 
 
Table 4.10:  Differential Deletions in LMS 
 Region Cytoband Count 
Region 
Length (Mb) 
Freq. in 
LMS (%) 
Freq. in 
Others (%) 
p-value q-bound 
Genes  
In Atlas 
Chr 1 
1,151,667-1,161,955 p36.33 1 0.01 57.1 3.1 0.0000 0.08 - 
3,184,391-3,448,830 p36.32 3 0.26 47.6 3.1 0.0002 0.11 PRDM16
‡
 
Chr 10 103,015,529-103,301,856 q24.32 1 0.29 61.9 21.9 0.0045 0.19 BTRC 
Chr 11 
78,557,943-78,714,348 q14.1 1 0.16 47.6 3.1 0.0002 0.11 - 
92,589,653-92,644,197 q14.3 1 0.05 57.1 15.6 0.0025 0.17 - 
   7      2 
Genomic regions shown have a differential frequency of deletion > 40% in LMS (compared with average of 
other STS subtypes with complex karyotype) and p < 0.05 as judged by the Fisher’s exact test.  Only affected 
genes that have been implicated in cancer are shown in the last column.  One gene with reported gain of copy 
number and/or function abnormalities in cancer (likely passenger) is shown in grey.  
 
‡ 
- gene with possible role in mesenchymal cell lineage differentiation. 
Differential aberration analysis was carried out using Nexus
®
 Copy Number software and gene function 
information was obtained from Atlas of Genetics and Oncology and PubMed literature reviews.    
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4.4.1.7 Summary of Candidate Genes in LMS 
Using the different statistical tools, a total of 95 candidate genes were identified in LMS and 
summarised in Table 4.11.  There was a predominance of amplified genes identified as candidates 
(68 out of 95) and most of these were involved in enriched pathways.  Two candidate genes 
including MYH11 and PRDM16 (amplified and deleted, respectively) have reported roles in 
mesenchymal lineage differentiation, while one deleted gene, CEP55 is involved in genome 
maintenance. 
Six amplified and five deleted candidate genes were identified using more than one analysis tool and 
comprise the strongest of the candidate genes (summarised on Table 4.12).  They include important 
putative oncogenes such as PIK3R1 and tumour suppressor genes such as TP53, RB1 and FAS. 
Table 4.11:  Summary of Candidate genes identified in LMS   
Analysis Tool Amplified candidate Genes  Deleted Candidate Genes 
Common Aberration  
ARHGEF2 
CKS1B 
ELL 
GDF15 
GMPS 
MAP2K4 
MLF1 
MYOCD 
NOTCH2 
NQ01 
PDE4DIP 
PIK3R1 
SHC1 
 
ARL11 
BMPR1A 
BOK 
CEP55* 
CLDN7 
DFFB 
DLG4 
FAS 
ING5 
INPP5D 
INTS6 
KCTD11 
KLLN 
LGI1 
MUC2 
PHF11 
PRDM16
 ‡
 
PTEN 
RB1 
RBP4 
RCBTB1 
RCBTB2 
TNFRSF14 
TNFSF12 
TNKS2 
TP53 
 (n = 13)  (n = 25) 
Pathway Enrichment 
ACTN1 
ARHGAP5 
ARHGEF2 
BCAR1 
BCL2 
BCL2L1 
CAV2 
CBLB 
CCNE1 
CKS1B 
COL3A1 
COL5A2 
COL6A1 
COL6A2 
DAXX 
DIAPH1 
E2F2 
FOS 
FYN 
GRB2 
IKBKB 
ITGA11 
ITGA5 
ITGA9 
ITGB5 
JUN 
LAMA3 
LAMA4 
LAMC1 
LAMC2 
MAP2K3 
MAP3K4 
MAP4K5 
MAPK1 
MAPK6 
MAPK7 
MAPKAP 
MYC 
MYLK 
MYLPF 
PIK3CA 
PIK3R1 
PIP5K1B 
PTGS2 
RAP1A 
ROCK1 
RPS6KA 
SHC1 
SHC3 
SHC4 
SMAD3 
SOS2 
SRC 
SRF 
TGFBR2 
TNR 
TRAF4 
VAV3 
 
FAS 
RB1 
SIRT1 
SUMO1 
TP53 
 
 (n = 58)  (n = 5) 
Differential aberration  ACTN1 
MYH11 
‡ 
 
PRDM16 ‡ 
 (n = 2)  (n = 1) 
Total Individual Genes 69 
 
27 
Genes shown in red have reported gain of copy number and/or function abnormalities in cancer, while those 
shown in green have reported loss of copy number and/or function abnormalities.  Genes that were identified 
using more than one analysis tool are highlighted in grey.   
‡ 
- gene with possible role in mesenchymal cell lineage differentiation. 
* - gene with potential role in maintenance of genome integrity 
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Table 4.12:  Strong Candidate genes identified in LMS   
 Gene Putative Biologic Function Frequency (%) Likely Pathogenetic Role 
Previously Identified in 
STS? 
Amplified 
ARHGEF2 
Guanine nucleotide exchange factor for Rho GTPase – 
cell migration/invasion 
62 Tumour Progression Yes 
PIK3R1 Positive regulation of PIK3/Akt signalling pathway 43 
Oncogenesis 
Tumour progression 
No 
ACTN1 Cell motility  57 
Tumour Progression 
Mesenchymal differentiation 
No 
SHC1 Ras regulation, growth factor signalling and survival 62 
Oncogenesis 
Tumour progression 
No 
Deleted 
PRDM16 Negative regulation of myogenic differentiation 48 Mesenchymal differentiation No 
FAS Induction of apoptosis 52 
Oncogenesis 
Tumour progression 
No 
RB1 Tumour suppressor 67 
Oncogenesis 
Cell Cycle Regulation 
Yes 
TP53 Cell cycle regulation 52 Oncogenesis Yes 
All genes shown were identified as significantly aberrant among LMS by two or more of the statistical approaches (Common Aberration, Pathway Enrichment and Differential 
Aberration) used in this study.   
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4.4.2 Copy Number Aberrations in Gastrointestinal Stromal Tumours 
4.4.2.1 GIST Cases 
Eleven GIST cases were analysed by array CGH, including one case (GIST 11) that was re-
classified as a GIST based on its array CGH profile as discussed in Section 4.5.  Characteristics of 
all the GIST cases are summarised in Table 4.13 below.  With one exception (GIST 07), the patients 
were in the 6
th
 - 8
th
 decade of life at the time of surgery with fairly even distribution (5:6) of male and 
female gender, respectively.  
The majority of samples (10 out of 11) were primary tumours that originated in the stomach, which is 
the commonest site for GIST (Fletcher, Bridge et al. 2013).  Only one case (GIST 08) was sampled 
from a liver metastasis of a gastric primary tumour.    The eleven tumours ranged in size from 27 to 
100mm in maximum dimension, with a fairly even distribution of tumour grade (Table 4.13).  FFPE 
tumour material was used for array CGH in all cases with half of the samples being five years or 
more in age at the time of analysis in 2012.    
 
Table 4.13:  Summary of GIST cases used for common focal SCNA Identification  
Case 
Sampling 
Date 
Gender 
Age (years)  
at diagnosis 
Site Size Grade 
GIST 01 2009 Female 75 Stomach 62 High 
GIST 02 2010 Male 70 Small bowel 100 Intermediate 
GIST 03 2011 Female 71 Small bowel 35 High 
GIST 04 2010 Female 59 Stomach 39 Intermediate 
GIST 05 2004 Female 76 Stomach 70 Low 
GIST 06 2004 Male 61 Stomach 27 Low 
GIST 07 2005 Male 27 Small Bowel 95 Intermediate 
GIST 08 2006 Male 58 Liver Met 67 High 
GIST 09 2010 Male 74 Stomach 50 Intermediate 
GIST 10 2010 Female 73 Stomach 54 Low 
GIST 11 1994 Male 79 Stomach 30 - 
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4.4.2.2 Recurrent Gains and Losses 
In general, GISTs had simple genomic copy number profiles when compared with LMS.  Profiles 
were characterised mostly by large whole- or near whole-arm chromosomal aberrations.  A majority 
of large aberrations detected were losses while the focal SCNA were mostly amplifications.  The 
common gains and losses detected among GIST are summarised as a penetrance plot in Figure 
4.10.   
Loss of the long arm of chromosome 14 was the most common aberration, seen in all but two cases 
(82%).  Other frequent losses were seen on 22q (55%), 1p (45%) and 15q (36%).  These findings 
were in concordance with reports from previous studies (Barretina, Taylor et al. 2010, Ylipaa, Hunt et 
al. 2011). 
 
Figure 4.10:  Frequency Plot of Common Genomic Copy Number Aberrations among 11 
Gastrointestinal Stromal Tumours 
Commonly aberrant regions are plotted as a function of their chromosomal position.  Red bars to the 
left of the chromosome represent frequency of deletions and blue bars to the right of the 
chromosome represent amplifications.  The heights of the bars correspond to the frequency of 
aberrations among the cases. 
All SCNAs are detected using the FASST2 algorithm  
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4.4.2.3 Common Focal SCNA 
Using the minimal common region (MCR) method, only 93 common aberrations affecting 
approximately 7% of the genome were identified with a prevalence of at least 20% among GIST.  
Eight of these which were in non-coding regions of the genome and a further 11 SCNAs (9 
amplifications and 2 deletions) representing CNVs were excluded from further analysis.   
Of the remaining 74 focal SCNA, 47 were amplifications that ranged in size from 0.032 to 0.318Mb 
(mean = 0.282Mb, median = 0.237Mb) and involved loci for around 7 genes on average.  The most 
frequent amplification (seen in 64% of cases) was a 0.13Mb region located at 6p22.2 and involving a 
cluster of histone genes.  Focal deletions were fewer (27 out of the 74 aberrations), but larger in size 
overall (mean = 5.2Mb, median 0.615Mb).  Three of these deletions were very large (over 5Mb in 
size, so technically losses), including a near whole-arm loss on chromosome 14 that was 50Mb in 
size and covered as many as 510 gene loci.  
4.4.2.4 Significance Testing of Common Focal SCNA 
STAC 
About a third of the 47 common focal amplifications in GIST were determined to be significant (p < 
0.05) using the STAC algorithm (summarised in Table 4.14).  However, none of the common focal 
deletions was found to be statistically significant.  This was not surprising because the STAC 
algorithm tests the significance of SCNA using the average copy number state of the whole 
chromosome arm as a background and unlike the amplifications, many of the common deletions in 
GIST either occurred within or were large common aberrations that involved near whole 
chromosome arms.  The significant SCNA identified by STAC are summarised in Table 4.9 and 
comprehensive list of affected genes is provided in Tables A1 and A2 of Appendix 5. 
The significant amplifications identified by STAC covered loci for 75 genes, among which eight have 
previously been implicated in cancer (Table 4.14).  For 3 of these genes however, missense 
mutation, deletion and/or reduced expression are the previously-reported abnormalities, making their 
amplification unlikely to be driver abnormalities.  Four of the remaining five genes have consistently 
been reported to have gain of function abnormalities in relation to cancer including JUND, which 
encodes a member of the well-known family of oncogenes.  They were thus readily included among 
candidate drivers for GIST.   
The last gene FHL2 was initially described as down-regulated among rhabdomyosarcoma cells 
compared to normal myoblasts (Genini, Schwalbe et al. 1997).  It has however subsequently been 
described as frequently up-regulated in a primary tissue, in vitro cell cultures and even tumour 
xenografts of a number of other cancers, including ovarian (Gabriel, Mildenberger et al. 2004), 
gastrointestinal (Wang, Yang et al. 2007), breast (Martin, Kleiber et al. 2007) and prostate cancers 
(Heemers, Regan et al. 2007) as well as high grade gliomas (Li, Wang et al. 2008).  Further, FHL2 
up-regulation has been associated with adverse outcomes in breast and prostate cancer (Gabriel, 
Fischer et al. 2006, Kahl, Gullotti et al. 2006).  These latter findings are more in keeping with the 
putative gene functions, which include roles in tumour cell survival, adhesion and motility (Kleiber, 
Strebhardt et al. 2007).   
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Table 4.14:  Significant Common Focal Amplifications among GIST (STAC) 
 Cytoband Region 
Length 
(Mb) 
Frequency 
(%) 
P-Value Genes 
Genes in 
Atlas 
Chr 1 
q24.2 168,378,978-168,685,455 0.31 27 0.004 3 - 
q32.2 207,984,254-208,137,993 0.15 45 0.000 1 - 
Chr 2 q12.1 - q12.2 105,949,598-106,147,840 0.20 36 0.000 1 FHL2 
Chr 5 
p15.33 1,035,059-1,353,444 0.32 45 0.000 6 - 
q31.3 141,696,250-142,040,249 0.34 45 0.000 2 - 
Chr 6 
p25.2 2,836,816-3,001,306 0.16 36 0.020 6 - 
p22.2 26,124,423-26,250,955 0.13 64 0.000 16 - 
p21.31 34,958,314-35,188,392 0.23 36 0.020 3 - 
Chr 7 q36.1 150,913,717-150,954,753 0.04 45 0.000 3 - 
Chr 9 q22.32 97,847,752-98,088,612 0.24 36 0.007 1 FANCC 
Chr 11 
q23.3 117,706,762-117,781,447 0.07 36 0.000 3 - 
q13.3 69,906,662-70,052,101 0.15 36 0.000 2 - 
Chr 12 
p13.1 12,863,830-12,896,612 0.03 27 0.000 2 CDKN1B 
q24.31 124,988,479-125,313,180 0.32 27 0.001 2 - 
Chr 17 p13.1 8,017,959-8,127,962 0.11 27 0.002 6 PER1 
Chr 19 p13.11 18,380,369-18,583,639 0.20 45 0.000 9 
ELL 
GDF15 
JUND 
Chr 20 q13.33 61,818,375-62,138,166 0.32 27 0.010 9 EEFIA2 
      75 8 
Minimum frequency of SCNA = 20%, p < 0.05.  Only affected genes found to be implicated in cancer are shown.  
Genes with gain of copy number and/or function abnormalities in cancer are in red and those reported in 
sarcoma are highlighted in bold.  Any genes that show the opposite abnormalities in cancer are shown in grey.   
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GISTIC 
In contrast to the STAC algorithm, only focal deletions were identified as significant among the GIST 
cases.  Four deletions were identified in total, all of which were large genomic regions (losses) 
ranging in size from 29 to 121Mb (mean = 62.5Mb, median 49.6Mb) and represented most of 1p, 
14q, 15q and 22q (summarised in Table 4.15).  The extended regions involved over 2000 gene loci 
in total, while the peak regions contained only five genes.   
Given the large number of affected genes in the extended regions, only those genes in the peak 
regions were examined individually in terms of biologic function.   The remaining genes in the 
extended regions were examined by enrichment analysis (Section 4.4.2.5) and a full list of genes is 
presented in Appendix 5 (Tables B).  None of the five peak region genes has any known abnormality 
that has been associated with cancer, and three of their loci corresponded exactly with a known CNV 
on chromosome 22 that was confirmed in other STS subgroups in this study (data not shown).   
  
Table 4.15:  Significant Common Focal Deletions among GIST (GISTIC) 
 Cytoband Region 
Length 
(Mb) 
G-Score Q-Bound 
No. of  
Genes 
Genes 
in Peak 
Genes 
In Atlas 
Chr 1 p36.33 - p11.2 chr1:0-121,322,377 121.3 4.91 0.004 1098 - - 
Chr 14 q21.1 - q32.33 43,345,398-107,349,540 64.0 7.04 0.003 433 - - 
Chr 15 q24.1 - 32.33 72,998,432-102,531,392 29.5 3.15 0.046 225 
TM2D3 
TARSL2 
- 
Chr 22 q11.1-13.33 16,133,474-51,304,566 35.2 5.56 0.004 459 
GSTTP1 
GSTT1 
GSTTP2 
- 
      2215 5 
 
Minimum G-score = 1.0, q < 0.05.  None of the genes in the peak regions was found to be implicated in cancer.  
The remaining genes in the affected regions were functionally examined using enrichment analysis (see below). 
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4.4.2.5 Enrichment Analysis of Affected Genes 
Amplified Genes 
A total of 350 genes whose loci were within the common amplified SCNA regions in GIST were 
submitted to DAVID for enrichment analysis.  The only molecular pathway that was significantly over-
represented among these genes was the KEGG Systemic Lupus Erythematosus (SLE) pathway 
(EASE p-value = 0.003).  The pathway is not cancer-related and all 7 affected genes belong to a 
cluster of histone genes located at 6p22 (described in section 4.4.2.3). 
Deleted Genes 
Enrichment analysis of the 1557 genes affected by deleted regions showed significant over-
representation of genes in 6 molecular pathways, which are summarised on Table 4.16 below. The 
involved genes are shown on Table C of Appendix 5.  None of the pathways or genes involved have 
any biologic relevance to tumour pathogenesis in GIST.  Enrichment analysis of the 2215 genes 
affected by significant deletions identified using the GISTIC algorithm (Section 4.4.2.4) identified the 
exact same pathways.   
 
Table 4.16:  Molecular Pathways significantly over-represented among commonly deleted focal 
SCNA among GIST 
Pathway ID Term 
Gene 
Count 
Fisher 
p-value 
EASE 
p-value 
Fold 
Enrichment 
BIOCARTA 
h_cpsfPathway 
Polyadenylation of mRNA 3 2.3E-02 2.33E-02 11.34 
BIOCARTA  
h_circadianPathway 
Circadian Rhythms 4 2.4E-04 4.69E-03 10.08 
KEGG 
hsa04740 
 
Olfactory transduction 92 5.3E-28 2.16E-27 3.35 
KEGG 
hsa03050 
Proteasome 10 1.6E-03 5.73E-03 2.93 
KEGG 
hsa00600 
Sphingolipid metabolism 8 6.0E-03 2.01E-02 2.83 
All genes involved in amplified focal SCNA with a frequency ≥ 20% among GIST were submitted for enrichment 
analysis.  Only cancer-related pathways with EASE p-value < 0.05 are shown in order of their fold enrichment.  
None of the affected genes are shown because none of them have been described with loss of copy number 
and/or function abnormalities in cancer. 
Enrichment analysis was carried out using DAVID Bioinformatics tool (http://david.abcc.ncifcrf.gov, accessed March 2013) 
based on information from Biocarta
® 
(http://www.biocarta.com/genes/index.asp, accessed March 2013) and KEGG
®
 
(http://www.genome.jp/kegg/pathway.html, accessed March 2013) databases. 
4.4.2.6 Differential Aberration Analysis 
Differential aberration analysis of the common SCNA among GIST compared with those in all other 
STS subtypes in this study showed that whole arm deletions of 1p, 14q and 22q, were not only the 
most frequent aberrations, but also the most significant (Fisher’s p-value < 0.05).  As the significant 
differential aberrations were mostly large losses and not focal SCNA, they are presented graphically 
in Figure 4.11.  One small region of significant aberration highlighted at 13q14 was deleted with a 
significantly higher frequency among other STS subtypes (particularly LMS and UPS) and not in 
GIST. 
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Figure 4.11:  Frequency Plots of Common Genomic Copy Number Aberrations among Gastrointestinal Stromal Tumours compared with other STS Subtypes 
Significant differentially aberrant regions (highlighted by the red (deletion) and blue (amplification) bars in the ‘significant’ track) were calculated based on an absolute difference in 
frequency ≥ 40% and Fisher p-value < 0.05.   
In the bottom panel, commonly aberrant regions in GIST (above) and other STS subtypes (below) are plotted as a function of their chromosomal position.  Red downward bars 
represent frequency of deletions and blue upward bars represent amplifications.  The heights of the bars correspond to the frequency of aberrations among the cases. 
Unlike the other significant differential aberrations shown, the differentially deleted region on chromosome 13 (circled in green) is commonly deleted among other STS subtypes 
(mainly LMS and UPS) but not among GIST. 
All SCNAs are detected using the FASST2 algorithm  
 
 
GIST 
(n = 11) 
Other 
STS 
Subtypes 
(n = 32) 
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4.4.2.7 Summary of Candidate Aberrations in GIST 
The candidate genomic aberrations identified among GIST are summarised in Table 4.17 below.  
Only five final individual candidate gene aberrations were identified by statistical analysis of common 
focal SCNA among GIST, none of which was a deletion.  Three near-whole chromosome arm losses 
were however identified by both common and differential aberration analyses.  All three losses are 
described in literature as being common in GIST and this pattern of losses led to the reclassification 
of one of the STS cases in this study (discussed in detail in Section 4.5)  
 
Table 4.17:  Summary of Candidates identified in GIST   
Analysis Tool Amplified Candidates Deleted Candidates 
Common Aberration  
FHL2 
ELL 
GDF15 
JUND 
EEFIA2 
 1p 
 14q 
 22q 
 (n = 5) (n = 3) 
Pathway Enrichment - - 
Differential aberration  - 
 1p 
 14q 
 22q 
  (n = 3) 
Total 5 3 
Genes shown in red have reported gain of copy number and/or function abnormalities in cancer, while genomic 
regions shown in green have reported loss of copy number abnormalities.  Aberrations that were identified 
using more than one analysis tool are highlighted in grey.   
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4.4.3 Copy Number Aberrations in Undifferentiated Pleomorphic Sarcoma 
4.4.3.1 Undifferentiated Pleomorphic Sarcoma Cases 
Sixteen (16) UPS cases were included for common aberration analysis and their clinical 
characteristics are summarised in Table 4.18.  Among these, four cases (UPS 04, 05, 06 and 07) 
were analysed as fresh frozen samples while the others were FFPE samples.  The tumours ranged 
in size between 55 and 270mm in maximum dimension, with the largest located in the abdominal 
cavity, although the majority were from the lower limb.  All but two tumours were high grade 
(Trojani Grade 3), as expected in this STS subgroup (Fletcher, Bridge et al. 2013).  There was an 
almost equal mix of patient gender and ages ranged between 34 and 82 years.   
   
Table 4.18:  Summary of LMS Cases used for Identification of Common Focal SCNA  
Case Gender Age Site Size (mm) Grade Status 
UPS 01 Male 65 Lower Limb 120 3 Dead 
UPS 02 Female 54 Lower Limb 230 3 Alive 
UPS 03 Male 44 Trunk 108 3 Dead 
UPS 04 Female 36 Lower Limb 72 2 Alive 
UPS 05 Male 76 Lower Limb 175 3 Dead 
UPS 06 Female 67 Lower Limb 115 3 Dead 
UPS 07 Female 74 Upper Limb 90 3 Dead 
UPS 08 Female 75 Lower Limb 102 3 Dead 
UPS 09 Female 34 Intraabdominal 270 3 Dead 
UPS 10 Male 82 Trunk 93 3 Alive 
UPS 11 Male 64 Intraabdominal 100 3 Alive 
UPS 12 Male 65 Lower Limb 113 3 Alive 
UPS 13 Male 82 Trunk 87 3 Dead 
UPS 14 Male 66 Lower Limb 48 3 Alive 
UPS 15 Female 67 Lower Limb 72 2 Alive 
UPS 16 Male 80 Lower Limb 55 3 Alive 
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4.4.3.2 Recurrent Gains and Losses 
All but one of the 16 UPS cases showed highly complex genomic copy number profiles with 
multiple SCNA present on almost every chromosome.  A frequency plot showing gains and losses 
detected in at least 20% of cases is shown below in Figure 4.12.  There was a fairly even 
distribution of frequent gains and losses.   
The most frequent aberration was the near whole-arm loss of 13q, seen in around 80% of cases.  
Other frequent aberrations (seen in > 40% of cases) included near-whole losses of both arms of 
chromosome 10 and losses at telomeric ends of 1q, 4q, and 11q.  Frequent gains involved whole 
or near-whole arms of 1p, 3p, 5p, 7p, 9q, 12p, 20q, as well as centromeric ends of 1q and 3q.   
 
Figure 4.12:  Frequency Plot of Common Genomic Copy Number Aberrations among 16 
Undifferentiated Pleomorphic Sarcomas 
Commonly aberrant regions are plotted as a function of their chromosomal position.  Red bars to 
the left of the chromosome represent frequency of deletions and blue bars to the right of the 
chromosome represent amplifications.  The heights of the bars correspond to the frequency of 
aberrations among the cases. 
All SCNAs are detected using the FASST2 algorithm  
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4.4.3.3 Common Focal SCNA 
Reflecting the complexity of their copy number profiles, over 2000 common focal SCNA spread 
over all autosomes and involving about one-third of the genome were detected with a minimum 
frequency of 20% among UPS.   Approximately 200 of these SCNA were excluded from further 
analysis because they lay in non-coding genomic regions and/or represented germ-line CNVs, 
including a small (0.2Mb) region of copy number amplification at 14q11.2 that was detected in all 
sixteen UPS samples.  The remaining focal SCNA comprised 956 amplifications and 888 deletions 
with a size range of SCNA of between 4.0kB and 4.3Mb (mean = 0.36Mb, median = 0.24Mb). 
Around 7000 genes in total were affected by common focal SCNA in UPS (3815 amplified and 
3359 deleted).  Both the common focal deletions and amplifications contained around 4 gene loci 
on average.  The most common aberration was a deletion at 13q14.2 detected in 14 out of the 16 
cases (87.5%) that contains the locus for a single gene, SUCLA2.  The region lies in very close 
proximity to the locus for the RB1 tumour suppressor gene, which was involved in a focal deletion 
seen in 13 out of 16 cases (81.25%).  The most common amplification involved a 0.5Mb region on 
1p22 that was seen in 75% of cases (12 out of 16) and contained the locus for the well-known JUN 
oncogene.   
 
4.4.3.4 Significance Testing of Common Focal SCNA 
STAC 
The STAC algorithm found nearly twice as many common focal deletions as amplifications in UPS 
to be statistically significant (p< 0.05).   There were 10 significant amplifications involving loci for 14 
genes as summarised in Table A1 of Appendix 6.  Half of the involved genes have previously been 
implicated in cancer, including STS (for 3 genes) and all have reported abnormalities that would 
support a driver role for their amplification in UPS (Table 4.19).  One of the genes, RAD51B may 
have implications for genomic instability because reported evidence in leukaemia suggests that its 
enhanced activity via the BCR/ABL kinase pathway is associated with defective homologous 
recombination and disease progression (Slupianek, Jozwiakowski et al. 2009).    
Nineteen significant common focal deletions in UPS involved loci for over 130 genes spread over 
eight chromosomes.  All the deleted SCNA identified using the STAC algorithms are summarised 
on Table 4.20 and the full list of affected genes is presented in Appendix 6 (Table A2).  Only five of 
the affected genes have been implicated in cancer and all have been described as having reduced 
copy number or expression in relation to various cancers, although increased expression of FAT1 
has also been associated with migration and invasion of breast cancer (Kwaepila, Burns et al. 
2006).   
  
 105 
 
Table 4.19:  Significant Common Focal Amplifications among UPS (STAC) 
 Cytoband Region 
Length 
(Mb) 
Frequency 
(%) 
P-Value 
No. of 
Genes 
Genes in 
Atlas 
Chr 1 
p32.1 59,228,562-59,722,944 0.49 75 0.000 2 JUN 
q21.1 145,070,378-145,278,200 0.21 69 0.000 3 PDE4DIP 
Chr 2 q12.3 108,867,623-108,889,968 0.02 38 0.024 1 - 
Chr 3 p12.1 86,880,017-87,076,959 0.20 69 0.012 1 VGLL3 
Chr 4 q12 54,400,737-54,592,199 0.19 44 0.013 1 PDGFRA 
Chr 7 q33 135,033,284-135,102,970 0.07 63 0.022 1 - 
Chr 8 q12.1 59,724,608-59,965,524 0.24 50 0.042 1 - 
Chr 11 p13 35,080,110-35,282,073 0.20 44 0.000 2 CD44 
Chr 14 q24.1 68,824,970-69,144,273 0.32 56 0.027 1 RAD51B 
Chr 21 q22.12 36,617,496-36,764,360 0.15 44 0.001 1 RUNX1 
      14  
Genomic regions shown have amplification frequency ≥ 20% and p < 0.05 as judged by the STAC algorithm.  
Only regions that involve at least one known gene locus are listed and only the affected genes that have been 
implicated in cancer are shown.  Genes with reported gain of copy number and/or function abnormalities in 
cancer (candidate driver genes) are in shown in red while those that have been described with the opposite 
abnormalities in cancer are shown in grey (likely passengers).  Genes that have been implicated in STS are 
highlighted in bold red text.   
STAC analysis was carried out using Nexus
®
 Copy Number Software and gene function information was 
obtained from Atlas of Genetics and Oncology and PubMed literature reviews.    
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Table 4.20:  Significant Common Focal Deletions among UPS (STAC) 
 Cytoband Region 
Length 
(Mb) 
Frequency 
(%) 
P-Value 
No. of 
Genes 
Genes in 
Atlas 
Chr 4 
q35.1 184,425,375-185,143,402 0.72 56 0.032 5 ING2 
q35.1 - q35.2 186,797,948-187,792,442 1.00 56 0.032 9 
FAT1 
SORBS2 
q35.2 188,398,868-189,739,168 1.30 56 0.032 3 - 
q35.2 190,624,209-191,154,276 0.50 63 0.001 37 DUX4 
Chr 11 
q24.1 121,300,330-121,397,853 0.10 63 0.018 1 - 
q24.1 122,766,398-123,471,184 0.70 63 0.018 4 - 
q24.2 125,355,927-126,358,069 1.00 63 0.018 22 FEZ1 
q24.3 129,023,372-130,446,982 1.40 63 0.018 10 - 
Chr 14 q32.33 104,566,967-104,715,087 0.10 31 0.042 2 - 
Chr 17 
q11.2 26,726,585-27,042,613 0.32 50 0.006 13 - 
q11.2 27,203,586-27,211,735 0.01 56 0.000 1  
q11.2 27,623,194-27,880,882 0.26 63 0.000 1 - 
q11.2 28,424,381-28,525,378 0.10 56 0.000 3 - 
q11.2 29,041,847-29,371,754 0.33 63 0.000 7 - 
Chr 19 p13.3 0-350,965 0.40 44 0.016 7 -- 
Chr 20 
p13 0-210,288 0.20 38 0.043 5 - 
p13 398,763-434,066 0.04 38 0.043 2 -- 
Chr 21 q22.3 47,760,929-47,790,354 0.03 56 0.000 1 - 
      135 5 
Genomic regions shown have deletion frequency ≥ 20% and p < 0.05 as judged by the STAC algorithm.  Only 
regions that involve at least one known gene locus are listed and only the affected genes that have been 
implicated in cancer are shown.  Genes with reported loss of copy number and/or function abnormalities in 
cancer (candidate driver genes) are in shown in red.  Genes that have been implicated in STS are highlighted 
in bold red text.  
‡ 
- gene with role in mesenchymal lineage differentiation  
STAC analysis was carried out using Nexus
®
 Copy Number Software and gene function information was 
obtained from Atlas of Genetics and Oncology and PubMed literature reviews.    
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GISTIC 
Of the nearly 2000 SCNA detected among UPS, the GISTIC algorithm found only seven (four 
amplifications and 3 deletions) to be significant with G-score > 1.0 and q-bounds < 0.05.  They 
ranged between 1.7 and 16.6Mb in size, covering loci for between 6 and 57 genes.  A total of 194 
genes were affected with a fairly even ratio of amplified to deleted genes (summarised in Tables B1 
and B2 of Appendix 6). 
 With a mean G-score of 9.7, the significantly amplified SCNA occurred with an average frequency 
of 50.2% among UPS.  Their extended regions covered a total of 95 genes, but peak regions 
involved only 2 gene loci.  Fifteen of the genes affected by significant deletions have been 
implicated in cancer, among which six genes were described as being amplified and/or 
overexpressed in STS of various subtypes (Table 4.21).  Two of these genes, YAP1 and VGLL3 
were also identified using the STAC approach (Section 4.6.3.1).  One of the significant amplicons 
located at 5p15.2 has been highlighted in a number of previous studies in sarcoma and three of the 
genes involved, TRIO, CTNND2 and DNAH5 have been suggested as candidate drivers (Ylipaa, 
Hunt et al. 2011). 
Table 4.21:  Significant Common Focal Amplifications among UPS (GISTIC) 
 Cytoband Region 
Length 
(Mb) 
Frequency 
(%) 
G-Score Q-Bound 
No. of 
Genes 
Genes 
in Peak 
Genes in 
Atlas 
Chr 3 3p12.1-11.1 
86,816,036-
88,468,010 
1.7 63 8.19 0.03 6 CHMP2B VGLL3 
Chr 5 5p15 
10,606,546-
16,879,792 
6.3 56 7.96 0.03 14 - 
TRIO 
CTNND2 
DNAH5 
Chr 7 7q11 
77,437,091-
94,074,985 
16.6 38 8.06 0.03 57 SEMA3E 
AKAP9 
CDK6 
HGF 
DMTF1 
ABCB1 
STEAP1 
STEAP2 
COL1A2 
Chr 
11 
11q22.1 - q22.3 
101,263,543-
103,276,617 
2.0 50 14.43 0.00 18 - 
YAP1 
BIRC2 
BIRC3 
       95  15 
Genomic regions shown have amplification G-score ≥ 1.0 and q < 0.05 as judged by the GISTIC algorithm.  
Only affected genes that have been implicated in cancer are shown in the last column.  Genes with reported 
gain of copy number and/or function abnormalities in cancer (candidate driver genes) are in shown in red while 
those that have been described with the opposite abnormalities in cancer are shown in grey (likely 
passengers).  Cancer-implicated genes with as yet undetermined or inconsistent functional status are shown in 
black.  Genes that have been implicated in STS are highlighted in bold red text.   
GISTIC analysis was carried out using Nexus
®
 Copy Number software and gene function information was 
obtained from Atlas of Genetics and Oncology and PubMed literature reviews.    
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The most frequent deleted SCNA at 13q14 was highly significant (q-bound = 0.00001) and its peak 
region specifically contained the locus for the RB1 gene.  The three significant deleted regions 
identified by GISTIC covered a total of 99 genes, among which only four have previously been 
implicated in cancer (Table 4.22).   Apart from RB1, the deleted regions involved the locus of one 
other well-known tumour suppressor gene, NF1 that is located at 17q11.2  and has previously been 
identified as frequently deleted in pleomorphic sarcomas (Taylor, Barretina et al. 2008).  The other 
two cancer-related genes involved, OPCML and INTS6 have also been described either deleted or 
inactivated in various cancers.   
Table 4.22:  Significant Common Focal Deletions among UPS (GISTIC) 
 
 
Cytoband Region 
Length 
(Mb) 
Frequency 
(%) 
G-Score Q-Bound 
No. of 
Genes 
Genes 
in 
Peak 
 Genes 
in Atlas 
Chr 11 
11q24.3 - 
q25 
128,837,921-
135,006,516 
6.2 56 6.13 0.03 23 - OPCML 
Chr 13 13q14 
47,927,728-
52,108,681 
4.2 81 10.80 0.00 31 
RB1 
LPAR6 
INTS6 
*RB1 
Chr 17 17q11.2 
27,203,586-
29,571,405 
2.4 63 6.91 0.01 34 TAOK1 
NF1 
TAOK1 
       99  2 
Genomic regions shown have deletion G-score ≥ 1.0 and q < 0.05 as judged by the GISTIC algorithm.  Only 
affected genes that have been implicated in cancer are shown in the last column.  Genes with reported loss of 
copy number and/or function abnormalities in cancer (candidate driver genes) are in shown in red.   Genes 
that have been implicated in STS are highlighted in bold red text. 
* - gene with role in maintenance of genome integrity 
GISTIC analysis was carried out using Nexus
®
 Copy Number software and gene function information was 
obtained from Atlas of Genetics and Oncology and PubMed literature reviews.    
 
4.4.3.5 Enrichment Analysis of Affected Genes 
Amplified Genes 
Over 3000 amplified genes identified by common aberration analysis in UPS were submitted for 
analysis.  Sixteen pathways in total were significantly enriched (EASE p-value < 0.05) as shown in 
Appendix 6 (Table C1).  Among these, only 6 pathways were cancer-related (summarised in Table 
4.23).  One of these, the Mitogen-Activated Protein Kinase (MAPK) signalling pathway was 
enriched based on data from both KEGG
®
 and Biocarta
®
 databases.  The more detailed schematic 
of the MAPK signalling pathway from the KEGG
®
 database is shown in Figure 4.13.  Interestingly 
this pathway was also enriched among LMS, as was the functionally related focal adhesion 
pathway (shown in Figure 4.14).  
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Table 4.23:  Cancer-related Molecular Pathways significantly over-represented in commonly 
amplified focal SCNA among UPS 
Pathway 
ID 
Term 
Gene 
Count 
Fisher’s  
p-value 
EASE 
p-Value 
Genes Involved 
Fold 
Enrichment 
KEGG 
hsa04510 
Focal 
adhesion 
52 0.0003 0.0005 
JUN 
COL11A1 
RAC3 
COL6A1 
PTENP1 
COL5A1 
COL1A2 
CTNNB1 
COL6A2 
PIK3CG 
TLN2 
VEGFB 
CRK 
ITGA9 
VAV2 
PAK6 
MYL12B 
COL3A1 
PAK1 
LAMB4 
ITGA1 
PRKCA 
HGF 
COL6A3 
LAMA5 
MYL12A 
RELN 
LAMA1 
COL4A1 
LAMB1 
ITGB5 
MET 
COL4A2 
FYN 
TNC  
LAMA3 
ARHGAP5 
BAD 
ITGA11 
RAPGEF1 
COL5A2 
CAV3 
SHC3 
PDGFB 
EGFR 
PARVA 
RAC2 
BRAF 
TNR 
PAK4 
ITGA2 
LAMA4 
1.59 
KEGG 
hsa04010 
MAPK 
signalling 
pathway 
62 0.0016 0.0026 
NTRK2 
TGFBR2 
NTF3 
TRAF2 
CACNG1 
IL1R1 
FGF7 
ACVR1B 
MAP3K7 
FGF10 
JUN 
GNA12 
RAC3 
NFATC4 
MECOM 
MOS 
MAP3K2 
NFATC2 
MAP3K14 
GADD45A 
CRK 
 MAP2K4 
CACNA1D 
MAP2K7 
TGFB1 
PAK1 
PRKCA 
CACNG4 
MAPK7 
MAP2K6 
RASGRP1 
FGF20 
CACNA1C 
MAP3K11 
IL1A 
NR4A1 
MKNK1 
MAX 
CACNG5 
CACNA1E 
PLA2G4E  
TAB2 
MAP2K3 
JUND 
CACNA2D3 
MAP4K2 
ARRB1 
PDGFB 
PPP3R2 
CACNA1I 
EGFR 
TGFBR1 
MAP3K6 
RELA 
GNG12 
DUSP7 
PLA2G2C 
RAC2 
BRAF 
TGFB3 
STK3 
ECSIT 
1.42 
KEGG 
hsa05200 
Pathways 
in cancer 
72 0.0035 0.0052 
PTCH1 
TGFBR2 
APC2 
TRAF2 
RALB 
FGF7 
ACVR1B 
FGF10 
JUN 
RAC3 
WNT16 
GLI3 
PTENP1 
CTNNB1 
MECOM 
CDKN2A 
SHH 
DVL1 
CDKN2B 
KIT 
RXRA 
TGFB1 
WNT5A 
LAMB4 
PRKCA 
HGF 
SMAD3 
RET 
CDK6 
PIK3CG 
VEGFB 
RALBP1 
CRK 
EGLN3 
RUNX1T1 
CEBPA 
CDKN1B 
BAD 
MAX 
ARNT2 
MMP1 
LAMA5 
LAMA1 
COL4A1 
LAMB1 
FGF20 
NFKBIA 
TFG 
MET 
MITF 
COL4A2 
EGLN2 
LAMA3 
PDGFB 
RARB 
EGFR 
BCL2L1 
TGFBR1 
RELA 
AXIN2 
DAPK1 
RAC2 
BRAF 
TPR 
TGFB3 
RALGDS 
WNT2 
RXRG 
IL6 
ITGA2 
MLH1 
LAMA4 
1.35 
KEGG 
hsa05222 
Small cell 
lung 
cancer 
23 0.0066 0.0132 
TRAF2 
PTENP1 
PIK3CG 
CDKN2B 
FHIT 
RXRA 
LAMB4 
CDK6 
LAMA5 
LAMA1 
COL4A1 
LAMB1 
NFKBIA 
COL4A2 
LAMA3 
CDKN1B 
MAX 
RARB 
BCL2L1 
RELA 
RXRG 
ITGA2 
LAMA4 
1.68 
KEGG 
hsa05212 
Pancreatic 
cancer 
20 
9.30E-
03 
0.0189 
TGFBR2 
RALB 
ACVR1B 
RAC3 
CDKN2A 
PIK3CG 
VEGFB 
RALBP1 
TGFB1 
SMAD3 
CDK6 
BAD 
EGFR 
BCL2L1 
TGFBR1 
RELA 
RAC2 
BRAF 
TGFB3 
RALGDS 
1.70 
KEGG 
hsa04520 
Adherens 
junction 
20 0.0200 0.0368 
TGFBR2 
ACVR1B 
MAP3K7 
RAC3 
CTNNB1 
SNAI2 
WASL 
SSX2IP 
SMAD3 
MLLT4 
MET 
FYN 
INSR 
BAIAP2 
EGFR 
TGFBR1 
WASF2 
PTPN1 
RAC2 
PTPRF 
1.59 
All genes involved in amplified focal SCNA with a frequency ≥ 20% among UPS were submitted for 
enrichment analysis.  Only cancer-related pathways with EASE p-value < 0.05 are shown in decreasing order 
of fold enrichment.  All affected genes are listed with genes with gain of copy number and/or function 
abnormalities in cancer (candidate driver genes) shown red.  Genes that have been described with deletion or 
loss of function in cancer are shown in grey (likely passengers).   
Enrichment analysis was carried out using DAVID Bioinformatics tool (http://david.abcc.ncifcrf.gov, accessed March 2013) 
based on information from Biocarta
® 
(http://www.biocarta.com/genes/index.asp, accessed March 2013) and KEGG
®
 
(http://www.genome.jp/kegg/pathway.html, accessed March 2013) databases. 
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Figure 4.13:  Graphic output showing enrichment of members of the KEGG® Mitogen-activated Protein Kinase (MAPK) Signalling pathway among genes 
frequently deleted in UPS 
All genes involved in deleted focal SCNA with a frequency ≥ 20% among UPS were submitted for analysis and the MAPK Signalling pathway was significantly enriched (EASE p-
value <0.05). Arrows represent activation while capped lines represent inhibition.  
+
p denotes phosphorylation while 
–
p denotes dephosphorylation.  Pathway members coded for by 
genes that are frequently deleted in UPS are highlighted by red stars.   
Pathway and highlighted genes are graphical results automatically generated (http://david.abcc.ncifcrf.gov, accessed March 2013) based on information from KEGG
®
 database 
(http://www.genome.jp/kegg-bin/show_pathway?hsa04010, accessed March 2013). 
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Figure 4.14:  Graphic output showing enrichment of members of the KEGG® Focal Adhesion pathway among genes frequently deleted in UPS and LMS. 
All genes involved in deleted focal SCNA with a frequency ≥ 20% among UPS and LMS were submitted for analysis and the Focal Adhesion pathway was significantly enriched 
(EASE p-value < 0.05) in both STS subtypes. Arrows represent activation while capped lines represent inhibition.  
+
p denotes phosphorylation while 
–
p denotes dephosphorylation.  
Pathway members coded for by genes that are frequently deleted in UPS and LMS are highlighted by red and yellow stars, respectively showing that important pathway mediators 
such as integrins (IGTA) and Caveolin were affected in both subtypes.  
Pathway and highlighted genes are modified graphical results automatically generated following enrichment analysis by the DAVID analysis tool (http://david.abcc.ncifcrf.gov, 
accessed March 2013) based on information from KEGG
®
 database (http://www.genome.jp/kegg/pathway/hsa/hsa04510.html, accessed March 2013). 
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Deleted genes 
The commonly deleted focal SCNA in UPS involved 2740 genes, among which 11 biological 
pathways were significantly over-represented (EASE p-value < 0.05) as shown in Table C2 of 
Appendix 6.  Four of the enriched pathways were cancer-related and these are summarised in Table 
4.24.  
In addition to the frequent homozygous deletions affecting 13q14 locus of the RB1 gene in UPS, the 
RB1 tumour suppressor/cell cycle checkpoint pathway was over-represented with almost all key 
mediators affected (Figure 4.15).  This suggests that this SCNA likely plays an important role in the   
genetic instability as well as malignant phenotype that is evident in these tumours.  The other 
enriched pathways include the closely-related cdc25/chek1 regulatory pathway in response to DNA 
damage, as well as the FAS signalling and caspase cascade pathways that are important for 
induction of apoptosis and/or maintenance of genome integrity.  
 
Figure 4.15:  Schematic Representation of the Biocarta® RB Tumour Suppressor/Checkpoint 
Signalling in response to DNA damage pathway. 
All genes involved in deleted focal SCNA with a frequency ≥ 20% among LMS were submitted and the PML 
pathway was significantly enriched (EASE p-value <0.05).  Yellow arrows represent activation while red lines 
represent inhibition.  Pathway members coded for by genes deleted in LMS are highlighted by red stars.  With 
the exception of cdc25, loss of all other affected mediators would favour genetic instability and tumour 
phenotype  
Pathway and highlighted genes are graphical results automatically following enrichment analysis by the DAVID 
analysis tool (http://david.abcc.ncifcrf.gov, accessed March 2013).  Pathway information is based on Biocarta
®
 
database (http://www.biocarta.com/pathfiles/m_rbPathway.asp, accessed March 2013).   
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Table 4.24:  Cancer-related Molecular Pathways significantly over-represented in commonly deleted 
focal SCNA among UPS 
Category Term 
Gene 
Count 
Fisher’s 
p-value 
EASE 
p-value 
Genes 
Involved 
Fold 
Enrichment 
BIOCARTA 
h_rbPathway: 
RB Tumour Suppressor/Checkpoint 
Signaling in response to DNA damage 
7 0.0003 0.0024 
NPAT 
RB1 
CDK1 
MYT1 
CHEK1 
RASGRF1 
TP53 
4.34 
BIOCARTA 
h_cdc25Pathway: 
cdc25 and chk1 Regulatory Pathway in 
response to DNA damage 
5 0.0017 0.0140 
NPAT 
CDK1 
MYT1 
CHEK1 
RASGRF1 
4.65 
BIOCARTA 
h_caspasePathway: 
Caspase Cascade in Apoptosis 8 0.0099 0.0319 
APAF1 
CASP7 
CASP3 
CASP4 
CASP8 
CASP10 
LMNB1 
PRF1 
2.48 
BIOCARTA 
h_fasPathway: 
FAS signaling pathway ( CD95 ) 9 0.0170 0.0449 
CASP7 
CASP3 
CFLAR 
PTPN13 
CASP8 
RB1 
CASP10 
LMNB1 
FAS 
2.16 
All genes involved in deleted focal SCNA with a frequency ≥ 20% among UPS were submitted for enrichment 
analysis.  Only cancer-related pathways with EASE p-value < 0.05 are shown in decreasing order of fold 
enrichment.  All affected genes are listed with genes with loss of copy number and/or function abnormalities in 
cancer (candidate driver genes) shown red.  Genes that have been described with amplification or gain of 
function in cancer are shown in grey (likely passengers).   
Enrichment analysis was carried out using DAVID Bioinformatics tool (http://david.abcc.ncifcrf.gov, accessed March 2013) 
based on information from Biocarta
® 
(http://www.biocarta.com/genes/index.asp, accessed March 2013) database. 
 
 
 
4.4.3.6 Differential Aberration Analysis 
Areas of the genome with significantly different aberration frequency in UPS compared with other 
STS with complex genomic profiles (as described in Section 4.4.5) were identified using 40% 
difference in frequency and Fisher’s exact test p-value < 0.05 as thresholds.  Thirty-four focal copy 
number amplifications were found to be significant, affecting a total of 53 genes as summarised in 
Table D1 of Appendix 6.  Nine of those genes have been implicated in various cancers as having 
gain of copy number and/or function abnormalities (Table 4.25).  Of note are the focal amplifications 
at 1p32.1 and 3p12.1 affecting JUN and VGLL3, respectively that have previously been shown to be 
significant using one or both common aberration algorithms (Section 4.4.3.4).   
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Table 4.25:  Differential Amplifications in UPS 
 Region Cytoband 
Gene 
Count 
Length 
(Mb) 
Freq. in 
NOS (%) 
Freq. in  
Others (%) 
p-value 
Genes in 
Atlas 
Chr 1 
17,236,783-17,280,446 p36.13 1 0.04 56.25 16.22 0.0064 - 
33,570,565-33,600,936 p35.1 1 0.03 56.25 10.81 0.0010 - 
34,489,528-34,777,012 p35.1 – p34.3 1 0.29 56.25 16.22 0.0064 - 
54,724,167-54,779,132 p32.3 1 0.05 50.00 8.11 0.0014 - 
59,228,562-59,247,642 p32.1 1 0.02 75.00 29.73 0.0056 JUN 
63,085,146-63,097,309 p31.3 1 0.01 50.00 8.11 0.0014 - 
Chr 3 
 
63,310,435-63,415,348 p14.2 1 0.10 50.00 8.11 0.0014 - 
85,152,448-86,003,801 p12.1 1 0.69 50.00 5.41 0.0005 - 
86,880,017-87,076,959 p12.1 1 0.20 68.75 13.51 0.0001 VGLL3 
87,727,265-88,074,845 p11.2 – p11.1 1 0.35 56.25 8.11 0.0004 - 
89,441,269-89,908,861 p11.1 1 0.47 50.00 5.41 0.0005 EPHA3 
Chr 7 
15,302,504-15,335,686 p21.2 1 0.03 62.50 18.92 0.0034 - 
15,964,268-16,510,513 p21.2 – p21.1 2 0.55 56.25 16.22 0.0064 SOSTDC1 
17,985,333-18,169,473 p21.1 1 0.18 62.50 18.92 0.0034 - 
18,349,312-19,091,057 p21.1 1 0.12 68.75 24.32 0.0045 - 
19,808,883-20,020,725 p21.1 1 0.21 62.50 18.92 0.0034 - 
20,390,109-20,400,245 p21.1 1 0.01 62.50 21.62 0.0098 - 
22,696,520-22,969,146 p15.3 3 0.27 62.50 18.92 0.0034 IGF2BP3 
23,301,525-23,362,857 p15.3 3 0.06 56.25 16.22 0.0064 IL6 
24,593,062-24,738,029 p15.3 2 0.14 62.50 16.22 0.0023 DFNA5 
25,241,387-25,274,221 p15.3 1 0.03 68.75 21.62 0.0017 - 
26,387,705-26,400,185 p15.2 1 0.01 56.25 16.22 0.0064 - 
27,792,941-27,803,481 p15.2 1 0.01 56.25 13.51 0.0023 - 
30,417,431-30,561,717 p14.3 2 0.14 56.25 16.22 0.0064 GGCT 
116,680,093-116,921,396 q31.2 2 0.24 50.00 8.11 0.0014 ST7 
135,033,284-135,102,970 q33 1 0.07 62.50 21.62 0.0098 - 
Chr 9 
77,295,023-77,307,482 q21.13 1 0.01 56.25 10.81 0.0010 - 
100,186,536-100,230,335 q22.33 1 0.04 50.00 8.11 0.0014 - 
Chr 11 
101,384,809-101,437,354 q22.1 1 0.05 43.75 0.00 0.0001 TRPC6 
102,169,359-102,234,053 q22.2 2 0.06 43.75 2.70 0.0005 
BIRC3 
BIRC2 
102,393,563-102,740,197 q22.2 9 0.35 43.75 0.00 0.0001 
MMP7 
MMP20 
MMP27 
MMP8 
MMP10 
MMP1 
MMP3 
MMP12 
102,822,550-103,076,857 q22.2 – q22.3 3 0.25 43.75 0.00 0.0001 MMP13 
Chr 20 
31,009,725-31,128,856 q11.21 1 0.12 56.25 16.22 0.0064 ASXL1 
31,866,250-31,890,835 q11.21 1 0.02 56.25 16.22 0.0064 - 
   53     22 
Genomic regions shown have a differential frequency of amplification > 40% in UPS (compared with average of 
other STS subtypes with complex karyotypes) and are statistically significant (p < 0.05) as judged by the 
Fisher’s exact test.  Only affected genes that have been implicated in cancer are shown in the last column.  
Genes with reported gain of copy number and/or function abnormalities in cancer (candidate driver genes) are 
in shown in red.   
Differential aberration analysis was carried out using Nexus
®
 Copy Number software and gene function 
information was obtained from Atlas of Genetics and Oncology and PubMed literature reviews. 
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Of the 44 genes affected by 27 significant differentially deleted focal SCNA (p< 0.05), only 4 have 
been implicated in cancer with loss of copy number/function abnormalities (summarised in Table 
4.26 and Table D2 of Appendix 6).  Focal deletions on 17p involving the NF1 tumour suppressor 
gene and  TAOK1, a gene that is believed to function as part of the spindle checkpoint (Draviam, 
Stegmeier et al. 2007) were previously highlighted using the GISTIC algorithm (Section 4.4.3.4).   
Table 4.26:  Differential Deletions in UPS 
 Region Cytoband Count 
Length 
 (Mb) 
Freq. in 
 NOS (%) 
Freq. in 
Others (%) 
p-
value 
Genes 
Chr 1 
213,443,234-213,697,129 q32.3 1 0.25 43.75 2.70 0.0005 - 
213,980,880-214,338,265 q32.3 1 0.36 43.75 2.70 0.0005 PROX1 
215,302,569-215,751,141 q41 2 0.45 43.75 2.70 0.0005 - 
216,043,174-216,684,943 q41 1 0.64 43.75 2.70 0.0005 - 
216,731,644-217,224,745 q41 1 0.49 43.75 2.70 0.0005 ESRRG 
234,357,539-234,437,898 q42.2 1 0.08 50.00 5.41 0.0005 - 
242,489,058-242,528,211 q43 1 0.39 43.75 2.70 0.0005 - 
245,514,462-245,689,504 q44 1 0.18 50.00 5.41 0.0005 - 
Chr 13 
70,404,055-70,857,794 q21.33 2 0.21 75.00 32.43 0.0066 - 
19,296,544-19,550,188 q11 - q12.11 1 0.25 75.00 29.73 0.0056 - 
24,831,951-24,864,286 q12.12 1 0.03 68.75 27.03 0.0064 - 
26,218,732-26,263,107 q12.13 1 0.04 81.25 32.43 0.0021 ATP8A2 
37,588,232-37,598,673 q13.3 1 0.01 68.75 27.03 0.0064 - 
58,178,513-58,211,706 q21.1 1 0.03 81.25 37.84 0.0063 - 
67,442,419-67,451,208 q21.32 1 0.01 75.00 32.43 0.0066 - 
74,152,253-74,320,849 q22.1 1 0.17 81.25 32.43 0.0021 KLF12 
92,058,034-92,596,337 q31.3 1 0.05 68.75 24.32 0.0045 GPC5 
96,808,522-97,090,785 q32.1 1 0.28 68.75 24.32 0.0045 - 
Chr 15 83,773,547-83,780,826 q25.2 1 0.01 43.75 2.70 0.0005 - 
Chr 16 6,127,389-6,503,206 p13.3 1 0.38 50.00 8.11 0.0014 - 
Chr 17 
26,726,585-27,042,613 q11.2 14 0.31 50.00 5.41 0.0005 
 
RAB34 
27,203,586-27,211,735 q11.2 1 0.01 56.25 8.11 0.0004 - 
27,862,668-27,880,882 q11.2 1 0.02 62.50 13.51 0.0006 TAOK1* 
28,458,050-28,525,378 q11.2 2 0.07 56.25 13.51 0.0023 - 
29,464,657-29,476,900 q11.2 1 0.01 56.25 16.22 0.0064 NF1 
8,574,964-8,676,013 p13.1 2 0.1 56.25 16.22 0.0064 - 
Chr 21 47,760,929-47,790,354 q22.3 1 0.03 56.25 10.81 0.0010 - 
   44     8 
Genomic regions shown have a differential frequency of deletion > 40% in UPS (compared with average of 
other STS subtypes with complex karyotype) and are statistically significant (p < 0.05) as judged by the Fisher’s 
exact test.  Only affected genes that have been implicated in cancer are shown in the last column.  Genes with 
reported gain of copy number and/or function abnormalities in cancer (likely passenger) is shown in grey.  
 
* 
- gene with possible role in cell spindle checkpoint. 
Differential aberration analysis was carried out using Nexus
®
 Copy Number software and gene function 
information was obtained from Atlas of Genetics and Oncology and PubMed literature reviews.    
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4.4.3.7 Summary of Candidate Genes in UPS 
Combined statistical analysis of array CGH data identified 174 candidates in UPS.  Summarised in 
Table 4.27, they comprise 148 amplified and 26 deleted genes.  As with LMS, the majority of these 
were highlighted by pathway enrichment.  Strong candidates that were identified by two or more 
independent analysis methods comprised 9 amplified and 2 deleted genes, summarised in Table 
4.28.  They included genes located in the most frequent focal amplification and deletion seen in this 
subtype, JUN and RB1 respectively. 
Table 4.27:  Summary of Candidate genes identified in UPS   
Analysis Tool Amplified candidate Genes  Deleted Candidate Genes 
Common Aberration  
ABCB1 
BIRC2 
BIRC3 
CD44 
CDK6 
COL1A2 
CTNND2 
DNAH5 
HGF 
JUN 
MMP1 
PDE4DIP 
PDGFRA 
RAD51B 
RUNX1 
SEMA3A 
STEAP1 
STEAP2 
TRIO 
TRPC6 
VGLL3 
 
DUX4 
FEZ1 
ING2 
INTS6  
NF1 
OPCML 
RB1 
SORBS2 
TAOK1 
 (n = 21)  (n = 9) 
Pathway Enrichment 
ARHGAP5 
ARNT2 
ARRB1 
BAIAP2 
BCL2L1 
BRAF 
CACNA1C 
CACNA1D 
CACNA1E 
CACNA1I 
CACNA2D3 
CACNG4 
CACNG5 
CAV3 
CDK6 
COL11A1 
COL1A2 
COL3A1 
COL5A2 
COL6A1 
COL6A2 
COL6A3 
CRK 
CTNNB1 
DUSP7 
DVL1 
ECSIT 
EGFR 
EGLN2 
FGF10 
FGF20 
FGF20  
FGF7 
FYN 
GADD45A 
GLI3 
GNA12 
HGF 
IL1A 
IL1R1 
IL6 
INSR 
ITGA11 
ITGA9 
ITGB5 
JUN 
JUND 
KIT 
LAMA1 
LAMA3 
LAMA4 
LAMA5 
LAMB1 
LAMB4 
MAP2K3 
MAP2K4 
MAP2K6 
MAP2K7 
MAP3K11 
MAP3K14 
MAP3K2 
MAP3K6 
MAP3K7 
MAP4K2 
MAPK7 
MAX 
MECOM 
MET 
MITF 
MKNK1 
MMP1 
MOS 
MYL12A 
MYL12B  
NFATC2 
NFATC4 
NR4A1 
NTF3 
NTRK2 
PAK1 
PAK4 
PAK6 
PARVA 
PDGFB 
PIK3CG 
PLA2G4E  
PRKCA 
PTPN1 
PTPRF 
RAC2 
RAC3 
RALB 
RALBP1 
RALGDS 
RAPGEF1 
RASGRP1 
RELA 
RELN 
RET 
SHC3 
SHH 
SMAD3 
SNAI2 
SSX2IP 
TAB2 
TFG 
TGFB1 
TGFB3 
TGFBR1 
TNC  
TNR 
TPR 
TRAF2 
VAV2 
VEGFB 
WASF2 
WASL 
WNT16 
WNT2 
WNT5A 
 
 
APAF1 
CASP10 
CASP3 
CASP4 
CASP7 
CASP8 
CDK1 
CHEK1 
FAS 
LMNB1 
MYT1 
PRF1 
PTPN13 
RB1 
TP53 
 
 (n = 120)  (n = 15) 
Differential aberration  
BIRC2 
BIRC3  
EPHA3  
GGCT 
IGF2BP3 
IL6  
JUN 
MMP1 
MMP10 
MMP12 
MMP13 
MMP20 
MMP27 
MMP3 
MMP7 
MMP8 
VGLL3 
 
ATP8A2 
NF1 
PROX1 
TAOK1 
 (n = 17)  (n = 4) 
Total Individual Genes 148 
 
26 
Genes shown in red have reported gain of copy number and/or function abnormalities in cancer, while those 
shown in green have reported loss of copy number and/or function abnormalities.  Genes that were identified 
using more than one analysis tool are highlighted in grey.   
‡ 
- gene with possible role in mesenchymal cell lineage differentiation. 
* - gene with potential role in maintenance of genome integrity 
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Table 4.28:  Strong Candidate genes identified in UPS   
 Gene Putative Biologic Role  Frequency (%) Likely Pathogenetic Role 
Previously Identified 
in STS? 
Amplified 
JUN Putative Oncogene, p53 inhibition 75 
Oncogenesis 
Tumour progression, 
Yes 
HGF Tumour cell proliferation, survival, motility, and morphogenesis 38 Tumour progression No 
CDK6 G1-S phase checkpoint 38 Tumour Progression No 
COL1A2 Matrix Interaction and Integrin signalling 38 Tumour Progression No 
IL6 Growth factor signalling 56 Tumour progression No 
VGLL3 
Transcription factor co-activator 
Negative regulation of adipocytic differentiation 69 
Tumour progression 
Mesenchymal differentiation 
Yes 
YAP1 Transcription Factor co-activator 50 Tumour Progression Yes 
BIRC2 Inhibition of apoptosis 50 Tumour progression No 
BIRC3 Inhibition of apoptosis 50 Tumour progression No 
Deleted 
RB1 Tumour suppressor, G1-S phase checkpoint 81 
Oncogenesis 
Tumour Progression 
Genetic instability 
Yes 
TAOK1 Spindle cell cycle checkpoint 63 Genetic Instability No 
NF1 Tumour suppressor 63 Oncogenesis Yes 
All genes shown were identified as significantly aberrant among UPS (n=16) by two or more of the statistical approaches (Common Aberration, Pathway Enrichment and 
Differential Aberration) used in this study. 
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4.5 RECLASSIFICATION OF A CASE BASED ON ARRAY CGH PROFILING 
Prior to 1998 and the identification of the sensitive and specific KIT (CD117) staining for GIST 
(Sarlomo-Rikala, Kovatich et al. 1998), many cases were classified as LMS, which sometimes bore 
histological resemblance and also stained positive for CD34.  Based on the differential aberrations 
identified in GIST, genomic copy number profiles of all LMS cases in this study were examined.  One 
tumour (originally identified as LMS 06 in Chapter 3) had all three differential deletions identified 
among GIST, but did not possess any of the differential aberrations identified among LMS (Figure 
4.16).  The tumour, which was resected in 1994 had been classified as LMS based on the 
knowledge at the time.  Subsequent immunohistochemistry of the tumour tissue for CD117 showed 
strong positivity (Figure 4.17).  The tumour was thus reclassified as a GIST (case identified as GIST 
11).  All data analysis was then repeated with the correct tumour classification before being 
presented in this chapter.       
Figure 4.16:  Genome View Ideogram of a case initially classified as LMS, which may be a GIST 
Differential aberrations found to be significant among GIST (whole or near whole arm losses of 1p, 14 q and 
22q) were all present in this tumour and it was considered for reclassification, The Aberrant regions are shown 
as coloured shading on the chromosome (blue represents amplification and red represents deletion).   Dots 
represent individual probes.  Black vertical lines represent mean log ratio for the corresponding region on the 
chromosome.  Horizontal distance to the right (amplification) or left (deletion) of the vertical capped zero line 
represents the amplitude of log ratio.   
All SCNAs are detected using the FASST2 algorithm  
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Figure 4.17:  Immunohistochemical detection of KIT (CD117) in STS sections 
FFPE sections were immuno-stained with antibodies against KIT (brown) and counterstained with haematoxylin (blue). Representative micrographs are shown. A:  Negative 
control (LMS 06 stained without primary antibody).  B:  LMS 06 staining strongly positive for CD117 leading to its re-designation as GIST 11.  C:  Positive control (known GIST 
tumour obtained from Histopathology laboratory), stained concurrently.  
Original magnifications: × 200  
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4.6 DISCUSSION 
Since array CGH is only able to detect unbalanced karyotypic abnormalities and not balanced ones, 
it is of limited use in those tumour subtypes that are almost exclusively driven by balanced 
chromosomal translocation such as synovial sarcoma, extraskeletal myxoid chondrosarcoma, 
alveolar soft part sarcoma.  This was confirmed by the featureless array CGH profiles seen with 
these STS subtypes (Section 4.3).  This array CGH study aimed to identify subtype-specific ‘driver’ 
SCNA in STS and this was reflected in subtype preference of FFPE cases that were sampled, 
focusing on subtypes with complex karyotypes.   The resulting bias meant that identification of SCNA 
that are common to all STS subtypes was not possible using this sample population.  
The majority of LMS and UPS tumours tend to exhibit highly malignant behaviour (Fletcher, Bridge et 
al. 2013) and this was clearly reflected in the high Trojani grade of the majority of cases in this study.  
The combination of prospective and retrospective cases also meant that survival data was not 
available for all cases.  Therefore, in addition to the relatively small sample size of STS subtypes, 
there were few clinical features with which  copy number data could be correlated in the context of 
this project.   Contribution of the data to pooled sets in the form of collaborations and online 
databases such as Oncomine (Rhodes, Yu et al. 2004) however means that beyond this PhD 
project, more aspects of the array CGH data will be explored sooner rather than later and that the 
statistical analyses will subsequently have sufficient power.  In spite of these limitations, the results 
from this study confirm the findings of multiple larger-scale studies thus adding validity to the novel 
observations.    
Candidates in Leiomyosarcoma 
Analysis of the amplified focal SCNA among LMS resulted in 69 potential driver genes in total (Table 
4.11).   Among these is MYOCD, a transcription cofactor gene located at 17p13 that has been shown 
to induce smooth muscle differentiation in  cells (Wang, Wang et al. 2003, van Tuyn, Knaän-Shanzer 
et al. 2005).  It was amplified in around 43% (nine out of 21) of LMS cases in this study, most of 
which were intraabdominal tumours.  These results concur with those Perot and colleagues, who 
demonstrated differential amplification and overexpression of MYOCD among retroperitoneal LMS 
(Perot, Derre et al. 2009).  They also showed in vitro functional effects of its knockdown that have 
resulted in the current view that MYOCD is a putative driver gene for the LMS subtype (Taylor, 
Barretina et al. 2011).  The differentially aberrant candidate gene, MYH11 is of related interest 
because it encodes smooth muscle myosin heavy chain (SMMHC), a definitive marker of smooth 
muscle differentiation (Tamama, Sen et al. 2008, Kurpinski, Lam et al. 2010) whose expression can 
be induced via overexpression of MYOCD in embryonic or mesenchymal stem cells (Raphel, 
Talasila et al. 2012).  It also has a possible role in oncogenesis because it is involved in a fusion 
protein with CBFβ in acute non-lymphoblastic leukaemia, although its exact role in this tumour is yet 
to be determined.   
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Another candidate that was amplified in 15 out of 21 LMS cases (71%) and identified using both 
common aberration algorithms was PDE4DIP, which encodes a golgi/centromere protein called 
myomegalin.  Myomegalin is a putative activator of platelet-derived growth factor receptor-β 
(PDGFRB), with which it forms a fusion protein in chronic eosinophilic leukaemia (Wilkinson, Velloso 
et al. 2003).  Increased levels of PDE4DIP expression were reported in oesophageal carcinoma cells 
following the detection of antibodies to myomegalin in sera from patients (Shimada, Kuboshima et al. 
2007).  Another frequently aberrant candidate gene at a nearby locus on chromosome 1 is  
ARHGEF2, which encodes a putative oncogene (Brecht, Steenvoorden et al. 2005).  A guanine 
nucleotide exchange factor for RhoGTPase, the ARHGEF2 gene product was found to be 
overexpressed in p53-mutant U2OS osteosarcoma cell lines (Mizuarai, Yamanaka et al. 2006) and  
down-regulated in GIST tumours that were treated with Imatinib, a receptor tyrosine kinase inhibitor 
that targets PDGFR (Frolov, Chahwan et al. 2003).  Neither candidate gene has been previously 
reported as amplified in LMS and these SCNA may identify a subset of LMS with potential 
therapeutic susceptibility  to Imatinib. 
Deletion of the RB1 locus at 13q14 was one of the most common aberrations detected among LMS 
in this study.  This contrasts with findings from a previous study in the same laboratory where 
common amplifications detected at 13q21 - 32 among LMS led to the proposal that the nearby RB1 
locus may be co-amplified and extra copies of RB1 were visualised using FISH (Ul-Hassan, Sisley et 
al. 2009).  Those studies were however based on chromosome CGH, the available technology at the 
time which has a limited resolution of around 10Mb (Tan, Lambros et al. 2007) and the authors admit 
that polyploidy could not be ruled out as an explanation of the FISH observations.  While this high-
resolution aCGH study did show amplifications at regions slightly telomeric to 13q32 in around 20% 
of LMS cases (Figure 4.5), specific and frequently homozygous deletion of the RB1 locus was far 
more prevalent.  It was seen in two-thirds of cases analysed and had the highest GISTIC score of all 
the commonly aberrant regions in LMS (Table 4.7). 
Enrichment analysis showed pathogenic pathways for three cancers (including chronic myeloid 
leukaemia, small and non-small cell lung cancer) were over-represented among the amplified genes 
in LMS and that all 3 have the PIK3/Akt/PTEN signalling pathway in common.  A well-characterised 
pathway, gain of function mutations and/or amplifications in key genes along the pathway such as 
the oncogene PIK3CA have described in many cancers, including myxoid liposarcoma (Italiano, 
Chen et al. 2012).   In addition to the strong candidate PIK3R1, amplifications involving PIK3CA were 
seen in more than half of the LMS cases in this series.  When combined with the frequent deletions 
involving two important genes, PTEN and TP53 (deleted in 52% each of LMS cases) that regulate 
this pathway via their antagonist effects (Cully, You et al. 2006), all but one case possessed SCNA 
whose overall effect would in theory, result in increased cell survival via modulation the 
PIK3/Akt/PTEN pathway.  Not only are both antagonist genes known to be frequently deleted in LMS 
(Italiano, Chen et al. 2012), they are candidates identified in this study.  Further, genes in the PTEN 
pathway that act downstream of its inhibitory effects were overrepresented among amplified genes in 
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LMS. Taken together, there is a strong overall suggestion that the PIK3/Akt/PTEN pathway may be 
an oncogenic mechanism for LMS potentially comparable to the MDM2 driver amplifications currently 
being exploited for targeted therapy in liposarcoma (Taylor, Barretina et al. 2011).  The results are in 
concordance with in vivo observations in transgenic mice by Hernando et al who concluded that 
dysregulation of the PIK3/Akt/PTEN pathway was vital to development of LMS (Hernando, 
Charytonowicz et al. 2007). 
The other molecular signalling pathways with overrepresented genes in LMS, Mitogen-activated 
Protein Kinase (MAPK) and Epidermal growth factor receptor (EGFR) pathways have significant 
cross talk with the PIK3/Akt/PTEN pathway and with each other. They result in the activation of 
transcription proteins that drive cell proliferation, activation of matrix metalloproteinases and 
induction of angiogenesis (Wagner and Nebreda 2009) with an overall effect of  contributing to 
tumour progression.  Actin modification via amplification of members within the Rho signalling 
pathway and ECM matrix interactions could also contribute to tumour progression in LMS.  Further 
investigation of these signalling pathways with a proteomic approach, as well as specific inhibitors 
could lead to identification of valuable targets within these druggable pathways that could be used for 
molecular therapeutic development in LMS. 
Deleted SCNA yielded a final list of 26 potential driver genes, four of which were strong candidates.  
Focal deletion at 1p36.32 involving PRDM16 was significant using both common and differential 
aberration approaches.  Although the exact functional relevance in cancer is still unclear, knockdown 
of PRDM16 was shown to favour differentiation of cells into a myogenic lineage instead of brown fat 
(Seale, Bjork et al. 2008), suggesting a possible role in the myogenic differentiation of LMS.  Another 
candidate gene of interest, CEP55 encodes a centrosome protein that interacts with BRCA2 and 
mediates the cytokinesis step of mitosis (Fabbro, Zhou et al. 2005, Mondal, Rowley et al. 2012).  Its 
deletion in around half of the LMS cases may contribute to the aneuploidy and chromosomal 
instability that is characteristic of these tumours. 
The only enriched cancer-relevant pathway among deleted genes was the promyelocytic leukaemia 
protein (PML) pathway that participates in tumour suppression and apoptosis.  It involves the 
interaction of several well-known genes including RB1, TP53 and FAS.  Other genes that were 
involved in deleted SCNAs identified as relevant by both common aberration approaches include the 
pro-apoptotic genes TNFSRF14 and BOK, which have been implicated in follicular lymphoma 
(Launay, Pangault et al. 2012) and colorectal cancer (Zeilstra, Joosten et al. 2011), respectively.  
Taken together, these results strongly suggest that inhibition of apoptosis via targeted gene deletion 
may be relevant to the pathogenesis of LMS.   
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Candidates in GIST 
The majority of STS subtypes with known characteristic genetic aberrations have simple karyotypes 
(Taylor, Barretina et al. 2011) with few or no SCNA.  This may account for the relatively simple 
genomic profiles seen among the cKIT mutation-driven GISTs.  Non-focal genomic losses were the 
predominant aberration and the most frequent of them (those on 14q, 1p and 22q) were also found 
to be specific for GIST.  This observation led to the re-classification of one of the older LMS cases 
and confirmation by immunohistochemistry for cKIT (Section 4.5).   
Among only five candidate genes affected by focal amplifications was the proto-oncogene JUND, 
which encodes a member of the activator protein 1 (AP-1) transcription factor complex.  
Overexpression of JUND has been shown to be involved in inhibition of apoptotic signals in prostate 
cancer (Zerbini, de Vasconcellos et al. 2011) and the induction of matrix metallo-proteinases in skin-
invasive Adult T-cell leukaemia (Nakachi, Nakazato et al. 2011).   Amplified in nearly five out of the 
11 (nearly 50%) cases, this focal SCNA may therefore represent a secondary abnormality that 
contributes to tumour progression among GIST. 
Candidates in UPS 
The high degree of karyotypic complexity of UPS was evidenced by the involvement of around 33% 
of the genome in common focal SCNA, compared with an average of around 10% genomic 
involvement in focal SCNA observed in a wide range of cancers (Beroukhim, Mermel et al. 2010), 
and 20% in LMS.  Statistical analysis identified nearly 200 potential drivers, including 12 strong 
candidate genes (Tables 4.27 and 4.28).  Among the amplified candidate genes, not only was JUN 
the most frequently affected, it was identified by differential aberration and pathway enrichment 
analyses as well.  This makes it statistically one of the strongest candidate genes identified in this 
study.  A well-known putative oncogene, it encodes a key member of the AP-1 transcription factor 
complex that has been shown to promote cell proliferation via activation of cyclin D and inhibit 
apoptosis via inhibition of p53 and p21 (Shaulian 2010).   Recently, Mariani and colleagues based on 
observations from array CGH results demonstrated a functional association between JUN 
amplification/overexpression and de-differentiated liposarcomas (Mariani, Brennetot et al. 2007). 
They concluded that the aberration blocked adipocytic differentiation and resulted in an aggressive 
phenotype.  Interestingly, the JUN amplification observed was independent of amplifications on 6q or 
12q involving ASK or MDM2, respectively as reported in de-differentiated liposarcoma (Mariani, 
Brennetot et al. 2007).  This suggests that JUN amplification may play a more prominent role in early 
oncogenesis of pleomorphic sarcomas than previously thought, with a secondary role in preventing 
lineage differentiation and should be the subject of further study. 
Other candidate genes are of potential relevance to lack of specific lineage differentiation that is 
characteristic of UPS.  Overexpression of the strong candidate VGLL3 was recently shown to inhibit 
differentiation of mesenchymal cells into an adipocytic lineage (Halperin, Pan et al. 2013) while 
CDK6 expression is known to inhibit the differentiation of osteoblasts (Grossel and Hinds 2006).  The 
deleted candidate gene DUX4, on the other hand has been shown to be involved in promoting 
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myogenic differentiation (Winokur, Chen et al. 2003).  It also participates in the characteristic CIC-
DUX4 fusion in undifferentiated paediatric primitive sarcomas that is believed to result in loss of its 
function (Graham, Chilton-MacNeill et al. 2012). Nearly all the UPS cases showed aberrations 
affecting one or more of these three genes.   
Further, amplification of VGLL3 was highlighted as significant using common aberration as well as 
the differential aberration approaches making it a strong, subtype-specific candidate gene for UPS.  
Along with YAP1, another candidate gene located at 11q22.2, it has previously been reported as 
amplified and overexpressed in a subset of sarcomas that included UPS (Helias-Rodzewicz, Perot et 
al. 2010).  Both genes encode a cofactor of the TEAD family of transcription cofactors and 
knockdown of their expression resulted in reduced in vitro tumour cell migration, suggestive of 
possible roles in tumour progression (Helias-Rodzewicz, Perot et al. 2010). 
Copy number amplification of regions on 5p have been the subject of previous studies in STS and a 
number of candidate genes were proposed e.g. CTNND2, which encodes a cell adhesion protein 
called -catenin whose overexpression is functionally implicated in metastatic cancers (Taylor, 
Barretina et al. 2008).   Another gene within the same amplicon, TRIO encodes a Rho Guanine-
nucleotide Exchange Factor (RhoGEF) that regulates actin cytoskeleton modification via which it is 
involved in triggering cell motility, proliferation and differentiation.  TRIO amplification has been 
reported various cancers including breast cancer (Lane, Martin et al. 2008) and glioblastoma (Salhia, 
Tran et al. 2008), where it was functionally associated with tumour progression (Salhia, Tran et al. 
2008).   Over-representation (among the amplified genes in UPS) of the focal adhesion signalling 
pathway (Table 4.23), which acts via RhoGTPase signalling adds validity to the selection of this gene 
as a candidate for tumour progression in UPS. 
The 26 deleted candidate genes in UPS include some very important and well-known tumour 
suppressor genes such as RB1 and NF1.  Germ-line deletion in both these genes causes a 
predisposition to STS (discussed in chapter 1) and frequent somatic deletions have been described 
in various cancers including ovarian cancer (The Cancer Genome Atlas Research Network 2011), 
glioblastoma (The Cancer Genome Atlas Research Network 2008) and pleomorphic STS (Taylor, 
Barretina et al. 2008).  Neurofibromin, the product of NF1 is a negative regulator of the RAS 
oncogene, an upstream kinase in the overrepresented PIK3 and MAP kinase pathways seen among 
amplified genes in UPS.  Inactivating events of this gene therefore probably facilitates increased 
proliferation among and evasion of apoptosis by UPS tumour cells.   
The RB1 product in addition to it tumour suppressor role, functions as a key member of a G1/S 
phase cell cycle checkpoint pathway, many members of which were frequently deleted in UPS 
(Table 4.24).   The important cdc25/Chk1 cell cycle checkpoint, as well as multiple apoptosis- 
regulating pathways was also over-represented among deleted genes.  Frequent deletions were 
detected affecting TAOK1, a kinase that has been shown to function in the G2/M phase in response 
to both ultraviolet and ionising radiation acting via the p38 MAPKinase pathway (Raman, Earnest et 
al. 2007).  With these multiple abnormalities in genome maintenance machinery, it is not surprising 
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that genomic instability is highly characteristic of UPS tumours.  In addition, TAOK1 deletion alone or 
in combination with deletion of multiple pro-apoptotic caspase genes may confer resistance to 
radiotherapy on a subset of UPS and warrants further investigation.  
Summary 
Taken together, it appears that both LMS and UPS may utilise similar signalling pathways to drive 
cell proliferation and that ECM interaction and Rho signalling is probably relevant to tumour 
progression in both subtypes. However, while LMS favour inactivation of the PTEN and p53 tumour 
suppressor pathways, UPS tend to favour RB1 and NF1 inactivation.  Even more exciting is the 
identification with very high levels of statistical significance of candidate genes that are likely to be of 
importance in determination of the phenotypic appearance and thus classification of specific STS 
subtypes e.g. MYH11 in LMS and VGLL3 in UPS.  These genes also appear to contribute to tumour 
progression and may be targetable with therapeutics.  
Since copy number aberrations frequently but do not always correlate with gene expression, the 
observations for this array CGH study require further investigation using expression and functional 
approaches in model systems.  They however serve as a useful starting point for areas of focus in 
further studies, an approach that has led to elucidation of pathogenesis in various cancers.   
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CHAPTER FIVE 
RESULTS:  PRIMARY TISSUE CULTURE 
5  
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5.1 INTRODUCTION 
Functional testing of molecular genetic candidates using in vitro disease models is usually the first 
step in therapeutic target validation and serves as a screening tool before their evaluation in more 
complex in vivo models and subsequent clinical trials (Taylor, Barretina et al. 2011).  Commercial cell 
lines are a widely used in vitro model for initial functional validation studies because they are a 
readily available, endlessly replicating source of tumour material from which results obtained are 
usually reproducible (Cree, Glaysher et al. 2010).   
There has however, been increasing recognition of the limitations of commercial cell lines as a 
disease model stemming from reports of poor correlation of the response in these cell lines with in 
vivo tumour response (Cree, Glaysher et al. 2010, Kamb 2010, Smith, Stewart et al. 2010).   With 
cellular adaptation to artificial culture conditions, cell lines have been shown to grow more rapidly 
than parent tumour cells and acquire phenotypic changes that may alter their therapeutic response, 
such as dependence on growth factors in culture media or adherence to plastic (Kato, Espinoza et al. 
2008, Pan, Kumar et al. 2009).  In addition, the heterogeneity of tumour cell clones characteristic of 
many cancers is lacking in cell lines in which single clones have been selected for and results may 
not reflect resistant tumour cell clones or cancer ‘stem’ cells that are believed to be responsible for 
tumour recurrence and late therapeutic failure.   
These observations resulted in a paradigm shift that led to the use of a panel of cell lines for drug 
testing in each cancer that presumably represent the variability of in vivo therapeutic responses.  
Notable examples include the National Cancer Institute (NCI-60) panel that includes 60 cell lines that 
represent nine different cancers (Shoemaker 2006) and a similar Japanese panel of 39 cell lines 
representing nine cancers (Yamori 2003).  Cell lines included in these panels have been used in 
research for nearly 30 years and proven useful for elucidation of important pathogenetic pathways as 
well as cytotoxic and targeted therapy development in many cancers (Gillet, Varma et al. 2013) and 
more recent genomic and transcriptomic studies of these cell lines support their continued relevance 
to research (Beroukhim, Mermel et al. 2010, Bignell, Greenman et al. 2010).   
In STS however, there is a limited number of in vitro disease models (tumour cell lines) available for 
functional testing and target validation.   Data from large-scale cancer cell line studies such as the 
Cancer Cell Line Encyclopaedia (Barretina, Caponigro et al. 2012) and Sanger Cancer Cell Line 
Project (Forbes, Bindal et al. 2011) showed that less than 2% of commercially available cell lines are 
derived from STS, the majority of which are translocation-driven.  With improvements in the 
technology for genomic aberration mapping e.g. high-resolution array CGH, combined SNP and 
oligonucleotide arrays and more recently, next generation sequencing leading to an increased rate of 
candidate identification (Barretina, Taylor et al. 2010, Taylor, Barretina et al. 2011), there is a 
growing need to establish a wider range on STS cell lines (Taylor, Barretina et al. 2011).   
While it is widely accepted that the best alternative to established cell lines as in vitro disease 
models is the use of cells cultured directly from tumours (primary cell cultures), this is fraught with 
many problems (Luca, Privitera et al. 2007).  Fresh tumour tissue has to be donated by patients and 
obtained during surgery with the associated ethical and logistic constraints.  When it is available, the 
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behaviour of tumour cells is generally unpredictable with a variable rate of successful establishment 
in culture (Luca, Privitera et al. 2007).  Further, parent tumours contain many normal cells e.g. 
fibroblasts that may grow instead of or alongside tumour cells in culture (Brouquet, Taleb et al. 2011).  
These normal cells need to be distinguished from tumour cells using biomarkers if available as their 
presence may confound experimental results, as demonstrated in array CGH studies (Neill, Torchia 
et al. 2010).   As a result, many researchers now believe that successful bench to bedside translation 
of in vitro results is well worth the effort of obtaining primary cell cultures for all in vitro work.  Others 
use results from primary cultures to augment those from readily available commercial cell lines, 
instead of replacing them entirely (Cree, Glaysher et al. 2010).   
Primary cell culture is also gaining relevance in the selection of cytotoxic drugs for cancer treatment.  
Historic practice has been the selection of cytotoxics that statistically are efficacious in cancer types 
based on their histopathology.  For rare cancers or patient who have failed to respond to 
conventional cytotoxics, an emerging strategy is drug selection based on high throughput 
chemosensitivity assays on primary cells cultured from biopsy samples (Kamiyama, Rauenzahn et al. 
2013, Mitra, Mishra et al. 2013).  This personalised medicine strategy was demonstrated, to be 
effective in a case of rare pancreatic acinar cancer (Armstrong, Von Hoff et al. 2011) and other 
researchers are developing methods that increase the efficiency of primary cell culture to be used for 
such purposes (Hidalgo, Bruckheimer et al. 2011, Kamiyama, Rauenzahn et al. 2013).   
In this study, establishment of primary cell cultures was attempted with all fresh STS tissue collected. 
A number of methods were utilised to examine their genetic and phenotypic characteristics of the 
cultured cells in relation to the parent tumours and thus their suitability for functional validation 
studies.  Cultures were grown as long as possible and frozen down at intervals at early passages.  
This chapter presents the results of the attempts at primary tissue culture and describes the 
characteristics of long-term cell cultures established during this PhD project. 
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5.2 RESULTS 
5.2.1 STS Cases 
Fresh tissue samples were collected from 53 patients with suspected STS (based on clinical, 
radiological or biopsy findings) over a 30-month period from February 2010 to August 2012.  
Cultures were set up as described in Section 2.3.1.1 with laboratory designations based on their 
chronological order and the year they were obtained, with ‘STS’ as a prefix.  For example, cultures 
derived from the second tumour obtained in 2010 were referred to as STS 02/10 and the sixth 
tumour in 2012 was called STS 06/12, etc.  Detailed clinical features of all the fresh STS included in 
this study are summarised in Appendix 1. 
Six cases subsequently received definitive diagnoses of benign or epithelial malignant tumours 
including one leiomyoma (STS 03/10), one melanoma (STS 08/10), one breast carcinoma (STS 
07/11), two lipomas (STS 12/11 and 23/11) and a benign chondroma (STS 24/11).  They were 
therefore excluded from the study.  The remaining 47 cases had confirmed STS diagnoses 
comprising 16 different subtypes (summarised on Table 5.1).  All but five cases were primary 
tumours.  Three cases, all well-differentiated liposarcomas, were local tumour recurrences while two 
others were metastatic tumours (one pleomorphic Liposarcoma and one angiosarcoma).   Four out 
of five primary angiosarcomas sampled occurred at sites that had previously been exposed to 
radiotherapy for breast cancer, while the fifth occurred secondary to chronic lower limb 
lymphoedema (Stewart-Treves syndrome).     
In four cases (STS 07/10, 16/11, 20/11 and 05/12), neo-adjuvant radiotherapy was given locally to 
reduce the tumour sizes and render them operable.  Two other patients received systemic 
preoperative chemotherapy as part of their treatment protocol for a rhabdomyosarcoma (STS 12/10) 
and Ewing’s sarcoma (STS 13/11).   As a result, all six cases that had been exposed to neoadjuvant 
therapy, as well as the two alveolar soft part sarcomas and the myxoid liposarcoma (nine cases in 
total) could not be graded histologically using the Trojani system (Coindre 2006).  Of the remaining 
38 cases , over 60% (25 cases) were Trojani grade 3; three cases Trojani grade 2; and 10 cases low 
grade, including seven well-differentiated liposarcomas that are Trojani grade 1 by default  (Fletcher, 
Bridge et al. 2013).  
5.2.2 Primary Tissue Culture  
5.2.2.1 Washes 
Seventy per cent of STS cases (33 out of 47) established adherent cells in culture, which reached 
confluence within the flasks.  Cells settled either as individual cells that had been mechanically 
dissociated from the tumour tissue or from tissue explants that were adherent to the plastic (Figure 
5.1A).  In some cases, adherent cultures were eventually established in washes of viable non-
adherent cells that were set up (as described in Section 2.3.1.2) in addition to the original flasks or 
slopes.  Cell cultures from washes were designated with a ‘w’ prefix to the passage number.  For 
example, cells from the second wash of an original culture and currently in their third passage were 
designated were designated w2p3 while cells from a wash of the original slopes at the same 
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passage were designated wsp3.  Cells from original cultures and washes were maintained as 
separate variants with all relevant precautions to prevent cross-contamination.   
5.2.2.2 Senescence 
Proliferating cells were cultured until they became senescent (Figure 5.1B).  After senescence was 
observed, cells were kept in culture for at least 6 weeks, during which they were media-changed 
regularly and observed for any change in proliferation rate or morphology before they were 
eventually discarded.   
Figure 5.1:   Phase-contrast Micrographs of Proliferating and Senescent cells in primary Soft Tissue 
Sarcoma cultures. 
A – An example of early culture showing proliferating spindle-shaped cells growing radially outwards from an 
adherent piece of tissue (tumour explant) shown by the white arrows.  B – a representative  example of senescent 
cells in a primary STS culture.  
Images were captured at x40 magnification. 
5.2.2.3 Outcome 
Table 5.1 summarises the outcome of culture in all the STS cases by subtype.  Early senescence 
was observed within the first or second passage (p1 – p2) in ten cases, typically in the first two to 
three weeks of culture.  Later senescence occurred in a third of cases and was generally observed at 
two points. The first was around the passage 5 (p4-p7) and the second, around passage 10 (p9 – 
p12).   All cells lines that grew beyond passage 12 went on to become long term cultures, i.e. 
maintained proliferative cultures for one year or more.  Cells were frozen every 3 - 4 passages, 
within the first 15 passages to provide cells with less cultural adaptation for future experiments.   
Well-differentiated liposarcomas had the poorest tissue culture outcome overall with only one of the 
seven cases able to establish cells in culture, which subsequently underwent early senescence.  
Both cases where the patient had neo-adjuvant chemotherapy established cells that reached the 
tenth passage, approximately before they became senescent. One of the 4 tumours that received 
neo-adjuvant radiotherapy, (STS 20/11) formed a long term culture while the others failed to 
establish any cells in culture.  Undifferentiated pleomorphic sarcomas were the most successful in 
culture overall with all cases that had not been exposed to neo-adjuvant therapy establishing cells in 
culture and a long term culture outcome in three out of five cases.  Table 5.2 summarises the 
features of the tumours that established long term primary cell culture. 
A B 
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Table 5.1:  A Summary of Fresh Soft Tissue Sarcoma Subtypes obtained and their Primary Cell Culture Outcomes. 
STS Subtype 
Number of Cases 
Obtained 
Not Established in 
Culture 
Early Senescence Senescent around p5 
Senescent around 
p10 
Long Term Culture 
Alveolar Soft Part Sarcoma 2 - - 1 1 - 
Angiosarcoma 6 - 3
‡
 2 1 - 
Dedifferentiated Liposarcoma 7 3 2 - - 2* 
Ewing’s Sarcoma 1 - - - 1* - 
Extraskeletal Myxoid Chondrosarcoma 1 - - 1 - - 
Leiomyosarcoma 3 1 - - 1 1 
Low grade Myofibroblastic  Sarcoma 1 - - 1 - - 
Malignant Peripheral Nerve Sheath Tumour 1 - - 1 - - 
Malignant Solitary fibrous Tumour 1 - - 1 - - 
Myxofibrosarcoma 5 - 3 - 1 1 
Myxoid Liposarcoma 1 1 - - - - 
Pleomorphic Liposarcoma 2 1* - 1
‡
 - - 
Pleomorphic Rhabdomyosarcoma 1 - - - 1* - 
Synovial Sarcoma 1 - - 1 - - 
Undifferentiated Pleomorphic Sarcoma 7 2** 1 - 1 3 
Well-differentiated Liposarcoma 7 6
§
 1 - - - 
Total 47 14 10 9 7 7 
* - One case received neo-adjuvant radiotherapy or chemotherapy ** - Two cases received neo-adjuvant radiotherapy or chemotherapy 
§  - Three cases were recurrent tumours     ‡ - One case was a metastatic tumour 
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Table 5.2:  Characteristics of Soft Tissue Sarcoma tumours that established Long-term Primary Cell Cultures 
Laboratory  
Designation 
Age/Gender STS Subtype Site Size Date Obtained 
Duration 
 in Culture 
(months) 
Number of 
Passages  
(by April 2013) 
Current Clinical 
Status 
(as of April 2013) 
STS 09/10 68y/F De-differentiated Liposarcoma Retroperitoneal 300mm June 2010 33 70 Dead 
STS 14/10 53y/F 
Undifferentiated pleomorphic 
sarcoma 
Lower Limb 230mm August 2010 31 70 NP 
STS 02/11 62y/F Leiomyosarcoma Pelvis 135mm January 2011 26 65 NP 
STS 06/11 76y/M 
Undifferentiated pleomorphic 
sarcoma 
Lower Limb 170mm February 2011 25 85 Dead 
STS 09/11 66y/F 
Undifferentiated pleomorphic 
sarcoma 
Lower Limb 115mm April 2011 23 35 Dead 
STS 20/11 70y/F De-differentiated Liposarcoma Lower Limb 170mm October 2011 17 24 Metastatic Disease 
STS 21/11 73y/M Myxofibrosarcoma Upper Limb 50mm 
November 
2011 
17 30 Metastatic Disease 
NP – no disease progression 
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5.2.3 Characterisation of Cells in Culture 
5.2.3.1 DNA Profiling 
Routine precautions were taken in cell culture to avoid cross-contamination and cultures were 
routinely monitored by phase contrast microscopy.  The appearance of cell clones with distinct 
morphology raised the possibility of cross-contamination.  One instance of cross-contamination was 
suspected in cultures from the first wash of STS 04/11.  Prior to the tenth passage, the cultures 
consisted of spindle-shaped fibroblast-like cells with many senescent-looking cells (Figure 5.2A).   A 
morphologically-distinct clone of polygonal, histiocyte-like cells was observed in one of the flasks at 
passage w1p10 (Figure 5.2B).  By the thirteenth passage (w1p14), the new clone of cells had 
completely replaced the original cells the culture flask (Figure 5.2C).   
 
Figure 5.2:  Phase-contrast micrographs of cells from STS 04/11 showing suspected cross-
contamination 
A – Original morphological appearance of STS 04/11 cells in culture before the ninth passage (w1p9).   
B – Emergence of a morphologically-distinct clone of cells (white arrows) in STS 04/11 culture at w1p10.   
C – Complete overgrowth of STS 04/11 culture with new clone of cells by w1 p13. 
All images were captured at x40 magnification 
 
  
A 
C 
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Such potential cross-contamination was further investigated by DNA profiling of cells in culture by 
Short Tandem Repeat (STR) analysis and done using services provided by the University of 
Sheffield Core Genomic Facility service.  Briefly, it involves the amplification of 10 STR loci in 
genomic DNA extracted from the cells in culture by multiplex PCR with fluorescent-labelled primers.   
The PCR product sizes are then determined using capillary electrophoresis and correspond to the 
number of nucleotide repeats in the STR (alleles).  A graphical profile of all 10 STR alleles for each 
cell culture is then generated and compared with those of other cell lines in the laboratory to rule out 
or confirm a genetic match indicative of contamination.   
Large studies have shown 99% confirmation of relatedness of cell lines by STR analysis when the 
allele match is 75 - 80% with up to 98% confirmation when allele match is >50% (American Type 
Culture Collection Standards Development Organization Workgroup 2010, Capes-Davis, Reid et al. 
2013).  The Sheffield Core Genomics Facility utilises a 70% allele match threshold for determination 
of probable relatedness.   Comparison is also made with cell lines in the Children's Oncology Group 
Cell Culture and Xenograft Repository Database (www.COGcell.org) which also includes STR 
profiles for commercial cell line collections such as the American Type Culture Collection (ATCC), 
German Collection of Microorganisms and Cell Cultures (DSMZ), Japanese Collection of Research 
Bioresources (JCRB), and the RIKEN Research database (RIKEN). 
STR analysis was performed on all the cell cultures in the laboratory at the time of suspected cross 
contamination and again after a further 15 months in culture to ensure that the cultures remained 
uncontaminated.   The results are summarised on Table 5.3.  Cells in STS04/11 culture by w1p13 
had a profile that was completely different from those in w1p9, but identical to both variants of STS 
02/11 (discussed in detail in Section 5.2.6).  This confirmed that cells from STS 02/11 had cross-
contaminated the STS 04/11 cultures and because they had a faster proliferative rate, were able to 
completely replace the native cells.  
Comparison of the remaining cell cultures with profiles from the COGcell database showed no allele 
matches that exceeded 72%.  None of the cell lines identified within the database with allele match 
over 70% had ever been used in the Sheffield laboratory, making them an unlikely source of 
contamination.  Further, array CGH analysis confirmed close similarity between all the primary cell 
lines and their parent tissue (discussed in detail in subsequent sections).  STR analysis of the same 
primary tumour cultures after further 30 – 40 passages showed that the profiles were largely 
maintained, with only three instances of allelic disparity identified (Table 5.3).  All 3 instances were 
loss of heterozygosity (LOH) events as would be expected among cells in culture (Capes-Davis, 
Reid et al. 2013) and were not surprising considering the level genomic instability that is inherent 
among the primary tumours. 
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Table 5.3:  Short Tandem Repeat (STR) Profiles of Soft Tissue Sarcoma Primary Cell Cultures 
Lab ID Passage THO1 D21S11 D5S818 D13S317 D7S820 D16S539 CSFIPO AMEL vWA TPOX Allele Match Cell line(s) 
*STS 09/10 
W2p35 6 29,32 12,13 8,14 9,10 9,10 10,14 X 17,18 11 72.2% HE55 
W2P70 6 29,32 12,13 8,14 9, 10 9,10 10,14 X 17,18 11 < 70% - 
*STS 14/10 
p31 6,7 27,30 12,13 8,11 8 14 12 X 16 8 < 70% - 
p68 6,7 27,30 12,13 8,11 8 13,14 12 X 16 8 < 70% - 
*STS 02/11  
W1p16 9 27,30 11 14 10,11 11 10,12 X 16 8 72.2% 
HCC3153 
MKN1 
W1p54 9 27,30 11 14 10,11 11 10 X 16  < 70% - 
Wsp27 9 27,30 11 14 10,11 11 10,12 X 16 8 72.2% 
HCC3153 
MKN1 
Wsp63 9 27,30 11 14 10,11 11 10,12 X 16 8 72.2% 
STS 04/11 
W1p13 9 27,30 11 14 10,11 11 10,12 X 16 8 72.2% 
HCC 3153 
MKN1 
W1p9 7,9 29,30.2 11 12 10 10,12 11,14 X 14,17 8,11 72.2% HUC-F2 
*STS 06/11 
p41 6,9.3 29,31 9,13 14 8,11 11 10,11 X,Y 17,18 8 <70% - 
p83 6,9.3 29,31 9,13 14 8,11 11 10,11 X 17,18 8 <70% - 
STS 09/11 P34 9.3 28,31.2 9,12 11 10 9 10 X 17 8 72.2% 
H647 
H865 
HCC4018 
STS 20/11 p2 9 29 9 14 10,12 12 12 X 20 9,11 < 70% - 
STS 21/11 W1p35 8 30,31.2 12,13 13 8,9 12 10 X,Y 14,16 11 < 70% - 
Profiles comprise the number of repeats in 10 STR loci (10 alleles) and were compared with one another and STR profiles for cell lines in the COGcell database.  Only cell lines with >70% allele match 
are shown in the last column 
STS 04/11 w1p13 cells (shown in red) had identical alleles to STS 02/11 cells of both variant passages (in blue), but different from STS 04/11 w1p9 cells (in green), confirming the contamination and 
overgrowth of STS 04/11 w1p13 by STS 02/11 cells. 
* - STR profiling was repeated after 15 months (30-40 subsequent passages) and any disparities in allele matching is highlighted in grey  
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5.2.3.2 Karyotyping 
In order to avoid cultural artefacts, attempts were made to obtain karyotype information before cells 
became too highly adapted to culture.  This was however very technically challenging and in the 
majority of cases proved unsuccessful.   In cases where available metaphase spreads were 
available, Giemsa staining for chromosome banding (G-banding) carried out on metaphase spreads 
and chromosome counts were obtained.  Chromosome counting was in some cases was carried out 
by Kristin Wright or Dr Leslie Hoh.  Full karyotype analysis by G-banding (when eventually 
successful) was done by Dr Karen Sisley.   
Repeated attempts at Giemsa staining did not always yield clear chromosome banding.  Detailed 
structural karyotype analysis was therefore not possible even though chromosome enumeration was 
carried out and gross structural chromosomal abnormalities were observed.  An example is shown in 
Figure 5.3 below.   
Figure 5.3:  Metaphase Chromosome Spread from STS 06/11 cells 
Chromosome Preparations were obtained from cells at passage 65.  The chromosomes and adjacent intact 
nucleus are stained with Leishmann’s stain.  The tumour cells are polyploid with the metaphase spread 
containing of 105 chromosomes in total, some of which have gross structural abnormalities such as double 
centromeres/constrictions (white arrows).  
Picture was captured n at X63 magnification    
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Metaphase chromosomes were obtained from early cultures in only two cases (STS 04/11 and STS 
20/11).  Average chromosome counts obtained from 11 metaphases in STS 04/10 (synovial 
sarcoma) cells following their first passage suggest a diploid karyotype, while those from STS 20/11 
(dedifferentiated liposarcoma) at passage two had a near triploid karyotype (70 chromosomes on 
average) based on 12 metaphases counted.    Chromosome spreads at later stages in culture were 
available from cells in all the long-term primary cultures.  Table 5.4 summarises the chromosome 
counts obtained from primary STS cultures in this study. 
 
Table 5.4:  Chromosome counts of cells from Soft Tissue Sarcoma Primary Cell Cultures 
Lab ID Passage 
Number of  
Metaphases 
counted 
Range Mean Median Mode 
STS 04/10 P1 11 40 - 50 46 46 46 
STS 09/10 W2P70 23 43 - 106 77 93 48 
STS 14/10 P68 21 63 - 74 68 68 68 
STS 02/11 
Wsp62 22 101 - 147 125 130 130 
W1p51 23 110 - 138 132 134 136 
STS 06/11* 
P15 10 56 – 66 60 59 56 
P65 28 60 - 214 120 112 105 
P82 13 95 - 135 117 116 115 
STS 09/11 P17 31 47 - 68 57 58 50 
STS 20/11* 
p2 12 63 - 73 70 72 73 
P12 31 51 - 154 109 128 69 
STS 21/11 
W1p22 23 63-179 111 99 66 
* - metaphase chromosomes were obtained at more than one passage 
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5.2.3.3 Array CGH 
Array CGH was carried out using DNA from cultured primary cells and their genomic copy number 
profiles were compared to those of the parent tumour tissue.  A total of fourteen cases compared in 
this way are summarised on Table 5.5.  Apart from known, non-pathologic copy number variations 
(CNV), the genomic profiles from both tumour tissue and cultured cells were featureless in four 
cases and thus uninformative.  All 4 cell cultures (STS 02/10, 04/10, 05/10 and 15/10) became 
senescent around the fifth passage.     
 
Table 5.5:  Primary Soft Tissue Sarcoma Cell Cultures analysed by Array CGH 
Lab ID STS Subtype 
Passage from which 
DNA was extracted for 
aCGH 
Genomic Profile of 
Parent Tumour Tissue 
Genomic Profile of 
Cultured Cells 
STS 02/10 
Extraskeletal Myxoid 
Chondrosarcoma 
P2 No SCNA No SCNA 
STS 04/10 Synovial Sarcoma P1 No SCNA No SCNA 
STS 05/10 Angiosarcoma P2 No SCNA No SCNA 
STS 09/10 De-differentiated Liposarcoma W2p35 Complex SCNA Complex SCNA 
STS 12/10 Pleomorphic Liposarcoma P6 Complex SCNA No SCNA 
STS 14/10 
Undifferentiated Pleomorphic 
Sarcoma 
P5 Complex SCNA Complex SCNA 
STS 15/10 Alveolar soft Part Sarcoma W1p1 No SCNA No SCNA 
STS 16/10 Myxofibrosarcoma P6 Complex SCNA No SCNA 
STS 01/11 
Malignant Peripheral Nerve 
Sheath Tumour 
P1 Complex SCNA No SCNA 
STS 02/11 Leiomyosarcoma Wsp27 Complex SCNA Complex SCNA 
STS 06/11 
Undifferentiated Pleomorphic 
Sarcoma 
P41 Complex SCNA Complex SCNA 
STS 09/11 
Undifferentiated Pleomorphic 
Sarcoma 
P26 Complex SCNA Complex SCNA 
STS 20/11 De-differentiated Liposarcoma P2 Complex SCNA Complex SCNA 
STS 21/11 Myxofibrosarcoma W2p28 Complex SCNA Complex SCNA 
For cases shown in blue, no SCNA were detected in either cultured cells or parent tissue, 
 
In another 3 cases, tumour tissue showed complex genomic profiles but the corresponding cultured 
cells (STS 12/10, 16/10 and 01/11) had featureless array CGH profiles, suggesting that cells in 
culture were unlikely to represent the tumour and were probably normal cell ‘contaminants’ that had 
managed to establish in culture.  Not surprisingly, none of the cell cultures went on to grow in the 
long term.  An example of such disparate tissue vs. cell culture array CGH profiles (for STS 01/11) is 
shown in Figure 5.4.   Array CGH profiling was carried out on DNA from cells in at least one variant 
of each long-term primary cell culture.   In all cases, the genomic profiles showed features that were 
remarkably similar to those of the parent tumour tissue.  These cases are described in detail in the 
subsequent sections. 
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Figure 5.4:  Genome View Ideograms of STS 01/11 comparing cultured cells with parent tumour 
tissue 
Panel A – whole genome ideogram for STS 01/11 parent tumour tissue DNA showing multiple SCNA detected 
across the genome, compared with Panel B – whole genome ideogram of DNA from cells cultured from STS 
01/11 tissue (at passage 1) showing no SCNA detected across all the autosomes. 
Aberrant regions are shown as coloured shading on the chromosome (blue represents amplification and red 
represents deletion).   Small dots represent individual probes.  Black vertical lines represent mean log ratio for 
the corresponding region on the chromosome.  Horizontal distance to the right (amplification) or left (deletion) of 
the vertical capped zero line represents the magnitude of aberration (log ratio). All CNAs were detected using the 
FASST2 algorithm  
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5.2.4 STS 09/10:  De-differentiated Liposarcoma 
5.2.4.1 Tumour Characteristics 
Tumour samples were kindly donated by a 68-year old female patient whose tumour was diagnosed 
as a Trojani Grade 3 retroperitoneal dedifferentiated liposarcoma with a maximum dimension of 
approximately 300mm.  No distant metastases were evident at the time of surgical excision, but the 
tumour was locally invasive.  
 
5.2.4.2 Primary Tissue Culture Characteristics 
Tissue culture was set up as described in Section 2.3.1.1.  Two washes were set up because it 
appeared that viable cells remained in suspension.  Cells from the original flasks, slope and first 
wash became senescent before the tenth passage. 
Cells from the second wash, given the specific designation ‘STS 09/10 W2’ however became 
established in culture after approximately four weeks.  The cells were mostly spindle-shaped, a few 
being slightly polygonal (Figure 5.5).  They have remained viable in culture since August 2010 and 
been passaged over 70 times.  The doubling time, based on MTT proliferation assay was estimated 
at 49.5 hours (Figure 5.6).    
 
Figure 5.5:  Phase-contrast Micrographs showing STS 09/10 cells in culture  
Cells shown were at passage 71 and were derived from the second wash of cultures set up from STS 09/10 
tissue.  A – Images captured at x40 magnification showing the pattern of growth without distinct colonies.  B- 
Images captured at x100 magnification showing the fibroblast-like spindle shaped morphology of most cells. 
 
A B 
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Figure 5.6:  STS 09/10 cell Growth evaluated by MTT proliferation assay  
Cells were at passage 70 and were derived from the second wash of cultures set up from STS 09/10 tissue.  
Data is representative of experiments done in quadruplicate.  Curve fitting was done using GraphPad
®
 Prism 
software (version 6) and the doubling time was calculated using the Exponential Growth Equation in the same 
software. 
 
5.2.4.3 Genetic Characterisation 
Karyotype 
None of the metaphase spreads obtained from the cells in culture had a normal chromosome 
number.  The majority were however near-diploid, having around 48 chromosomes (Table 5.4).   
Array CGH 
Array CGH was carried out using DNA extracted from cells after 35 passages and the genomic copy 
number profile compared to that from the fresh frozen parent tissue as shown in Figure 5.7.   Both 
profiles showed very similar SCNA patterns on most chromosomes, including identical discrete 
amplicons on 12q13 –15 that involve the putative driver genes, MDM2 and CDK4.   Another ten 
chromosomes showed near-identical aberration breakpoints such as those detected in chromosomal 
regions such as 1q, 2q-ter, 5p, 6q, 7q, 8p, 8q, 9p, 10p, 14q, and 16p  (Figure 5.7).   Two 
chromosomes (3 and 21) showed no SCNA in either sample.  A number of genomic regions showed 
dissimilar copy number profiles, most notable of which was chromosome 11.   These dissimilarities 
however were relatively few (on six chromosomes) compared to the remarkable similarities seen on 
13 chromosomes (Figure 5.7).   
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Figure 5.7:  Genome View Ideograms of STS 09/10 comparing cultured cells with parent tumour 
tissue 
Panel A – whole genome ideogram for STS 09/10 parent tumour tissue DNA showing multiple SCNA detected 
across the genome, compared with Panel B – whole genome ideogram of DNA from cells (at passage 35) 
derived from a wash taken off original cultures of STS 09/10 tissues that were set up in flasks, showing multiple 
SCNA detected across all autosomes and similar average log ratio patterns overall. 
Aberrant regions are shown as coloured shading on the chromosome (blue represents amplification and red 
represents deletion).   Small dots represent individual probes.  Black vertical lines represent mean log ratio for 
the corresponding region on the chromosome.  Horizontal distance to the right (amplification) or left (deletion) of 
the vertical capped zero line represents the magnitude of aberration (log ratio). All CNAs were detected using the 
FASST2 algorithm  
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5.2.5 STS 14/10:  Undifferentiated Pleomorphic Sarcoma 
5.2.5.1 Tumour Characteristics 
Tumour samples were obtained from a large (230mm maximum dimension) tumour that was widely 
excised from the right thigh of a 54-year old female patient.  Distant metastases were not evident at 
the time of surgical resection and no neo-adjuvant therapy had been administered.  The tumour was 
diagnosed as an undifferentiated pleomorphic sarcoma of Trojani grade 3. 
 
5.2.5.2 Primary Tissue Culture Characteristics 
Primary cultures were set up as described in Section 2.3.1.1.  No washes were required as most 
cells became established as adherent cultures within a few days.  Cultures are composed of a 
morphologically homogenous clone of fibroblast-like spindle-shaped cells (Figure 5.8).  The cells 
proliferate with an estimated doubling time of 40.5 hours (Figure 5.9) and have been passaged more 
than 70 times in over 30 months of culture.   
 
Figure 5.8:  Phase-contrast Micrographs showing STS 14/10 cells in culture  
Cells shown were at passage 72 and were derived from cultures set up from STS 14/10 tissue.   
A – Images captured at x40 magnification showing the pattern of growth without distinct colonies.   
B- Images captured at x100 magnification showing the fibroblast-like spindle shaped morphology of most cells. 
 
A B 
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Figure 5.9:  STS 14/10 Cell Growth evaluated by MTT proliferation assay  
Cells were at passage 69 and were derived from cultures set up from STS 14/10 tissue.  Data is representative 
of experiments done in quadruplicate.  Curve fitting was done using GraphPad
®
 Prism software (version 6) and 
the doubling time was calculated using the Exponential Growth Equation in the same software. 
 
5.2.5.3 Genetic Characterisation 
Karyotyping 
Metaphase spreads were obtained from STS 14/10 cells at passage 68.  A pseudo-triploid karyotype 
was seen in most metaphases spreads with cells containing between 63 and 74 chromosomes and a 
mean chromosome count of 69 (Table 5.4).   
Array CGH 
The copy number profile of DNA obtained from STS 14/10 cells at the fifth passage was compared to 
that from the parent tissue.  Profiles showed near-identical SCNA breakpoints on 9 different 
chromosomes, including a specific deletion on 13q14 that involved the locus of the RB1 gene (Figure 
5.10).   Three chromosomes (2, 3 and 11) showed no SCNA in either cultured cell or parent tissue 
copy number profiles.  Only the aberrations detected on 4p, 6p, 7q and 20p were notably dissimilar 
between the profiles, which are shown in whole genome ideograms in Figure 5.10.    
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Figure 5.10:  Genome View Ideograms of STS 14/10 comparing cultured cells with parent tumour 
tissue 
Panel A – whole genome ideogram for STS 14/10 parent tumour tissue DNA showing multiple SCNA detected 
across the genome, compared with Panel B – whole genome ideogram of DNA from cells cultured from STS 
14/10 tissue (at passage 5) showing multiple SCNA detected across all autosomes and similar average log ratio 
patterns overall. 
Aberrant regions are shown as coloured shading on the chromosome (blue represents amplification and red 
represents deletion).   Small dots represent individual probes.  Black vertical lines represent mean log ratio for 
the corresponding region on the chromosome.  Horizontal distance to the right (amplification) or left (deletion) of 
the vertical capped zero line represents the magnitude of aberration (log ratio). All CNAs were detected using the 
FASST2 algorithm. 
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5.2.6 STS 02/11:  Leiomyosarcoma 
5.2.6.1 Tumour Characteristics 
Tumour samples were a kindly donated from by a 62-year old female patient who had wide resection 
as initial treatment for a 135mm Trojani grade 3 vaginal leiomyosarcoma.  
5.2.6.2 Primary Tissue Culture Characteristics 
Cultures initially established slowly proliferating spindle-shaped cells and washes set up from the 
slopes and flasks were designated ‘ws’ and ‘w1’, respectively.  An appearance suggestive of early 
senescence was observed in all the cultures but they were maintained in culture as per protocol.   
Variant 1 – ‘STS 02/11 ws’ 
After around 8 weeks in culture during which they were passaged only twice, a single clone of 
polygonal cells with distinct nuclei was observed among the largely senescent cells in the cultures 
designated ‘ws’.  This clone eventually outgrew all other cells in the flask and has now been 
proliferating since March 2011 without notable further change in morphology.  The cells grew in tight 
colonies that increased in size until confluence (Figure 5.11).  The cells have so far been sub-
cultured over 65 times and have an estimated doubling time of approximately 45 hours (Figure 5.12).   
Variant 2 – ‘STS 02/11 w1’ 
Following an even longer lag phase (around 12 weeks in culture), another distinct clone of cells was 
observed in cultures designated w1.  Compared to the clone that formed the ws variant, these cells 
were spindle-shaped rather than polygonal and had less distinct nuclei.  They however also grew in 
tight colonies (Figure 5.13).  Initial suspicion of contamination of STS 02/11 cell cultures by cells from 
another cell line was allayed by STR profiling of cells from both variants that showed identical alleles 
for both clones, which were distinct from all other cell lines used in the same laboratory (Table 5.3).   
Cells from the W1 variant have now been in passaged over 55 times and have an estimated doubling 
time of 27.4 hours (Figure 5.14) 
5.2.6.3 Genetic Characterisation 
Karyotyping 
Metaphase spreads from STS 02/11 ws variant cells were highly polyploid and contained between 
101 and 147 chromosomes each, many of which had gross structural abnormalities (not shown).   
Similar chromosome counts were obtained from the w1 variant cells that were examined, which had 
110 – 138 chromosomes per metaphase spread (Table 5.4). 
Array CGH 
Genome view ideograms of the DNA copy number profiles of STS 02/11 ws cells at passage 27 and 
that from the parent tumour tissue were compared as shown in Figure 5.15.  A number of SCNA 
detected in the cultured cells were different from those in parent tissue.  For example, deletions on 
5p seen in the parent tissue were not identified in this clone the cultured cells and conversely, 
deletions on 7q observed in the cultured cells but not in the parent tissue (Figure 5.15).  However, 
moving average patterns of probe log ratios on many chromosomes were very similar in both profiles 
and had near identical breakpoints as seen on 9p, 11q, 19q and 20q.  Two chromosomes (2 and 21) 
bore no SCNA in either sample.  
 147 
 
 
Figure 5.11:  Phase-contrast Micrographs showing the ‘ws’ variant of STS 02/11 cells in culture  
Cells shown were at passage 69 and were derived from a wash taken off cultures of STS 02/ 11 tissues that 
were set up in slopes.  A – Images captured at x40 magnification showing the pattern of growth in tightly-pack 
colonies.  B- Images captured at x100 magnification showing the polygonal morphology of most cells with 
distinct nuclei. 
 
Figure 5.12:  STS 02/11 ‘ws’ variant Cell Growth evaluated by MTT Proliferation Assay  
Cells were at passage 63 and were derived from a wash taken off cultures of STS 02/ 11 tissues that were set 
up in slopes.  Data is representative of experiments done in quadruplicate.  Curve fitting was done using 
GraphPad® Prism software (version 6) and the doubling time was calculated using the Exponential Growth 
Equation in the same software. 
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Figure 5.13:  Phase-contrast Micrographs showing STS 02/11 cells in culture  
Cells shown are at passage 56 and were derived from the first wash taken off cultures of STS 02/ 11 tissues 
that were set up in flasks.  A – Images captured at x40 magnification showing the pattern of growth in tightly-
packed colonies.  B- Images captured at x100 magnification showing the fibroblast-like spindle shaped 
morphology of most cells. 
 
 
Figure 5.14:  STS 02/11 ‘w1‘ variant cell Growth evaluated by MTT proliferation assay  
Cells were at passage 70 and were derived from the first wash taken off cultures of STS 02/ 11 tissues that 
were set up in flasks.  Data is representative of experiments done in quadruplicate.  Curve fitting was done 
using GraphPad
®
 Prism software (version 6) and the doubling time was calculated using the Exponential 
Growth Equation in the same software. 
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Figure 5.15:  Genome View Ideograms of STS 02/11 comparing cultured cells of the ‘ws’ variant with 
parent tumour tissue 
Panel A – whole genome ideogram for STS 02/11 parent tumour tissue DNA showing multiple complex SCNA 
detected across the genome, compared with Panel B – whole genome ideogram of DNA obtained from cells (at 
passage 27) derived from a wash taken off cultures of STS 02/ 11 tissues that were set up in slopes, showing 
multiple SCNA detected across all autosomes and similar average log ratio patterns overall. 
Aberrant regions are shown as coloured shading on the chromosome (blue represents amplification and red 
represents deletion).   Small dots represent individual probes.  Black vertical lines represent mean log ratio for 
the corresponding region on the chromosome.  Horizontal distance to the right (amplification) or left (deletion) of 
the vertical capped zero line represents the magnitude of aberration (log ratio). All CNAs were detected using the 
FASST2 algorithm  
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5.2.7 STS 06/11:  Undifferentiated Pleomorphic Sarcoma 
5.2.7.1 Tumour Characteristics 
An 83-year old male patient kindly donated the tumour samples from which cultures were derived.  
With a maximum dimension of 170mm, the tumour was located in his right thigh and was surgically 
excised without neo-adjuvant therapy.   It was subsequently diagnosed as an undifferentiated 
pleomorphic sarcoma of Trojani grade 3 and no metastases were evident at the time of surgery. 
5.2.7.2 Primary Tissue Culture Characteristics 
Cultures set up according to normal protocol became established within a few days.  Designated 
STS 06/11, the cells have remained slightly pleomorphic in culture but majority have a spindle-
shaped morphology (Figure 5.16).  They grow in loose colonies and lack contact inhibition, able to 
form multiple layers in culture that if left long enough, can be seen macroscopically (not shown).  
In culture since February 2011, the rapidly proliferating STS 06/11 cells have an estimated doubling 
time of 35.38 hours (Figure 5.17) and have been passaged over 90 times. They also exhibit in vitro 
migratory and invasive capabilities when used in micro-chemotactic Boyden chamber assay 
(discussed in detail in chapter 6).   
 
 
Figure 5.16:  Phase-contrast Micrographs showing STS 06/11 cells in culture  
Cells shown are at passage 91 and were derived from cultures set up from STS 06/11 tissue.   
A – Images captured at x40 magnification showing the pattern of growth without distinct colonies.   
B- Images captured at x100 magnification showing the fibroblast-like spindle shaped morphology of most cells. 
 
 
 
A B 
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Figure 5.17:  STS 06/11 cell Growth evaluated by MTT proliferation assay  
Cells were at passage 83 and were derived from cultures set up from STS 06/11 tissue.  Data is representative 
of experiments done in quadruplicate.  Curve fitting was done using GraphPad
®
 Prism software (version 6) and 
the doubling time was calculated using the Exponential Growth Equation in the same software. 
 
5.2.7.3 Genetic Characterisation 
Karyotyping 
Metaphase spreads were initially obtained from STS 06/11 cells at passage 15, when the 
chromosome counts were between 56 and 66 (Table 5.4).    With prolonged culture, the number of 
chromosomes per cell increased and became more variable.  Metaphase chromosomes obtained 
from cultures at passage 82 ranged from 95 to 135 per cell (n = 20; mean = 117; median = 116; 
mode = 115).    Full karyotype analysis is currently on-going. 
Array CGH 
Genomic copy number profile of STS 06/11 cells after 41 passages in culture bore remarkable 
similarity to that of the parent tumour tissue as shown in Figure 5.18.  Nearly all affected 
chromosomes showed SCNA with identical breakpoints, including complex aberrations such as 
those on 11q.   Log ratio amplitudes of SCNA were higher in the cultured cells than the parent 
tumour tissue in certain genomic regions such as those on the short arm of chromosome 9.  
However, the overall pattern of log ratio moving averages in this region remained similar (Figure 
5.18). 
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Figure 5.18:  Genome View Ideograms of STS 06/11 comparing cultured cells with parent tumour 
tissue 
Panel A – whole genome ideogram for STS 06/11 parent tumour tissue DNA showing multiple SCNA detected 
across the genome, compared with Panel B – whole genome ideogram of DNA from cells cultured from STS 
09/10 tissue (at passage 41) showing multiple SCNA detected across all autosomes and similar average log 
ratio patterns overall. 
Aberrant regions are shown as coloured shading on the chromosome (blue represents amplification and red 
represents deletion).   Small dots represent individual probes.  Black vertical lines represent mean log ratio for 
the corresponding region on the chromosome.  Horizontal distance to the right (amplification) or left (deletion) of 
the vertical capped zero line represents the magnitude of aberration (log ratio). All CNAs were detected using the 
FASST2 algorithm  
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5.2.8 STS 09/11:  Undifferentiated Pleomorphic Sarcoma 
5.2.8.1 Tumour Characteristics 
Tumour samples were a kind donation from a 76-year-old female patient who had wide surgical 
excision of a right lower limb tumour.  Measuring 115mm in maximum dimension, the tumour was 
subsequently diagnosed as a Trojani grade 3, undifferentiated pleomorphic sarcoma.  Distant 
metastases were not evident at the time of surgery and neo-adjuvant therapy was not administered. 
5.2.8.2 Primary Tissue Culture Characteristics 
Cultures were set as per normal protocol (Section 2.3.1.1) and washes were not required.   Adherent 
cells in culture had a long, fibroblast-like morphology and grew in loose colonies that formed 
monolayers (Figure 5.19).  STS 09/11 cells showed a relatively slow rate of proliferation with their 
doubling time estimated at approximately 63 hours using the MTT assay (Figure 5.20).  Even though 
the cells have been in culture since June 2011, they have only been passaged around 35 times. 
 
Figure 5.19:  Phase-contrast Micrographs showing STS 09/11 cells in culture  
Cells shown are at passage 35 and were derived from cultures set up from STS 09/11 tissue.   
A – Images captured at x40 magnification showing the pattern of growth of cells in loose colonies.   
B- Images captured at x100 magnification showing the long fibroblast-like spindle-shaped morphology of most 
cells. 
 
A B 
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Figure 5.20:  STS 09/11 cell Growth evaluated by MTT proliferation assay  
Cells were at passage 35 and were derived from cultures set up from STS 09/11 tissue.  Data is representative 
of experiments done in quadruplicate.  Curve fitting was done using GraphPad
®
 Prism software (version 6) and 
the doubling time was calculated using the Exponential Growth Equation in the same software. 
 
5.2.8.3 Genetic Characteristics 
Karyotyping 
Metaphase spreads were obtained from STS 09/11 cells at passage 17.  None of the metaphases 
examined had a diploid chromosome number and karyotypes were composed of between 47 and 68 
chromosomes each (Table 5.4).  Detailed structural analysis of the chromosomes is currently on-
going.   
Array CGH  
Comparison of the array CGH profile of STS 09/11 cells at passage 26 with that of the parent tissue 
showed close similarity on the majority of autosomes (Figure 5.21).   Few genomic regions, such as 
chromosomes 3p, 5 and 9 showed SCNAs in the cultured cells that were different form the parent 
tumour.  Examination of the moving average pattern of log ratios even in regions with complex 
aberrations, showed close similarity in both profiles including regions such as that on 17q where the 
calling algorithm identified differential aberrations (Figure 5.21).  
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Figure 5.21:  Genome View Ideograms of STS 09/11 comparing cultured cells with parent tumour 
tissue 
Panel A – whole genome ideogram for STS 09/11 parent tumour tissue DNA showing multiple SCNA detected 
across the genome, compared with Panel B – whole genome ideogram of DNA from cells cultured from STS 
09/10 tissue (at passage 26) showing multiple SCNA detected across all autosomes and similar average log 
ratio patterns overall. 
Aberrant regions are shown as coloured shading on the chromosome (blue represents amplification and red 
represents deletion).   Small dots represent individual probes.  Black vertical lines represent mean log ratio for 
the corresponding region on the chromosome.  Horizontal distance to the right (amplification) or left (deletion) of 
the vertical capped zero line represents the magnitude of aberration (log ratio). All CNAs were detected using the 
FASST2 algorithm  
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5.2.9 STS 20/11:  Dedifferentiated Liposarcoma 
5.2.9.1 Tumour Characteristics 
The 70 year old female patient who donated the tumour designated as STS 20/11 had a large 
(170mm maximum dimension) tumour widely excised from her left thigh.   Distant metastases were 
not evident at the time of surgery, but the tumour was locally invasive and required neo-adjuvant 
radiotherapy before it could be safely resected.  Subsequent histopathological analysis led to its 
classification as a de-differentiated liposarcoma with around 30% viability.   Trojani grading was not 
applicable because of the high level of radiation-induced necrosis (Coindre, Nguyen et al. 1988).  
However, dedifferentiated liposarcomas are generally regarded as high grade tumours (Fletcher, 
Bridge et al. 2013). 
5.2.9.2 Primary Tissue Culture Characteristics 
Cultures were set up according to normal protocol (Section 2.3.1.1).  Washes were not required 
because viable cells formed adherent cultures in the original flasks.  This was surprising considering 
the high level of necrosis in the tumour as a whole.  The cells formed loose colonies in culture 
(Figure 5.22A) and consisted of a combination of spindle-shaped fibroblast-like cells and more 
polygonal cells with distinct nuclei (Figure 5.22B).  They proliferate at a slow rate relative to other 
STS cultures in this study and have an estimated doubling time of around 58 hours (Figure 5.23).  
They have only been passaged around 25 times in the last 18 months. 
 
Figure 5.22:  Phase-contrast Micrographs showing STS 20/11 cells in culture  
Cells shown are at passage 22 and were derived from original cultures set up from STS 20/11 tissue.  A – 
Images captured at x40 magnification showing the pattern of growth in loose colonies.  B- Images captured at 
x100 magnification showing the mixture of fibroblast-like spindle-shaped morphology of most cells and an ad-
mixture of polygonal cells with more distinct nuclei. 
 
A B 
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Figure 5.23:  STS 20/11 Cell Growth evaluated by MTT proliferation assay  
Cells were at passage 23 and were derived from original cultures set up from STS 20/11 tissue.  Data is 
representative of experiments done in quadruplicate.  Curve fitting was done using GraphPad
®
 Prism software 
(version 6) and the doubling time was calculated using the Exponential Growth Equation in the same software. 
 
5.2.9.3 Genetic Characteristics 
Karyotyping 
Metaphase spreads were initially obtained from STS 20/11 cells at passage 2, when chromosome 
counts were around 70 on average and ranged between 63 and 73.  Subsequent chromosome 
harvests carried out around passage 15 showed a much wider range of chromosome counts of 51 – 
154.  However, the modal count of 69 was close to that from the previous chromosome harvest 
(Table 5.4). 
Array CGH  
Comparison of the array CGH profile of STS 20/11 cells with that of the parent tissue was carried out 
at the second passage.  The genomic profiles showed close similarity on the majority of autosomes 
(Figure 5.24) with very few regions such as the short arm of chromosome 5 and long arm of 
chromosome 12 showing differential aberrations.  Regions with very complex aberration patterns 
such as chromosome 20 retained near-identical breakpoints in the cultured cells (Figure 5.24). 
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Figure 5.24:  Genome View Ideograms of STS 20/11 comparing cultured cells with parent tumour 
tissue 
Panel A – whole genome ideogram for STS 20/11 parent tumour tissue DNA showing multiple SCNA detected 
across the genome, compared with Panel B – whole genome ideogram of DNA from cells cultured from STS 
20/11 tissue (at passage 2) showing multiple SCNA detected across all autosomes and similar average log ratio 
patterns overall. 
Aberrant regions are shown as coloured shading on the chromosome (blue represents amplification and red 
represents deletion).   Small dots represent individual probes.  Black vertical lines represent mean log ratio for 
the corresponding region on the chromosome.  Horizontal distance to the right (amplification) or left (deletion) of 
the vertical capped zero line represents the magnitude of aberration (log ratio). All CNAs were detected using the 
FASST2 algorithm  
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5.2.10 STS 21/11:  Myxofibrosarcoma 
5.2.10.1 Tumour Characteristics 
Tumour tissue was kindly donated by a 73 year old gentleman who was having a high grade 
myxofibrosarcoma removed from his left arm.  Tissue samples were obtained following surgical 
excision, the initial treatment modality for this 50mm tumour.  Distant metastases were not evident at 
the time of surgery.   
 
5.2.10.2 Primary Tissue Culture Characteristics 
Cultures were set up according to normal protocol (Section 2.3.1.1).  A wash was taken off the 
original culture flasks because viable non-adherent cells were observed in media.  Adherent cell 
cultures were established within the wash, designated ‘w1’, while the cells in the original flasks 
became senescent after two to three passages.  Similar to STS 02/11 ws cells, the cell form STS 
21/11 w1 cultures had a histiocyte-like polygonal morphology, but their nuclei are not as distinct 
(Figure 5.25B).  The cells grow in distinct colonies (Figure 5.25A) and have an estimated doubling 
time of approximately 60 hours (Figure 5.26).  They have been passaged around 35 times in the 
approximately 18 months of culture. 
 
Figure 5.25:  Phase-contrast Micrographs showing STS 21/11 cells in culture  
Cells shown are at passage 35 and were derived from washes taken off original cultures set up from STS 21/11 
tissue.  A – Images captured at x40 magnification showing the pattern of growth in distinct colonies.  B- Images 
captured at x100 magnification showing the polygonal morphology of most cells. 
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Figure 5.26:  STS 21/11 cell Growth evaluated by MTT proliferation assay  
Cells were at passage 35 and were derived from the first wash taken off original cultures set up from STS 21/11 
tissue.  Data is representative of experiments done in quadruplicate.  Curve fitting was done using GraphPad
®
 
Prism software (version 6) and the doubling time was calculated using the Exponential Growth Equation in the 
same software. 
 
5.2.10.3 Genetic Characteristics 
Karyotyping 
Metaphase spreads obtained from STS 21/11 cells at passage 28 comprised between 44 and 118 
chromosomes per cell.  Most cells had around 88 chromosomes (Table 5.4) and the karyotypes 
included numerous small, likely abnormal chromosomes (not shown). 
Array CGH  
DNA from STS 21/11 cells at passage 35 was analysed by array CGH and the genomic profile 
compared to that from the fresh frozen parent tissue (Figure 5.27).  The moving average pattern of 
copy number aberrations was similar across the majority of chromosomes although the positive and 
negative amplitudes were greater in the more homogenous cultured cells than the parent tumour 
tissue with possible adjacent normal cell content.  This was most evident in regions with complex 
aberrations on 4q, 5p 10q and 20q.     Differential aberrations were noted on only two chromosome 
arms 8p and 21q.   
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Figure 5.27:  Genome View Ideograms of STS 21/11 comparing cultured cells with parent tumour 
tissue 
Panel A – whole genome ideogram for STS 21/11 parent tumour tissue DNA showing multiple SCNA detected 
across the genome, compared with Panel B – whole genome ideogram of DNA from cells (at passage 35) 
derived from a wash taken off cultures of STS 21/ 11 tissues that were set up in flasks, showing multiple SCNA 
detected across all autosomes and similar average log ratio patterns overall. 
Aberrant regions are shown as coloured shading on the chromosome (blue represents amplification and red 
represents deletion).   Small dots represent individual probes.  Black vertical lines represent mean log ratio for 
the corresponding region on the chromosome.  Horizontal distance to the right (amplification) or left (deletion) of 
the vertical capped zero line represents the magnitude of aberration (log ratio). All CNAs were detected using the 
FASST2 algorithm   
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5.3 DISCUSSION 
In this study, the success rate for establishment of confluent cell cultures from primary STS tissue 
was over 70% (33 out of 47 cases) and more than half of the established cultures were able to 
undergo four passages or more (Table 5.2).  This rate is very comparable to previous studies which 
reported success rates of between 5 and 33% when cultures were attempted from primary solid 
tumours as in this study, and slightly higher success rates from tumour metastases (McBain, Weese 
et al. 1984, Gazdar, Kurvari et al. 1998, Nayak, Kakati et al. 2000) or xenograft-derived cultures 
(Dangles-Marie, Pocard et al. 2007, Kamiyama, Rauenzahn et al. 2013).  Seven tumours (15% of 
cases) have grown as long-term cultures. 
Among the 14 cases that failed to establish cultures, eight were well-differentiated or myxoid 
liposarcomas that had high fat and/or myxoid components relative to cell number, which reduced the 
likelihood of adherent culture using the manual mechanical tissue dissociation, applied in this study.  
Simultaneous use of the explant method of culture establishment (Mitra, Mishra et al. 2013) in some 
of these cases only yielded slow-growing, fibroblast-like cells that failed to reach confluence (data 
not shown).   Application of the principle of differential attachment described by Nayak and 
colleagues (Nayak, Kakati et al. 2000) led to establishment of long term cultures in washes in  three 
cases (STS 09/10, 02/11 and 21/11), while cells in the original culture flask became senescent at 
earlier stages.  It also led to the establishment of long term cultures of two morphologically distinct 
but genetically related variants of STS 02/11 (Figure 5.10, 5.12 and Table 5.2).  Since both variants 
have been exposed to otherwise identical culture conditions, and it is most likely that the variants 
represent separate clones present within the parent tumour rather than differential adaptation to 
culture conditions.  Similar observations have been made in multiple cases of primary breast 
carcinoma tissue culture (McBain, Weese et al. 1984). 
Characterisation of primary cells cultures for use as models in target validation studies is essential 
due to the potential for fibroblast overgrowth in early cultures (Mitra, Mishra et al. 2013) and cross 
contamination by other established cell lines in long term cultures (Gillet, Varma et al. 2013).  
Morphological characterisation may be unreliable because of the potential effects of an artificial in 
vitro microenvironment on tumour cell morphology.  In most cancers therefore, detection of 
biomarker expression by immunochemistry or flow cytometry are commonly used for characterisation.  
The common biomarkers of tumour cell lineage such as CD34, cytokeratin (CK), smooth muscle 
actin (SMA), desmin and S100, however are not specific for many STS subtypes (Coindre 2003, 
Fisher 2011).  For example, none of these markers is commonly expressed in UPS or 
myxofibrosarcomas, while others such as epithelial cell marker CK may be expressed in some LMS 
and synovial sarcomas. Immunohistochemistry for panels of these markers however remains 
relevant to diagnostic practice as an adjunct to histology is effective for the exclusion of benign and 
non-mesenchymal tumours; identification of certain STS subtypes and choosing appropriate 
molecular genetic tests for difficult subtype-specific STS diagnoses (Fisher 2011).  It however 
requires interpretation with an appropriate level of expertise. 
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Since the majority of STS are characterised by complex molecular genetic profiles, the cell lines 
developed form these tumours were characterised using array CGH, a method that has contributed 
significantly to the recent WHO classification of STS (Fletcher, Bridge et al. 2013).  This method is 
unable to detect balanced translocations that are known to drive some STS subtypes, including three 
of the four cases (Table 5.5) that gave inconclusive featureless array CGH profiles in both cultured 
cells and parent tissue.  The fourth such case - STS 05/10 was diagnosed as an epitheloid 
angiosarcoma, an STS subtype that is described in literature as having complex genomics (Guillou 
and Aurias 2009).  However, array CGH did not detect any SCNA in any of the three angiosarcoma 
cases analysed in this study.  All three tumours were very haemorrhagic, as is typical of these 
tumours (Fletcher, Bridge et al. 2013) and macroscopically sampled thus raising the possibility that 
their percentage tumour cell content was below the threshold (around 25%) that is readily detectable 
by array CGH (Neill, Torchia et al. 2010).  In three other cases of STS subtypes known to have 
complex genomics that were confirmed by array CGH such as the malignant peripheral nerve sheath 
tumour designated STS 01/11, the absence of SCNA in the cultured cells (Figure 5.4) implied that 
were not representative of their parent tumours and were probably fibroblasts that subsequently 
became senescent before the tenth passage when they presumably reached their Hayflick’s number 
(Macieira-Coelho 1998). 
STR profiling, the currently recommended standard for cell line identification (American Type Culture 
Collection Standards Development Organization Workgroup 2010) was used to resolve issues of 
potential cross contamination and reliably confirm all seven long term cultures in this study as 
separate entities.  Subsequent characterisation on the basis of genomic copy number profile 
comparison showed overall similarity in log ratio patterns to the corresponding parent tumours in all 
seven long-term cell cultures when thresholding of the aberration detection algorithm are taken into 
account (discussed in section 3.3).    A number of real SCNA differences were noted.  In line with the 
clonal evolution model of cancer, inherent genetic instability and rapid proliferation of tumour cells is 
expected to result in heterogeneity of tumour cell clones, which would be selected for in culture but 
be a part of the whole in the parent tissue (Anderson, Lutz et al. 2011, Greaves and Maley 2012).    
With prolonged in vitro cell culture, these factors would also result in accumulation of genomic copy 
number or structural karyotypic aberrations, most of which are functionally neutral, i.e. ‘passengers’ 
(Greaves and Maley 2012, Gillet, Varma et al. 2013).   
Overall however, these differences are few when compared to the genomic regions that show similar 
SCNA with near-identical breakpoints even after 40 passages in culture (Figure 5.13).  In addition, 
recent large-scale studies evaluating the relevance of established cell lines in various cancers have 
shown that ‘driver’ genomic aberrations are nearly always retained in well-established commercial 
cell lines and vice versa (Beroukhim, Mermel et al. 2010, Gazdar, Gao et al. 2010, Barretina, 
Caponigro et al. 2012).  Moreover, early passages of all the long term cultures that presumably more 
bear a closer genomic and phenotypic resemblance to parent tumour have been banked and can be 
used to confirm promising finding in target validation studies. 
All seven long term cell cultures established have remained proliferative in culture for between one 
and three years, and been passaged at least 25 times each with doubling times that are comparable 
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to those of commercial sarcoma cell lines such as SKLMS1 (leiomyosarcoma), U2OS 
(osteosarcoma) and other primary cancer cell lines (McBain, Weese et al. 1984) , thus reflecting their 
possession of the cancer hall marks of increased proliferation and survival (Hanahan and Weinberg 
2011).  All seven showed abnormal chromosome numbers and in some cases, significant changes in 
chromosome numbers with increased time in culture, further reflecting their genomic instability.  One 
of the cultures, STS 06/11 was also shown to have migratory and invasive properties (discussed in 
detail in Chapter 6).   
Among the seven tumours that established long term cultures, three were undifferentiated 
pleomorphic sarcomas, representing half of the cases that were obtained of this characteristically 
aggressive STS subtype (Fletcher, Bridge et al. 2013).  The other STS subtypes that formed long 
term cultures were also of a high grade.   This suggests that overall, high grade and aggressive 
clinical course in STS correlates with amenability to in vitro growth, as was observed in primary 
cultures of breast (Gazdar, Kurvari et al. 1998) and colorectal cancer tissue (McBain, Weese et al. 
1984).  However, other aggressive tumour subtypes such as angiosarcoma and myxofibrosarcoma 
with high grade tumours represented in this study did not show any such correlation.  Again, this may 
explained by other factors such the result of the physical and biologic properties of these tumours as 
observed in the angiosarcomas, where high blood cell content of samples makes reliable 
macroscopic sampling of tumour cell-rich areas difficult.    
Three of the cell lines represent undifferentiated pleomorphic sarcomas with very different 
morphology and chromosome numbers; the leiomyosarcoma-derived cultures comprise two 
morphological variants of the same tumour, and one of the de-differentiated liposarcoma cultures 
was derived from a patient who received neo-adjuvant radiotherapy with partial response and 
probably represents a radio-resistant clone of cells present within that tumour.   Given this range of 
features, these seven long term cultures are potential much-needed additions to the number of cell 
lines of STS with complex genomics available that could comprise panels for drug testing akin to the 
NCI-60 panel that includes only more-prevalent cancers (Shoemaker 2006, Taylor, Barretina et al. 
2011).  In addition, the previously-irradiated and therefore likely radio-resistant STS cell line, STS 
20/11 may be utilised for the study of tumour response to radiation, either alone or in combination 
with sensitising agents, as demonstrated with PARP inhibitors in Ewings’ sarcoma cell lines (Garnett, 
Edelman et al. 2012).   
The results of primary tissue culture in this study show the potential for fairly reliable establishment of 
short- and long term cell cultures from STS tissue that can serve as a source of tumour material for 
reliable translational research.  Even though time constraints, as well as karyotypic complexity did 
not permit the completion of cytogenetic analysis of the cultured cells within this PhD project, 
molecular genetics was used to establish that the vast majority of cultured cells lines in this study 
were representative of their parent tumours.  When combined with their rapid proliferation and 
abundance, the long term cell lines represent an excellent model in vitro validation of genomic and 
transcriptomic targets in STS.  The combination for banking of early passages of these characterised 
cell lines as well as the potential to develop prospective short term cultures from other tumours of the 
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same STS subtypes will serve to mitigate some of the concerns that have been raised with existing 
cell lines. 
Full characterisation of the malignant phenotype of the long term cultures using in vitro assays such 
as soft agar colony-forming; migration and invasion; and telomere length assays would be useful.  In 
addition, assessment of their in-vivo tumour xenograft-forming ability could potentially lead to the 
development of in vivo models suitable for robust preclinical target validation.  Although time and 
cost constraints meant that these assays could not be carried out within this PhD study, they serve 
as areas for additional work in the near future. 
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CHAPTER SIX 
RESULTS:  AMPLIFICATION OF TRIO IS A POSSIBLE 
TARGET IN UPS 
6  
 167 
 
6.1 INTRODUCTION 
Tumour metastasis remains an important cause of cancer mortality, accounting for up to 90% of 
deaths from solid tumours (Gupta and Massague 2006).  In order to metastasize, cancer cells must 
undergo a complex series of processes including invasion of, and migration through surrounding 
tissues; intravasation and survival within the bloodstream; extravasation at distant sites; and 
subsequent colonisation (Steeg 2006).  Elucidation of molecular mechanisms that are responsible for 
these processes in specific cancers is therefore required for development of effective novel targeted 
therapies (Brabletz 2012).  
The initial steps in metastasis - tumour cell migration and invasion require cell motility, which is 
regulated at the molecular level by the Rho subfamily of small guanine nucleotide-binding proteins 
(g-proteins) called rhoGTPases.  As illustrated in Figure 6.1, specific rhoGTPases promote the 
formation of actin-containing structures that cells require for migration (Gupta and Massague 2006) 
including lamellopodia and membrane ruffles (mediated by Rac1) (Ridley, Paterson et al. 1992), 
filopodia (mediated by Cdc42) (Kozma, Ahmed et al. 1995), and actomyosin stress fibres (mediated 
by RhoA) (Ridley and Hall 1992). 
 
Figure 6.1:  Simplified Representation of the Role of RhoGTPases in Tumour Cell Migration and 
Invasion.   
Activation of Specific RhoGTPases (red highlights) leads to the formation of cytoskeletal structures that are 
used for tumour cell migration and invasion. 
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More recently, rhoGTPases have also been shown to be involved in other cancer-relevant roles such 
as cell cycle progression; DNA transcription; cell-cell and cell-matrix interactions (Keely, Westwick et 
al. 1997, Chan, Coniglio et al. 2005, Jaffe and Hall 2005).  While activating mutations of rhoGTPase 
genes have rarely been reported in cancer (Lazer and Katzav 2011), increased levels of Rac1 and 
RhoA activity and/or expression have been shown to correlate with tumour progression in various 
cancers (Fritz, Just et al. 1999, Abraham, Kuriakose et al. 2001, Fritz, Brachetti et al. 2002, Kamai, 
Yamanishi et al. 2004, Pan, Bi et al. 2004).  
RhoGTPase activation occurs via a number of mechanisms, important among which are a group of 
proteins referred to as Rho Guanine-nucleotide Exchange Factors (rhoGEF).  By specific interaction 
with rhoGTPase proteins in their inactive (GDP–bound) state, they cause a conformational change 
that results in GDP dissociation and its subsequent replacement by the more physiologically-
abundant GTP, thus switching the g-protein to its active state (Bos, Rehmann et al. 2007).  This is 
illustrated schematically in Figure 6.2. 
 
Figure 6.2:  Mechanism of GEF Activation of RhoGTPases 
Binding of the Rho Guanine-nucleotide Exchange Factors (GEF) to the inactive (GDP-bound) rhoGTPase leads 
to conformational change and dissociation of the guanidine di-phosphate (GDP) nucleotide.  This interaction is 
transient however, and the GEF soon dissociates and is replaced by the more physiologically abundant 
guanidine tri-phosphate (GTP) nucleotide, switching the rhoGTPase molecule to its active state  
 
The first rhoGEF identified in mammalian cells, Dbl was isolated from B-cell lymphoma cDNA on the 
basis of its oncogenic (transforming) activity in NIH3T3 fibroblast cells (Hart, Eva et al. 1991).  Over 
70 different human rhoGEF proteins have been identified to date, the majority of which possess a 
Dbl-conserved domain (DH) (Lazer and Katzav 2011) that was shown to be required for GEF activity 
(Hart, Eva et al. 1994).  Some of these, including Ect2 and Ost were also initially identified as 
oncogenes capable of transforming fibroblasts (Miki, Smith et al. 1993, Yamanaka, Blumenthal et al. 
2001) and subsequently found to possess the characteristic DH- domains and GEF activity (Lazer 
and Katzav 2011).   
In addition to their putative oncogenic properties, abnormally increased levels of RhoGEFs 
expression have also been demonstrated in various cancers and the sum total of this evidence has 
led to the prevailing theory among researchers that activation of rhoGEFs causing dysregulation of 
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rhoGTPases and actin cytoskeleton organisation is responsible for tumour progression and 
metastases (Sahai and Marshall 2002, Lazer and Katzav 2011).  This emerging target has thus been 
the focus of recent anti-cancer drug development with encouraging preclinical results (Lu, Chan et al. 
2009, Routhier, Astuccio et al. 2010, Lazer and Katzav 2011, Barrio-Real and Kazanietz 2012). 
One rhoGEF, Trio is unusual because it has not one, but two putative DH – domains with specific 
GEF activity termed GEF1 and GEF2 (Seipel, Medley et al. 1999).  The N-terminal GEF1 interacts 
specifically with RhoG and Rac1, via which it mediates mesenchymal-type cell motility and axon 
guidance, respectively (van Rijssel, Hoogenboezem et al. 2012) while the C-terminal GEF2 activates 
RhoA and thus regulates a different form of cell motility known as amoeboid cell movement (Sanz-
Moreno, Gadea et al. 2008).  Its encoding gene, TRIO is located on the short arm of chromosome 5 
and was initially identified in adult T-cell leukaemia cells as its truncated cDNA isoform termed Tgat, 
which encodes only the RhoA-specific GEF domain.   Like a number of other rhoGEFs, Tgat was 
found to be a putative oncogene, able to induce transformation in NIH3T3 cells with subsequent 
tumour formation in nude mice via activation of RhoA (Yoshizuka, Moriuchi et al. 2004).   
Copy number gains affecting the TRIO locus have been described as frequent aberrations in various 
cancers including soft tissue sarcoma (Adamowicz, Radlwimmer et al. 2006), bladder cancer (Zheng, 
Simon et al. 2004), cervical cancer (Kloth, Oosting et al. 2007, Ng, Winder et al. 2007), oral cancer 
(Baldwin, Garnis et al. 2005), squamous oesophageal cancer (Chattopadhyay, Singh et al. 2010) 
and small cell lung cancer (Coe, Henderson et al. 2005).  Gene expression studies in brain tumours 
found that TRIO was expressed at higher levels in aggressive glioblastoma multiforme when 
compared with low-grade gliomas (Salhia, Tran et al. 2008) and silencing its expression led to 
reduced proliferation of glioblastoma cells in culture, as well as impairment of their invasive 
capabilities in vitro and ex-vivo (Salhia, Tran et al. 2008, Kwiatkowska, Didier et al. 2012).  
Furthermore, protein levels of Trio and other rhoGEFs have been correlated with poor patient 
outcomes in both glioblastoma (Salhia, Tran et al. 2008)
 
and breast cancer (Lane, Martin et al. 2008), 
supporting a possible role for TRIO in tumour progression. 
In view of this accumulating evidence, inhibitors directed specifically against the Trio rhoGEF 
domains have been under development.  The first of these include TRIPα and other aptamer-derived 
peptides, which were shown to specifically inhibit the GEF2 domain and prevent RhoA activation 
(Schmidt, Diriong et al. 2002).  They also abrogated oncogenic effects of Tgat in cell lines and 
tumour xenografts (Bouquier, Fromont et al. 2009).  More recently, a small molecule inhibitor named 
ITX3 was shown to specifically inhibit the GEF1 domain, blocking the activation of RhoG and Rac1.  
ITX3 in normal mammalian cells showed comparable effects to complete Trio knockdown (using 
siRNA) and the downstream Rac1-specific inhibitor NSC23766, but is believed to avoid their off-
target effects due to its specificity for the GEF1 domain (Bouquier, Vignal et al. 2009).  Its effects on 
human tumour cells expressing Trio are however, yet to be examined (Lazer and Katzav 2011).   
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Using array CGH, TRIO was identified as a candidate gene among UPS, where it was amplified in 
around 60% of tumours examined in this study (Figure 6.3 and Section 4.7.3.2).   FISH, utilising 
custom probes on 3 primary cell cultures derived from UPS as well as FFPE tumour sections was 
used to visualise the copy numbers of the TRIO locus.  Immunohistochemistry was used to examine 
the expression of Trio rhoGEFs protein in STS samples.  Further, the effects of ITX3 treatment on 
proliferation, migration and invasion were examined.  The preliminary results of these studies are 
presented in this chapter. 
Figure 6.3:  Frequency plot of SCNA affecting the TRIO gene locus among 16 UPS cases. 
Top shows the chromosomal region and corresponding frequency plot of aberrations for all 16 cases, plotted as 
percentages along the y-axis. Blue shading above zero line represents amplification frequency and red shading 
below zero line represents deletion frequency. Known CNV region is shown as the purple track.  Horizontal lines 
below represent individual samples and identities are shown on the left.  Grey segments have normal copy 
number, blue segments represent gains and red segments represent losses. Vertical lines show exact 
alignment of SCNA breakpoints. 
All CNAs are detected using the FASST2 algorithm  
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6.2 RESULTS 
6.2.1 Visual Confirmation of TRIO Amplification by FISH 
Fluorescence in situ Hybridisation (FISH) was used to visualise the copy number status of the TRIO 
gene locus at 5p15.2.  No commercial FISH probes specific for that gene locus were available, so 
custom probes were prepared from specific human DNA sequences cloned into Bacterial Artificial 
Chromosomes (BAC clones).  BAC clones that mapped to the TRIO gene locus were identified using 
the University of California at Santa Cruz (UCSC) genome browser (Figure 6.4) and chosen from 
well-annotated libraries including the RPCI human BAC library 11 (RP11) and the CalTech human 
BAC library D (CTD).  
The TRIO gene consists of 30 exons, with 24 known splice variants.  It spans a region of around 400 
kb in length and hence no single BAC clone insert (average size < 200kb) reliably mapped to the 
entire gene.  A pair of clones including RP11-586K23 and CTD-2505B6 that mapped to the 5’ and 3’ 
ends of the gene respectively, with a small overlap in the middle of the gene was therefore chosen 
(Figure 6.4).  Nick translation was used to label these BAC clones inserts with a SpectrumGreen
®
 
fluorophore for use as FISH probes (BAC probes) as described in Methods Section 2.3.8.2.   
In order to distinguish target locus-specific amplification from aneuploidy, chromosome enumeration 
probes (CEP probes) for the chromosome on which the target gene lies are commonly included 
simultaneously for FISH experiments.  These probes hybridise to specific repetitive alphoid DNA 
sequences in the centromeric regions of chromosomes.  Chromosome 5 on which the TRIO gene 
locus lies is however known to possess high alphoid DNA sequence homology with chromosomes 1 
and 19 (Puechberty, Laurent et al. 1999), which results in cross hybridisation of their CEP probes.   
To provide an idea of the overall ploidy status of the genome therefore, an alternative chromosome 
(chromosome 3) with previously optimised CEP probes was chosen for enumeration.  In view of the 
overall karyotypic complexity of these tumours as demonstrated by preliminary cytogenetic studies 
shown in Section 5.2.3.4, aneuploidy of chromosome 3 was regarded to be no better and no worse 
than any other chromosome for which specific centromeric enumeration would be possible.  
Commercial SpectrumOrange
®
-labelled (red) CEP3 probes and SpectrumGreen
®
-labelled (green) 
BAC probes were therefore simultaneously hybridised to STS tumour material as described in 
Methods Section 2.3.8.4. 
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Figure 6.4:  UCSC Genome Browser Mapping of BAC clones to TRIO gene locus 
Top shows the base position of the genome browser as well as its chromosomal location on chromosome 5 (marked in red).  Bottom panel shows the 5’ to 3’ mapping of the 
TRIO gene to that genomic locus (blue arrows) with the blue vertical lines representing the exon positions of known transcripts and blue horizontal lines showing the introns.   
BAC clones that map to the same locus are shown in the middle as labelled black horizontal lines with arrows that show their 5’ to 3’ mapping and black horizontal lines 
showing start and end points.  The two BAC clones that were chosen map to the 5’ and 3’ ends of the locus of the largest known transcript with an overlap that involves exon 
11, and are highlighted in red. 
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6.2.1.1 Control Experiments  
Initial control experiments were carried out to determine the hybridisation efficiency and 
chromosomal localisation of the BAC probes.  Varying amounts (100 – 300ng) of each BAC probe 
were hybridised to interphase nuclei and metaphase spreads prepared from normal leucocytes 
(Figure 6.5). Both showed good signal intensity when 300ng of BAC probe was used.  In all 10 
metaphase chromosome spreads examined, two sets of paired green signals were observed.  They 
were located on two long sub-metacentric (Denver Group B) chromosomes, just short of the 
telomeric ends of their short arms, equivalent to the locus of TRIO at 5p15.2 (Figure 6.5 A, B and C).   
Figure 6.5:  Representative Images from control FISH experiments  
A:  Schematic roughly-scaled representation of the Chromosome 5 banding with 5p15.2 that contains the TRIO gene 
locus highlighted in green.  B – Metaphase spread from normal leucocyte showing sub-telomeric localisation of paired 
green signals (RP11586K23 BAC probe) on short arms of two long chromosomes (white arrows).  The sub-
metacentric structure of these chromosomes identifies them as Denver Group B (centromeres show relatively high 
blue DAPI staining – double white arrows) C – Identical localisation of CTD-2505B6 BAC probe (green signals) on 
chromosomes (white arrows) in a normal metaphase spread  
D – Interphase nucleus from the same experiment (as panel C), showing two distinct green signals. E – Combination 
of both BACs in one probe (green signals) showing identical localisation as single BACs without doubling of signals.  F 
– FFPE section of normal tonsil showing two green signals (combined BAC probe) and two red signals (CEP3) in most 
nuclei (blue DAPI counterstain). 
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Since FFPE samples provide a relatively difficult target for hybridisation, the possibility of using a 
combination of the BAC probes in order to increase the likelihood of success was explored.  Equal 
amounts of both BAC probes (200ng each) were therefore co-precipitated and used for FISH 
experiments on normal metaphase chromosome spreads.  The combined BAC clone probe (cBAC) 
retained the locus specificity of single probes and no increase in green background signal was 
detected (Figure 6.5 E).   Subsequent application of the cBAC probe to 4µm-thick sections of normal 
tonsil tissue showed good signal intensity.   
In addition to background auto-fluorescence, one of the technical challenges faced while performing 
FISH on FFPE sections is the three-dimensional nature of the tissue architecture.  All the probe 
signals present in one nucleus are rarely on a single horizontal focal plane and fine adjustments of 
the vertical distance are needed in order to accurately enumerate all the signals present.  This 
makes scoring of nuclei and capturing representative images much more problematic compared with 
interphase nuclei from cultured cells.   
Cut-off values for green (cBAC) and red (CEP3) probes were derived from three control experiments 
on FFPE sections from normal tonsil tissue.  One hundred nuclei each from the three controls were 
evaluated for green and red signals.  The majority of nuclei showed the expected ratio of 2 green 
and red signals each (Figure 6.5 F and Table 6.1) and cut-off values were calculated as Mean 
frequency + 2 times standard deviation of signal observed in the three controls (Table 6.1).  
Amplification of the TRIO locus was confirmed when the aberrant signal ratios (cBACs > CEP3) 
occurred with a frequency above the cut-off value of 18.1% of nuclei. 
Table 6.1:  Cut-off Values for FISH probes from Interphase Nuclei in Normal Tissue 
Sample 
(100 nuclei) 
Signal Ratios Green (cBAC) signals Red (CEP3) signals 
cBACs< CEP3 cBACs = CEP3 cBACs > CEP3 <2 2  >2 <2 2 >2 
Tonsil 1 10 88 2 6 92 2 8 90 2 
Tonsil 2 8 79 13 6 94 0 13 84 3 
Tonsil 3 4 90 6 2 95 3 10 85 5 
Mean 7 86 7 5 94 2 10 86 3 
S.D 3.05 5.86 5.57 2.31 1.53 1.53 2.52 3.21 1.53 
Cut-off 
(Mean + 2 S.D.) 
16% 97.4% 18.1% 9.3% 96.7% 4.7% 15.4% 92.8% 6.4% 
Amplification of TRIO gene locus was considered positive if the percentage of cells showing a cBAC > CEP3 
signals ≥18.1% (highlighted in red). 
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6.2.1.2 FFPE Sections and Metaphase Spreads 
Interphase FISH was performed on 4µm sections of FFPE tumour samples from three UPS cases – 
UPS 02, UPS 05 and UPS 06.  In all three cases, amplification affecting the TRIO locus had been 
detected by array CGH in fresh tissue samples (Figure 6.3 and Table 6.2) and long-term primary cell 
cultures were derived (as described in Chapter 5) for use in subsequent functional studies.  Both 
array CGH and FISH analyses were performed on the cultured cells in order to confirm that they 
retained the relevant targeted amplification.  A summary of the results is shown in Table 6.2.  
Table 6.2:  Comparison of Copy Number Status of TRIO gene locus by Array CGH and FISH in STS 
tissue and Cultured Cells 
STS 
Case 
Sample 
Type 
Array CGH 
Status of 
TRIO locus 
% of cells with 
CBAC > CEP 3 
signals 
(n = 100) 
Median (range) 
of CBAC signals 
Median (range) 
of CEP 3 
signals 
FISH 
Status of 
TRIO locus 
UPS 02 
Tumour Tissue Amplified 93 5 (2 – 10) 2 (1 – 4) Amplified 
Cultured Cells 
(STS 14/10) 
Amplified 100 7 (6 – 8) 4 (3 – 5) Amplified 
UPS 05 
Tumour Tissue 
 Highly 
Amplified 
100 +++ 3 (2 – 4) 
Highly 
Amplified 
Cultured Cells 
(STS 06/11) 
Highly 
Amplified 
100 >40 16 (13 – 23) 
Highly 
Amplified 
UPS 06 
Tumour Tissue Amplified 91 5 (2 – 12) 2 (1 – 6) Amplified 
Cultured Cells 
(STS 09/11) 
Normal 47 3 (2 – 4) 2 (1 – 4) Amplified 
cBAC – combined BAC probes for TRIO locus 
CEP3 – chromosome 3 enumeration probe 
+++ - Green cBAC signals that were so numerous and clumped together that they were indistinct and difficult to 
enumerate (see figure 6.5A - C)   
 
Array CGH results suggested that the TRIO locus amplification was retained in cultured cells derived 
from UPS 02 and UPS 05, but not UPS 06 (Table 6.2).  Unlike aCGH however, visualisation of this 
locus using FISH not only confirmed the amplification in FFPE sections of UPS 06 parent tissue 
(Figure 6.6A), but also in corresponding cultured STS 09/11 cells (Figure 6.6B and C).  Of one 
hundred STS 09/11 cells examined (both interphase nuclei and metaphase chromosome spreads), 
the majority (approximately 70%) had more than two green TRIO locus signals (Figure 6.6B and C).     
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Even though there was a similar range of green (cBAC) and red (CEP3) signals, around half of the 
cell population samples showed higher than normal green to red signal ratios (Table 6.2), exceeding 
the cut-off of 18.1% determined in normal control tissue (Section 6.2.1.1).   The overall picture that 
suggests a mosaic amplification of the TRIO locus in STS 09/11 cells at such a low overall 
magnitude that it could have been missed by array CGH (false negative).     
Figure 6.6:  Two-colour Fluorescence in situ Hybridisation (FISH) for confirmation of TRIO 
amplification on FFPE sections from UPS 06 and corresponding STS 09/11 cells.  
The cBAC probe for the TRIO locus (green signals) and commercial CEP3 (red signals) were applied simultaneously 
and the nuclei and chromosomes were counter-stained with DAPI (in blue), except in panel C where CEP3 was not 
used.  A - FFPE section of UPS 06 captured in a single focal plane showing 5 green TRIO locus signals in an 
interphase nucleus and 2 red CEP3 signals.   B – Interphase nucleus of STS 09/11 cells that were derived from long 
term culture of UPS 06 tissue showing multiple, large green signals (TRIO amplicons) as seen in parent tissue (in 
Panel A).   C – Interphase nucleus and adjacent metaphase chromosome spread of STS 09/11 cells showing single 
copy TRIO locus amplification of around four green cBAC signals each with 3 and 4 red CEP3 signals, respectively.   
All images were captured using x100 objective  
Parent tissue from UPS 05 showed a high-level amplification affecting the TRIO locus (mean log 
ratio of 3.1 for probes in the SCNA region) that in theory suggests the presence of around eighteen 
copies on average of the TRIO locus in each tumour cell.  In concordance, FISH on UPS 05 FFPE 
sections showed green (TRIO locus) signals that were so numerous that they were indistinct and 
exact counts were difficult (Figure 6.7A, B and C) while red CEP3 signals however, suggested 
trisomy 3 in the majority of cells (Table 6.2).   
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Subsequent experiments on the corresponding cultured cells (STS 06/11) showed that this high level 
amplification was retained with the green signals more distinct and numbering >40 per interphase 
nucleus (Figure 6.7D and Table 6.2).  Examination of metaphase spreads showed the pattern of 
amplification as numerous single copy amplifications dispersed across various chromosomes, as 
well as some clusters present on abnormal-looking chromosomes (Figure 6.5E).    
Figure 6.7: Two-colour Fluorescence in situ Hybridisation (FISH) for confirmation of TRIO 
amplification on FFPE sections from UPS 05 and corresponding STS 06/11 cells   
The cBAC probe for the TRIO locus (green signals) and commercial CEP3 (red signals) were applied simultaneously 
and the nuclei and chromosomes were counter-stained with DAPI (in blue).  A, B and C – interphase nuclei from FFPE 
section of UPS 05 captured in a single focal plane showing high number of green TRIO locus signals and 2-3 red 
CEP3 signals (white arrows). Changing the focal plane showed that most nuclei contained similar number of red and 
green signals.  D – Interphase nucleus and partial metaphase spread of STS 06/11 cells that were derived from long 
term culture of UPS 05 tissue showing that they retain the high level TRIO amplification but also have numerous 
copies of CEP3, compared with parent tissue in B.  E – Metaphase chromosome spread of STS 06/11 cells showing 
TRIO amplification pattern as numerous single copy amplifications dispersed among various chromosomes.  Some of 
the green signals are clustered on abnormal chromosomes, where they are in close proximity to red CEP3 signals 
(yellow arrows).  Only four of the CEP3 signals appear to be centromeric in location (white arrows).   
All images were captured with x100 objective  
Around sixteen red CEP3 signals were visualised on average in interphase nuclei (Table 6.2).  
Surprisingly, only four of these were centromeric in location while the remaining were mostly in close 
proximity to clustered green signals on abnormal chromosomes (Figure 6.5E).  In order to rule out 
non-specific binding from an excess of red CEP3 probe, repeat experiments were carried out using 
as little as 20% dilution of the probe (based on optimisation by experienced colleagues in the RTRG 
laboratory).  All showed identical distribution of red CEP3 signals on multiple metaphase 
chromosome spreads. 
Similarly, TRIO locus amplification detected by array CGH in UPS 02 tissue was visually confirmed 
by FISH analysis of FFPE sections (Figure 6.8A) as well long-term cultured STS 14/10 cells (Figure 
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6.8B and C).  Metaphase chromosomes derived from these cells showed a near-triploid karyotype 
with seven copies of the TRIO probe on average, only two of which appeared to be on normal-
looking Denver Group B chromosomes (Figure 6.8B and C).  One of four red CEP3 signals was 
localised on an acrocentric chromosome (Figure 6.8B and C). 
 
Figure 6.8:  Two-colour Fluorescence in situ Hybridisation (FISH) for confirmation of TRIO 
amplification on FFPE sections from UPS 02 and corresponding STS 14/10 cells 
The cBAC probe for the TRIO locus (green signals) and commercial CEP3 (red signals) were applied simultaneously 
and the nuclei and chromosomes were counter-stained with DAPI (in blue).  A – Interphase nuclei from FFPE section 
of UPS 02 captured in a single focal plane showing >2 green cBAC signals in the majority of cells.  Adjustment of the 
focal plane showed that most nuclei contained similar numbers of green and red signals in a ratio of 5:2, respectively.   
B and C – Metaphase chromosome spreads and partial Interphase nucleus of STS 14/10 cells that were derived from 
long-term culture of UPS 02 tissue showing a near-triploid karyotype and that the tumour cells retain the TRIO 
amplification seen with parent tissue in Panel A with additional red CEP3 signals,.  Only two of the green signals 
appear to be on Denver group B chromosome (white arrows), and one of four red CEP3 signals is located abnormally 
on an acrocentric chromosome (yellow arrows).   
All images were captured with x100 objective  
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6.2.2 Evaluation of Trio RhoGEF Protein Expression  
Immunohistochemistry to confirm Trio protein expression was carried out on 4µm-thick tissue 
sections that were pre-treated to quench endogenous peroxidase and expose relevant epitopes in 
1% H2O2 and Tris-EDTA buffer (pH 9.0) respectively, as described in the Methods Section 2.3.9.2.  A 
rabbit polyclonal antibody directed against a recombinant Trio protein epitope signature tag (PrEST) 
was used.   Also referred to as mono-specific antibodies, PrEST antibodies are generated against 
highly specific 100-150 amino acid fragments of the target protein identified by in-silico proteomic 
analysis.  When used for immunohistochemistry, they have been shown to demonstrate specificity 
comparable to corresponding traditional monoclonal antibodies (Nilsson, Paavilainen et al. 2005).   
6.2.2.1 Control Experiments 
The DAB colorimetric system was used to detect positive protein expression (brown staining) with 
haematoxylin as a counter-stain (blue staining).  Normal tonsil tissue, which has physiologic Trio 
expression was used as positive control and the cells showed strong positive cytoplasmic staining 
(Figure 6.9A).  Negative experimental controls in which the primary antibody was omitted were set 
up simultaneously for every stained section (including positive controls).  As shown in the example in 
Figure 6.9B, they only showed blue haematoxylin counter-stain.   
Figure 6.9:  Experimental controls for Trio protein detection by Immunohistochemistry 
A – Micrograph of FFPE section of normal tonsil tissue immuno-stained with Trio antibody (brown) with 
haematoxylin counterstain (blue) showing strong positive staining in cells but not acellular areas.  B – Negative 
control (primary antibody omitted) of same normal tonsil tissue showing only blue haematoxylin counterstain.   
Images were captured at 400x magnification of original 
6.2.2.2 Trio RhoGEF Protein Expression in STS 
Evaluation of all immuno-stained sections was carried out at 200x magnification and confirmed by 
experienced Sarcoma Histopathologist, Dr Malee Fernando.  Samples were classified as positive or 
negative for Trio expression based on cytoplasmic-stain detection in tumour cells.  In the positive 
cases, the stain was detected in both small and bizarre giant tumour cells, which stained fairly 
uniformly. Positive staining was sub-classified as strong, moderate or weak based on the intensity of 
staining detected in tumour cells (Figure 6.10).  
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Figure 6.10:  Semi-quantitative Analysis of Trio Protein Expression in STS Samples using 
Immunohistochemistry 
Representative micrographs of FFPE sections of STS cases immuno-stained with Trio antibody (brown) and 
counterstained with haematoxylin (blue) showing the classification of staining intensities of tumour cells.  A1, A2 
– negative staining seen in LMS 22 and LMS 14, respectively.  B1, B2 – weak positive staining in LMS 11 and 
LMS 17, respectively.  C1, C2 – moderate positive staining in UPS 15 and UPS 13, respectively.  D1, D2 – 
strong positive staining seen in UPS 05 and UPS 06, respectively. 
Images were captured at 200x magnification of original and semi-quantitative scoring carried out by M. 
Fernando (experienced Sarcoma Pathologist). 
 181 
 
Cases for immunohistochemical analysis were chosen to include UPS and another subtype (LMS) in 
which some cases showed TRIO amplification by array CGH while others did not.  A total of nineteen 
cases comprising nine (9) UPS and ten (10) LMS tumours were analysed.  All but one of these cases 
(LMS 22) had previously been analysed by array CGH.   Results of immunohistochemistry for Trio 
and corresponding array CGH results are summarised on Table 6.3.   
6.2.2.3 Correlation of TRIO Copy Number Status with Protein Expression  
All UPS cases analysed were positive for Trio protein expression with at least moderate stain 
intensity, regardless of array CGH status.  All three cases that were confirmed to have TRIO 
amplification (UPS 02, 05 and 06) showed strong staining intensity.  Overall, a good correlation (r
2
 = 
0.7; n = 8) was demonstrated between aCGH status and staining intensity for Trio in UPS when 
analysed by the Spearman’s rank test.  Among the LMS cases on the other hand, the majority were 
either negative for Trio protein expression or only showed weak stain intensity that had poor rank 
correlation with copy number status (r
2
 = 0.0002; n = 9).    
Table 6.3:  Comparison of Trio protein Expression with Copy Number Status of TRIO gene locus 
among STS cases 
Case 
aCGH Status 
of TRIO locus 
Staining Intensity 
of Trio RhoGEF Protein 
UPS 02 Amplified Strong 
UPS 05 Amplified Strong 
UPS 06 Amplified Strong 
UPS 07 Normal Strong 
UPS 09 Deleted Moderate 
UPS 12* Normal Focally Strong 
UPS 13 Deleted Moderate 
UPS 14 Normal Moderate - Strong 
UPS 15 Normal Moderate 
   
LMS 04 Amplified Moderate 
LMS 06 Normal Weak - Moderate 
LMS 11 Amplified Weak 
LMS 13 Normal Weak 
LMS 14 Normal Negative 
LMS 15 Normal Negative 
LMS 16 Normal Weak- Moderate 
LMS 17 Amplified Weak 
LMS 21 Deleted Moderate 
LMS 22* NP Negative 
*- Sample excluded from Spearman’s rank correlation analysis 
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6.2.4 Effect of Trio RhoGEF Inhibition on Tumour Cell Proliferation 
The proliferation of STS 06/11 cells treated with varying concentrations of the Trio GEF1-specific 
inhibitor, ITX3 was evaluated using the MTT assay as descried in Methods Section 2.3.11.    The 
range of treatment concentrations was based on a review of the literature in which a significant 
reduction in Rac1 levels was demonstrated in mammalian cells that were treated with ITX3 at 100µM 
(Bouquier, Vignal et al. 2009).  An immortalised retinal epithelial cell line, hTERT-RPE1 was used as 
non-malignant cell control. 
Results were based on five replicate wells and showed that hTERT-RPE1 cells showed no 
significant reduction in proliferation at any of the treatment doses compared with DMSO vehicle-
treated controls.   When compared with dose-matched STS 06/11 cells however, two-way ANOVA 
(with Bonferroni’s post hoc test correction) showed that tumour cells treated with ≥ 200µM ITX3 for 
72-hours showed significantly reduced proliferation (p < 0.05) (Figure 6.11).  These results suggest a 
tumour cell-specific inhibition of cell survival by ITX3. 
 
 
Figure 6.11:  Summary of the effects of ITX3 treatment on STS 06/11 cell proliferation in an MTT 
assay 
Relative MTT activities were calculated as the ratio of absorbance in treatment to control wells after 72 hours of 
treatment and the data is displayed as Mean + SEM of five replicates.  Significant reduction in proliferation 
(p<0.05) was seen in STS 06/11 cells treated with ≥ 200µM ITX3 (marked with *) compared with dose-matched 
hTERT-RPE1 cells as judged by two-way ANOVA with Bonferroni post-hoc correction. 
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6.2.6 Effect of Trio RhoGEF Inhibition on Tumour Cell Invasion 
The Boyden chamber assay was used to assess the invasive ability of STS 06/11 cells through a 
porous membrane coated with an extracellular matrix surrogate as described in methods section 
2.3.12.   Treatment doses (concentrations) of ITX3 were chosen as described in the preceding 
section.  Membranes were examined at high power (400x original magnification) in order to 
distinguish invaded cells present on the underside of the membrane from cells remaining on the top 
surface as shown in Figure 6.12.  
Figure 6.12:  Representative micrograph of 
invasive STS 06/11 cells from Boyden’s 
chamber assay 
Cells on the underside of porous polycarbonate 
membranes were stained with haematoxylin and the 
membrane mounted flat on a glass slide with the 
underside facing upwards.  Membranes were 
examined at high power (x400 magnification) at which 
images were captured.  Only cells that came into 
focus while the 8µm pores were still blurred (white 
arrows) were considered to be on the underside of 
the membrane and counted.  
Image was captured at 400x original 
 
 
The average cell counts obtained from five random fields in three replicate wells were plotted against 
the corresponding dose of Trio inhibitor and the results presented in Figure 6.13.   Although ITX3 
appeared to have a dose-dependent inhibition on STS 06/11 cell invasion (Figure 6.13), comparison 
of the mean cell counts by one-way ANOVA with Bonferroni’s post-hoc correction (for multiple 
treatment groups) did not reveal any statistically significant difference in any of the treated groups 
compared with DMSO controls. 
 
Figure 6.13:  Summary of 
the effects of ITX3 treatment 
on STS 06/11-tumour cell 
invasion in the Boyden 
Chamber Assay. 
The data is displayed as Mean + 
SEM of the number of invaded 
cells seen in five random 
microscopy fields at x400 
magnification and based on 
triplicate experiments.  No 
significant reduction (p<0.05) 
was seen in any of the treatment 
groups compared with DMSO 
control as judged by one-way 
ANOVA with Bonferroni’s post-
hoc correction. 
 
 184 
 
6.3 DISCUSSION 
Despite recent developments in molecular classification of STS, the UPS subtype remains largely a 
diagnosis of exclusion with little known about the molecular characteristics of these tumours apart 
from genetic instability and karyotypic complexity (Fletcher et al., 2013).  On the basis of this relative 
dearth of specific molecular characteristics, one of the targets identified among UPS using genome-
wide array CGH screening (in chapter 4) was chosen for further evaluation.  The high frequency of 
TRIO amplification among these tumours, combined with biological evidence for its role in tumour 
progression as derived from various other cancers made this gene a strong candidate driver and 
thus the subject of this chapter.  The availability of primary cells in stable long–term culture from 
three separate UPS cases in this PhD project provided a suitable model for the requisite validation 
studies, the preliminary results of which were presented. 
Within this time-limited PhD study, only a few techniques could be optimised for validation studies 
and for some of these, few cases could be analysed in detail.  Relevant FISH probes had to be 
prepared from BAC DNA and then optimised for use on FFPE samples before actual time-consuming 
analysis of individual cases as parent tissue and corresponding cultured cells.  Similar optimisation 
had to be carried out with the antibodies for immunohistochemistry, leaving little time for other 
expression studies and functional in vitro experiments.  Definite conclusions can therefore not be 
arrived at based on the results presented here.  However, this chapter demonstrates the approach to 
target validation and all the methods discussed have now been optimised with pilot data that is being 
used to drive further studies with sufficient numbers and statistical power.  
Amplification affecting the TRIO locus relative to chromosome 3 centromere was confirmed using 
FISH on FFPE sections of all three UPS cases and analysis of the corresponding long-term cultured 
cells showed that the amplification was retained. In the case of UPS 06 where array CGH analysis of 
the cultured STS 09/11 cells failed to show the TRIO amplification that was present in parent tissue, 
direct, targeted visualisation by FISH identified a low-level amplification that was seen in less than 
half the cells.  These results confirm that the primary cell lines are valid models for further evaluation 
of TRIO amplification as a target and support the hypothesis that this frequent and targeted 
amplification is important for tumour pathogenesis, since it persists in tumour cells despite long 
periods of in vitro culture.  The findings also raise the possibility that the frequency of TRIO 
amplification among UPS tumours may have been underestimated by array CGH, a well-recognised 
limitation of any genome-wide screening technique. Following the successful development and 
optimisation of the requisite probes, analysis of more cases including UPS cases that did not show 
TRIO amplification by array CGH as well as other STS subtypes will be carried out as follow-on work 
from this project.  This will also explore the potential diagnostic utility of FISH for UPS in general or 
identification of tumours that are likely to respond to Trio rhoGEF-targeted therapeutics.  Similarly, 
any other potential genomic aberrations of interest deserve further targeted exploration to confirm 
(and accurately estimate) their frequency. 
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While both UPS 02 and UPS 06 showed modest TRIO locus amplification, UPS 05 showed very 
high-level amplification and had a relatively rapid establishment in culture as well as a short doubling 
time (see Section 5.2.7).  Similar variation in the levels of amplification of pathogenetic genes have 
been described in various other cancers, notable examples including ERBB2 in breast cancer and 
MYCN in neuroblastoma (Albertson, 2006; Mondello et al., 2010).  Further, associations have been 
described between these different levels of amplification and patient survival and/or response to 
targeted therapy in ERBB2-amplified breast cancer (Arnould, Arveux et al. 2007, Guiu, Gauthier et 
al. 2010, Gullo, Bettio et al. 2013), raising another important question in relation to TRIO 
amplification in UPS that requires exploration in further study.   
Good quality metaphase chromosome spreads from the primary tumour cell lines allowed analysis of 
the patterns of amplification in UPS 02 and 05.  The pattern of single copy amplifications spread over 
various chromosomes (dispersed insertions) was seen in both cases but UPS 05 showed in addition, 
clusters of the amplified TRIO locus reminiscent of homogenously-stained regions (HSR) on three 
abnormal-looking chromosomes.  A similar pattern of amplification has been described in the MYCN 
gene in neuroblastoma (Schwab, 1999), and more recently in EGFR amplifications in gliomas 
(Lopez-Gines et al., 2010), where it is believed to result from the re-incorporation of extra-
chromosomal copies of amplified DNA (dmins) into various genomic regions, where they remain as 
single copies or undergo further replication to form HSR (Albertson, 2006; Schwab, 1999).   
Another interesting feature of UPS 05 metaphase FISH (shown in Figure 6.7) was the proximity of 
non-centromeric CEP3 signals to the clustered TRIO amplicons.  This was confirmed by repeat 
experiments and absent from control experiments suggesting that the pattern was not due to non-
specific CEP3 probe binding.  One possible explanation however is chromothripsis, a phenomenon 
recently described in molecular detail by Stephen et al using paired-end analysis (Stephens, 
Greenman et al. 2011) and that is increasingly being recognised as a mechanism for genomic 
instability in cancer cells (Korbel and Campbell 2013, Zack, Schumacher et al. 2013).  Instead of, or 
in addition to traditional view of progressive acquisition of mutations or chromosome aberrations by a 
tumour cell, a single ‘cataclysmic’ event is believed to result in the shattering of one or few 
chromosomes.    The fragments are then ‘stitched’ together, by non-homologous end-joining (NHEJ), 
which in addition to non-uniform cytokinesis gives rise to complex rearrangements on chromosome 
arms with multiple copy number states on contiguous genomic regions (Stephens, Greenman et al. 
2011).   
Chromothripsis can also result in the formation of circular double minutes consisting of DNA from 
different chromosomes as clearly described by Rausch et al in medulloblastoma cells where it 
targeted two frequently co-amplified genes MYCN and GL12 (Rausch, Jones et al. 2012).  Re-
incorporation of such double minutes into chromosomal structure can result in the pattern of 
colocalisation of red CEP 3 and green TRIO locus signals seen in STS 06/11 cells.  Also interesting 
is that retrospective examination of the array CGH profile of UPS 05 (and STS 06/11) showed the 
presence of a high level amplification detected at the centromeric end of 3p, which was seen in 
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around 60% of UPS cases and involves the locus for VGLL3, one of the strong candidate genes 
identified by this study (Section 4.4.3.7). 
Multiple studies have found the frequency of chromothripsis to be between 2 and 5% of cancers in 
general, but up to 16% in highly genetically-unstable glioblastomas and even 25% among bony 
mesenchymal tumours such as osteosarcomas and chordomas (Stephens, Greenman et al. 2011, 
Kim, Xi et al. 2013, Zack, Schumacher et al. 2013) and chromothripsis events have been shown to 
be more common in regions involved in putative driver genomic aberrations with high level 
amplifications, most of which were detected using the GISTIC algorithm (Zack, Schumacher et al. 
2013). Given the high level of genomic instability of UPS and some of the copy number aberration 
profiles seen by array CGH in this and other studies, chromothripsis as a contributor to pathogenesis 
in STS is not unlikely.    Although time did not permit within this PhD study, further FISH analysis of 
the pattern of CEP probes other than chromosome 3 on STS 06/11 metaphases spreads would be a 
logical first step in discerning the specificity of the co-localisation while PCR and paired-end wise 
analysis using next generation sequencing would help confirm whether the exact structural variation 
based on genomic sequences (Hillmer, Yao et al. 2011, Stephens, Greenman et al. 2011). 
Evaluation of Trio protein expression by immunohistochemistry, which was carried out on selected 
UPS and LMS cases also yielded very interesting results.   The choice of LMS for subtype 
comparison was based on the availability of array CGH results on over 20 samples, around a quarter 
of which showed TRIO copy number amplification.  Moderate to strong positive staining intensity and 
good correlation with array CGH copy number was seen among the UPS cases in contrast to LMS 
where the overall stain intensity was lower, even in cases where array CGH showed increased gene 
copy number.  These results support the hypothesis that the pathological role of TRIO amplification 
is more specific among UPS, where the copy number amplification is more frequent and correlates 
with higher expression levels, similar to the correlation between ERBB2 amplification and 
overexpression in breast cancer (Gullo, Bettio et al. 2013).  Further confirmation of Trio expression 
levels in both tissue samples and the cell line models using techniques that are noted for their 
quantitative application such as western blotting or quantitative real-time PCR will however be 
required.      
Statistically significant reduction in the proliferation of the primary UPS cell line STS 06/11 treated 
with specific GEF-inhibitor ITX3 correlated with findings from siRNA–mediated TRIO knockdown 
studies that showed reduced proliferation of glioblastoma cells that were found to be over-expressing 
Trio (Salhia et al., 2008a).  More importantly however, ITX3 inhibition had no effect on the normal 
epithelial cell line controls, suggesting that its effects are tumour cell-specific - the ‘holy grail’ of 
cancer therapeutics.  Tumour cell invasion appeared to be attenuated by ITX3 treatment, although 
this was not statistically significant.  It is noteworthy, however that the data is limited to a single 
Boyden chamber experiment with a small range of inhibitor concentrations.  Clearly, no definite 
conclusions are drawn in terms of functional effects of Trio inhibition, but the copy number and 
expression data remain very promising in light of future work with this exciting potential target.  
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CHAPTER SEVEN 
FINAL DISCUSSION 
7  
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Figure 7.1:  Outline of the Approach used in this PhD Study for Pathogenetic Target Identification in Soft Tissue Sarcoma. 
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7.1 SUMMARY OF APPROACH TO TARGET IDENTIFICATION IN STS 
In cancers such as STS where they are pervasive, the study of how focal SCNA impact cancer 
development and evolution remains very important (Zack, Schumacher et al. 2013).  With 
technological advancements in molecular genetic analytic methodologies such as high resolution 
array CGH and next generation sequencing, the resultant accumulation of larger and more detailed 
genomic data means that comprehensive approaches are required in addition to statistical analysis 
to decipher which SCNA are drivers and how best to identify therapeutic targets.  A summary of the 
approach to molecular pathway identification used in this PhD study is outlined in Figure 7.1.   
The optimisation of a suitable methodology for analysis of available FFPE tumour samples was 
addressed in the first results chapter (Chapter 3).  This led to accumulation of sufficient tumour 
sample numbers to permit statistical analysis of the array CGH data with identification of candidate 
genes and molecular pathways, the results of which are presented in Chapter 4.  The next logical 
steps were the evaluation of karyotypic patterns of focal SCNA in individual tumours and their effects 
on target gene expression and tumour phenotype, as demonstrated in the final results chapter 
(Chapter 6) exploring Trio RhoGEF as a potential target in UPS tumours.  To permit this evaluation 
however, suitable material for functional analysis of tumour phenotype in the form of an in vitro 
model was successfully established and validated for a range of STS subtypes, the details of which 
were presented in Chapter 5.   
7.2 STUDY LIMITATIONS 
The primary limitation that was identified very early in the study was a perceived unsuitability of 
FFPE tumour samples for high-resolution analysis of genomic copy number by array CGH.  Fresh 
tissue collection was required for the development of primary cell lines, an essential part of the 
project but it became clearly evident that this approach would yield insufficient tumour numbers for 
such a rare tumour as STS.  Further, the prospective tumour collection would likely yield a random 
assortment of STS subtypes, which would preclude meaningful subtype-specific analysis - one of the 
primary aims of the PhD study.  Successful tackling of the technical problem as demonstrated in 
Chapter 3 by optimising the use of relatively abundant FFPE tumour samples meant that even 
though fresh tissue from only 7 UPS, 3 LMS and no GIST cases were obtained in the entire course 
of the study (Table 5.1), reliable data from 16 UPS, 21 LMS and 11 GIST cases among other 
subtypes was eventually analysed and this methodology led to the first peer-reviewed publication 
from this PhD project (Salawu, Ul-Hassan et al. 2012). 
Another important constraint identified was the limited time available to perform all the required 
experiments.  In order to be pragmatic therefore, different aspects of the project such as primary cell 
line development, array CGH optimisation and data analysis were undertaken concurrently.  Since 
sufficient time had to be allowed for further evaluation of an identified target, the strongest candidate 
gene from statistical analysis of aCGH data from one of the most enigmatic STS subtypes, i.e. TRIO 
amplification in UPS was chosen as the subject for Chapter 6.  This however meant that candidate 
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genes that were subsequently identified with even stronger statistical evidence such as JUN and 
VGLL3 amplifications in UPS could not be explored further within the context of this study.    
7.3 STUDY FINDINGS 
Subtype-specific candidate genes for LMS, UPS and GIST that were identified have been discussed 
previously (Section 4.6).  The discussion in this chapter is therefore focused on more general 
observations in the context of STS in general and possible implications for tumour biology, 
classification and targeted-therapeutic development in LMS and UPS.    
Figure 7.2 below summarises some of the most important candidate genes and molecular pathways 
identified in STS from this study and the likely areas of tumour biology in which they are involved.   
 
 
Figure 7.2: An Illustration of the Subtype-specific and Overlapping Candidate Genes and Pathways 
identified among Leiomyosarcoma (LMS) and Undifferentiated Pleomorphic Sarcoma (UPS) in this 
study.   
Candidate gene identification and likely roles in tumour biology are based on genomic copy number analysis 
and evidence in literature.  Genes and pathways shown in red are involved in amplifications while those in green 
are involved in deletions.  The highlighted gene, TRIO has been further evaluated in this study with additional 
expression and functional basis for a role in tumour progression.   
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7.3.1 STS subtypes display a wide range of karyotypic complexity  
Array CGH profiles from the wide range of STS subtypes analysed generally correlated with the 
prevailing theory that those with known specific translocations or other genetic characteristics such 
as synovial sarcoma, alveolar soft part sarcoma and GIST have relatively few unbalanced 
chromosomal abnormalities and thus simpler array CGH profiles (Mertens, Panagopoulos et al. 2009, 
Fletcher, Bridge et al. 2013).  Among the subtypes with complex karyotypes however, there was 
significant variation in the degree of karyotypic complexity evidenced by the proportion of the 
genome that was involved with focal SCNA.  UPS showed the most numerous focal SCNA overall 
with frequent common aberrations affecting up to a third of the genome, compared to only one-fifth of 
the genome seen in LMS or an average of 10% of the genome as reported for cancers in general 
(Beroukhim, Mermel et al. 2010).   In keeping with this apparently worse magnitude of genomic 
instability, deletion of several candidate genes and pathways that normally function in genome 
maintenance including RB1 and TAOK1 were identified among UPS in this study many of which 
have not been previously reported among STS (discussed in Section 4.6).   
7.3.2 Are certain focal SCNA and molecular pathway abnormalities common 
to various STS subtypes? 
The most obvious shared frequent aberration between UPS and LMS was the deletion on 13q 
affecting the RB1 gene locus.  Interestingly, this was one of the most common deletions in both 
subtypes, affecting 13 out of 16 UPS cases (81%) and 14 out of 21 LMS cases (67%).  These results 
are in keeping with previous studies that reported frequent RB1 losses among STS with complex 
karyotypes (Taylor, Barretina et al. 2008, Mertens, Panagopoulos et al. 2009) as well as radiation-
related sarcomas that include osteosarcomas, LMS and UPS (Gonin-Laurent, Hadj-Hamou et al. 
2007).  Further, up to 30% of secondary tumours described in familial retinoblastoma patients (who 
carry germ-line RB1 gene loss) are STS and while most of the secondary tumours in these patients 
appeared to be radiotherapy-related, the majority of secondary LMS occurred outside the radiation 
field, suggesting a radiation-independent role for the inherited RB1 loss in sarcomagenesis 
(Kleinerman, Schonfeld et al. 2012).  
One of the most well-studied tumour-suppressor genes, functional disruption of the Rb1 pathway by 
inactivating mutations, copy number loss or epigenetic mechanisms have been reported in a wide 
range of cancers (Di Fiore, D'Anneo et al. 2013).  Numerous reviews, including a recent one by 
Henley and Dick highlight the important role RB1 plays in the G1-S phase cell cycle checkpoint and 
control of cellular proliferation (Henley and Dick 2012) and evidence suggests that RB1 disruption in 
itself may be sufficient for tumour initiation (Liu, Sanchez-Tillo et al. 2013).  More recently, objective 
evidence that inactivation of even one copy of RB1 promotes telomere dysfunction and genetic 
instability has been demonstrated (Alessio, Bohn et al. 2013, Gonzalez-Vasconcellos, Anastasov et 
al. 2013).   
The pattern of deletion of the RB1 locus detected in this study was particularly notable.   The majority 
of tumours had homozygous focal deletion of the RB1 gene locus, either on a background of 
hemizygous 13q loss or with normal diploid 13q.  This resulted in highest deletion G-scores assigned 
to this locus by the GISTIC algorithm in both subtypes (Tables 4.7 and 4.22).  This deletion pattern 
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suggests that the RB1 locus was specifically targeted for copy number loss, a finding that supports a 
pathogenetic role for RB1 loss that is statistically valid in itself, but even more exciting in the context 
of the functional role of the RB1 gene.  Interestingly, although frequent RB1 loss among STS has 
been reported in literature, this specific pattern of RB1 deletion is a novel finding in STS or any other 
cancers for that matter that adds strong evidence this abnormality being a ‘driver’.  The specific 
mechanism by which this targeted loss occurs however still remains unidentified. 
Further, enrichment analysis of the frequently deleted genes in both LMS and UPS subtypes in this 
study revealed significant disruption of the PML and cdc25/chk1 pathways respectively (Sections 
4.4.1.5 and 4.4.3.5), both of which are positively regulated by the RB1 gene product with important 
roles in genome and telomere maintenance (Zhong, Hu et al. 1999, Dai and Grant 2010, Chang, 
McGhie et al. 2013). Taken together, there is a strong overall suggestion that RB1 pathway 
disruption is an important pathogenetic mechanism in STS and may be an early event, particularly in 
the karyotypically-complex subtypes where RB1 appears to be specifically targeted copy number 
loss.  Conversely, it is possible that RB1 disruption may be of less importance among translocation-
driven sarcomas, which generally exhibit less genomic instability and have alternative putative 
initiation mechanisms. 
Another common pathway that was highlighted in this study was the Mitogen-activated Protein 
Kinase (MAPK) pathway, which was detected by enrichment analysis of amplified genes in both UPS 
and LMS subtypes (Table 4.8 and 4.23).  An important molecular signalling pathway for cancer, the 
MAPK pathway functions via a three-tiered kinase module that links extracellular influences such as 
growth factors and stress signals to cellular proliferation and other tumour phenotypic characteristics 
such as cell survival, metastasis and even angiogenesis (Dhillon, Hagan et al. 2007, Yang, 
Sharrocks et al. 2013).  Among the chief regulators of this pathway are members of the Ras or Raf 
family of proteins that phosphorylate MEK1 and MEK2, which subsequently phosphorylate ERK1 
and ERK2, the main mediators of the MAP kinase pathway.  Yet other MAPK pathways are known to 
exist.  They are regulated via p38 and Janus-related kinase (JNK) and have significant cross-talk 
with the Ras/Raf/MEK pathway and different levels of significance in specific tumour types.  Detailed 
reviews of the MAPK pathways and their role in cancer pathogenesis are available in literature 
(Dhillon, Hagan et al. 2007, Neuzillet, Tijeras-Raballand et al. 2013). 
Implicated in up to a third of cancers, the majority of MAPK pathway-activating molecular lesions 
involve genes that encode regulatory proteins as frequently seen in pancreatic adenocarcinoma 
(RAS mutation in up to 90% of tumours), melanoma (BRAF mutation in 60%) and/or overexpression 
of growth factor receptors such as ERBB2 in breast cancer (Downward 2003).    The frequency of 
activation of members of the MAPK pathway and/or regulators in cancer therefore make it an 
attractive target for novel drug development with a number of inhibitors already in clinical use and 
many others in clinical trials (Neuzillet, Tijeras-Raballand et al. 2013).   There is however, a relative 
paucity of data in literature regarding the role of the MAPK pathway in STS with the majority of 
available sarcoma data obtained from bone sarcomas.    
Silvany et al first demonstrated constitutional activation of the MAPK pathway in cells transformed 
using the EWS-FLI fusion gene (that is characteristic for Ewings’ sarcoma) and that treatment with 
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specific MAPK inhibitors resulted in loss of anchorage-independent proliferation (Silvany, Eliazer et 
al. 2000).  Subsequent studies showed that the MAPK pathway-targeted inhibitors alone or in 
combination with cytotoxic agents caused a dose-dependent inhibition of proliferation and migration 
in Ewing sarcoma cell lines (Benini, Manara et al. 2004, Yamamoto, Ohno et al. 2009, Keir, Maris et 
al. 2010).  These and other similar results in osteosarcoma (Huang, Lee et al. 2009, Pignochino, 
Grignani et al. 2009, Na, Kim et al. 2012) and chondrosarcoma (Papachristou, Papachristou et al. 
2005, Lu, Tang et al. 2010) have led to a number of on-going clinical trials (Chandhanayingyong, 
Kim et al. 2012, Widemann, Kim et al. 2012) with encouraging results seen among patients with 
inoperable osteosarcoma treated with the  RAF inhibitor Sorafenib (Grignani, Palmerini et al. 2012). 
Sasaki and colleagues who carried out in vitro studies in UPS cells to evaluate the role of the MAPK 
pathway and found increased MEK1 and MEK2 mRNA levels in three cell lines (Sasaki, Hitora et al. 
2011), findings which correlate with the enrichment analysis of frequent amplifications seen among 
UPS cases seen in this study (Table 4.23).   In that study, treatment of the UPS cell lines with a 
MEK-specific inhibitor (U0126) caused reduction in the levels of phosphorylated downstream ERK as 
well as reduced cell proliferation.  Another study based on an NF1-deficient transgenic mouse model 
of MPNST and UPS demonstrated tumour growth inhibition when treated with the MEK inhibitor 
PD325901, which is accompanied by reduced tumour cell proliferation but not increased apoptosis 
(Dodd, Mito et al. 2013).   It is notable that NF1 was one of the strong candidate deleted genes 
identified among UPS in this study, highlighted by multiple statistical approaches including common 
aberration and pathway enrichment analyses. Yet another study in STS demonstrated decreased 
proliferation and increased apoptosis in tumour-derived synovial sarcoma cells treated with the Raf-
inhibitor, Sorafenib (Peng, Guo et al. 2009).  The sum total of evidence therefore suggests that the 
MAPK pathway is a druggable target that is worthy of further preclinical and maybe even clinical 
evaluation in UPS and other STS, regardless of karyotypic complexity.  
An important consideration in molecular pathway targeting is the ‘cross-talk’ (bidirectional signalling 
interaction) that exists among various pathways that have been established as a common 
mechanism of tumour cell resistance.  Two pathways that have close cancer-relevant interactions 
with the MAPK pathway are the PIK3/PTEN and integrin signalling (focal adhesion) pathways 
(Giancotti and Ruoslahti 1999, Shimizu, Tolcher et al. 2012).  Recently published data established a 
rationale for and showed that co-inhibition of the MAPK and PIK3/PTEN pathways had a synergistic 
effect on proliferation in rhabdomyosarcoma cell lines as well as xenograft tumours (Renshaw, 
Taylor et al. 2013).  Similar dual pathway inhibition strategies have shown encouraging results in 
Ewing’s tumours (Yamamoto, Ohno et al. 2009) and Kaposi’s sarcoma (Lambert, Shahrier et al. 
2007), as well as potential efficacy and tolerance advantages over single pathway inhibition in Phase 
I clinical trials (Shimizu, Tolcher et al. 2012).  This is particularly interesting in the context of relevant 
amplifications and deletions detected among LMS in this study that implicate the PIK3/PTEN 
pathway (Section 4.4.1.5).    
Also commonly enriched among amplified genes in both LMS and UPS subtypes in this study was 
the integrin signalling/focal adhesion pathway.  A known mechanism of MAPK pathway regulation 
based on extracellular matrix (ECM) interaction with integrin molecules expressed on the cell 
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membrane, this pathway is involved in physiologic cell proliferation (Giancotti and Ruoslahti 1999).  
Dysregulation of this pathway (mainly via increased expression of specific integrins) has been 
implicated in tumour progression as a mechanism of epithelial-mesenchymal transition (Guo and 
Giancotti 2004).   It is therefore plausible that activation of this pathway in addition to MAPK would 
be of pathogenetic relevance in such high-grade mesenchymal tumours as UPS and LMS.  
 
7.3.3 Do specific STS Subtypes have different mechanisms for activating a 
Common Molecular Pathway?        
The results from copy number analysis in this study strongly suggest that in the case of STS with 
complex karyotypes, the MAP kinase pathway is activated by copy number amplification of key 
genes that result from genomic instability, possibly initiated by RB1 loss.  This study is the first to 
demonstrate frequent copy number amplification of not only key member of the MAP kinase pathway, 
but also the related PIK3/PTEN and integrin signalling pathways in these two STS subtypes.   
Considering the frequency of MAPK pathway activation among other STS subtypes, especially those 
that do not show a similar degree of genomic copy number imbalance, it is possible that they utilise 
other alternative molecular mechanisms for MAP kinase pathway activation.   In Ewing’s sarcoma for 
instance, MAPK pathway activation is believed to be directly linked to the EWS-FLI1 fusion (Silvany, 
Eliazer et al. 2000, Rocchi, Manara et al. 2010) and manipulation of the MAPK kinase pathway by 
Human Herpes Virus 8 (HHV8) is well established and likely pathogenetic in Kaposi’s sarcoma 
development (Lambert, Shahrier et al. 2007).  It is therefore proposed that MAPK pathway activation 
is a pan-sarcoma pathogenetic mechanism that is triggered using subtype-specific mechanisms. 
Likely to be involved in tumour progression, particularly in UPS is the amplification and 
overexpression of the Trio RhoGEF that was confirmed in Chapter 6.   Signalling via all three 
RhoGTPases (Rac1, cdc42 and RhoA) known to be activated by Trio RhoGEF is closely related to 
both the MAPK and Focal Adhesion pathways (see Figures 4.13 and 4.14).  The Rho signalling 
pathway was significantly enriched among amplified genes in LMS (Table 4.8) suggesting that 
activation of Rho signalling may be common to both UPS and LMS subtypes, and possibly a wider 
range of STS as suggested by in vitro studies on amoeboid non-human sarcoma cells (Kosla, 
Pankova et al. 2013).  However, the subtype-specificity of Trio RhoGEF overexpression 
demonstrated in this study (Section 6.2.2.3) leads to the inference that this mechanism of Rho 
signalling pathway activation is specific to the UPS subtype while LMS may have an alternative 
mechanism of achieving the same and contribution to tumour progression.  
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7.3.4 Do LMS and UPS have similar origins? 
Considerable overlap between the candidate tumour initiation and progression pathways identified in 
UPS and LMS in this study (Figure 7.2) are keeping with a similar origin for both tumours as 
suggested by the differentiation theory for sarcomagenesis.  That the two STS subtypes may 
represent a spectrum of mesenchymal tumours with different degrees of differentiation is further 
supported by candidates in UPS such as JUN and VGLL3 that promote mesenchymal de-
differentiation; and MYOCD and MYH11 in LMS, which promote smooth muscle differentiation.  
While this preliminary study does not exclude the possibility that the two subtypes are completely 
distinct in origin and biology, the proposed spectrum could include yet other STS with complex 
karyotypes and would warrant further exploration within a mesenchymal stem cell context. 
7.4 FUTURE WORK 
This study has identified several potentially important candidate genes, as well as relevant disease 
models to facilitate even more detailed exploration of pathogenetic abnormalities in different STS 
subtypes.  While data mining can help overcome the limitation of sample size and add statistical 
power, a further step for identification of even stronger pathogenetic candidates is the application of 
next-generation exome or whole genome sequencing.  Able to provide additional genomic 
information such as gene mutations and actual SCNA breakpoints, the potential of their application 
to STS when combined with robust statistical data analysis is likely to give rise to even stronger 
candidate genes with exciting potential implications for sarcoma biology and therapy.  As 
demonstrated in Chapter 6, actual visualisation of copy number abnormalities aids confirmation of 
SCNA but in addition shows the patterns of amplification or deletion that gives insights to 
pathogenesis (e.g. a possible role for chromothripsis) and may be exploited for its diagnostic 
potential. 
It is important to correlate genomic copy number abnormalities to actual gene expression, more so in 
the context of molecular pathway abnormalities.  This is because gene expression is highly complex 
and regulated by various genetic and epigenetic factors in addition to genomic copy number.  Whole 
transcriptome analysis carried out on the same tumours would be ideal for correlation analysis.  
However, in spite of recent technological developments such analysis on old FFPE samples remains 
technically challenging.  Again, data mining for expression microarray data on a similar set of STS 
samples would circumvent this problem.  Based on the findings from this study, focused protein 
expression analysis using pathway-specific protein arrays on cell lines or fresh tissue or 
immunohistochemistry for specific proteins, as demonstrated in Chapter 6 would help correlate copy 
number to expression and validate candidate genes and pathway so far highlighted. 
Availability of an in vitro disease model in the form of long term cell lines for both UPS and LMS 
subtypes with potential for tumour xenograft development will ultimately make functional analysis by 
single or multiple pathway inhibition feasible.  With some of the methods already optimised and initial 
pilot data generated for a sample candidate gene, further functional analysis of target genes and 
pathways can be carried out within a relatively short time.  Overall, the results from this PhD study 
are encouraging and set up exciting potential for future research into sarcoma pathogenesis. 
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STS Subtype 
Subtype  
No. 
Gender 
Age 
(years) 
Site Size Grade 
Neoadjuvant 
Therapy 
Sample Type aCGH 
Tissue 
Culture 
Culture 
Designation 
Culture outcome 
Alveolar Soft Part Sarcoma (ASPS) 
01 Female 30 Lower Limb 92 - - FRESH Yes Yes STS 01/10 p5 
02 Male 18 Trunk 38 - - FRESH Yes Yes STS 15/10 p9 
Angiosarcoma (ANGIO) 
01 Female 68 Trunk 70 3 - FRESH Yes Yes STS 05/10 p5 
02 Male 48 Trunk 120 3 - FRESH Yes Yes STS 10/11 p5 
03 Male 69 Lower Limb 60 3 - FRESH Yes Yes STS 21/10 p9 
04 Female 41 Trunk 35 3 - FRESH No Yes STS 03/12 Early Senescence 
05 Female 76 Trunk 27 3 - FRESH No Yes STS 06/12 Early Senescence 
06 Female 59 Trunk 40 3 - FRESH No Yes STS 08/12 Early Senescence 
De-differentiated Liposarcoma 
(DDLPS) 
01 Female 68 Retroperitoneum 300 3 - FRESH Yes Yes STS 09/10 Long Term 
02 Male 65 Retroperitoneum 80 3 - FRESH Yes Yes STS 17/11 Early Senescence 
03 Female 69 Retroperitoneum 170 3 - FRESH Yes Yes STS 19/11 Nil 
04 Female 64 Retroperitoneum 210 3 - FRESH Yes Yes STS18/10 Nil 
05 Female 77 Lower Limb 340 3 - FRESH No Yes STS 13/10 Nil 
06 Female 70 Lower Limb 170 3 Radiotherapy FRESH Yes Yes STS 20/11 Long Term 
07 Female 57 Retroperitoneum 200 3 - FRESH No Yes STS 01/12 Early Senescence 
Ewings’ Sarcoma (EWING) 01 Male 23 Pelvis 40 - 
Chemotherap
y 
FRESH Yes Yes STS 13/11 p9 
Extraskeletal Myxoid 
Chondrosarcoma (EMCS) 
01 Male 30 Lower Limb 103 2 - FRESH Yes Yes STS 02/10 p5 
Gastrointestinal Stromal Tumour 
(GIST) 
01 Male 75 Stomach 62 High - FFPE Yes No - - 
02 Male 70 Small bowel 100 Intermediate - FFPE Yes No - - 
03 Male 71 Small bowel 35 High - FFPE Yes No - - 
04 Male 59 Stomach 39 Intermediate - FFPE Yes No - - 
05 Male 76 Stomach 70 Low - FFPE Yes No - - 
06 Male 61 Stomach 27 Low - FFPE Yes No - - 
07 Male 27 Small Bowel 95 Intermediate - FFPE Yes No - - 
08 Male 58 Liver Met 67 High - FFPE Yes No - - 
09 Male 74 Stomach 50 Intermediate - FFPE Yes No - - 
10 Female 73 Stomach 54 Low - FFPE Yes No - - 
11 Male 79 Stomach 30 - - FFPE Yes No - - 
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STS Subtype 
Subtype  
No. 
Gender 
Age 
(years) 
Site Size Grade 
Neoadjuvant 
Therapy 
Sample Type aCGH 
Tissue 
Culture 
Culture 
Designation 
Culture outcome 
Leiomyosarcoma (LMS) 
01 Female 63 Intraabdominal 210 3 - FFPE Yes No - - 
02 Female 38 Lower Limb 60 3 - FFPE Yes No - - 
03 Female 47 Lower Limb 50 3 - FFPE Yes No - - 
04 Male 67 Pelvis 85 3 - FFPE Yes No - - 
05 Female 63 Intraabdominal 50 2 - FFPE Yes No - - 
06 Female 82 Lower Limb 60 3 - FFPE Yes No - - 
07 Male 37 Pelvis 50 3 - FFPE Yes No - - 
08 Female 63 Pelvis 50 3 - BOTH Yes Yes STS 02/11 Long Term 
09 Male 39 Intraabdominal 95 3 - BOTH Yes Yes STS 11/11 Nil 
10 Female 49 Pelvis 85 1 - BOTH Yes Yes STS 18/11 p9 
11 Female 80 Intraabdominal 60 3 - FFPE Yes No - - 
12 Female 58 Pelvis 85 3 - FFPE Yes No - - 
13 Female 76 Intraabdominal 40 3 - FFPE Yes No - - 
14 Male 77 Pelvis 130 3 - FFPE Yes No - - 
15 Male 54 Pelvis 160 3 - FFPE Yes No - - 
16 Female 69 Head and Neck 50 2 - FFPE Yes No - - 
17 Female 54 Pelvis 15 3 - FFPE Yes No - - 
18 Female 49 Intraabdominal 180 3 - FFPE Yes No - - 
19 Female 52 Intraabdominal 79 3 - FFPE Yes No - - 
20 Female 69 Intraabdominal 82 3 - FFPE Yes No - - 
21 Female 49 Lower Limb 35 1 - FFPE Yes No - - 
Low Grade Myofibroblastic 
Sarcoma (LGMFS) 
01 Female 37 Lower Limb 80 1 - FRESH No Yes STS 07/12 P5 
Malignant Peripheral Nerve sheath 
Tumour (MPNST) 
01 Female 46 Lower Limb 88 3 - FRESH Yes Yes STS 01/11 p5 
Myxofibrosarcoma (MFS) 
01 Male 65 Lower Limb 105 3 - FRESH Yes Yes STS 08/11 Early Senescence 
02 Male 43 Lower Limb 35 3 - FRESH Yes Yes STS 16/10 p9 
03 Male 73 Upper Limb 50 3 - FRESH Yes Yes STS 21/11 Long Term 
04 Female 43 Lower Limb 80 1 - FRESH No Yes STS 22/11 Early Senescence 
05 Male 82 Lower Limb 210 3 - FRESH No Yes STS 04/12 Early Senescence 
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STS Subtype 
Subtype  
No. 
Gender 
Age 
(years) 
Site Size Grade 
Neoadjuvant 
Therapy 
Sample Type aCGH 
Tissue 
Culture 
Culture 
Designation 
Culture outcome 
Myxoid Liposarcoma (MLPS) 01 Female 46 Lower Limb 112 - - FRESH No Yes STS 10/10 Nil 
Pleomorphic Liposarcoma (PLPS) 
01 Male 83 Lower Limb 190 - Radiotherapy FRESH Yes Yes STS 07/10 Nil 
02 Male 77 Lower Limb 60 3 - FRESH Yes Yes STS 03/11 p5 
03 Male 65 Lower Limb 100 3 - FFPE Yes No - - 
Pleomorphic 
Rhabdomyosarcoma (PRMS) 
01 Female 31 Lower Limb 50 - 
Chemotherap
y 
FRESH Yes Yes STS 12/10 p9 
Undifferentiated Pleomorphic 
Sarcoma (UPS) 
01 Male 65 Lower Limb 120 3 - FFPE Yes No - - 
02 Female 54 Lower Limb 230 3 - BOTH Yes Yes STS 14/10 Long Term 
03 Male 44 Trunk 108 3 - FFPE Yes No - - 
04 Female 36 Lower Limb 72 2 - FRESH Yes Yes STS 04/11 p9 
05 Male 76 Lower Limb 175 3 - FRESH Yes Yes STS 06/11 Long Term 
06 Female 67 Lower Limb 115 3 - BOTH Yes Yes STS 09/11 Long Term 
07 Female 74 Upper Limb 90 3 - FRESH Yes Yes STS 15/11 Early Senescence 
08 Female 75 Lower Limb 102 3 - FFPE Yes No - - 
09 Female 34 Intraabdominal 270 3 - FFPE Yes No - - 
10 Male 82  93 3 - FFPE Yes No - - 
11 Male 64 Intraabdominal 100 3 - FFPE Yes No - - 
12 Male 65 Lower Limb 113 3 - FFPE Yes No - - 
13 Male 82 Trunk 87 3 - FFPE Yes No - - 
14 Male 66 Lower Limb 48 3 - FFPE Yes No - - 
15 Female 67 Lower Limb 72 2 - FFPE Yes No - - 
16 Male 80 Lower Limb 55 3 - FFPE Yes No - - 
17 Male 72 Trunk 165 - Radiotherapy FRESH No Yes STS 16/11 Nil 
18 Female 73 Lower Limb 230 - Radiotherapy FRESH No Yes STS 05/12 Nil 
Malignant Solitary Fibrous Tumour 
(SFT) 
01 Female 63 Lower Limb 100 2 - FRESH Yes Yes STS 17/10 p5 
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STS Subtype 
Subtype  
No. 
Gender 
Age 
(years) 
Site Size Grade 
Neoadjuvant 
Therapy 
Sample Type aCGH 
Tissue 
Culture 
Culture 
Designation 
Culture outcome 
Synovial Sarcoma (SYN) 01 Female 19 Trunk 40 3 - FRESH Yes Yes STS 04/10 p5 
Well-differentiated Liposarcoma 
(WDLPS) 
01 Male 82 Trunk 180 1 - FRESH Yes Yes STS 06/10 Nil 
02 Male 53 Trunk 62 1 - FRESH Yes Yes STS 11/10 Nil 
03 Male 62 Retroperitoneal 195 1 - FRESH Yes Yes STS 14/11 Early Senescence 
04 Female 50 Limb 105 1 - FRESH Yes Yes STS 19/10 Nil 
05 Male 52 Lower Limb 240 1 - FRESH No Yes STS 20/10 Nil 
06 Male 63 Neck 87 1 - FRESH No Yes STS 05/11 Nil 
07 Male 81 Lower Limb 115 1 - FRESH No Yes STS 02/12 Nil 
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Table A:  General Laboratory Reagents 
Reagent Supplier 
 Agarose Fischer
®
 Scientific, UK 
Bromophenol blue  Sigma-Aldrich
®
, UK 
Deionised water  
DePex vWR
® 
International, UK 
EDTA Fischer
®
 Scientific, UK 
Ethanol Fischer
®
 Scientific, UK 
Ethidium bromide  Fischer
®
 Scientific, UK 
Gill’s haematoxylin Fischer
®
 Scientific, UK 
Glacial acetic acid  Fischer
®
 Scientific, UK 
Hydrochloric acid  Fischer
®
 Scientific, UK 
Hydrogen peroxide   
Magnesium sulphate  Fischer
®
 Scientific, UK 
Methanol Fischer
®
 Scientific, UK 
Nail varnish  
Rubber solution  
Sodium acetate Fischer
®
 Scientific, UK 
Sodium bicarbonate  Fischer
®
 Scientific, UK 
Sodium citrate Fischer
®
 Scientific, UK 
Sodium hydroxide  Fischer
®
 Scientific, UK 
Sterile phosphate buffered saline (PBS)  vWR
® 
International, UK 
Sucrose Fischer
®
 Scientific, UK 
Tris base Fischer
®
 Scientific, UK 
Tween 20 Sigma-Aldrich
®
, UK 
Xylene Fischer
®
 Scientific, UK 
 
 
 
  
APPENDIX 2 
227 
 
Table B:  Laboratory Consumables 
Consumable Supplier 
Sterile plastic syringes Becton Dickinson
®
, UK 
Sterile needles (21G, 23G) Becton Dickinson
®
, UK 
Sterile scalpels Swann Morton
®
, UK 
10, 20, 200 and 1000μl pipette tips StarLab
®
, UK 
10, 20, 200 and 1000μl filter pipette tips  StarLab
®
 UK 
0.22um sterile filters Millipore
®
, UK 
22x 22/32/50mm coverslips vWR
®
 International, UK 
Plastic disposable pipettes Scientific Laboratory Supplies
®
, UK 
Plastic universal tubes (25ml) Starstedt
®
, UK 
Centrifuge tubes (15ml, 25ml, 50ml) Starstedt
®
 UK 
Eppendorf Microfuge tubes (0.2, 0.5, 1.5 and 2ml)  Starstedt
®
, UK 
Latex examination gloves Schottlander
®
 UK 
10ml and 25ml Stripettes  
Tissue Culture Plates (6, 12, 24  and 96- well)  Corning
®
, UK 
Sterile petri dishes Corning
®
, UK 
Tissue Culture flasks (T25, T75) Corning
®
, UK 
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Cytoband Region 
Length  
(Mb) 
Freq. 
% 
P-Value 
Gene 
Count 
Genes 
% of CNV 
Overlap 
Chr 1 
p36.33 2,270,056-2,285,830 0.016 28 2.00E-02 2 LOC100129534, MORN1 100 
p36.32 2,930,401-3,075,672 0.145 28 2.00E-02 4 
ACTRT2, FLJ42875, MIR4251, 
PRDM16 
14 
p36.32 3,142,248-3,304,483 0.162 28 2.00E-02 1 PRDM16 100 
p32.1 59,247,642-59,722,944 0.475 32 0.00E+00 3 HSD52, JUN, LOC100131060 35 
p32.1 59,878,157-59,889,297 0.011 30 2.00E-03 1 FGGY 0 
p31.3 66,723,046-66,828,021 0.105 28 2.00E-02 1 PDE4B 0 
q21.1 144,991,860-144,995,110 0.003 41 0.00E+00 1 PDE4DIP 100 
q21.1 145,112,508-145,166,867 0.054 43 0.00E+00 1 SEC22B 100 
q21.2 149,216,636-149,301,125 0.084 34 0.00E+00 1 LOC388692 100 
q21.2 149,818,426-149,865,193 0.047 34 0.00E+00 10 
HIST2H2AA3, HIST2H2AA4, 
HIST2H2AB, HIST2H2AC, 
HIST2H2BC, HIST2H2BE, 
HIST2H3A, HIST2H3C, HIST2H4A, 
HIST2H4B 
100 
q21.3 152,615,218-152,784,882 0.170 30 1.70E-02 12 
C1orf68, KPRP, LCE1B, LCE1C, 
LCE1D, LCE1E, LCE1F, LCE2A, 
LCE2B, LCE2C, LCE2D, LCE4A 
100 
q21.3 153,479,293-153,560,344 0.081 31 4.00E-03 5 
S100A2, S100A3, S100A4, S100A5, 
S100A6 
0 
q21.3 154,413,442-154,457,437 0.044 31 4.00E-03 2 IL6R, SHE 0 
q21.3 154,789,066-154,804,436 0.015 35 0.00E+00 1 KCNN3 0 
q21.3 154,899,255-154,958,577 0.059 38 0.00E+00 7 
CKS1B, FLAD1, MIR4258, PBXIP1, 
PMVK, PYGO2, SHC1 
0 
q22 155,177,125-155,182,550 0.005 34 0.00E+00 2 MTX1, THBS3 100 
q22 155,995,099-156,045,700 0.051 32 1.00E-03 4 
LAMTOR2, MEX3A, RAB25, 
UBQLN4 
2 
q23.3 164,765,823-164,846,101 0.080 34 0.00E+00 1 PBX1 0 
q23.3 165,117,251-165,195,584 0.078 32 1.00E-03 1 LMX1A 54 
q24.2 168,235,779-168,258,696 0.023 30 1.70E-02 1 TBX19 100 
q24.2 168,460,188-168,614,561 0.154 32 1.00E-03 2 XCL1, XCL2 2 
q24.3 172,098,669-172,150,518 0.052 34 0.00E+00 5 
DNM3, DNM3OS, MIR199A2, 
MIR214, MIR3120 
0 
q24.3 172,340,818-172,372,191 0.031 35 0.00E+00 1 DNM3 0 
q25.1 173,144,090-173,262,290 0.118 31 4.00E-03 2 LOC100506023, TNFSF4 0 
q25.1 175,470,159-175,529,973 0.060 30 1.70E-02 1 TNR 100 
Chr 2 
p11.1 91,693,395-91,906,643 0.213 34 0.00E+00 1 LOC654342 100 
q32.2 189,837,546-189,953,549 0.116 20 0.00E+00 5 
COL3A1, COL5A2, MIR1245A, 
MIR1245B, MIR3606 
0 
Chr 3 
p25.3 10,447,023-10,596,307 0.149 26 1.00E-02 1 ATP2B2 0 
p25.3 10,653,365-10,961,465 0.308 26 1.00E-02 2 LINC00606, SLC6A11 0 
p21.31 50,387,910-50,392,620 0.005 28 0.00E+00 3 CYB561D2, NPRL2, TMEM115 100 
q13.2 111,674,780-111,690,254 0.015 23 2.80E-02 1 PHLDB2 0 
q13.31 114,115,098-114,383,728 0.269 23 2.80E-02 1 ZBTB20 5 
q21.1 - q21.2 123,632,424-123,883,936 0.252 23 2.80E-02 4 CCDC14, KALRN, MIR5002, ROPN1 8 
q21.3 126,728,262-126,749,827 0.022 23 2.80E-02 1 PLXNA1 0 
q23 141,076,875-141,137,481 0.061 27 0.00E+00 1 ZBTB38 0 
q25.1 151,066,762-151,172,224 0.105 23 2.80E-02 3 IGSF10, MED12L, P2RY12 16 
q25.31 156,147,410-156,404,495 0.257 23 2.80E-02 5 
KCNAB1, KCNAB1-AS1, SSR3, 
TIPARP, TIPARP-AS1 
67 
q26.31 170,940,571-171,081,942 0.141 23 2.80E-02 1 TNIK 0 
q29 195,435,600-195,450,340 0.015 24 3.00E-03 1 MUC20 100 
Chr 4 
p16.3 3,292,884-3,360,378 0.067 24 4.80E-02 1 RGS12 14 
p16.1 6,360,943-6,472,783 0.112 28 0.00E+00 1 PPP2R2C 23 
p16.1 7,199,456-7,232,868 0.033 28 0.00E+00 1 SORCS2 100 
p16.1 7,616,190-7,705,764 0.090 31 0.00E+00 1 SORCS2 100 
p16.1 7,791,491-7,824,654 0.033 26 7.00E-03 1 AFAP1 100 
p16.1 8,250,485-8,362,583 0.112 26 7.00E-03 1 HTRA3 100 
p16.1 10,099,082-10,209,246 0.110 27 0.00E+00 1 WDR1 100 
p15.32 15,335,720-15,462,229 0.127 26 7.00E-03 1 C1QTNF7 15 
p15.32 16,404,273-16,706,812 0.303 24 4.80E-02 2 LDB2, MIR548AX 5 
Chr 5 
p15.33 1,056,507-1,117,314 0.061 41 0.00E+00 2 MIR4635, SLC12A7 100 
p15.33 1,198,260-1,242,452 0.044 41 0.00E+00 2 SLC6A18, SLC6A19 21 
p15.31 9,428,015-9,548,941 0.121 38 1.30E-02 3 
LOC100505806, SEMA5A, 
SNORD123 
1 
p15.2 14,207,189-14,318,260 0.111 42 0.00E+00 1 TRIO 3 
q31.2 136,536,367-136,685,175 0.149 24 4.40E-02 1 SPOCK1 0 
q33.3 158,139,982-158,293,641 0.154 28 0.00E+00 1 EBF1 3 
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Cytoband Region 
Length  
(Mb) 
Freq. 
% 
P-Value 
Gene 
Count 
Genes 
% of CNV 
Overlap 
Chr 6 
p22.2 26,124,423-26,191,035 0.067 27 0.00E+00 5 
HIST1H1E, HIST1H2AC, 
HIST1H2BD, HIST1H2BE, 
HIST1H4D 
64 
q21 112,072,112-112,177,222 0.105 24 0.00E+00 1 FYN 3 
q21 112,442,154-112,458,332 0.016 22 1.50E-02 1 LAMA4 0 
Chr 7 
p22.3 1,076,058-1,084,756 0.009 35 8.00E-03 1 C7orf50 1 
p22.3 1,277,550-1,314,845 0.037 35 8.00E-03 0 
 
100 
p22.3 2,119,407-2,221,398 0.102 36 1.00E-03 1 MAD1L1 56 
p15.2 27,165,134-27,196,532 0.031 41 0.00E+00 6 
HOXA-AS3, HOXA3, HOXA4, 
HOXA5, HOXA6, HOXA7 
100 
p14.1 38,291,860-38,364,472 0.073 57 0.00E+00 1 TARP 100 
q21.11 81,241,202-81,429,130 0.188 28 3.40E-02 1 HGF 1 
q31.2 115,843,542-115,869,356 0.026 28 3.40E-02 1 TES 64 
q32.3 130,570,363-130,648,215 0.078 28 3.40E-02 2 FLJ43663, LOC646329 0 
q32.3 131,792,652-132,166,465 0.374 32 0.00E+00 1 PLXNA4 35 
q33 134,373,878-134,558,594 0.185 31 1.00E-03 1 CALD1 1 
q34 142,348,015-142,384,712 0.037 30 6.00E-03 1 MTRNR2L6 100 
q36.1 150,918,904-150,949,877 0.031 30 6.00E-03 4 ABCF2, CHPF2, MIR671, SMARCD3 23 
q36.3 155,267,123-155,298,608 0.031 31 1.00E-03 1 CNPY1 100 
q36.3 157,624,156-157,657,275 0.033 31 1.00E-03 2 LOC100506585, PTPRN2 100 
Chr 8 
p23.1 7,722,742-7,943,546 0.221 24 2.00E-03 8 
DEFB103A, DEFB103B, 
DEFB109P1B, DEFB4A, FAM66E, 
USP17L3, USP17L8, ZNF705B 
100 
p21.3 22,516,604-22,551,427 0.035 23 1.60E-02 2 BIN3, EGR3 100 
p11.22 39,267,045-39,354,153 0.087 30 0.00E+00 1 ADAM3A 100 
q24.3 142,250,663-142,369,023 0.118 30 5.00E-03 2 GPR20, LOC731779 62 
q24.3 142,440,081-142,461,553 0.021 30 5.00E-03 2 MROH5, PTP4A3 100 
q24.3 143,453,630-143,656,045 0.202 30 5.00E-03 2 BAI1, TSNARE1 96 
q24.3 144,877,684-144,985,070 0.107 30 5.00E-03 5 
EPPK1, MIR937, NRBP2, PUF60, 
SCRIB 
59 
q24.3 145,022,535-145,036,930 0.014 32 0.00E+00 1 PLEC 100 
q24.3 145,662,057-145,715,477 0.053 30 5.00E-03 4 CYHR1, FOXH1, KIFC2, TONSL 100 
Chr 9 
p11.2 43,686,924-44,259,464 0.573 31 0.00E+00 1 CNTNAP3B 100 
q13 - q21.11 68,369,294-69,194,128 0.825 32 0.00E+00 4 
LOC100132352, LOC440896, 
LOC642236, PGM5P2 
100 
q22.31 93,924,918-93,992,140 0.067 27 5.00E-03 1 AUH 0 
q22.32 97,847,752-97,893,329 0.046 27 5.00E-03 5 
C9orf3, FANCC, MIR24-1, MIR27B, 
MIR3074 
0 
q34.3 139,480,157-139,577,038 0.097 26 2.80E-02 3 AGPAT2, EGFL7, MIR126 100 
Chr 11 p15.5 2,722,900-2,748,031 0.025 26 0.00E+00 1 KCNQ1 0 
Chr 12 
p13.33 2,280,958-2,506,203 0.225 22 2.50E-02 3 
CACNA1C, CACNA1C-AS4, 
CACNA1C-IT3 
6 
q13.13 52,770,362-52,844,548 0.074 22 1.00E-03 4 KRT6B, KRT75, KRT82, KRT84 100 
q13.13 53,035,044-53,091,207 0.056 22 1.00E-03 3 KRT1, KRT2, KRT77 25 
q13.13 54,382,251-54,441,012 0.059 22 1.00E-03 8 
HOXC10, HOXC4, HOXC5, HOXC6, 
HOXC8, HOXC9, MIR196A2, MIR615 
100 
q24.31 124,951,417-124,978,160 0.027 22 1.00E-03 1 NCOR2 100 
Chr 13 q34 110,918,305-111,046,505 0.128 23 0.00E+00 2 COL4A1, COL4A2 8 
Chr 14 
q13.1 33,983,246-34,106,522 0.123 27 2.30E-02 1 NPAS3 100 
q22.1 51,983,513-52,116,762 0.133 30 1.00E-03 3 FRMD6, FRMD6-AS1, FRMD6-AS2 6 
q24.1 68,917,581-69,163,933 0.246 34 0.00E+00 1 RAD51B 61 
Chr 15 
q22.2 63,009,973-63,140,185 0.130 26 3.60E-02 2 MIR190A, TLN2 0 
q22.2 63,328,861-63,370,712 0.042 26 3.60E-02 1 TPM1 0 
q22.31 63,793,316-63,891,739 0.098 26 3.60E-02 3 FBXL22, LOC100130855, USP3 13 
q26.2 96,861,171-96,901,074 0.040 26 3.60E-02 2 MIR1469, NR2F2 100 
Chr 16 
p13.3 704,825-751,634 0.047 30 0.00E+00 7 
FBXL16, JMJD8, RHBDL1, RHOT2, 
STUB1, WDR24, WDR90 
100 
p13.3 1,107,394-1,230,023 0.123 30 0.00E+00 4 
C1QTNF8, CACNA1H, SSTR5, 
SSTR5-AS1 
100 
p11.2 33,549,833-33,604,960 0.055 35 0.00E+00 1 RNU6-76 100 
Chr 17 
p11.2 17,725,378-17,784,405 0.059 31 0.00E+00 2 SREBF1, TOM1L2 100 
q23.1 57,816,707-57,935,524 0.119 22 3.90E-02 2 MIR21, VMP1 2 
q25.3 78,792,051-78,943,986 0.152 23 9.00E-03 1 RPTOR 100 
q25.3 78,996,511-79,025,995 0.029 26 0.00E+00 2 BAIAP2, BAIAP2-AS1 100 
q25.3 79,043,133-79,108,656 0.066 26 0.00E+00 6 
AATK, BAIAP2, MIR1250, MIR3065, 
MIR338, MIR657 
100 
q25.3 79,204,713-79,252,341 0.048 26 0.00E+00 3 C17orf89, ENTHD2, SLC38A10 100 
Chr 18 q21.1 46,332,876-46,349,548 0.017 23 0.00E+00 1 CTIF 59 
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Cytoband Region 
Length  
(Mb) 
Freq. 
% 
P-Value 
Gene 
Count 
Genes 
% of CNV 
Overlap 
Chr 19 
p13.11 18,429,433-18,539,026 0.110 31 0.00E+00 6 
GDF15, LRRC25, LSM4, MIR3189, 
PGPEP1, SSBP4 
0 
q12 30,459,500-30,521,228 0.062 23 7.00E-03 1 URI1 91 
q12 31,213,939-31,839,232 0.625 24 1.00E-03 2 DKFZp566F0947, TSHZ3 2 
Chr 20 
p12.2 10,498,625-10,544,746 0.046 27 0.00E+00 1 SLX4IP 0 
p12.2 10,595,495-10,632,707 0.037 27 0.00E+00 2 JAG1, SLX4IP 0 
q13.13 48,909,768-49,005,661 0.096 34 8.00E-03 1 LOC284751 13 
q13.13 49,144,167-49,195,548 0.051 32 4.10E-02 1 PTPN1 0 
q13.33 61,974,698-61,991,078 0.016 35 1.00E-03 1 CHRNA4 100 
Chr 21 
q22.3 46,468,637-46,671,553 0.203 22 1.30E-02 2 ADARB1, SSR4P1 1 
q22.3 46,702,083-46,712,289 0.010 22 1.30E-02 2 LOC642852, POFUT2 0 
q22.3 46,734,765-46,866,052 0.131 22 1.30E-02 3 
COL18A1, COL18A1-AS1, 
COL18A1-AS2 
93 
q22.3 47,384,850-47,435,984 0.051 22 1.30E-02 1 COL6A1 16 
Chr 22 
q11.21 20,128,525-20,149,725 0.021 30 0.00E+00 2 LOC388849, ZDHHC8 100 
q11.21 20,303,536-20,309,261 0.006 27 1.00E-03 1 DGCR6L 100 
q11.23 24,398,622-24,412,555 0.014 24 4.00E-02 2 CABIN1, GSTTP2 100 
q12.3 36,665,486-36,730,556 0.065 26 6.00E-03 1 MYH9 0 
q13.31 46,449,007-46,491,493 0.042 34 0.00E+00 4 
C22orf26, LOC150381, MIR3619, 
MIRLET7BHG 
100 
q13.32 48,910,656-49,017,773 0.107 24 4.00E-02 2 FAM19A5, LOC284933 100 
q13.32 49,048,111-49,112,319 0.064 24 4.00E-02 1 FAM19A5 14 
      293   
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 Cytoband Region 
Length 
(Mb) 
Freq 
% 
p-value 
Gene 
Count 
Genes 
% of CNV 
overlap 
Chr 1 
p36.33 956,608-1,068,631 0.112 27 0.00E+00 3 AGRN, C1orf159, RNF223 100 
p36.33 1,075,323-1,107,787 0.032 30 0.00E+00 4 
LOC254099, MIR200A, MIR200B, 
MIR429 
100 
p36.32 2,371,593-2,419,712 0.048 24 4.00E-03 1 PLCH2 100 
p36.32 2,472,466-2,539,213 0.067 24 4.00E-03 5 
FAM213B, LOC100133445, 
LOC115110, MMEL1, TNFRSF14 
100 
p36.32 3,923,830-4,136,628 0.213 23 3.30E-02 1 LOC728716 2 
p36.22 10,016,474-10,200,060 0.184 28 0.00E+00 3 NMNAT1, RBP7, UBE4B 0 
p35.3 28,619,691-28,928,183 0.308 27 0.00E+00 11 
MED18, PHACTR4, RAB42, RCC1, 
SNHG12, SNHG3, SNORA16A, 
SNORA44, SNORA61, SNORD99, 
TRNAU1AP 
21 
p35.3 29,009,502-29,055,824 0.046 27 0.00E+00 1 GMEB1 1 
p35.2 31,508,693-31,648,449 0.140 23 3.30E-02 1 PUM1 1 
p34.3 35,521,725-35,777,359 0.256 24 4.00E-03 3 SFPQ, ZMYM1, ZMYM4 12 
p34.1 45,864,086-46,013,665 0.150 24 4.00E-03 4 
CCDC163P, MMACHC, PRDX1, 
TESK2 
30 
p13.2 113,478,891-113,605,851 0.127 23 3.30E-02 1 SLC16A1 100 
p11.2 121,031,118-121,322,377 0.291 23 3.30E-02 2 EMBP1, SRGAP2D 100 
q21.2 148,936,653-149,185,842 0.249 23 0.00E+00 1 LOC645166 100 
q21.3 153,978,323-154,095,056 0.117 22 0.00E+00 1 NUP210L 4 
q25.2 179,343,150-179,387,834 0.045 20 1.00E-03 1 AXDND1 4 
q31.3 196,790,444-196,812,218 0.022 26 0.00E+00 1 CFHR1 100 
q42.11 224,317,312-224,426,566 0.109 24 0.00E+00 3 DEGS1, FBXO28, NVL 96 
q42.3 235,273,856-235,483,275 0.209 23 0.00E+00 5 
ARID4B, MIR4753, RBM34, 
SNORA14B, TOMM20 
58 
q42.3 235,506,903-235,601,351 0.094 23 0.00E+00 2 GGPS1, TBCE 100 
q42.3 235,710,197-235,744,621 0.034 22 0.00E+00 1 GNG4 100 
q43 240,317,906-240,395,286 0.077 20 1.00E-03 1 FMN2 100 
q43 240,708,989-240,931,477 0.222 23 0.00E+00 1 GREM2 0 
q43 242,156,886-242,185,035 0.028 20 1.00E-03 1 MAP1LC3C 100 
q44 248,733,443-248,796,977 0.064 24 0.00E+00 3 OR2T10, OR2T11, OR2T34 100 
q44 248,983,071-249,250,621 0.268 26 0.00E+00 5 
MIR3124, PGBD2, SH3BP5L, 
ZNF672, ZNF692 
78 
Chr 2 
p23.3 24,085,415-24,215,135 0.130 30 0.00E+00 2 ATAD2B, UBXN2A 0 
p23.3 26,076,849-26,285,068 0.208 27 1.00E-03 3 ASXL2, KIF3C, RAB10 100 
p22.3 32,189,545-32,388,583 0.199 32 0.00E+00 3 DPY30, MEMO1, SPAST 2 
p21 42,648,727-42,869,815 0.221 26 1.30E-02 2 KCNG3, MTA3 0 
p21 47,566,725-47,610,197 0.043 27 1.00E-03 2 EPCAM, MIR559 0 
p15 61,737,824-61,859,483 0.122 34 0.00E+00 1 XPO1 72 
q21.3 136,065,879-136,201,097 0.135 28 1.00E-03 1 ZRANB3 100 
q33.1 203,075,213-203,095,429 0.020 31 0.00E+00 1 SUMO1 1 
q33.1 - q33.2 203,141,016-203,353,381 0.212 32 0.00E+00 5 
BMPR2, NOP58, SNORD11, 
SNORD11B, SNORD70 
18 
q33.2 203,626,882-203,666,675 0.040 28 1.00E-03 2 FAM117B, ICA1L 3 
q33.2 203,975,036-204,095,433 0.120 32 0.00E+00 1 NBEAL1 0 
q33.2 204,263,410-204,271,749 0.008 27 1.00E-02 1 ABI2 0 
q36.3 228,558,973-228,645,211 0.086 27 1.00E-02 1 SLC19A3 0 
q36.3 230,795,681-230,895,774 0.100 35 0.00E+00 1 FBXO36 100 
q37.1 232,365,447-232,533,640 0.168 27 1.00E-02 3 C2orf57, LINC00471, NMUR1 0 
q37.1 232,744,204-232,758,888 0.015 27 1.00E-02 1 MIR1471 100 
q37.1 232,776,466-232,787,523 0.011 27 1.00E-02 1 NPPC 100 
q37.1 233,017,240-233,129,262 0.112 28 1.00E-03 1 DIS3L2 22 
q37.1 233,419,593-233,427,159 0.008 28 1.00E-03 1 EIF4E2 80 
q37.1 233,451,131-233,561,148 0.110 28 1.00E-03 1 EFHD1 0 
q37.1 233,968,460-234,082,483 0.114 31 0.00E+00 1 INPP5D 0 
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Chr 2 
q37.1 234,984,549-235,056,307 0.072 28 1.00E-03 1 SPP2 9 
q37.1 235,166,511-235,422,424 0.256 28 1.00E-03 1 ARL4C 0 
q37.2 235,930,332-236,368,103 0.438 30 0.00E+00 1 SH3BP4 0 
q37.2 236,464,405-236,970,235 0.506 30 0.00E+00 1 AGAP1 28 
q37.3 241,747,277-241,763,176 0.016 34 0.00E+00 1 KIF1A 100 
q37.3 242,503,450-242,825,417 0.322 34 0.00E+00 10 
ATG4B, BOK, CXXC11, D2HGDH, 
DTYMK, GAL3ST2, ING5, NEU4, 
PDCD1, THAP4 
100 
q37.3 242,930,739-243,199,373 0.269 41 0.00E+00 1 LOC728323 64 
Chr 3 
p22.1 41,835,995-42,009,669 0.174 20 1.00E-03 1 ULK4 31 
p21.31 47,839,057-47,880,973 0.042 20 1.00E-03 1 DHX30 16 
p21.31 48,294,309-48,307,250 0.013 20 1.00E-03 1 ZNF589 100 
p21.31 48,965,902-48,976,775 0.011 20 1.00E-03 1 ARIH2 0 
p21.31 49,299,147-49,543,299 0.244 20 1.00E-03 9 
AMT, C3orf62, DAG1, GPX1, 
MIR4271, NICN1, RHOA, TCTA, 
USP4 
3 
p21.2 51,469,972-51,621,766 0.152 28 0.00E+00 2 RAD54L2, VPRBP 5 
p14.3 57,453,906-57,530,400 0.076 26 0.00E+00 1 DNAH12 9 
q13.13 109,113,547-109,143,938 0.030 20 0.00E+00 1 FLJ25363 0 
q29 196,000,424-196,206,380 0.206 20 0.00E+00 6 
PCYT1A, RNF168, TCTEX1D2, 
TM4SF19, TM4SF19-TCTEX1D2, 
UBXN7 
100 
Chr 4 
p14 39,662,567-39,715,730 0.053 27 0.00E+00 1 UBE2K 27 
p14 39,963,576-40,082,025 0.118 27 0.00E+00 3 LOC344967, N4BP2, PDS5A 75 
p14 40,486,730-40,542,205 0.055 23 0.00E+00 2 MIR4802, RBM47 13 
q12 57,671,380-57,779,724 0.108 24 1.30E-02 2 REST, SPINK2 39 
q31.3 151,923,034-152,012,891 0.090 27 0.00E+00 1 LRBA 100 
q35.1 184,425,375-184,842,296 0.417 24 1.30E-02 5 
ING2, LOC389247, RWDD4, STOX2, 
TRAPPC11 
13 
q35.2 187,113,646-187,446,183 0.333 24 1.30E-02 4 CYP4V2, F11, KLKB1, LOC285441 57 
q35.2 188,944,897-189,042,012 0.097 31 0.00E+00 1 TRIML2 100 
q35.2 190,125,160-190,427,650 0.302 24 1.30E-02 1 HSP90AA4P 100 
Chr 5 
p15.1 16,888,013-16,994,509 0.106 20 0.00E+00 1 MYO10 5 
q12.1 61,583,390-61,735,907 0.153 22 0.00E+00 3 DIMT1, IPO11, KIF2A 100 
q13.2 68,428,997-68,564,076 0.135 27 0.00E+00 4 CCNB1, CDK7, CENPH, MRPS36 0 
q13.2 68,786,099-68,849,653 0.064 28 0.00E+00 1 OCLN 100 
q13.2 70,778,491-70,800,177 0.022 22 0.00E+00 1 BDP1 94 
q13.3 76,055,243-76,180,392 0.125 20 0.00E+00 2 F2RL1, S100Z 41 
q14.1 78,443,225-78,565,349 0.122 23 0.00E+00 1 JMY 25 
q14.1 79,573,522-79,634,971 0.061 24 0.00E+00 2 LOC644936, SPZ1 0 
q23.2 125,889,774-126,113,364 0.224 20 0.00E+00 4 ALDH7A1, C5orf48, LMNB1, PHAX 2 
q31.1 132,277,458-132,377,408 0.100 23 0.00E+00 2 AFF4, ZCCHC10 1 
q31.1 134,104,930-134,137,607 0.033 22 0.00E+00 1 DDX46 0 
q35.1 171,529,719-171,703,493 0.174 22 0.00E+00 3 EFCAB9, STK10, UBTD2 96 
q35.1 172,408,450-172,524,339 0.116 22 0.00E+00 3 ATP6V0E1, CREBRF, SNORA74B 10 
q35.2 176,522,090-176,585,808 0.064 23 0.00E+00 2 FGFR4, NSD1 78 
Chr 6 
p21.32 32,465,385-32,532,311 0.067 20 2.10E-02 2 HLA-DRB5, HLA-DRB6 100 
q13 74,050,467-74,067,397 0.017 27 0.00E+00 1 DPPA5 0 
q13 74,099,505-74,195,846 0.096 26 0.00E+00 3 DDX43, MB21D1, MTO1 2 
q14.1 76,462,056-76,510,198 0.048 22 1.10E-02 1 MYO6 0 
q15 90,497,575-90,599,843 0.102 23 0.00E+00 2 CASP8AP2, MDN1 46 
q21 107,444,141-107,492,203 0.048 27 0.00E+00 1 PDSS2 100 
q21 108,522,069-108,672,999 0.151 22 1.10E-02 2 LACE1, SNX3 94 
q21 110,991,764-111,325,700 0.334 22 1.10E-02 4 AMD1, CDK19, GTF3C6, RPF2 13 
q25.1 150,086,688-150,096,190 0.010 23 0.00E+00 1 PCMT1 0 
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Chr 7 
p22.1 6,058,613-6,125,961 0.067 22 3.00E-03 3 AIMP2, ANKRD61, EIF2AK1 100 
p22.1 6,312,742-6,401,731 0.089 20 3.60E-02 1 FAM220A 100 
p14.1 40,212,869-40,287,726 0.075 24 0.00E+00 1 C7orf10 76 
p13 44,805,831-44,819,347 0.014 22 3.00E-03 1 ZMIZ2 0 
p11.2 55,896,581-55,958,866 0.062 23 0.00E+00 1 SEPT14 100 
q36.1 152,298,801-152,428,614 0.130 20 0.00E+00 1 XRCC2 3 
Chr 8 
p12 30,521,548-30,639,277 0.118 31 0.00E+00 2 GSR, UBXN8 26 
p11.22 39,229,932-39,254,152 0.024 39 0.00E+00 1 ADAM5 100 
p11.22 39,354,153-39,368,808 0.015 41 0.00E+00 1 ADAM3A 100 
Chr 9 
p24.1 6,604,848-6,770,652 0.166 24 1.00E-03 2 GLDC, KDM4C 100 
p22.1 19,073,617-19,095,812 0.022 24 1.00E-03 1 HAUS6 100 
p22.1 19,328,279-19,336,610 0.008 22 4.90E-02 1 DENND4C 100 
p13.3 34,020,894-34,172,360 0.151 26 0.00E+00 2 DCAF12, UBAP2 28 
p13.3 36,197,774-36,210,370 0.013 23 8.00E-03 1 CLTA 100 
p13.3 - p13.2 36,238,083-36,602,433 0.364 23 8.00E-03 3 GNE, MELK, RNF38 60 
q21.32 86,538,847-86,579,313 0.040 20 1.10E-02 1 C9orf64 100 
q22.1 90,942,429-91,026,524 0.084 27 0.00E+00 1 SPIN1 3 
q22.32 99,068,141-99,166,239 0.098 20 1.10E-02 2 SLC35D2, ZNF367 10 
q31.2 110,185,871-110,312,825 0.127 22 1.00E-03 1 KLF4 3 
q31.3 114,225,250-114,374,017 0.149 22 1.00E-03 4 
KIAA0368, LRRC37A5P, PTGR1, 
ZNF483 
45 
q31.3 - q32 114,899,274-114,978,317 0.079 23 0.00E+00 2 MIR3134, SUSD1 4 
q33.3 127,912,225-128,098,776 0.187 28 0.00E+00 4 GAPVD1, HSPA5, PPP6C, RABEPK 5 
q34.11 131,209,624-131,324,980 0.115 20 1.10E-02 3 GLE1, ODF2, SPTAN1 2 
q34.11 131,586,233-131,592,085 0.006 31 0.00E+00 1 C9orf114 100 
q34.3 137,970,025-138,031,761 0.062 20 1.10E-02 1 OLFM1 10 
q34.3 140,569,189-140,833,019 0.264 22 1.00E-03 4 
CACNA1B, EHMT1, FLJ40292, 
MIR602 
41 
Chr 10 
p12.31 21,824,360-21,930,936 0.107 39 1.70E-02 1 MLLT10 47 
q21.3 70,020,324-70,058,211 0.038 39 1.00E-02 1 PBLD 0 
q21.3 70,117,022-70,139,117 0.022 43 0.00E+00 1 RUFY2 0 
q21.3 70,448,059-70,560,756 0.113 42 0.00E+00 3 CCAR1, SNORD98, TET1 91 
q22.1 70,612,594-70,658,476 0.046 42 0.00E+00 1 STOX1 41 
q22.1 74,378,863-74,431,837 0.053 41 1.00E-03 1 MICU1 0 
q22.1 74,695,200-74,882,869 0.188 39 1.00E-02 3 NUDT13, P4HA1, PLA2G12B 1 
q22.2 75,088,327-75,190,252 0.102 38 4.90E-02 3 ANXA7, MSS51, TTC18 3 
q22.2 75,979,373-76,068,813 0.089 38 4.90E-02 1 ADK 100 
q22.2 76,539,809-76,624,155 0.084 39 1.00E-02 1 KAT6B 4 
q23.33 94,118,854-94,208,531 0.090 38 4.90E-02 1 MARK2P9 31 
q23.33 96,313,938-96,405,785 0.092 38 4.90E-02 1 HELLS 0 
q23.33 96,483,383-96,501,601 0.018 38 4.90E-02 1 CYP2C18 0 
q24.1 98,598,111-98,639,457 0.041 38 4.90E-02 1 LCOR 48 
Chr 11 
p15.5 975,029-1,054,782 0.080 26 3.00E-03 2 AP2A2, MUC6 100 
p15.4 3,752,511-3,833,652 0.081 24 2.90E-02 2 NUP98, PGAP2 60 
p15.4 9,291,259-9,433,407 0.142 32 0.00E+00 2 IPO7, TMEM41B 27 
p15.1 17,216,087-17,328,061 0.112 24 2.90E-02 1 NUCB2 5 
p15.1 18,384,389-18,566,743 0.182 26 3.00E-03 6 
GTF2H1, LDHA, LDHAL6A, LDHC, 
TSG101, UEVLD 
13 
p11.2 47,685,266-47,775,861 0.091 26 3.00E-03 2 AGBL2, FNBP4 0 
q22.3 107,770,408-107,898,857 0.128 45 0.00E+00 2 CUL5, RAB39A 100 
q23.1 112,001,948-112,013,997 0.012 35 4.70E-02 1 IL18 0 
q23.3 116,854,116-117,006,852 0.153 36 9.00E-03 1 SIK3 4 
q23.3 118,598,334-118,631,072 0.033 35 4.70E-02 1 DDX6 0 
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Chr 11 
q24.1 122,858,214-122,972,257 0.114 36 9.00E-03 3 CLMP, HSPA8, LOC341056 8 
q24.1 123,024,491-123,037,487 0.013 36 9.00E-03 1 CLMP 0 
q24.2 125,355,927-125,367,110 0.011 35 4.70E-02 1 FEZ1 19 
q24.2 125,561,636-126,152,231 0.591 35 4.70E-02 12 
CDON, DDX25, FAM118B, 
FOXRED1, HYLS1, PATE1, PATE2, 
PATE3, PATE4, PUS3, RPUSD4, 
SRPR 
65 
q24.3 129,941,688-130,298,215 0.357 36 9.00E-03 4 ADAMTS8, APLP2, ST14, ZBTB44 100 
Chr 12 
p13.33 1,087,151-1,143,274 0.056 27 0.00E+00 1 ERC1 12 
p13.31 7,837,530-7,904,204 0.067 38 0.00E+00 3 CLEC4C, DPPA3, GDF3 100 
p13.2 12,378,259-12,486,780 0.109 28 0.00E+00 2 LRP6, MANSC1 24 
p13.1 13,005,969-13,035,585 0.030 28 0.00E+00 1 RPL13AP20 4 
p12.3 19,494,831-19,609,167 0.114 24 2.90E-02 2 AEBP2, PLEKHA5 100 
q13.12 51,127,712-51,247,966 0.120 20 0.00E+00 3 ATF1, DIP2B, TMPRSS12 1 
q23.2 101,863,963-101,904,060 0.040 22 0.00E+00 1 SPIC 2 
q24.23 118,507,406-118,519,199 0.012 23 0.00E+00 1 VSIG10 0 
q24.31 122,469,774-122,665,202 0.195 22 0.00E+00 4 BCL7A, IL31, LRRC43, MLXIP 8 
q24.31 123,975,245-124,001,234 0.026 20 0.00E+00 1 RILPL1 0 
Chr 13 
q14.13 45,907,934-45,944,432 0.036 50 0.00E+00 3 SNORA31, TPT1, TPT1-AS1 4 
q14.13 46,052,795-46,062,566 0.010 45 2.50E-02 1 COG3 1 
q14.2 48,961,498-49,034,756 0.073 49 0.00E+00 2 LPAR6, RB1 2 
q14.2 49,229,080-49,281,746 0.053 47 0.00E+00 1 CYSLTR2 100 
q14.2 50,015,335-50,058,363 0.043 47 0.00E+00 2 CAB39L, SETDB2 1 
q14.2 50,123,069-50,223,067 0.100 47 0.00E+00 2 ARL11, RCBTB1 1 
q14.2 50,395,858-50,553,767 0.158 51 0.00E+00 2 CTAGE10P, SPRYD7 19 
q14.3 52,907,036-52,975,980 0.069 45 2.50E-02 1 THSD1 100 
q22.1 73,587,724-73,617,924 0.030 46 4.00E-03 1 PIBF1 53 
Chr 14 
q11.2 20,224,270-20,405,952 0.182 38 0.00E+00 5 
OR4K1, OR4K2, OR4K5, OR4M1, 
OR4N2 
100 
q13.1 35,045,934-35,056,862 0.011 32 0.00E+00 1 SNX6 100 
q23.2 64,024,743-64,309,341 0.285 31 0.00E+00 2 SGPP1, WDR89 16 
q24.2 73,442,657-73,558,351 0.116 28 3.40E-02 2 RBM25, ZFYVE1 4 
q24.3 73,996,129-74,029,564 0.033 30 4.00E-03 2 ACOT1, HEATR4 100 
q24.3 74,281,839-74,537,345 0.256 32 0.00E+00 7 
ALDH6A1, CCDC176, COQ6, 
ENTPD5, FAM161B, PTGR2, 
ZNF410 
0 
q32.33 104,048,530-104,117,267 0.069 28 3.40E-02 2 APOPT1, KLC1 0 
q32.33 104,566,967-104,715,087 0.148 31 0.00E+00 4 ASPG, KIF26A, MIR203, MIR3545 63 
Chr 15 
q11.2 21,217,563-22,134,343 0.917 27 0.00E+00 4 
CXADRP2, LOC646214, NF1P2, 
POTEB 
100 
q11.2 22,311,626-22,395,369 0.084 28 0.00E+00 3 LOC727924, OR4M2, OR4N4 100 
q11.2 22,550,035-22,662,192 0.112 32 0.00E+00 1 REREP3 100 
q15.1 41,409,196-41,592,148 0.183 24 9.00E-03 3 CHP1, EXD1, OIP5-AS1 12 
q15.1 41,665,226-41,739,919 0.075 24 9.00E-03 3 NDUFAF1, NUSAP1, RTF1 0 
q15.3 44,479,587-44,509,992 0.030 27 0.00E+00 1 FRMD5 0 
q15.3 44,571,354-44,655,162 0.084 27 0.00E+00 1 CASC4 0 
q21.2 50,726,619-50,862,207 0.136 26 1.00E-03 3 TRPM7, USP50, USP8 68 
q21.2 50,874,701-50,958,619 0.084 26 1.00E-03 1 TRPM7 100 
q21.2 51,052,550-51,089,434 0.037 26 1.00E-03 1 SPPL2A 100 
q21.3 55,734,880-55,762,580 0.028 31 0.00E+00 2 DYX1C1, DYX1C1-CCPG1 0 
q22.31 64,769,454-64,836,946 0.067 28 0.00E+00 1 ZNF609 3 
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Chr 16 
q21 58,612,157-58,835,213 0.223 34 5.00E-03 3 CNOT1, GOT2, SLC38A7 100 
q22.1 68,761,997-68,928,133 0.166 32 3.50E-02 2 CDH1, TANGO6 41 
q22.1 69,215,073-69,271,226 0.056 32 3.50E-02 1 SNTB2 46 
q23.1 74,366,198-74,436,209 0.070 34 5.00E-03 1 LOC283922 100 
q23.2 81,181,342-81,195,711 0.014 32 3.50E-02 1 PKD1L2 100 
Chr 17 
p13.3 172,499-344,123 0.172 34 0.00E+00 4 
C17orf97, FAM101B, 
LOC100506388, RPH3AL 
70 
p13.3 511,145-555,195 0.044 32 1.00E-03 1 VPS53 20 
p13.3 2,665,936-2,769,575 0.104 32 1.00E-03 1 RAP1GAP2 23 
p13.2 5,136,618-5,181,043 0.044 31 3.00E-03 2 LOC100130950, SCIMP 3 
p13.1 7,565,085-7,611,407 0.046 31 3.00E-03 3 EFNB3, TP53, WRAP53 0 
q11.2 27,735,232-27,764,959 0.030 28 0.00E+00 1 TAOK1 0 
q11.2 27,984,473-28,129,484 0.145 24 1.00E-03 1 SSH2 0 
q11.2 29,117,045-29,216,285 0.099 31 0.00E+00 2 ATAD5, CRLF3 1 
q11.2 30,161,501-30,258,051 0.097 26 0.00E+00 2 COPRS, UTP6 38 
q12 35,710,467-35,718,781 0.008 35 0.00E+00 1 ACACA 100 
q12 37,461,700-37,519,729 0.058 22 2.20E-02 1 FBXL20 26 
Chr 18 q11.2 19,209,847-19,239,318 0.029 24 1.00E-03 2 ABHD3, SNRPD1 100 
Chr 19 
q13.32 47,802,665-47,833,309 0.031 24 2.00E-02 1 C5AR1 2 
q13.33 48,041,626-48,139,184 0.098 24 2.00E-02 2 GLTSCR1, ZNF541 0 
q13.33 48,255,738-48,563,754 0.308 24 2.00E-02 39 
BSPH1, CABP5, CRX, ELSPBP1, 
GLTSCR2, PLA2G4C, SEPW1, 
SNAR-A1, SNAR-A10, SNAR-A11, 
SNAR-A12, SNAR-A13, SNAR-A14, 
SNAR-A2, SNAR-A3, SNAR-A4, 
SNAR-A5, SNAR-A6, SNAR-A7, 
SNAR-A8, SNAR-A9, SNAR-C1, 
SNAR-C2, SNAR-C3, SNAR-C4, 
SNAR-C5, SNORD23, SULT2A1, 
TPRX1 
61 
q13.41 53,501,507-53,551,665 0.050 24 2.00E-02 2 ERVV-1, ERVV-2 100 
q13.42 54,235,078-54,300,229 0.065 35 0.00E+00 18 
MIR1283-2, MIR371A, MIR371B, 
MIR372, MIR373, MIR516A1, 
MIR516A2, MIR516B1, MIR517C, 
MIR518A2, MIR518D, MIR519A1, 
MIR519A2, MIR520H, MIR521-1, 
MIR522, MIR527, NLRP12 
45 
Chr 20 p12.3 5,677,855-5,749,604 0.072 23 0.00E+00 1 C20orf196 80 
Chr 21 
p11.1 11,066,993-11,132,953 0.066 28 0.00E+00 5 
BAGE, BAGE2, BAGE3, BAGE4, 
BAGE5 
100 
q22.11 34,789,786-34,886,279 0.096 24 1.00E-03 4 
DNAJC28, GART, IFNGR2, 
TMEM50B 
41 
q22.12 37,616,924-37,740,911 0.124 28 0.00E+00 2 DOPEY2, MORC3 100 
q22.3 45,818,895-45,899,492 0.081 23 1.20E-02 3 LRRC3, LRRC3-AS1, TRPM2 100 
Chr 22 
q11.1 17,721,150-17,873,514 0.152 30 9.00E-03 1 CECR3 24 
q12.1 29,021,468-29,050,839 0.029 31 1.00E-03 1 TTC28 0 
q12.1 29,060,638-29,160,547 0.100 31 1.00E-03 3 CHEK2, HSCB, TTC28 54 
q12.2 31,819,400-31,830,361 0.011 30 9.00E-03 1 DRG1 100 
q13.32 49,017,773-49,105,738 0.088 32 0.00E+00 1 FAM19A5 45 
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 Peak Region Extended Region Q-Bound G-Score 
No. of 
Genes 
Frequency 
% 
Genes in Peak All genes 
Chr 1 
172,098,669-172,150,518 172,028,886-172,405,472 5.71E-05 18.4 6 35 
DNM3, MIR312, MIR214, DNM3OS, 
MIR199A2, 
DNM3, MIR312, MIR214, DNM3OS, MIR199A2, C1orf105 
145,112,508-145,166,867 144,009,907-145,340,062 3.85E-03 14.7 14 43 SEC22B 
SRGAP2B, LINC00623, LOC728875, PPIAL4B, PPIAL4C, 
PPIAL4A, LOC728875, PFN1P2, LOC653513, NBPF9, PDE4DIP, 
SEC22B, NOTCH2NL, NBPF10 
59,247,642-59,633,875 59,099,590-61,974,758 1.20E-02 13.0 10 32 JUN, LOC100131060, HSD52 
MYSM1, JUN, LOC100131060, HSD52, FGGY, MIR4711, 
HOOK1, CYP2J2, C1orf87, NFIA 
Chr 2 91,799,855-91,906,643 91,693,395-91,906,643 4.03E-02 11.2 1 34 LOC654342 LOC654342 
Chr 3 87,299,611-87,306,626 86,816,036-88,468,010 3.81E-02 11.3 8 21 CHMP2B 
VGLL3, MIR4795, CHMP2B, POU1F1, HTR1F, CGGBP1, 
ZNF654, C3orf38 
Chr 5 14,207,189-14,318,260 11,206,668-14,990,016 3.57E-04 16.9 9 42 TRIO 
CTNND2, CT49, DNAH5, TRIO, FAM105A, FAM105B, 
LOC100130744, ANKH, MIR4637 
Chr 7 
38,291,860-38,364,472 38,282,545-38,385,111 1.43E-04 17.6 2 57 TARP TARP, LOC100506776 
82,845,459-83,425,216 80,923,212-86,580,804 1.52E-02 12.7 8 28 SEMA3E 
HGF, CACNA2D1, PCLO, SEMA3E, SEMA3A, SEMA3D, GRM3, 
KIAA1324L 
Chr 8 
39,267,045-39,326,605 39,254,152-39,368,808 1.89E-02 12.4 2 30 ADAM3A ADAM5, ADAM3A 
72,348,163-72,380,339 72,104,731-73,824,911 1.89E-02 12.4 7 20 
EYA1, MSC, LOC100132891, RNU6-
83, TRPA1, LOC392232, KCNB2 
EYA1, MSC, LOC100132891, RNU6-83, TRPA1, LOC392232, 
KCNB2 
Chr 11 101,888,922-102,084,901 101,597,949-102,391,460 7.75E-06 19.9 8 <20 C11orf70, YAP1 
ANGPTL5, KIAA1377, C11orf70, YAP1, BIRC3, BIRC2, 
TMEM123, MMP7 
Chr 12 
69,214,969-69,274,789 69,152,516-69,644,424 1.13E-08 33.2 5 <20 MDM2, CPM SLC35E3, LOC100130075, MDM2, CPM, CPSF6 
58,177,011-58,193,558 58,114,609-58,265,541 1.13E-08 26.6 13 <20 TSFM, AVIL 
OS9, LOC100130776, AGAP2, TSPAN31, CDK4, MARCH9, 
CYP27B1, METTL1, METTL21B, TSFM, AVIL, MIR26A2, CTDSP2 
72,779,573-72,832,009 72,603,962-73,912,299 9.53E-03 13.3 2 <20 TRHDE TRHDE-AS1, TRHDE 
Chr 15 21,217,563-21,618,233 20,523,183-22,311,626 1.45E-04 17.6 12 <20 - 
HERC2P3, GOLGA6L6, GOLGA8CP, NBEAP1, POTEB, NF1P2, 
CT60, LOC646214, CXADRP2, POTEB, NF1P2, LOC727924 
Chr 16 704,825-751,634 601,203-804,072 4.44E-02 11.1 20 30 
WDR90, RHOT2, RHBDL1, STUB1, 
JMJD8, WDR24, FBXL16 
SOLH, C16orf11, NHLRC4, PIGQ, RAB40C, WFIKKN1, C16orf13, 
FAM195A, WDR90, RHOT2, RHBDL1, STUB1, JMJD8, WDR24, 
FBXL16, METRN, FAM173A, CCDC78, HAGHL, NARFL 
 
Chr 17 17,754,230-17,784,405 17,725,378-17,822,932 4.62E-03 14.4 2 31 TOM1L2 SREBF1, TOM1L2 
Chr 20 48,909,768-49,005,661 48,776,558-49,195,548 1.35E-02 12.9 3 32 LOC284751 CEBPB, LOC284751, PTPN1 
Chr 22 46,449,007-46,491,493 46,439,878-46,507,701 3.50E-02 11.4 5 34 
C22orf26, LOC150381, MIR3619, 
MIRLET7BHG 
LOC100271722, C22orf26, LOC150381, MIR3619, MIRLET7BHG 
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 Peak Region Extended Region Q-Bound G-Score 
No of 
Genes 
Frequency 
% 
Genes in Peak All genes 
Chr 1 
248,733,443-248,796,977 248,733,443-248,796,977 1.05E-06 20.3 3 24 OR2T34, OR2T10, OR2T11 OR2T34, OR2T10, OR2T11 
196,790,444-196,812,218 196,790,444-196,812,218 3.38E-02 11.3 1 26 CFHR1 CFHR1 
Chr 2 242,930,739-242,953,346 242,859,272-243,199,373 2.10E-09 26.0 1 41 - LOC728323 
Chr 4 69,307,839-69,405,506 69,307,839-69,546,914 1.37E-03 14.8 3 22 TMPRSS11E, UGT2B17, TMPRSS11E, UGT2B17, UGT2B15 
Chr 6 32,465,385-32,532,311 32,465,385-32,532,311 7.59E-07 20.5 2 20 HLA-DRB5, HLA-DRB6 HLA-DRB5, HLA-DRB6 
Chr 8 39,354,153-39,368,808 39,349,089-39,383,632 2.08E-09 58.5 1 41 ADAM3A ADAM3A 
Chr 9 21,936,953-22,013,183 21,824,934-23,653,364 3.01E-02 11.4 6 <20 
C9orf53, CDKN2A, 
CDKN2B, CDKN2B-AS1 
MTAP, C9orf53, CDKN2A 
CDKN2B, CDKN2B-AS1, DMRTA1, FLJ35282 
Chr 10 
70,612,594-70,641,422 70,117,022-70,813,318 1.85E-04 16.9 9 43 STOX1 
RUFY2, DNA2, SLC25A16, TET1, SNORD98, CCAR1, STOX1, 
DDX50, DDX21 
21,824,360-21,930,936 21,824,360-21,930,936 5.43E-04 15.8 1 39 MLLT10 MLLT10 
Chr 11 
55,393,589-55,416,668 55,381,793-55,444,601 8.32E-07 20.5 3 26 OR4P4 OR4P4, OR4S2, OR4C6 
134,790,729-135,006,516 128,837,921-135,006,516 1.31E-03 14.9 29 36 - 
ARHGAP32, BARX2, TMEM45B, NFRKB, PRDM10, LINC00167, 
APLP2, ST14, ZBTB44, ADAMTS8, ADAMTS15, C11orf44, 
SNX19, NTM, OPCML, SPATA19, MIR4697, LOC283174, IGSF9B, 
LOC100128239, JAM3, NCAPD3, VPS26B, THYN1, ACAD8, 
GLB1L3, GLB1L2, B3GAT1, LOC283177 
9,291,259-9,433,407 9,230,469-9,519,928 1.25E-02 12.3 6 32 TMEM41B, IPO7 
DENND5A, TMEM41B, IPO7, SNORA23, LOC644656, ZNF143 
 
Chr 13 48,992,576-49,034,756 48,413,942-49,467,005 2.08E-09 35.5 11 49 RB1, LPAR6 
SUCLA2, NUDT15, MED4-AS1, MED4, ITM2B, LINC00441, RB1, 
LPAR6, RCBTB2, LINC00462, CYSLTR2 
Chr 14 20,224,270-20,369,804 19,376,762-20,420,707 1.74E-02 11.9 15 38 
OR4M1 
OR4N2 
OR4K2 
OR11H12, LOC642426, POTEG, LINC00516, LOC101101776, 
LINC00516, LOC101101776, POTEM, OR11H2, OR4Q3, OR4M1, 
OR4N2, OR4K2, OR4K5, OR4K1 
Chr 15 22,505,176-22,534,833 22,497,998-22,662,192 1.48E-02 12.1 1 32 - REREP3 
Chr 16 74,366,198-74,436,209 73,260,280-74,790,855 1.72E-03 14.6 8 31 LOC283922 
LOC100506172, PSMD7, LOC283922, CLEC18B, GLG1, RFWD3, 
MLKL, FA2H 
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 Peak Region Extended Region Q-Bound G-Score 
No of 
Genes 
Frequency 
% 
Genes in Peak All genes 
Chr 17 
7,611,407-7,618,079 7,111,674-7,650,119 1.34E-05 18.7 50 31 EFNB3 
DLG4, ACADVL, MIR324, DVL2, PHF23, GABARAP, CTDNEP1, 
ELP5, CLDN7, SLC2A4, YBX2, EIF5A, GPS2, NEURL4, ACAP1, 
KCTD11, TMEM95, TNK1, PLSCR3, C17orf61-PLSCR3, 
TMEM256, NLGN2, SPEM1, C17orf74, TMEM102, FGF11, 
CHRNB1, ZBTB4, SLC35G6, POLR2A, TNFSF12, TNFSF12-
TNFSF13, TNFSF13, SENP3, SENP3-EIF4A1, SNORA48, EIF4A1, 
SNORD10, SNORA67, CD68, MPDU1, SOX15, FXR2, SHBG, 
SAT2, ATP1B2, TP53, WRAP53, EFNB3, DNAH2 
35,710,467-35,718,781 35,672,592-35,819,066 7.64E-03 12.9 3 35 ACACA ACACA, C17orf78, TADA2A 
Chr 18 77,944,237-78,077,248 77,622,155-78,077,248 1.70E-02 12.0 8 22 PARD6G 
KCNG2, PQLC1, HSBP1L1, TXNL4A, RBFA, ADNP2, PARD6G-
AS1, PARD6G 
Chr 19 54,235,078-54,300,229 52,885,325-55,554,280 1.23E-02 12.3 146 45 
MIR518D 
MIR516B1 
MIR518A2 
MIR517C 
MIR520H 
MIR521-1 
MIR522 
MIR519A1 
MIR527 
MIR516A1 
MIR1283-2 
MIR516A2 
MIR519A2 
MIR371A 
MIR371B 
MIR372 
MIR373 
NLRP12 
ZNF880, ZNF528, ZNF534, ZNF578, ZNF808, ZNF701, ZNF137P, 
ZNF83, ZNF611, ZNF600, ZNF28, ZNF468, ZNF320, ZNF321P, 
ZNF816-ZNF321P, ZNF816, ZNF702P, ERVV-1, ERVV-2, ZNF160, 
ZNF415, ZNF347, ZNF665, ZNF818P, ZNF677, VN1R2, VN1R4, 
FAM90A27P, BIRC8, ZNF845, ZNF525, ZNF765, TPM3P9, 
ZNF761, ZNF813, ZNF331, LOC284379, DPRX, MIR512-1, 
MIR512-2, MIR512-1, MIR512-2, MIR1323, MIR498, MIR520E, 
MIR515-1, MIR515-2, MIR519E, MIR520F, MIR515-1, MIR515-2, 
MIR519C, MIR1283-1, MIR520A, MIR526B, MIR519B, MIR525, 
MIR523, MIR518F, MIR520B, MIR518B, MIR526A1, MIR520C, 
MIR518C, MIR524, MIR517A, MIR519D, MIR521-2, MIR520D, 
MIR517B, MIR520G, MIR516B2, MIR526A2, MIR518E, MIR518A1, 
MIR518D, MIR516B1, MIR518A2, MIR517C, MIR520H, MIR521-1, 
MIR522, MIR519A1, MIR527, MIR516A1, MIR1283-2, MIR516A2, 
MIR519A2, MIR371A, MIR371B, MIR372, MIR373, NLRP12, 
MYADM, PRKCG, CACNG7, CACNG8, MIR935, CACNG6, 
VSTM1, TARM1, OSCAR, NDUFA3, TFPT, PRPF31, CNOT3, 
LENG1, TMC4, MBOAT7, TSEN34, RPS9, LILRB3, LILRA6, 
LILRB5, LILRB2, MIR4752, LILRA3, LILRA5, LILRA4, LAIR1, 
TTYH1, LENG8, LENG9, CDC42EP5, LAIR2, KIR3DX1, LILRA2, 
LILRA1, LILRB1, LILRB4, LILRP2, KIR3DL3, KIR2DL3, KIR2DL1, 
LOC100287534, KIR2DL4, KIR3DL1, KIR2DS4, KIR3DL2, FCAR, 
NCR1, NLRP7, RNU6-35, RNU6-64, NLRP2, GP6 
Chr 21 11,066,993-11,132,953 10,948,745-11,132,953 9.58E-03 12.6 5 28 
BAGE, BAGE2, BAGE3, 
BAGE4, BAGE5 
BAGE, BAGE2, BAGE3, BAGE4, BAGE5 
Chr 22 24,342,813-24,398,622 24,342,813-24,398,622 7.25E-07 20.6 5 <20 
GSTTP1, LOC3913, 22, 
GSTT1, GSTTP2 
GSTTP1, LOC3913, 22, GSTT1, GSTTP2 
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Cytoband Region Length (Mb) 
Freq 
% 
P-Value 
Gene 
Count 
Genes % of CNV Overlap 
Chr 1 
p12 - p11.2 120,563,106-120,756,223 0.19 48 0.0E+00 1 NOTCH2 100 
q21.1 144,009,907-144,995,110 0.99 71 0.0E+00 8 
NBPF9, PDE4DIP, PFN1P2, PPIAL4A, PPIAL4B, 
PPIAL4C, SRGAP2B 
100 
q21.1 145,112,508-145,278,200 0.17 76 0.0E+00 2 NOTCH2NL, SEC22B 100 
q21.2 149,311,087-149,596,705 0.29 62 1.6E-02 6 
FAM91A2, FCGR1C, HIST2H2BF, PPIAL4A, PPIAL4B, 
PPIAL4C 
100 
q21.2 149,818,426-149,873,111 0.05 62 1.6E-02 11 
BOLA1, HIST2H2AA3, HIST2H2AA4, HIST2H2AB, 
HIST2H2AC, HIST2H2BC, HIST2H2BE, HIST2H3A, 
HIST2H3C, HIST2H4A, HIST2H4B 
100 
q21.3 154,899,255-154,958,577 0.06 62 1.6E-02 6 CKS1B, FLAD1, PBXIP1, PMVK, PYGO2, SHC1 0 
q22 155,177,125-155,253,539 0.08 62 1.6E-02 8 
CLK2, FAM189B, GBA, GBAP1, HCN3, MTX1, 
SCAMP3, THBS3 
100 
q22 155,894,065-156,045,700 0.15 62 1.6E-02 8 
ARHGEF2, LAMTOR2, MEX3A, RAB25, RXFP4, 
SCARNA4, SSR2, UBQLN4 
16 
q24.2 168,235,779-168,258,696 0.02 62 1.6E-02 1 TBX19 100 
Chr 2 
q22.3 145,162,871-145,304,149 0.14 29 1.6E-02 1 ZEB2 3 
p22.2 37,823,758-38,245,167 0.42 33 9.0E-03 2 CDC42EP3, FAM82A1 75 
q11.2 97,527,264-97,623,299 0.01 38 0.0E+00 2 FAM178B, SEMA4C 54 
q13.13 048,766,079-49,005,661 0.24 52 0.0E+00 3 CEBPB, TMEM189, TMEM189-UBE2V1 65 
Chr 3 q26.31 171,958,976-172,051,964 0.09 52 3.0E-03 1 FNDC3B 0 
Chr 5 
p13.2 37,012,156-37,067,386 0.06 52 1.5E-02 1 NIPBL 0 
q11.2 54,728,700-54,928,310 0.20 43 4.3E-02 3 PPAP2A, RNF138P1, SLC38A9 70 
q12.3 64,264,133-64,412,850 0.15 43 4.3E-02 1 CWC27 1 
q13.1 67,067,899-67,548,574 0.48 43 4.3E-02 1 PIK3R1 18 
q13.2 71,430,376-71,606,831 0.18 48 1.0E-03 2 MAP1B, MRPS27 6 
q14.3 90,402,321-90,686,262 0.28 48 1.0E-03 2 ARRDC3, GPR98 8 
q32 148,717,819-148,929,994 0.21 43 4.3E-02 5 AFAP1L1, CSNK1A1, GRPEL2, IL17B, PCYOX1L 55 
Chr 6 p22.2 26,124,423-26,259,251 0.13 38 7.0E-03 17 
HIST1H1D, HIST1H1E, HIST1H2AC, HIST1H2AD, 
HIST1H2AE, HIST1H2BD, HIST1H2BE, HIST1H2BF, 
HIST1H2BG, HIST1H2BH, HIST1H3D, HIST1H3E, 
HIST1H3F, HIST1H4D, HIST1H4E, HIST1H4F, 
HIST1H4G 
47 
Chr 9 
p22.1 19,095,812-19,317,927 0.22 29 3.3E-02 3 DENND4C, HAUS6, PLIN2 100 
q22.31 94,034,499-94,186,403 0.15 38 1.2E-02 2 AUH, NFIL3 36 
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Cytoband Region Length (Mb) 
Freq 
% 
P-Value 
Gene 
Count 
Genes % of CNV Overlap 
Chr 11 
p13 135,110,040-35,316,017 0.20 29 6.0E-03 2 CD44, SLC1A2 63 
q12.3 162,314,338-62,641,063 0.33 24 3.0E-03 35 
B3GAT3, BSCL2, EEF1G, EML3, GANAB, GNG3, 
HNRNPUL2, HNRNPUL2-BSCL2, INTS5, LRRN4CL, 
METTL12,  MTA2, NXF1, POLR2G, ROM1, SLC3A2, 
SNHG1, SNORA57, SNORD22, SNORD25, SNORD26, 
SNORD27, SNORD28, SNORD29, SNORD30, 
SNORD31, STX5, TAF6L, TMEM179B, TMEM223, 
TTC9C, TUT1, UBXN1, WDR74, ZBTB3 
85 
Chr 12 q24.11 2109,123,797-109,147,883 0.02 33 4.0E-03 1 CORO1C 0 
Chr 13 q34 3110,918,305-111,046,505 0.13 43 0.0E+00 2 COL4A1, COL4A2 8 
Chr 14 
q22.1 451,964,027-52,127,715 0.16 57 2.0E-03 1 FRMD6 5 
q24.1 469,144,273-69,519,867 0.38 57 2.0E-03 3 ACTN1,  DCAF5, ZFP36L1 2 
Chr 16 
q22.1 669,228,790-69,753,047 0.52 29 4.3E-02 10 
COG8, CYB5B, NFAT5, NIP7, NQO1, PDF, SNTB2, 
TERF2, TMED6, VPS4A 
18 
q22.3 672,964,471-73,143,118 0.18 33 1.0E-03 2 HTA, ZFHX3 28 
q24.1 684,963,962-85,068,069 0.10 33 1.0E-03 1 ZDHHC7 3 
Chr 17 
q22 755,948,928-56,056,018 0.11 38 2.3E-02 2 CUEDC1, VEZF1 40 
q23.1 757,816,707-57,935,524 0.12 38 2.3E-02 1 VMP1 2 
Chr 19 p13.11 918,429,433-18,583,639 0.15 48 3.0E-03 7 
ELL, GDF15, ISYNA1, LRRC25, LSM4,, PGPEP1, 
SSBP4 
0 
Chr 22 q12.3 236,665,486-36,786,805 0.12 48 1.3E-02 1 MYH9 45 
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 Cytoband Region 
Length 
(Mb) 
Freq 
% 
P-Value 
Gene 
Count 
Genes 
% of CNV 
Overlap 
Chr 1 
p36.33 1,075,323-1,151,667 0.08 62 0.00E+00 3 TNFRSF18, TNFRSF4, TTLL10 100 
p36.33 1,870,020-2,195,283 0.33 38 9.00E-03 3 GABRD,  PRKCZ, SKI 88 
p36.32 2,472,466-2,539,213 0.07 52 0.00E+00 3 FAM213B, MMEL1, TNFRSF14 100 
p36.32 3,184,391-3,448,830 0.26 48 0.00E+00 3 ARHGEF16, MEGF6, PRDM16 100 
p36.32 4,793,782-5,354,520 0.56 38 9.00E-03 1 AJAP1 26 
q44 248,983,071-249,250,621 0.27 33 0.00E+00 4 
PGBD2, SH3BP5L, ZNF672, 
ZNF692 
78 
Chr 2 
q36.3 229,013,827-229,907,621 0.89 48 2.40E-02 2 PID1, SPHKAP 10 
q36.3 230,795,681-230,895,774 0.10 48 2.40E-02 1 FBXO36 100 
q37.1 233,213,865-233,427,159 0.21 52 1.00E-03 10 
ALPI, ALPP, ALPPL2, CHRND, 
CHRNG, ECEL1, ECEL1P2, 
EIF4E2, PRSS56, TIGD1 
99 
q37.1 233,903,041-234,336,019 0.43 48 2.40E-02 6 
ATG16L1, DGKD, INPP5D, SAG, 
SCARNA5, SCARNA6 
13 
q37.1 234,507,893-235,056,307 0.55 48 2.40E-02 14 
DNAJB3, HJURP,  MSL3P1, SPP2, 
TRPM8, UGT1A1, UGT1A10, 
UGT1A3, UGT1A4, UGT1A5, 
UGT1A6, UGT1A7, UGT1A8, 
UGT1A9 
16 
q37.2 235,880,185-236,368,103 0.49 52 1.00E-03 1 SH3BP4 0 
q37.3 241,538,072-241,782,200 0.24 57 0.00E+00 5 
AQP12A, AQP12B, CAPN10, 
GPR35, KIF1A 
100 
q37.3 242,503,450-242,825,417 0.32 57 0.00E+00 10 
ATG4B, BOK, CXXC11, D2HGDH, 
DTYMK, GAL3ST2, ING5, NEU4, 
PDCD1, THAP4 
100 
Chr 4 p16.1 8,771,782-8,886,137 0.11 33 2.00E-03 1 HMX1 100 
Chr 6 p25.3 1,696,679-1,919,998 0.22 38 1.90E-02 1 GMDS 0 
Chr 8 q24.3 143,656,045-144,082,427 0.43 33 1.90E-02 12 
ARC, CYP11B1, CYP11B2, GML, 
JRK, LY6D, LY6K, LYNX1, LYPD2, 
PSCA, SLURP1, THEM6 
71 
Chr 9 
q34.11 - q34.12 133,145,616-133,553,257 0.41 43 3.80E-02 3 ASS1, FUBP3, PRDM12 41 
q34.3 137,870,941-138,031,761 0.16 48 2.00E-03 1 OLFM1 6 
q34.3 140,630,365-140,833,019 0.20 57 0.00E+00 2 CACNA1B, EHMT1 33 
Chr 11 p15.5 1975,029-1,093,963 0.12 43 3.00E-03 3 AP2A2, MUC2, MUC6 100 
Chr 12 p13.31 27,796,205-7,921,641 0.13 38 2.60E-02 5 
APOBEC1, CLEC4C, DPPA3, 
GDF3, NANOGNB 
100 
Chr 14 q32.33 4104,561,057-104,763,502 0.20 33 2.00E-03 2 ASPG, KIF26A 70 
Chr 19 p13.3 90-307,937 0.31 29 2.00E-03 6 
FAM138A, FAM138F,  MIER2, 
OR4F17, PPAP2C, WASH5P 
80 
Chr 20 
q13.33 060,072,327-60,546,948 0.47 29 0.00E+00 1 CDH4 48 
q13.33 061,064,386-61,378,893 0.31 24 2.30E-02 2 NTSR1, SLCO4A1 100 
q13.33 061,638,941-61,818,375 0.18 24 2.30E-02 2 HAR1A, HAR1B, 100 
q13.33 062,844,161-63,025,520 0.18 33 0.00E+00 2 MYT1, PCMTD2 67 
Chr 21 q22.3 145,818,895-45,951,075 0.13 33 0.00E+00 3 LRRC3, TRPM2, TSPEAR 100 
Chr 22 q13.32 249,017,773-49,105,738 0.09 52 0.00E+00 1 FAM19A5 45 
      113   
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 Peak Region Extended Region 
Length 
(Mb) 
Freq 
(%) 
G-Score Q-Bound 
No. of 
Genes 
Genes in Peak All Genes 
Chr 1 
145,112,508 - 145,278,200 144,009,907 - 145,492,482 1.48 81 6.848 0.035 15 
SEC22B 
NOTCH2NL 
SRGAP2B, PPIAL4B, PPIAL4C, PPIAL4A, PFN1P2, 
NBPF9, PDE4DIP, SEC22B, NOTCH2NL, NBPF10, HFE2, 
TXNIP, POLR3GL, ANKRD34A, LIX1L 
230,350,913 - 230,412,939 228,255,947 - 231,657,562 3.40 24 6.493 0.049 36 GALNT2 
ARF1, MRPL55, GUK1, GJC2, IBA57, OBSCN, TRIM11, 
TRIM17, HIST3H3, HIST3H2A, HIST3H2BB, RNF187, 
DUSP5P1, RHOU, RAB4A, SPHAR, CCSAP, ACTA1, 
NUP133 
ABCB10, TAF5L, URB2 
GALNT2, PGBD5, COG2 
AGT, CAPN9, TTC13, ARV1, FAM89A, TRIM67,GNPAT, 
EXOC8, SPRTN, EGLN1, SNRPD2P2 
Chr 3 162,504,616 - 162,630,126 150,855,624 - 165,822,232 14.97 67 7.412 0.022 55 - 
GPR171, P2RY14, MED12L, GPR87, P2RY13, P2RY12, 
IGSF10, AADACL2, AADAC, SUCNR1, MBNL1-AS1, 
TMEM14E, MBNL1, P2RY1, RAP2B, ARHGEF26-AS1, 
ARHGEF26, DHX36, GPR149, MME, PLCH1, SLC33A1, 
GMPS, KCNAB1-AS2, KCNAB1, KCNAB1-AS1, SSR3, 
TIPARP-AS1, TIPARP, PA2G4P4, LEKR, CCNL1, VEPH1, 
PTX3, SHOX2, RSRC1, MLF1, GFM1, LXN, RARRES1, 
MFSD1, IQCJ, IQCJ-SCHIP1, SCHIP1, IL12A, IFT80, 
SMC4, TRIM59, SCARNA7, KPNA4, ARL14, PPM1L, 
B3GALNT1, NMD3, SPTSSB, OTOL1, CT64, SI, SLITRK3, 
BCHE 
Chr 14 22,588,308 - 22,958,571 22,394,168 - 23,535,702 1.14 76 6.643 0.040 16 - 
DAD1, ABHD4, OXA1L, SLC7A7, MRPL52, MMP14, 
LRP10, REM2, RBM23, PRMT5, HAUS4, AJUBA, PSMB5, 
PSMB11, CDH24, ACIN1 
Chr 17 12,159,777 - 12,638,186 11,235,749 - 14,746,194 3.51 43 8.084 0.017 13 
SHISA6, DNAH9, ZNF18, MAP2K4, 
MYOCD, ARHGAP44, ELAC2, 
HS3ST3A1, CDRT15P1, COX10-
AS1, COX10, CDRT15, 
MGC12916, HS3ST3B1 
SHISA6, DNAH9, ZNF18, MAP2K4, MYOCD, ARHGAP44, 
ELAC2, HS3ST3A1, CDRT15P1, COX10-AS1, COX10, 
CDRT15, MGC12916, HS3ST3B1 
       135   
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 Peak Region Extended Region 
Length 
(Mb) 
Freq 
(%) 
Q-Bound G-Score 
No. of 
Genes 
Genes in Peak All Genes 
Chr 1 3,277,968 - 3,402,895 2,285,830 - 4,637,196 2.35 48 0.002 9.69 23 PRDM16, ARHGEF16 
MORN1, RER1, PEX10, PLCH2, PANK4, HES5, TNFRSF14, FAM213B, 
MMEL1, TTC34, ACTRT2, FLJ42875, PRDM16, ARHGEF16, MEGF6, 
TPRG1L, WRAP73, TP73, TP73-AS1, CCDC27, SMIM1, LRRC47, CEP104, 
DFFB 
Chr 2 242,989,305 - 243,199,373 233,732,597 - 243,199,373 9.47 67 0.000 13.59 88 - 
NGEF, NEU2, INPP5D, ATG16L1, SCARNA5, SCARNA6, SAG, DGKD, 
USP40, UGT1A8, UGT1A10, UGT1A9, UGT1A7, UGT1A6, UGT1A5, 
DNAJB3, UGT1A4, UGT1A3, UGT1A1, HJURP, MSL3P1, TRPM8, SPP2, 
ARL4C, SH3BP4, AGAP1, GBX2, ASB18, IQCA1, CXCR7, COPS8, COL6A3, 
MLPH, PRLH, RAB17, LRRFIP1, RBM44, RAMP1, UBE2F, UBE2F-SCLY, 
SCLY, ESPNL, KLHL30, ILKAP, HES6, PER2, TRAF3IP1, ASB1, TWIST2, 
FLJ43879, MGC16025, HDAC4, NDUFA10, OR6B2, PRR21, OR6B3, 
MYEOV2, OTOS, GPC1, PP14571, ANKMY1, DUSP28, RNPEPL1, CAPN10, 
GPR35, AQP12B, AQP12A, KIF1A, AGXT, SNED1, MTERFD2, PASK, 
PPP1R7, ANO7, HDLBP, SEPT2, FARP2, STK25, BOK-AS1, BOK, THAP4, 
ATG4B, DTYMK, ING5, D2HGDH, GAL3ST2, NEU4, PDCD1, CXXC11 
Chr 10 89,569,335 - 90,067,948 81,212,702 - 99,855,478 18.64 52 0.030 7.97 133 
ATAD1, CFL1P1, 
KLLN, PTEN, RNLS 
EIF5AL1, SFTPA2, SFTPA1, MBL1P, SFTPD, TMEM254-AS1, TMEM254, 
PLAC9, ANXA11, MAT1A, DYDC1, DYDC2, FAM213A, TSPAN14, SH2D4B, 
NRG3, GHITM, CDHR1, LRIT2, LRIT1, RGR, CCSER2, GRID1-AS1, GRID1, 
WAPAL, OPN4, LDB3, BMPR1A, MMRN2, SNCG, AGAP11, FAM25A, 
GLUD1, FAM35A, FAM22A, FAM22D, MINPP1, PAPSS2, ATAD1, CFL1P1, 
KLLN, PTEN, RNLS, LIPJ, LIPF, LIPK, LIPN, LIPM, ANKRD22, STAMBPL1, 
ACTA2, FAS-AS1, FAS, CH25H, LIPA, IFIT2, IFIT3, IFIT1B, IFIT1, IFIT5, 
SLC16A12, PANK1, FLJ37201, KIF20B, HTR7, RPP30, ANKRD1, NUDT9P1, 
PCGF5, HECTD2, PPP1R3C, TNKS2, FGFBP3, BTAF1, CPEB3, MARCH5, 
MARK2P9, IDE, KIF11, HHEX, EXOC6, CYP26C1, CYP26A1, MYOF, CEP55, 
FFAR4, RBP4, PDE6C, FRA10AC1, LGI1, SLC35G1, PIPSL, PLCE1, NOC3L, 
TBC1D12, HELLS, CYP2C18, CYP2C19, CYP2C9, CYP2C8, PDLIM1, 
SORBS1, ALDH18A1, TCTN3, ENTPD1, LOC728558, C10orf131, CC2D2B, 
CCNJ, MIR3157, ZNF518A, BLNK, DNTT, OPALIN, TLL2, TM9SF3, PIK3AP1, 
LCOR, C10orf12, SLIT1, LOC100505540, ARHGAP19-SLIT1, ARHGAP19, 
FRAT1, FRAT2, RRP12, PGAM1, EXOSC1, ZDHHC16, MMS19, UBTD1, 
ANKRD2, C10orf62, MIR5692C2, HOGA1, MORN4, PI4K2A, AVPI1, 
MARVELD1, ZFYVE27, SFRP5, GOLGA7B, CRTAC1 
Chr 13 49,838,258 - 50,073,617 46,723,507 - 53,957,341 7.23 67 0.000 18.78 53 
CDADC1, CAB39L, 
SETDB2, PHF11 
LCP1, LRCH1, ESD, HTR2A, SUCLA2, NUDT15, MED4-AS1, MED4, ITM2B, 
RB1, LPAR6, RCBTB2, CYSLTR2, FNDC3A, MLNR, CDADC1, CAB39L, 
SETDB2, PHF11, RCBTB1, ARL11, EBPL, KPNA3, CTAGE10P, SPRYD7, 
TRIM13, KCNRG, DLEU2, DLEU1, ST13P4, DLEU7, DLEU7-AS1, 
RNASEH2B-AS1, RNASEH2B, GUCY1B2, FAM124A, SERPINE3, INTS6, 
WDFY2, DHRS12, CCDC70, ATP7B, ALG11, UTP14C, NEK5, NEK3, 
MRPS31P5, THSD1, VPS36, CKAP2, TPTE2P3, HNRNPA1L2, SUGT1, 
LECT1, PCDH8, OLFM4 
Chr 17 7,565,085 - 7,618,079 7,111,674 - 7,650,119 0.05 52 0.000 11.18 47 
TP53, WRAP53, 
EFNB3 
DLG4, ACADVL, DVL2, PHF23, GABARAP, CTDNEP1, ELP5, CLDN7, 
SLC2A4, YBX2, EIF5A, GPS2, NEURL4, ACAP1, KCTD11, TMEM95, TNK1, 
PLSCR3, PLSCR3, TMEM256, NLGN2, SPEM1, TMEM102, FGF11, 
CHRNB1, ZBTB4, SLC35G6, POLR2A, TNFSF12, TNFSF12-TNFSF13, 
TNFSF13, SENP3, SENP3-EIF4A1, SNORA48, EIF4A1, SNORD10, 
SNORA67, CD68, MPDU1, SOX15, FXR2, SHBG, SAT2, ATP1B2, TP53, 
WRAP53, EFNB3, DNAH2 
       344   
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Category Term Count 
Fisher  
p-value 
EASE  
p-value 
Genes 
Fold 
Enrichment 
BIOCARTA 
h_akap13Pathway 
Rho-Selective Guanine Exchange Factor 
AKAP13 Mediates Stress Fiber Formation 
4 2.90E-03 2.65E-02 PRKAR2A, AKAP13, PRKACA, LPAR1 5.59 
BIOCARTA 
h_pelp1Pathway 
Pelp1 Modulation of Estrogen Receptor Activity 4 2.90E-03 2.65E-02 MAPK1, CREBBP, ESR1, SRC 5.59 
BIOCARTA 
h_nthiPathway 
NFkB activation by Nontypeable Hemophilus 
influenzae 
10 5.20E-05 3.12E-04 
TNF, MYD88, DUSP1, MAP2K3, CREBBP, TGFBR2, SMAD3, NFKBIA, 
NR3C1, IKBKB 
4.07 
BIOCARTA 
h_cdMacPathway 
Cadmium induces DNA synthesis and 
proliferation in macrophages 
5 6.80E-03 3.53E-02 MAPK1, FOS, TNF, JUN, NFKBIA 3.76 
BIOCARTA 
h_etsPathway 
METS affect on Macrophage Differentiation 6 3.50E-03 1.75E-02 FOS, ETS2, JUN, DDX20, NCOR2, ETV3 3.67 
BIOCARTA 
h_il6Pathway 
IL 6 signaling pathway 7 1.80E-03 8.79E-03 FOS, CEBPB, GRB2, JUN, SHC1, IL6R, SRF 3.60 
BIOCARTA 
h_ecmPathway 
Erk and PI-3 Kinase Are Necessary for Collagen 
Binding in Corneal Epithelia 
8 9.10E-04 4.45E-03 
MAPK1, ARHGAP5, ROCK1, ROCK1P1, DIAPH1, FYN, SHC1, SRC, 
MYLK 
3.55 
BIOCARTA 
h_ptenPathway 
PTEN dependent cell cycle arrest and apoptosis 7 4.60E-03 1.87E-02 MAPK1, GRB2, BCAR1, PIK3CA, SHC1, FOXO3B, PIK3R1 3.11 
BIOCARTA 
h_insulinPathway 
Insulin Signaling Pathway 6 9.10E-03 3.63E-02 FOS, GRB2, JUN, SHC1, SRF, INSR 3.09 
BIOCARTA 
h_pyk2Pathway 
Links between Pyk2 and Map Kinases 8 3.10E-03 1.21E-02 MAPK1, GNAQ, GRB2, JUN, MAP2K3, BCAR1, SHC1, SRC 3.01 
BIOCARTA 
h_rhoPathway 
Rho cell motility signaling pathway 7 7.90E-03 2.85E-02 
ARHGAP5, ROCK1, ROCK1P1, DIAPH1, PIP5K1B, SRC, MYLK, 
ARHGEF11 
2.85 
KEGG 
hsa05020 
Prion diseases 10 2.30E-03 8.02E-03 
PRKACG, NCAM2, MAPK1, C7, FYN, C6, PRKACA, HSPA1A, LAMC1, 
HSPA5, HSPA1B 
2.74 
BIOCARTA 
h_carm-erPathway 
CARM1 and Regulation of the Estrogen 
Receptor 
7 1.00E-02 3.44E-02 MEF2C, GTF2E1, RLN3, CREBBP, ESR1, NCOR2, NRIP1 2.74 
KEGG 
hsa04320 
Dorso-ventral axis formation 7 1.20E-02 3.94E-02 NOTCH3, MAPK1, NOTCH2, HSD3B7, GRB2, ETS2, SOS2 2.68 
BIOCARTA 
h_egfPathway 
EGF Signaling Pathway 7 1.30E-02 4.11E-02 FOS, GRB2, JUN, PIK3CA, SHC1, SRF, PIK3R1 2.63 
BIOCARTA 
h_integrinPathway 
Integrin Signaling Pathway 9 5.40E-03 1.71E-02 
MAPK1, ROCK1, GRB2, ROCK1P1, FYN, JUN, BCAR1, RAP1A, SHC1, 
SRC 
2.59 
KEGG 
hsa04130 
SNARE interactions in vesicular transport 10 4.50E-03 1.40E-02 
STX5, STX4, VAMP8, STX18, VAMP5, USE1, SEC22B, VAMP2, STX1B, 
STX10 
2.52 
KEGG 
hsa05322 
Systemic lupus erythematosus 25 1.80E-05 5.31E-05 
HIST1H2AC, C7, HIST2H2AA3, HIST2H2AA4, TNF, HIST1H4K, 
HIST1H2AD, C6, HIST1H2AE, HIST2H4A, HIST2H4B, HIST2H2AB, 
HIST1H2BM, HIST1H2BN, FCGR1C, HIST1H2BL, HIST2H2AC, 
HIST1H4E, HIST1H4F, HIST1H4D, HIST3H3, HIST1H4J, HIST1H4G, 
HIST2H3A, HIST1H2BD, HIST1H2BE, HIST1H2BF, HIST1H2BG, 
HIST1H2BH, GRIN2A, ACTN1, HIST2H3C, HIST2H2BE, HIST2H2BF, 
HIST1H2AI, HIST1H2AK, HIST1H3D, HIST1H3E, HIST1H2AJ, HIST1H3F, 
HIST1H3H 
2.42 
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Category Term Count 
Fisher  
p-value 
EASE  
p-value 
Genes 
Fold 
Enrichment 
KEGG 
hsa05222 
Small cell lung cancer 21 9.90E-05 2.87E-04 
E2F2, CKS1B, FHIT, COL4A2, COL4A1, PTGS2, RXRB, NFKBIA, BCL2L1, 
CCNE1, LAMA4, LAMA3, BCL2, PIK3CA, LAMC2, RARB, LAMC1, IKBKB, 
MYC, PIK3R1, TRAF4 
2.39 
BIOCARTA 
h_pparaPathway 
Mechanism of Gene Regulation by Peroxisome 
Proliferators via PPARa(alpha) 
10 7.60E-03 2.14E-02 
TNF, DUSP1, JUN, CREBBP, NFKBIA, HSPA1A, HSPA1B, NCOR1, 
NCOR2, NR2F1, NRIP1 
2.33 
KEGG 
hsa04512 
ECM-receptor interaction 19 8.20E-04 2.10E-03 
COL4A2, COL4A1, COL3A1, ITGA11, ITGB5, COL5A2, ITGA9, LAMA4, 
LAMA3, CD44, ITGA5, TNR, COL6A2, COL6A1, LAMC2, LAMC1, THBS2, 
THBS3, THBS4 
2.17 
KEGG 
hsa05220 
Chronic myeloid leukemia 16 3.90E-03 9.34E-03 
E2F2, GRB2, TGFBR2, NFKBIA, SMAD3, BCL2L1, MAPK1, CBLB, SOS2, 
PIK3CA, SHC1, IKBKB, SHC3, MYC, PIK3R1, SHC4 
2.04 
KEGG 
hsa05223 
Non-small cell lung cancer 11 2.20E-02 4.95E-02 
FHIT, E2F2, MAPK1, GRB2, RXRB, RASSF1, SOS2, PIK3CA, RARB, 
FOXO3B, PIK3R1 
1.95 
KEGG 
hsa04510 
Focal adhesion 40 3.40E-05 7.42E-05 
CAV2, DIAPH1, GRB2, BCAR1, COL3A1, ITGA11, ITGB5, SRC, 
ARHGAP5, TNR, BCL2, SOS2, COL6A2, PIK3CA, COL6A1, SHC1, SHC3, 
THBS2, THBS3, PIK3R1, SHC4, THBS4, COL4A2, COL4A1, VAV3, 
ROCK1, MYLPF, ACTN1, COL5A2, MAPK1, ITGA9, LAMA4, LAMA3, FYN, 
ITGA5, ROCK1P1, JUN, RAP1A, LAMC2, LAMC1, MYLK 
1.91 
BIOCARTA 
h_mapkPathway 
MAPKinase Signaling Pathway 15 1.20E-02 2.63E-02 
GRB2, MAP2K3, NFKBIA, MAPKAPK2, DAXX, RPS6KA5, FOS, MAPK1, 
MAP4K5, MAP3K4, MAPK6, JUN, SHC1, MAPK7, IKBKB 
1.83 
KEGG 
hsa04660 
T cell receptor signaling pathway 19 1.50E-02 2.91E-02 
PTPRC, ITK, TNF, VAV3, GRB2, NFKBIA, MAPK1, FOS, CBLB, FYN, JUN, 
NCK1, SOS2, NFAT5, PIK3CA, NFATC4, NFATC2, IKBKB, PIK3R1 
1.68 
KEGG 
 hsa04912 
GnRH signaling pathway 17 2.40E-02 4.51E-02 
ADCY4, PLA2G10, GRB2, MAP2K3, ITPR1, SRC, PRKACG, MAPK1, 
PLA2G4A, MAP3K4, GNAQ, ADCY9, JUN, SOS2, PLA2G6, PRKACA, 
MAPK7 
1.66 
KEGG 
hsa04530 
Tight junction 23 1.10E-02 2.00E-02 
PARD6B, CLDN18, MYH15, MAGI1, MYH1, MYH3, MYH2, CSNK2B, 
MYH4, MYLPF, PRKCH, ACTN1, MYH9, MYH8, SRC, CGN, ASH1L, 
MYH11, MYH13, RAB13, PPP2R2C, TJP2, MYH10 
1.64 
KEGG 
hsa04910 
Insulin signaling pathway 23 1.20E-02 2.16E-02 
SREBF1, SOCS3, GRB2, PHKG2, PRKAB2, RHOQ, SOCS4, PCK2, 
PRKACG, MAPK1, PRKAR2A, CBLB, PPP1R3B, SOS2, PIK3CA, 
PRKACA, SHC1, PRKAA1, SHC3, IKBKB, INSR, PIK3R1, SHC4 
1.63 
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Category Term 
Gene 
Count 
Fisher  
p-value 
EASE 
p-value 
Genes 
Fold 
Enrichment 
BIOCARTA 
h_cremPathway 
Regulation of Spermatogenesis by CREM 5 1.20E-04 1.97E-03 XPO1, ADCY1, CREM, FSHB, FSHR 7.66 
BIOCARTA 
h_pmlPathway 
Regulation of transcriptional activity by PML 5 9.10E-03 4.28E-02 SUMO1, TP53, RB1, FAS, SIRT1 3.57 
KEGG 
hsa00040 
Pentose and glucuronate interconversions 6 4.50E-03 2.14E-02 
LOC729020, UGT1A1, UGT1A7, UGT1A10, UGT1A6, UGT2B17, 
UGT1A9, RPE, UGT1A8, UGT1A3, UGT1A5, UGT1A4, UGT2B4, 
UGT2A1, UGT2B15 
3.56 
KEGG 
hsa00140 
Steroid hormone biosynthesis 13 2.00E-04 7.77E-04 
HSD17B2, CYP11B1, CYP11B2, UGT1A1, AKR1C3, UGT1A7, 
AKR1C2, UGT1A10, UGT1A6, CYP17A1, UGT2B17, UGT1A9, 
AKR1C4, UGT1A8, UGT1A3, UGT1A5, UGT1A4, UGT2A1, UGT2B4, 
SRD5A2, UGT2B15 
3.02 
KEGG 
hsa00980 
Metabolism of xenobiotics by cytochrome P450 16 8.30E-05 2.93E-04 
CYP2C19, CYP2C18, CYP2C9, ALDH3B2, CYP2E1, UGT1A1, 
ALDH3B1, AKR1C3, UGT1A7, AKR1C2, UGT1A10, UGT1A6, 
UGT2B17, UGT1A9, AKR1C4, UGT1A8, UGT1A3, UGT1A5, UGT1A4, 
UGT2A1, UGT2B4, UGT2B15, MGST1, GSTP1 
2.85 
KEGG 
hsa00150 
Androgen and estrogen metabolism 9 5.90E-03 1.86E-02 
HSD17B2, CYP11B1, UGT1A1, UGT1A7, UGT1A10, UGT1A6, 
UGT2B17, UGT1A9, AKR1C4, UGT1A8, UGT1A3, UGT1A5, UGT1A4, 
UGT2B4, UGT2A1, SRD5A2, UGT2B15 
2.60 
KEGG 
hsa00982 
Drug metabolism 13 4.10E-03 1.09E-02 
CYP2C19, CYP2C18, CYP2C9, ALDH3B2, CYP2E1, UGT1A1, 
ALDH3B1, UGT1A7, UGT1A10, UGT1A6, UGT2B17, UGT1A9, 
UGT1A8, UGT1A3, UGT1A5, UGT1A4, UGT2A1, UGT2B4, UGT2B15, 
MGST1, GSTP1 
2.24 
KEGG 
hsa00830 
Retinol metabolism 11 1.00E-02 2.58E-02 
BCMO1, CYP2C19, CYP2C18, CYP2C9, UGT1A1, UGT1A7, 
UGT1A10, UGT1A6, DHRS3, UGT2B17, UGT1A9, UGT1A8, UGT1A3, 
UGT1A5, UGT1A4, CYP26B1, UGT2B4, UGT2A1, UGT2B15 
2.18 
KEGG 
hsa04740 
Olfactory transduction 66 2.20E-07 4.63E-07 
OR5C1, OR1A1, OR1A2, OR4D11, OR4D10, OR4C6, OR4S2, 
OR2T10, OR2T11, OR4C11, OR8A1, OR8G1, OR5AN1, OR10S1, 
OR1K1, OR5M1, OR4F17, OR4M2, OR4D9, OR4M1, OR1D2, OR1D5, 
OR4D6, OR1S2, OR1D4, OR1S1, OR4D5, OR6M1, OR8B8, OR4N4, 
OR4N2, OR8B4, OR6Q1, OR8U8, OR1L6, OR1L4, OR5A1, OR5A2, 
OR9Q1, OR10G4, OR1G1, OR9Q2, OR10G7, OR10G8, OR9I1, 
OR10G9, PDE1C, CALML3, OR4Q3, CALML5, OR2T34, OR4K5, 
OR5P3, OR4K2, OR5P2, OR5M10, OR5M11, OR8G2, OR8G5, 
OR6T1, OR4K1, OR8B12, OR10Q1, OR8D1, OR8D2, OR8D4, 
OR4P4, OR6X1 
1.86 
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Table D1:  Differential Amplifications in Leiomyosarcoma compared with other STS subtypes 
 Region 
Cytoband 
Location 
Length 
(Mb) 
Freq. in 
LMS (%) 
Freq. in 
Other 
STS (%) 
Difference q-bound p-value Count Genes 
Chr 1 
203,369,354-203,514,881 q32.1 0.15 52.4 9.4 43.0 0.21 0.0010 2 
PRELP 
OPTC 
183,311,689-183,353,653 q25.3 0.04 57.1 15.6 41.5 0.25 0.0025 1 NMNAT2 
Chr 14 69,333,317-69,519,867 q24.1 0.19 57.1 9.4 47.8 0.18 0.0003 2 
ACTN1 
DCAF5 
Chr 16 15,891,532-15,957,512 p13.11 0.07 52.4 6.3 46.1 0.15 0.0002 1 MYH11 
         6  
 
 
 
 
Table D2:  Differential Deletions in Leiomyosarcoma compared with other STS subtypes 
 Region 
Cytoband 
Location 
Length 
(Mb) 
Freq. in 
LMS (%) 
Freq. in 
Other 
STS (%) 
Difference p-value q-bound Count Genes 
Chr 1 
 1,151,667-1,161,955 p36.33 0.01 57.1 3.1 54.0 0.0000 0.08 1 SDF4 
 3,184,391-3,448,830 p36.32 0.26 47.6 3.1 44.5 0.0002 0.11 3 PRDM16 
Chr 10  103,015,529-103,301,856 q24.32 0.29 61.9 21.9 40.0 0.0045 0.19 1 BTRC 
Chr 11 
 78,557,943-78,714,348 q14.1 0.16 47.6 3.1 44.5 0.0002 0.11 1 TENM4 
 92,589,653-92,644,197 q14.3 0.05 57.1 15.6 41.5 0.0025 0.17 1 FAT3 
         7  
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 Cytoband Region 
Length 
(Mb) 
Frequency 
(%) 
p-value Genes Gene Symbols 
% of CNV 
Overlap 
Chr 1 
q24.2 168,378,978-168,685,455 0.31 27 4.00E-03 3 DPT, XCL1, XCL2 3 
q32.2 207,984,254-208,137,993 0.15 45 0.00E+00 1 CD34 3 
Chr 2 q12.1 - q12.2 105,949,598-106,147,840 0.20 36 0.00E+00 1 FXYD6, FXYD6-FXYD2, TMPRSS13 0 
Chr 5 
p15.33 1,035,059-1,353,444 0.32 45 0.00E+00 6 ANO1, FADD 6 
q31.3 141,696,250-142,040,249 0.34 45 0.00E+00 2 APOLD1, CDKN1B 0 
Chr 6 
p25.2 2,836,816-3,001,306 0.16 36 2.00E-02 6 NCOR2, SCARB1 20 
p22.2 26,124,423-26,250,955 0.13 64 0.00E+00 16 
ALOXE3, AURKB, HES7, PER1, 
TMEM107, VAMP2 
66 
p21.31 34,958,314-35,188,392 0.23 36 2.00E-02 3 
ELL, GDF15, ISYNA1, JUND, 
LRRC25, LSM4, PGPEP1, SSBP4 
12 
Chr 7 q36.1 150,913,717-150,954,753 0.04 45 0.00E+00 3 FHL2 0 
Chr 9 q22.32 97,847,752-98,088,612 0.24 36 7.00E-03 1 
ARFGAP1, BIRC7, CHRNA4, 
COL20A1, EEF1A2, FLJ16779, 
KCNQ2, NKAIN4, YTHDF1 
100 
Chr 11 
q23.3 117,706,762-117,781,447 0.07 36 0.00E+00 3 
CLPTM1L, NKD2, SLC12A7, 
SLC6A18, SLC6A19, TERT 
68 
q13.3 69,906,662-70,052,101 0.15 36 0.00E+00 2 FGF1, SPRY4 4 
Chr 12 
p13.1 12,863,830-12,896,612 0.03 27 0.00E+00 2 
DKFZP686I15217, MGC39372, 
NQO2, SERPINB1, SERPINB6, 
SERPINB9 
7 
q24.31 124,988,479-125,313,180 0.32 27 1.00E-03 2 
HIST1H1D, HIST1H1E, HIST1H2AC, 
HIST1H2AD, HIST1H2AE, 
HIST1H2BD, HIST1H2BE, 
HIST1H2BF, HIST1H2BG, 
HIST1H3D, HIST1H3E, HIST1H3F, 
HIST1H4D, HIST1H4E, HIST1H4F, 
HIST1H4G 
50 
Chr 17 p13.1 8,017,959-8,127,962 0.11 27 2.00E-03 6 ANKS1A, SCUBE3, TCP11 12 
Chr 19 p13.11 18,380,369-18,583,639 0.20 45 0.00E+00 9 ABCF2, CHPF2, SMARCD3 17 
Chr 20 q13.33 61,818,375-62,138,166 0.32 27 1.00E-02 9 FANCC, 22 
      75   
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 Peak Region 
Extended 
Region 
Length 
(Mb) 
Q-Bound G-Score 
No. of 
Genes 
Genes 
in Peak 
Genes 
Chr 1 
72,765,091-
72,812,744 
0-121,322,377 121.30 0.00 4.91 1266 - 
TNFRSF14, PRDM16, RPL22, CAMTA1, SDHB, PAX7, MDS2, ARID1A, LCK, SFPQ, THRAP3, MYCL1, MPL, MUTYH, 
TAL1, STIL, CDKN2C, EPS15, JUN, JAK1, FUBP1, BCL10, BCAR3, RBM15, TRIM33, NRAS, FAM46C, NOTCH2, OR4F5, 
SAMD11, NOC2L, KLHL17, PLEKHN1, C1orf170, HES4, ISG15, AGRN, TTLL10, TNFRSF18, TNFRSF4, SDF4, 
B3GALT6, FAM132A, UBE2J2, SCNN1D, ACAP3, PUSL1, CPSF3L, TAS1R3, DVL1, MXRA8, AURKAIP1, CCNL2, 
MRPL20, VWA1, ATAD3C, ATAD3B, ATAD3A, SSU72, MIB2, MMP23B, CDK11B, CDK11A, SLC35E2, NADK, GNB1, 
CALML6, TMEM52, KIAA1751, GABRD, PRKCZ, C1orf86, SKI, MORN1, RER1, PEX10, PLCH2, PANK4, HES5, MMEL1, 
ACTRT2, ARHGEF16, MEGF6, TPRG1L, WRAP73, TP73, CCDC27, LRRC47, CEP104, DFFB, C1orf174, AJAP1, NPHP4, 
KCNAB2, CHD5, RNF207, ICMT, HES3, GPR153, ACOT7, HES2, ESPN, TNFRSF25, PLEKHG5, NOL9, TAS1R1, 
ZBTB48, KLHL21, PHF13, THAP3, DNAJC11, VAMP3, PER3, UTS2, TNFRSF9, PARK7, ERRFI1, SLC45A1, RERE, 
ENO1, CA6, SLC2A7, SLC2A5, GPR157, H6PD, SPSB1, SLC25A33, TMEM201, C1orf200, PIK3CD, CLSTN1, CTNNBIP1, 
LZIC, NMNAT1, RBP7, UBE4B, KIF1B, PGD, APITD1, CORT, DFFA, PEX14, CASZ1, C1orf127, TARDBP, MASP2, SRM, 
EXOSC10, MTOR, ANGPTL7, UBIAD1, PTCHD2, FBXO2, FBXO44, FBXO6, MAD2L2, AGTRAP, MTHFR, CLCN6, NPPA, 
NPPB, KIAA2013, PLOD1, MFN2, MIIP, TNFRSF8, TNFRSF1B, VPS13D, DHRS3, AADACL4, AADACL3, C1orf158, 
PRAMEF12, PRAMEF1, PRAMEF11, HNRNPCL1, PRAMEF2, PRAMEF4, PRAMEF10, PRAMEF7, PRAMEF22, 
PRAMEF5, PRAMEF3, PRAMEF22, PRAMEF5, PRAMEF13, PRAMEF14, PRAMEF18, PRAMEF20, PRAMEF7, 
PRAMEF14, PRAMEF18, PRAMEF20, PDPN, PRDM2, KAZN, TMEM51, FHAD1, EFHD2, CTRC, CELA2A, CELA2B, 
CASP9, DNAJC16, AGMAT, DDI2, RSC1A1, PLEKHM2, SLC25A34, TMEM82, FBLIM1, SPEN, ZBTB17, C1orf64, HSPB7, 
CLCNKA, CLCNKB, FAM131C, EPHA2, ARHGEF19, RSG1, FBXO42, SPATA21, NECAP2, CROCC, MFAP2, ATP13A2, 
PADI2, PADI1, PADI3, PADI4, PADI6, RCC2, ARHGEF10L, ACTL8, IGSF21, KLHDC7A, TAS1R2, ALDH4A1, UBR4, 
MRTO4, AKR7L, AKR7A3, AKR7A2, PQLC2, CAPZB, NBL1, HTR6, TMCO4, RNF186, OTUD3, PLA2G2E, PLA2G2A, 
PLA2G5, PLA2G2D, PLA2G2F, PLA2G2C, UBXN10, VWA5B1, CAMK2N1, MUL1, FAM43B, CDA, PINK1, DDOST, KIF17, 
SH2D5, HP1BP3, EIF4G3, ECE1, NBPF3, ALPL, RAP1GAP, USP48, LDLRAD2, HSPG2, CELA3B, CELA3A, CDC42, 
WNT4, ZBTB40, EPHA8, C1QA, C1QC, C1QB, EPHB2, KDM1A, LUZP1, HTR1D, HNRNPR, ZNF436, C1orf213, ASAP3, 
E2F2, ID3, RPL11, TCEB3, PITHD1, LYPLA2, GALE, HMGCL, FUCA1, CNR2, PNRC2, MYOM3, IL22RA1, GRHL3, 
NIPAL3, RCAN3, SRRM1, CLIC4, RUNX3, SYF2, C1orf63, RHD, TMEM50A, RHCE, TMEM57, LDLRAP1, MAN1C1, 
SEPN1, PAQR7, STMN1, PAFAH2, EXTL1, SLC30A2, TRIM63, PDIK1L, ZNF593, CNKSR1, CATSPER4, CEP85, 
SH3BGRL3, UBXN11, CD52, AIM1L, ZNF683, LIN28A, DHDDS, HMGN2, RPS6KA1, PIGV, ZDHHC18, SFN, GPN2, 
GPATCH3, NR0B2, NUDC, C1orf172, TRNP1, FAM46B, SLC9A1, WDTC1, TMEM222, SYTL1, MAP3K6, FCN3, CD164L2, 
GPR3, WASF2, AHDC1, FGR, IFI6, FAM76A, STX12, PPP1R8, RPA2, SMPDL3B, XKR8, EYA3, PTAFR, DNAJC8, 
ATPIF1, SESN2, MED18, PHACTR4, RCC1, TRNAU1AP, RAB42, TAF12, GMEB1, YTHDF2, OPRD1, EPB41, 
TMEM200B, SRSF4, MECR, PTPRU, MATN1, LAPTM5, SDC3, PUM1, NKAIN1, SNRNP40, ZCCHC17, FABP3, 
SERINC2, TINAGL1, HCRTR1, PEF1, COL16A1, BAI2, SPOCD1, PTP4A2, KHDRBS1, TMEM39B, KPNA6, TXLNA, 
CCDC28B, IQCC, DCDC2B, TMEM234, EIF3I, FAM167B, HDAC1, MARCKSL1, TSSK3, BSDC1, ZBTB8A, ZBTB8OS, 
RBBP4, SYNC, KIAA1522, YARS, S100PBP, FNDC5, HPCA, TMEM54, RNF19B, AK2, ADC, TRIM62, ZNF362, PHC2, 
ZSCAN20, CSMD2, HMGB4, C1orf94, GJB5, GJB4, GJB3, GJA4, DLGAP3, ZMYM6, ZMYM1, ZMYM4, KIAA0319L, 
NCDN, TFAP2E, PSMB2, C1orf216, CLSPN, EIF2C4, EIF2C1, EIF2C3, TEKT2, ADPRHL2, COL8A2, TRAPPC3, MAP7D1, 
SH3D21, STK40, LSM10, OSCP1, MRPS15, CSF3R, GRIK3, ZC3H12A, MEAF6, SNIP1, DNALI1, GNL2, RSPO1, 
C1orf109, CDCA8, EPHA10, MANEAL, YRDC, C1orf122, MTF1, INPP5B, SF3A3, FHL3, UTP11L, POU3F1, RRAGC, 
MYCBP, GJA9, RHBDL2, AKIRIN1, NDUFS5, MACF1, KIAA0754, BMP8A, PABPC4, HEYL, NT5C1A, HPCAL4, PPIE, 
OXCT2, BMP8B, TRIT1, MFSD2A, CAP1, PPT1, RLF, TMCO2, ZMPSTE24, COL9A2, SMAP2, ZNF684, RIMS3, NFYC, 
KCNQ4, CITED4, SLFNL1, SCMH1, EDN2, HIVEP3, GUCA2B, GUCA2A, FOXJ3, RIMKLA, ZMYND12, PPCS, CCDC30, 
PPIH, YBX1, CLDN19, LEPRE1, C1orf50, CCDC23, ERMAP, ZNF691, SLC2A1, FAM183A, EBNA1BP2, WDR65, 
TMEM125, C1orf210, TIE1, CDC20, ELOVL1, MED8, SZT2, HYI, PTPRF, KDM4A, ST3GAL3, ARTN, IPO13, DPH2, 
ATP6V0B, B4GALT2, CCDC24, SLC6A9, KLF17, DMAP1, ERI3, RNF220, TMEM53, KIF2C, RPS8, BEST4, PLK3, 
TCTEX1D4, PTCH2, EIF2B3, HECTD3, UROD, ZSWIM5, HPDL, TOE1, TESK2, MMACHC, PRDX1, AKR1A1, NASP, 
CCDC17, GPBP1L1, TMEM69, IPP, MAST2, PIK3R3, TSPAN1, POMGNT1, RAD54L, LRRC41, UQCRH, NSUN4, FAAH, 
DMBX1, KNCN, MKNK1, ATPAF1, CYP4B1, CYP4A11, CYP4X1, CYP4Z1, CYP4A22, PDZK1IP1, CMPK1, FOXE3, 
FOXD2, SLC5A9, SPATA6, BEND5, AGBL4, ELAVL4, DMRTA2, FAF1, RNF11, TTC39A, OSBPL9, NRD1, RAB3B, KTI12, 
TXNDC12, BTF3L4, ZFYVE9, CC2D1B, ORC1, PRPF38A, ZCCHC11, GPX7, FAM159A, SELRC1, ZYG11B, ZYG11A, 
ECHDC2, SCP2, PODN, SLC1A7, CPT2, C1orf123, MAGOH, LRP8, DMRTB1, GLIS1, TMEM48, YIPF1, DIO1, HSPB11, 
LRRC42, LDLRAD1, TMEM59, TCEANC2, CDCP2, MRPL37, SSBP3, ACOT11, FAM151A, TTC4, PARS2, TTC22, 
C1orf177, DHCR24, TMEM61, BSND, PCSK9, USP24, PPAP2B, PRKAA2, C1orf168, C8A, C8B, DAB1, OMA1, 
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 Peak Region 
Extended 
Region 
Length 
(Mb) 
Q-Bound G-Score 
No. of 
Genes 
Genes 
in Peak 
Genes 
Chr 1 
72,765,091-
72,812,744 
0-121,322,377 121.30 0.00 4.91 1266 - 
DNAJC6, LEPROT, LEPR, PDE4B, SGIP1, TCTEX1D1, INSL5, WDR78, MIER1, SLC35D1, C1orf141, IL23R, IL12RB2, 
SERBP1, GADD45A, GNG12, DIRAS3, WLS, RPE65, DEPDC1, LRRC7, LRRC40, SRSF11, ANKRD13C, HHLA3, CTH, 
PTGER3, ZRANB2, NEGR1, LRRIQ3, FPGT, TNNI3K, C1orf173, CRYZ, TYW3, LHX8, SLC44A5, ACADM, RABGGTB, 
MSH4, ASB17, ST6GALNAC3, ST6GALNAC5, PIGK, AK5, ZZZ3, USP33, FAM73A, NEXN, DNAJB4, GIPC2, PTGFR, 
IFI44L, IFI44, ELTD1, LPHN2, TTLL7, PRKACB, SAMD13, DNASE2B, RPF1, GNG5, CTBS, SSX2IP, LPAR3, MCOLN2, 
MCOLN3, WDR63, SYDE2, C1orf52, DDAH1, CYR61, ZNHIT6, COL24A1, ODF2L, CLCA2, CLCA1, CLCA4, CLCA3P, 
SH3GLB1, SEP15, HS2ST1, LMO4, PKN2, GTF2B, CCBL2, GBP3, GBP1, GBP2, GBP7, GBP4, GBP5, GBP6, LRRC8B, 
LRRC8C, LRRC8D, ZNF326, BARHL2, ZNF644, HFM1, CDC7, TGFBR3, BRDT, EPHX4, BTBD8, KIAA1107, C1orf146, 
GLMN, RPAP2, GFI1, EVI5, RPL5, FAM69A, MTF2, TMED5, CCDC18, DR1, FNBP1L, DNTTIP2, GCLM, ABCA4, 
ARHGAP29, ABCD3, F3, SLC44A3, CNN3, ALG14, TMEM56, RWDD3, PTBP2, DPYD, SNX7, LPPR4, PALMD, FRRS1, 
AGL, SLC35A3, HIAT1, SASS6, LRRC39, DBT, CDC14A, GPR88, VCAM1, EXTL2, SLC30A7, DPH5, S1PR1, DNAJA1P5, 
OLFM3, COL11A1, RNPC3, AMY2B, AMY2A, AMY1C, AMY1C, AMY1C, PRMT6, NTNG1, VAV3, SLC25A24, NBPF4, 
FAM102B, HENMT1, PRPF38B, FNDC7, STXBP3, AKNAD1, GPSM2, CLCC1, WDR47, TAF13, TMEM167B, C1orf194, 
KIAA1324, SARS, CELSR2, PSRC1, MYBPHL, SORT1, PSMA5, SYPL2, ATXN7L2, CYB561D1, AMIGO1, GPR61, 
GNAI3, GNAT2, AMPD2, GSTM4, GSTM2, GSTM1, GSTM5, GSTM3, EPS8L3, CSF1, AHCYL1, ALX3, UBL4B, SLC6A17, 
KCNC4, SLC16A4, PROK1, KCNA10, KCNA2, KCNA3, CD53, LRIF1, DRAM2, CEPT1, DENND2D, CHI3L2, CHIA, 
OVGP1, WDR77, ATP5F1, C1orf162, ADORA3, RAP1A, DDX20, KCND3, CTTNBP2NL, WNT2B, ST7L, CAPZA1, MOV10, 
RHOC, PPM1J, FAM19A3, SLC16A1, LRIG2, MAGI3, PHTF1, RSBN1, PTPN22, BCL2L15, AP4B1, DCLRE1B, HIPK1, 
OLFML3, SYT6, BCAS2, DENND2C, AMPD1, CSDE1, SIKE1, SYCP1, TSHB, TSPAN2, NGF, VANGL1, CASQ2, NHLH2, 
SLC22A15, MAB21L3, ATP1A1, CD58, IGSF3, CD2, PTGFRN, CD101, TTF2, TRIM45, VTCN1, MAN1A2, GDAP2, WDR3, 
SPAG17, TBX15, WARS2, HAO2, HSD3B2, HSD3B1, ZNF697, PHGDH, HMGCS2, REG4, NBPF7, ADAM30, FAM72B, 
FCGR1B, DDX11L1, WASH7P, FAM138A, FAM138F, LOC729737, LOC100132062, LOC100132287, LOC100133331, 
OR4F16, OR4F29, OR4F3, OR4F16, OR4F29, OR4F3, LOC100133331, LOC100288069, LINC00115, LOC643837, 
FAM41C, LOC100130417, RNF223, C1orf159, LOC254099, MIR200B, MIR200A, MIR429, GLTPD1, LOC148413, 
ANKRD65, TMEM88B, TMEM240, C1orf233, MMP23A, SLC35E2B, MMP23A, LOC100129534, LOC115110, 
LOC100133445, FAM213B, TTC34, FLJ42875, MIR4251, MIR551A, TP73-AS1, SMIM1, LOC100133612, LOC728716, 
LOC284661, MIR4417, MIR4689, MIR4252, ENO1-AS1, MIR34A, APITD1-CORT, MTOR-AS1, DRAXIN, NPPA-AS1, 
MIR4632, SNORA59A, SNORA59B, LOC649330, PRAMEF8, PRAMEF6, LOC440563, PRAMEF6, PRAMEF8, 
PRAMEF15, PRAMEF9, PRAMEF19, PRAMEF16, PRAMEF21, PRAMEF8, PRAMEF15, PRAMEF9, PRAMEF19, 
PRAMEF17, PRAMEF21, LRRC38, C1orf126, UQCRHL, FLJ37453, SZRD1, CROCCP3, MIR3675, NBPF1, CROCCP2, 
MST1P2, MIR3675, ESPNP, MST1L, MIR3675, MIR4695, IFFO2, EMC1, LOC100506730, MINOS1, C1orf151-NBL1, 
LOC339505, LOC100506801, LINC00339, MIR4684, MIR4253, LOC729059, MIR3115, TCEA3, LOC100506963, MIR378F, 
SRSF10, IFNLR1, LOC284632, STPG1, RCAN3AS, NCMAP, LOC646471, MTFR1L, AUNIP, MIR3917, FAM110D, 
MIR1976, LOC644961, SCARNA1, THEMIS2, SNHG3, SNORD99, SNORA61, SNHG12, SNORA44, SNORA16A, RNU11, 
MATN1-AS1, MIR4420, SNORD103A, SNORD103B, SNORD103A, SNORD103B, SNORD85, LOC149086, LOC284551, 
MIR4254, MTMR9LP, FAM229A, ZBTB8B, MIR3605, LOC402779, SMIM12, LOC653160, ZMYM6NB, EVA1B, MIR4255, 
LOC728431, MIR5581, MIR3659, LOC339442, GJA9-MYCBP, PPIEL, SNORA55, ZFP69B, ZFP69, EXO5, 
LOC100130557, MIR30E, MIR30C1, CTPS1, SLFNL1-AS1, LOC100129924, SLC2A1-AS1, KDM4A-AS1, MIR5584, 
C1orf228, SNORD55, SNORD46, SNORD38A, SNORD38B, BTBD19, LOC400752, CCDC163P, RPS15AP10, LURAP1, 
LOC729041, MKNK1-AS1, MOB3C, TEX38, EFCAB14-AS1, EFCAB14, CYP4Z2P, PDZK1IP1-AS1, FOXD2-AS1, 
TRABD2B, SKINTL, C1orf185, MIR761, LOC100507564, SLC25A3P1, MIR4781, CYB5RL, MROH7, HEATR8-TTC4, 
LOC100507634, MIR4422, LOC100131060, HSD52, MIR4711, MGC34796, LINC00466, MIR4794, MIR3671, MIR101-1, 
MIR3117, GNG12-AS1, MIR1262, PIN1P1, ZRANB2-AS1, MIR186, ZRANB2-AS2, NEGR1-IT1, FPGT-TNNI3K, 
SNORD45C, SNORD45A, SNORD45B, MGC27382, MIR548AP, UOX, C1orf180, MIR4423, LOC646626, LOC339524, 
LOC100505768, RBMXL1, GBP1P1, FLJ27354, GEMIN8P4, HSP90B3P, SNORD21, SNORA66, LOC100131564, 
LOC100129046, MIR760, LOC729970, TMEM56-RWDD3, FLJ31662, DPYD-AS1, MIR137HG, MIR2682, MIR137, 
LOC729987, LPPR5, LOC100129620, MIR548AA1, MIR548D1, TRMT13, RTCA, MIR553, LOC100128787, RNU6-6, 
ACTG1P4, AMY1A, AMY1B, AMY1B, AMY1A, AMY1A, AMY1B, LOC100129138, VAV3-AS1, NBPF6, SRG7, SCARNA2, 
MIR197, STRIP1, LOC440600, LAMTOR5, CYMP, CHIAP2, PIFO, PGCP1, LOC100129269, FAM212B, LOC100506343, 
LOC643355, MIR4256, AKR7A2P1, LOC643441, AP4B1-AS1, ATP1A1OS, MIR320B1, MIR942, HSD3BP4, LINC00622, 
HIST2H2BA, SRGAP2D, EMBP1, MST1P9, TACSTD2, MYSM1, FGGY, HOOK1, CYP2J2, C1orf87, NFIA, TM2D1, INADL, 
L1TD1, KANK4, USP1, DOCK7, ANGPTL3, ATG4C, FOXD3, ALG6, ITGB3BP, EFCAB7, DLEU2L, PGM1, ROR1, UBE2U, 
CACHD1, RAVER2, AK4, 
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 Peak Region 
Extended 
Region 
Length 
(Mb) 
Q-Bound G-Score 
No. of 
Genes 
Genes 
in Peak 
Genes 
Chr 14 
106,883,633-
106,919,036 
43,345,398-
107,349,540 
64.00 0.00 7.04 562 - 
FSCB, C14orf28, KLHL28, FAM179B, PRPF39, SNORD127, FKBP3, FANCM, MIS18BP1, RPL10L, MDGA2, MIR548Y, 
LINC00648, RPS29, LRR1, RPL36AL, MGAT2, DNAAF2, POLE2, KLHDC1, KLHDC2, NEMF, ARF6, C14orf182, 
C14orf183, METTL21D, SOS2, L2HGDH, ATP5S, CDKL1, MAP4K5, ATL1, SAV1, NIN, ABHD12B, PYGL, TRIM9, TMX1, 
LINC00640, FRMD6-AS2, FRMD6, FRMD6-AS1, GNG2, C14orf166, NID2, PTGDR, PTGER2, TXNDC16, GPR137C, 
ERO1L, PSMC6, STYX, GNPNAT1, FERMT2, DDHD1, MIR5580, BMP4, CDKN3, CNIH, GMFB, CGRRF1, SAMD4A, 
GCH1, MIR4308, WDHD1, SOCS4, MAPK1IP1L, LGALS3, DLGAP5, FBXO34, ATG14, TBPL2, KTN1-AS1, KTN1, 
RPL13AP3, LINC00520, PELI2, C14orf101, OTX2, OTX2-AS1, EXOC5, AP5M1, NAA30, C14orf105, SLC35F4, C14orf37, 
ACTR10, PSMA3, FLJ31306, ARID4A, TOMM20L, TIMM9, KIAA0586, DACT1, DAAM1, GPR135, L3HYPDH, JKAMP, 
CCDC175, RTN1, PCNXL4, DHRS7, PPM1A, C14orf39, SIX6, SIX1, SIX4, MNAT1, TRMT5, SLC38A6, TMEM30B, 
PRKCH, FLJ22447, HIF1A, HIF1A-AS2, SNAPC1, SYT16, LINC00643, KCNH5, RHOJ, GPHB5, PPP2R5E, WDR89, 
SGPP1, SYNE2, ESR2, TEX21P, MTHFD1, AKAP5, ZBTB25, ZBTB1, HSPA2, PPP1R36, PLEKHG3, SPTB, CHURC1, 
GPX2, RAB15, CHURC1-FNTB, FNTB, MIR4706, MAX, LOC100506321, MIR4708, FUT8-AS1, FUT8, LINC00238, GPHN, 
FAM71D, MPP5, ATP6V1D, EIF2S1, PLEK2, TMEM229B, PLEKHH1, PIGH, ARG2, VTI1B, RDH11, RDH12, ZFYVE26, 
RAD51B, ZFP36L1, ACTN1, ACTN1-AS1, DCAF5, EXD2, GALNTL1, ERH, SLC39A9, PLEKHD1, CCDC177, KIAA0247, 
LOC100289511, SRSF5, SLC10A1, SMOC1, SLC8A3, ADAM21P1, COX16, SYNJ2BP-COX16, SYNJ2BP, ADAM21, 
ADAM20P1, ADAM20, MED6, TTC9, MAP3K9, PCNX, SNORD56B, LOC145474, SIPA1L1, RGS6, DPF3, DCAF4, 
ZFYVE1, RBM25, PSEN1, PAPLN, NUMB, C14orf169, HEATR4, ACOT1, ACOT2, ACOT4, ACOT6, DNAL1, PNMA1, 
ELMSAN1, MIR4505, PTGR2, ZNF410, FAM161B, COQ6, ENTPD5, CCDC176, ALDH6A1, LIN52, VSX2, ABCD4, VRTN, 
SYNDIG1L, MIR4709, NPC2, ISCA2, LTBP2, KIAA0317, FCF1, YLPM1, PROX2, DLST, RPS6KL1, PGF, EIF2B2, MLH3, 
ACYP1, ZC2HC1C, NEK9, TMED10, FOS, LOC731223, JDP2, BATF, FLVCR2, C14orf1, TTLL5, TGFB3, IFT43, 
GPATCH2L, RNU6-6, RNU6-19, ESRRB, VASH1, ANGEL1, C14orf166B, IRF2BPL, KIAA1737, ZDHHC22, TMEM63C, 
MIR1260A, NGB, POMT2, GSTZ1, TMED8, SAMD15, NOXRED1, VIPAS39, AHSA1, ISM2, SPTLC2, ALKBH1, SLIRP, 
SNW1, C14orf178, ADCK1, NRXN3, DIO2, DIO2-AS1, CEP128, TSHR, GTF2A1, SNORA79, STON2, SEL1L, FLRT2, 
LOC283585, GALC, GPR65, LOC283587, KCNK10, SPATA7, PTPN21, ZC3H14, EML5, TTC8, FOXN3, FOXN3-AS1, 
FOXN3-AS2, EFCAB11, TDP1, KCNK13, PSMC1, NRDE2, CALM1, LINC00642, TTC7B, RPS6KA5, SNORA11B, 
C14orf159, GPR68, CCDC88C, SMEK1, CATSPERB, TC2N, FBLN5, TRIP11, ATXN3, NDUFB1, CPSF2, SLC24A4, RIN3, 
LGMN, GOLGA5, CHGA, ITPK1, ITPK1-AS1, MOAP1, TMEM251, C14orf142, UBR7, BTBD7, COX8C, UNC79, PRIMA1, 
FAM181A-AS1, FAM181A, ASB2, LINC00521, OTUB2, DDX24, IFI27L1, IFI27, IFI27L2, PPP4R4, SERPINA10, 
SERPINA6, SERPINA1, SERPINA11, SERPINA9, SERPINA12, SERPINA4, SERPINA5, SERPINA3, SERPINA13P, GSC, 
DICER1, MIR3173, DICER1-AS1, CLMN, LINC00341, SYNE3, SCARNA13, SNHG10, GLRX5, TCL6, TCL1B, TCL1A, 
LINC00617, C14orf132, BDKRB2, BDKRB1, ATG2B, GSKIP, AK7, PAPOLA, VRK1, LOC100129345, C14orf64, C14orf177, 
BCL11B, SETD3, CCNK, CCDC85C, HHIPL1, MIR5698, CYP46A1, EML1, EVL, DEGS2, YY1, SLC25A29, MIR345, 
SLC25A47, WARS, WDR25, BEGAIN, LINC00523, DLK1, MIR2392, MEG3, MIR770, MIR493, MIR337, MIR665, MIR431, 
MIR433, RTL1, MIR127, MIR432, MIR136, MEG8, SNORD113-1, SNORD113-2, SNORD113-4, SNORD113-5, 
SNORD113-6, SNORD113-7, SNORD113-9, SNORD114-1, SNORD114-2, SNORD114-3, SNORD114-4, SNORD114-5, 
SNORD114-6, SNORD114-7, SNORD114-8, SNORD114-9, SNORD114-10, SNORD114-11, SNORD114-12, SNORD114-
13, SNORD114-14, SNORD114-15, SNORD114-16, SNORD114-17, SNORD114-18, SNORD114-19, SNORD114-20, 
SNORD114-21, SNORD114-22, SNORD114-23, SNORD114-24, SNORD114-25, SNORD114-26, SNORD114-27, 
SNORD114-28, SNORD114-29, SNORD114-30, SNORD114-31, MIR379, MIR411, MIR299, MIR380, MIR1197, MIR323A, 
MIR758, MIR329-1, MIR329-2, MIR494, MIR1193, MIR543, MIR495, MIR376C, MIR376A2, MIR654, MIR376B, MIR376A1, 
MIR300, MIR1185-1, MIR1185-2, MIR381, MIR487B, MIR539, MIR889, MIR655, MIR487A, MIR382, MIR134, MIR668, 
MIR485, MIR323B, MIR154, MIR496, MIR377, MIR541, MIR409, MIR412, MIR369, MIR410, MIR656, MEG9, DIO3OS, 
MIR1247, DIO3, LINC00239, PPP2R5C, DYNC1H1, HSP90AA1, WDR20, MOK, ZNF839, CINP, TECPR2, ANKRD9, 
MIR4309, RCOR1, TRAF3, AMN, CDC42BPB, EXOC3L4, TNFAIP2, LINC00605, SNORA28, EIF5, MARK3, CKB, 
TRMT61A, BAG5, APOPT1, KLC1, XRCC3, ZFYVE21, PPP1R13B, LINC00637, C14orf2, RD3L, TDRD9, ASPG, MIR203, 
MIR3545, KIF26A, C14orf180, TMEM179, MIR4710, INF2, ADSSL1, SIVA1, AKT1, ZBTB42, LINC00638, CEP170B, PLD4, 
AHNAK2, C14orf79, CDCA4, GPR132, JAG2, NUDT14, BTBD6, BRF1, PACS2, TEX22, MTA1, CRIP2, CRIP1, C14orf80, 
TMEM121, ELK2AP, KIAA0125, ADAM6, LINC00226, LINC00221 
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 Peak Region 
Extended 
Region 
Length 
(Mb) 
Q-Bound G-Score 
No. of 
Genes 
Genes 
in Peak 
Genes 
Chr 15 
102,156,415-
102,237,854 
72,998,432-
102,531,392 
29.50 0.05 3.15 297 
TM2D3 
TARSL2 
BBS4, ADPGK, ADPGK-AS1, NEO1, HCN4, C15orf60, NPTN, CD276, C15orf59, TBC1D21, LOXL1-AS1, LOXL1, 
STOML1, PML, GOLGA6A, LOC283731, ISLR2, ISLR, STRA6, CCDC33, CYP11A1, LOC729739, SEMA7A, UBL7, 
LOC440288, ARID3B, CLK3, EDC3, CYP1A1, CYP1A2, MIR4513, CSK, LMAN1L, CPLX3, ULK3, SCAMP2, MPI, 
FAM219B, COX5A, RPP25, SCAMP5, PPCDC, C15orf39, GOLGA6C, GOLGA6D, COMMD4, NEIL1, MIR631, MAN2C1, 
SIN3A, PTPN9, SNUPN, IMP3, SNX33, CSPG4, ODF3L1, DNM1P35, MIR4313, UBE2Q2, FBXO22, FBXO22-AS1, NRG4, 
C15orf27, TYRO3P, ETFA, ISL2, SCAPER, RCN2, PSTPIP1, TSPAN3, LINC00597, PEAK1, HMG20A, LINGO1, 
LOC253044, LOC645752, LOC91450, TBC1D2B, MIR5003, SH2D7, CIB2, IDH3A, ACSBG1, DNAJA4, WDR61, CRABP1, 
IREB2, AGPHD1, PSMA4, CHRNA5, CHRNA3, CHRNB4, LOC646938, ADAMTS7, MORF4L1, CTSH, RASGRF1, MIR184, 
LOC729911, ANKRD34C, TMED3, KIAA1024, MTHFS, ST20-MTHFS, ST20, C15orf37, BCL2A1, ZFAND6, FAH, 
LOC283688, ARNT2, FAM108C1, MIR549, KIAA1199, MESDC2, MIR4514, MESDC1, C15orf26, IL16, STARD5, TMC3, 
MEX3B, EFTUD1, FAM154B, LOC390660, GOLGA6L10, UBE2Q2P2, UBE2Q2P3, GOLGA6L9, LOC440297, LOC727849, 
AGSK1, RPS17L, RPS17, LOC390660, AGSK1, LOC727849, LOC440297, GOLGA6L10, UBE2Q2P2, UBE2Q2P3, 
GOLGA6L9, LOC440297, LOC727849, AGSK1, RPS17L, RPS17, CPEB1, LOC283692, AP3B2, LOC338963, LOC283693, 
SCARNA15, FSD2, WHAMM, HOMER2, FAM103A1, C15orf40, BTBD1, MIR4515, TM6SF1, HDGFRP3, BNC1, SH3GL3, 
ADAMTSL3, EFTUD1P1, LOC100505679, LOC642423, LOC440300, LOC388152, GOLGA6L4, DNM1P41, GOLGA6L5, 
UBE2Q2P1, LOC100506874, ZSCAN2, SCAND2, WDR73, NMB, SEC11A, ZNF592, ALPK3, SLC28A1, PDE8A, 
LOC642423, AKAP13, MIR1276, KLHL25, LOC727915, AGBL1, LINC00052, NTRK3, NTRK3-AS1, MRPL46, MRPS11, 
DET1, MIR1179, MIR7-2, MIR3529, AEN, ISG20, ACAN, HAPLN3, MFGE8, ABHD2, RLBP1, FANCI, POLG, MIR9-3, 
LOC254559, RHCG, LOC283761, TICRR, KIF7, PLIN1, PEX11A, WDR93, MESP1, MESP2, ANPEP, MIR5094, AP3S2, 
C15orf38-AP3S2, C15orf38, ZNF710, IDH2, SEMA4B, CIB1, GDPGP1, TTLL13, NGRN, GABARAPL3, ZNF774, IQGAP1, 
CRTC3, BLM, FURIN, FES, MAN2A2, HDDC3, UNC45A, RCCD1, LOC100507118, PRC1, VPS33B, SV2B, SLCO3A1, 
ST8SIA2, C15orf32, LOC100144604, FAM174B, ASB9P1, LOC100507217, MIR3175, CHD2, RGMA, MCTP2, 
LOC400456, LOC145820, NR2F2, MIR1469, SPATA8, LOC91948, ARRDC4, FAM169B, MIR4714, IGF1R, PGPEP1L, 
SYNM, TTC23, HSP90B2P, LRRC28, MEF2A, LYSMD4, DNM1P46, ADAMTS17, FLJ42289, CERS3, PRKXP1, LINS, 
ASB7, ALDH1A3, LRRK1, CHSY1, VIMP, SNRPA1, LOC100507472, PCSK6, TM2D3, TARSL2, OR4F6, OR4F15, 
OR4F13P, OR4F4, FAM138E, WASH3P, DDX1 
Chr 22 
24,342,813-
24,398,622 
16,133,474-
51,304,566 
35.20 0.00 5.56 552 
GSTTP1 
GSTT1 
GSTTP2 
LINC00516, LOC101101776, POTEH, OR11H1, CCT8L2, TPTEP1, ANKRD62P1-PARP4P3, XKR3, HSFY1P1, GAB4, 
CECR7, IL17RA, CECR6, CECR5, CECR5-AS1, CECR1, CECR3, CECR2, SLC25A18, ATP6V1E1, BCL2L13, BID, 
MIR3198-1, MICAL3, MIR648, FLJ41941, PEX26, TUBA8, USP18, GGT3P, DGCR6, PRODH, DGCR5, DGCR9, DGCR10, 
DGCR11, DGCR2, TSSK2, DGCR14, GSC2, SLC25A1, CLTCL1, HIRA, MRPL40, C22orf39, UFD1L, CDC45, CLDN5, 
LOC150185, SEPT5, SEPT5-GP1BB, GP1BB, TBX1, GNB1L, C22orf29, TXNRD2, COMT, MIR4761, ARVCF, MIR185, 
TANGO2, MIR3618, MIR1306, DGCR8, TRMT2A, RANBP1, ZDHHC8, LOC388849, LOC284865, LOC150197, MIR1286, 
RTN4R, DGCR6L, LOC729444, TMEM191B, PI4KAP1, RIMBP3, ZNF74, SCARF2, KLHL22, MED15, POM121L4P, 
TMEM191A, SERPIND1, PI4KA, SNAP29, CRKL, AIFM3, LZTR1, THAP7, THAP7-AS1, TUBA3FP, P2RX6, SLC7A4, 
P2RX6P, LOC400891, BCRP2, POM121L8P, RIMBP3C, RIMBP3B, HIC2, TMEM191C, PI4KAP2, RIMBP3B, RIMBP3C, 
UBE2L3, YDJC, CCDC116, SDF2L1, MIR301B, MIR130B, PPIL2, YPEL1, MAPK1, PPM1F, TOP3B, VPREB1, LOC96610, 
ZNF280B, ZNF280A, PRAME, LOC648691, POM121L1P, GGTLC2, MIR650, IGLL5, GNAZ, RTDR1, RAB36, BCR, 
FBXW4P1, CES5AP1, ZDHHC8P1, IGLL1, C22orf43, GUSBP11, RGL4, ZNF70, VPREB3, C22orf15, CHCHD10, MMP11, 
SMARCB1, DERL3, SLC2A11, MIF, LOC284889, GSTT2B, GSTT2, DDTL, DDT, GSTT2, GSTTP1, LOC391322, GSTT1, 
GSTTP2, CABIN1, SUSD2, GGT5, POM121L9P, SPECC1L, ADORA2A, ADORA2A-AS1, UPB1, GUCD1, SNRPD3, 
FAM211B, GGT1, BCRP3, POM121L10P, PIWIL3, TOP1P2, SGSM1, TMEM211, LOC100128531, KIAA1671, CRYBB3, 
CRYBB2, IGLL3P, LRP5L, CRYBB2P1, ADRBK2, MYO18B, SEZ6L, ASPHD2, HPS4, SRRD, TFIP11, MIR548J, TPST2, 
CRYBB1, CRYBA4, MIAT, MN1, PITPNB, MIR3199-1, MIR3199-2, TTC28-AS1, TTC28, CHEK2, HSCB, CCDC117, XBP1, 
ZNRF3, ZNRF3-AS1, C22orf31, KREMEN1, EMID1, RHBDD3, EWSR1, GAS2L1, RASL10A, SNORD125, MIR3653, 
AP1B1, RFPL1-AS1, RFPL1, NEFH, THOC5, NIPSNAP1, NF2, CABP7, ZMAT5, UQCR10, ASCC2, MTMR3, HORMAD2, 
LIF, OSM, GATSL3, TBC1D10A, SF3A1, CCDC157, KIAA1656, RNF215, SEC14L2, MTFP1, SEC14L3, SDC4P, 
SEC14L4, SEC14L6, GAL3ST1, PES1, TCN2, SLC35E4, DUSP18, MIR3200, OSBP2, MORC2-AS1, MORC2, TUG1, 
SMTN, SELM, INPP5J, PLA2G3, MIR3928, RNF185, LIMK2, PIK3IP1, PATZ1, DRG1, EIF4ENIF1, SFI1, PISD, PRR14L, 
DEPDC5, C22orf24, YWHAH, SLC5A1, AP1B1P1, C22orf42, RFPL2, SLC5A4, RFPL3, RFPL3-AS1, LOC339666, 
C22orf28, BPIFC, FBXO7, SYN3, TIMP3, MIR4764, LARGE, LOC100506195, ISX, HMGXB4, TOM1, MIR3909, HMOX1, 
MCM5, RASD2, MB, APOL6, APOL5, RBFOX2, APOL3, APOL4, APOL2, APOL1, MYH9, TXN2, FOXRED2, EIF3D, 
CACNG2, IFT27, PVALB, NCF4, CSF2RB, LOC100506241, TEX33, TST, MPST, KCTD17, 
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 Peak Region 
Extended 
Region 
Length 
(Mb) 
Q-Bound G-Score 
No. of 
Genes 
Genes 
in Peak 
Genes 
Chr 22 
24,342,813-
24,398,622 
16,133,474-
51,304,566 
35.20 0.00 5.56 552 
GSTTP1 
GSTT1 
GSTTP2 
TMPRSS6, IL2RB, C1QTNF6, SSTR3, RAC2, CYTH4, ELFN2, MFNG, CARD10, CDC42EP1, LGALS2, GGA1, SH3BP1, 
PDXP, LGALS1, NOL12, TRIOBP, H1F0, GCAT, GALR3, ANKRD54, MIR658, MIR659, EIF3L, MICALL1, C22orf23, 
POLR2F, SOX10, MIR4534, PICK1, SLC16A8, BAIAP2L2, PLA2G6, MAFF, TMEM184B, CSNK1E, LOC400927, KCNJ4, 
KDELR3, DDX17, DMC1, FAM227A, CBY1, TOMM22, JOSD1, GTPBP1, SUN2, DNAL4, NPTXR, CBX6, APOBEC3A, 
APOBEC3A_B, APOBEC3B, APOBEC3C, APOBEC3D, APOBEC3F, APOBEC3G, APOBEC3H, CBX7, PDGFB, 
SNORD83B, SNORD83A, RPL3, RNU86, SNORD43, SYNGR1, TAB1, LOC100506472, MGAT3, SMCR7L, ATF4, 
RPS19BP1, CACNA1I, ENTHD1, GRAP2, FAM83F, LOC100130899, TNRC6B, ADSL, SGSM3, MKL1, MCHR1, 
SLC25A17, MIR4766, ST13, DNAJB7, XPNPEP3, RBX1, MIR1281, EP300, L3MBTL2, CHADL, RANGAP1, ZC3H7B, TEF, 
TOB2, PHF5A, ACO2, POLR3H, CSDC2, PMM1, DESI1, XRCC6, NHP2L1, C22orf46, MEI1, CCDC134, SREBF2, 
MIR33A, SHISA8, TNFRSF13C, CENPM, LINC00634, SEPT3, WBP2NL, NAGA, FAM109B, C22orf32, NDUFA6, 
LOC100132273, CYP2D6, CYP2D7P1, TCF20, LOC388906, NFAM1, SERHL, RRP7A, SERHL2, RRP7B, POLDIP3, 
RNU12, CYB5R3, ATP5L2, A4GALT, ARFGAP3, PACSIN2, TTLL1, BIK, MCAT, TSPO, TTLL12, SCUBE1, MPPED1, 
EFCAB6-AS1, EFCAB6, SULT4A1, PNPLA5, PNPLA3, SAMM50, PARVB, PARVG, KIAA1644, LDOC1L, LINC00207, 
LINC00229, PRR5, PRR5-ARHGAP8, ARHGAP8, PHF21B, LOC100506714, NUP50, MIR1249, KIAA0930, UPK3A, 
FAM118A, SMC1B, RIBC2, FBLN1, ATXN10, MIR4762, WNT7B, LOC730668, LOC100271722, C22orf26, LOC150381, 
MIR3619, MIRLET7BHG, MIRLET7A3, MIR4763, MIRLET7B, PPARA, CDPF1, PKDREJ, TTC38, CN5H6.4, GTSE1, 
TRMU, CELSR1, GRAMD4, CERK, TBC1D22A, FLJ46257, MIR3201, LOC284933, FAM19A5, MIR4535, LOC100128946, 
C22orf34, LOC90834, BRD1, ZBED4, ALG12, CRELD2, PIM3, IL17REL, MLC1, MOV10L1, PANX2, TRABD, SELO, 
TUBGCP6, HDAC10, MAPK12, MAPK11, PLXNB2, DENND6B, PPP6R2, SBF1, ADM2, MIOX, LMF2, NCAPH2, SCO2, 
TYMP, ODF3B, KLHDC7B, SYCE3, CPT1B, CHKB-CPT1B, CHKB, LOC100144603, MAPK8IP2, ARSA, SHANK3, ACR, 
RABL2B, RPL23AP82 
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Table C1:  Over-represented (Enriched) Pathways among Commonly-amplified genes in 
Gastrointestinal Stromal Tumours 
Pathway ID Term 
Fisher 
p-value 
EASE 
p-value 
Gene 
Count 
Genes 
Fold 
Enrichment 
KEGG 
hsa05322 
Systemic lupus 
erythematosus 
5.80E-04 2.98E-03 7 
HIST1H2AC, HIST1H2BD, 
HIST1H2BE, HIST1H2BF, 
HIST1H2AD, HIST1H2BG, 
HIST1H2AE, HIST1H4E, 
HIST1H4F, HIST1H3D, HIST1H4D, 
HIST1H3E, HIST1H3F, HIST1H4G 
4.79 
 
 
 
 
Table C2:  Over-represented (Enriched) Pathways among Commonly-deleted genes in 
Gastrointestinal Stromal Tumours 
Pathway ID Term 
Fisher 
p-value 
EASE 
p-value 
Gene 
Count 
Genes 
Fold 
Enrichment 
BIOCARTA 
h_cpsfPathway 
Polyadenylation of mRNA 2.3E-02 
2.33E-
02 
3 
 
OR10A5, OR10A6, OR10A3, OR10A4, 
OR52H1, OR52A1, OR51D1, OR10A2, 
OR52A5, OR4K17, OR4L1, OR4S1, 
OR51Q1, OR6S1, OR52D1, OR4C3, 
OR4C13, OR5AU1, OR52L1, OR51T1, 
OR4C12, OR51L1, OR52B2, OR52B4, 
OR52B6, OR4A47, OR51G1, CNGA4, 
OR51G2, OR4E2, OR52K2, OR52K1, 
OR4K15, OR4K14, OR4N5, OR4K13, 
OR2D2, OR2D3, OR51B2, OR52J3, 
OR51F1, ADRBK2, OR51F2, OR11G2, 
OR10G2, OR10G3, OR52N2, OR56B4, 
OR52N5, OR52N4, OR52N1, OR6A2, 
OR56B1, OR51B5, OR51B6, OR51B4, 
OR51V1, OR52R1, OR4K5, OR5P3, 
OR2AG1, OR5P2, OR2AG2, OR52I1, 
OR52I2, OR52E2, OR4B1, OR11H4, 
OR52E4, OR51E1, OR51E2, OR4K1, 
OR56A3, OR56A4, OR51M1, OR4X1, 
OR56A1, OR52M1, OR51I2, OR51S1, 
OR4X2, OR52E6, OR11H6, OR52E8, 
OR52W1, OR51A2, OR4C45, OR51A4, 
OR51I1, OR51A7, OR56A5, CALM1 
11.34 
BIOCARTA  
h_circadianPathway 
Circadian Rhythms 2.4E-04 
4.69E-
03 
4 
 
CRY2, CSNK1E, ARNTL, LOC400927 
10.08 
KEGG 
hsa04740 
 
Olfactory transduction 5.3E-28 
2.16E-
27 
92 
 
PSMB5, PSMA1, PSMC6, PSMD13, 
PSME1, PSME2, PSMC3, PSMA3, 
PSMC1, PSMB11 
3.35 
KEGG 
hsa03050 
Proteasome 1.6E-03 
5.73E-
03 
10 
 
SPTLC2, SGPP1, GALC, ARSA, 
SMPD1, CERK, GAL3ST1, DEGS2 
2.93 
KEGG 
hsa00600 
Sphingolipid metabolism 6.0E-03 
2.01E-
02 
8 
 
PABPN1, PAPOLA, CSTF3 
2.83 
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Table A1:  Significant Common Focal Amplifications in Undifferentiated Pleomorphic Sarcoma 
(STAC) 
 Cytoband Region 
Length 
(Mb) 
Freq % P-Value Genes Gene Symbols 
% of CNV 
Overlap 
Chr 1 
q21.1 145,070,378-145,278,200 0.21 68.75 0.00E+00 3 NOTCH2NL, PDE4DIP, SEC22B 100 
p32.1 59,228,562-59,722,944 0.49 75 0.00E+00 2 HSD52, JUN 34 
Chr 2 q12.3 108,867,623-108,889,968 0.02 37.5 2.40E-02 1 SULT1C3 100 
Chr 3 p12.1 86,880,017-87,076,959 0.20 68.75 1.20E-02 1 VGLL3 2 
Chr 4 q12 54,400,737-54,592,199 0.19 43.75 1.30E-02 1 LNX1 21 
Chr 7 q33 135,033,284-135,102,970 0.07 62.5 2.20E-02 1 CNOT4 0 
Chr 8 q12.1 59,724,608-59,965,524 0.24 50 4.20E-02 1 TOX 0 
Chr 11 p13 35,080,110-35,282,073 0.20 43.75 0.00E+00 2 CD44, SLC1A2 79 
Chr 14 q24.1 68,824,970-69,144,273 0.32 56.25 2.70E-02 1 RAD51B 60 
Chr 21 q22.12 36,617,496-36,764,360 0.15 43.75 1.00E-03 1 RUNX1 100 
      14   
 
 
Table A2:  Significant Common Focal Deletions in Undifferentiated Pleomorphic Sarcoma (STAC) 
 Cytoband Region 
Length 
(Mb) 
Freq (%) P-Value Genes Gene Symbols 
% of CNV 
Overlap 
Chr 4 
q35.1 184,425,375-185,143,402 0.72 56.25 3.20E-02 5 
ENPP6, ING2,  RWDD4, STOX2, 
TRAPPC11 
16 
q35.1 - q35.2 186,797,948-187,792,442 0.99 56.25 3.20E-02 9 
CYP4V2, F11, FAM149A, FAT1, 
FLJ38576, KLKB1,MTNR1A, 
SORBS2, TLR3 
40 
q35.2 188,398,868-189,739,168 1.34 56.25 3.20E-02 3 TRIML1, TRIML2, ZFP42 100 
q35.2 190,624,209-191,154,276 0.53 62.5 1.00E-03 37 
DUX2, DUX4, DUX4L2, DUX4L3, 
DUX4L4, DUX4L5, DUX4L6, FRG1, 
FRG2 
74 
Chr 9 p21.3 21,936,953-22,013,183 0.08 43.75 1.00E-02 2 CDKN2A, CDKN2B 100 
Chr 11 
q24.1 121,300,330-121,397,853 0.10 62.5 1.80E-02 1 SORL1 37 
q24.1 122,766,398-123,471,184 0.70 62.5 1.80E-02 4 BSX, CLMP, GRAMD1B, HSPA8, 32 
q24.2 125,355,927-126,358,069 1.00 62.5 1.80E-02 22 
ACRV1, CDON, CHEK1, DCPS, 
DDX25, EI24, FAM118B, FEZ1, 
FLJ39051, FOXRED1, HYLS1, 
KIRREL3, PATE1, PATE2, PATE3, 
PATE4, PUS3, RPUSD4, SRPR, 
ST3GAL4, STT3A, TIRAP 
60 
q24.3 129,023,372-130,446,982 1.42 62.5 1.80E-02 10 
ADAMTS15, ADAMTS8, APLP2, 
ARHGAP32, BARX2, NFRKB, 
PRDM10, ST14, TMEM45B, ZBTB44 
38 
Chr 14 q32.33 104,566,967-104,715,087 0.15 31.25 4.20E-02 2 ASPG, KIF26A 63 
Chr 17 
q11.2 26,726,585-27,042,613 0.32 50 6.00E-03 13 
ALDOC, FOXN1,  PIGS, PROCA1, 
RAB34, SARM1, SDF2, SGK494, 
SLC13A2, SLC46A1, SPAG5, 
SUPT6H, UNC119 
1 
q11.2 27,203,586-27,211,735 0.01 56.25 0.00E+00 1 FLOT2 0 
q11.2 27,623,194-27,880,882 0.26 62.5 0.00E+00 1 TAOK1 9 
q11.2 28,424,381-28,525,378 0.10 56.25 0.00E+00 3 EFCAB5,  NSRP1, SLC6A4 7 
q11.2 29,041,847-29,371,754 0.33 62.5 0.00E+00 7 
ADAP2, ATAD5, CRLF3, DPRXP4, 
RNF135, SUZ12P1, TEFM 
16 
Chr 19 p13.3 0-350,965 0.35 43.75 1.60E-02 7 
FAM138A, FAM138F, FLJ45445, 
MIER2, OR4F17, PPAP2C, WASH5P 
83 
Chr 20 
p13 0-210,288 0.21 37.5 4.30E-02 5 
DEFB125, DEFB126, DEFB127, 
DEFB128, DEFB129 
69 
p13 398,763-434,066 0.04 37.5 4.30E-02 2 RBCK1, TBC1D20 20 
Chr 21 q22.3 47,760,929-47,790,354 0.03 56.25 0.00E+00 1 PCNT 22 
      135   
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Table B1:  Significant Common Focal Amplifications in Undifferentiated Pleomorphic Sarcoma (GISTIC) 
 Peak Region Extended Region 
Length 
(Mb) 
Frequency 
(%) 
G-Score Q-Bound 
No. of 
Genes 
Genes 
in Peak 
Genes 
Chr 3 86,816,036-88,468,010 87,299,611-87,306,626 1.7 63 8.19 0.03 6 CHMP2B VGLL3, CHMP2B, POU1F1, HTR1F, CGGBP1, ZNF654 
Chr 5 10,606,546-16,879,792 15,942,852-16,064,034 6.3 56 7.96 0.03 14 - 
ANKRD33B, DAP, CTNND2, CT49, DNAH5, TRIO, FAM105A, 
FAM105B, ANKH, FBXL7, MARCH11, ZNF622, FAM134B, 
MYO10 
Chr 7 77,437,091-94,074,985 82,845,459-83,425,216 16.6 38 8.06 0.03 57 SEMA3E 
PHTF2, RPL13AP17, MAGI2, GNAI1, GNAT3, CD36, SEMA3C, 
HGF, CACNA2D1, PCLO, SEMA3E, SEMA3A, SEMA3D, GRM3, 
DMTF1, TMEM243, TP53TG1, CROT, ABCB4, ABCB1, 
RUNDC3B, SLC25A40, DBF4, ADAM22, SRI, STEAP4, ZNF804B, 
DPY19L2P4, STEAP1, STEAP2, GTPBP10, CLDN12, CDK14, 
FZD1, MTERF, AKAP9, CYP51A1, LRRD1, KRIT1, ANKIB1, 
GATAD1, PEX1, RBM48, MGC16142, FAM133B, FAM133DP, 
CDK6, SAMD9, SAMD9L, HEPACAM2, CCDC132, CALCR, 
TFPI2, GNGT1, GNG11, BET1, COL1A2 
Chr 11 101,263,543-103,276,617 101,597,949-101,646,626 2.0 50 14.43 0.00 18 - 
TRPC6, ANGPTL5, YAP1, BIRC3, BIRC2, TMEM123, MMP7, 
MMP20, MMP27, MMP8, MMP10, MMP1, WTAPP1, MMP3, 
MMP12, MMP13, DCUN1D5, DYNC2H1 
 
       95   
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Table B2:  Significant Common Focal Deletions in Undifferentiated Pleomorphic Sarcoma (GISTIC) 
 Peak Region Extended Region 
Length  
(Mb) 
Frequency  
(%) 
G-Score Q-Bound 
No. of 
Genes 
Genes in Peak 
Genes 
 
Chr 1 248,733,443-249,250,621 248,733,443-248,811,992 0.5 69 9.49 0.00006 11 
OR2T34, OR2T10, OR2T11, 
OR2T35 
OR2T34, OR2T10, OR2T11, OR2T35, OR2T27, 
OR14I1, LYPD8, SH3BP5L, ZNF672, ZNF692, 
PGBD2 
Chr 11 128,837,921-135,006,516 134,590,936-134,623,445 6.2 56 6.13 0.03319 23 - 
ARHGAP32, BARX2, TMEM45B, NFRKB, PRDM10, 
APLP2, ST14, ZBTB44, ADAMTS8, ADAMTS15, 
SNX19, NTM, OPCML, SPATA19, IGSF9B, JAM3, 
NCAPD3, VPS26B, THYN1, ACAD8, GLB1L3, 
GLB1L2, B3GAT1 
 
Chr 13 47,927,728-52,108,681 48,961,498-49,034,756 4.2 81 10.80 0.00001 31 RB1, LPAR6 
SUCLA2, NUDT15, MED4, ITM2B, RB1, LPAR6, 
RCBTB2, CYSLTR2, FNDC3A, MLNR, CDADC1, 
CAB39L, SETDB2, PHF11, RCBTB1, ARL11, EBPL, 
KPNA3, CTAGE10P, SPRYD7, TRIM13, KCNRG, 
DLEU2, DLEU1, ST13P4, DLEU7, RNASEH2B, 
GUCY1B2, FAM124A, SERPINE3, INTS6 
Chr 17 27,203,586-29,571,405 27,845,429-27,862,668 2.4 63 6.91 0.01042 34 TAOK1 
FLOT2, DHRS13, PHF12, SEZ6, PIPOX, TIAF1, 
MYO18A, CRYBA1, NUFIP2, TAOK1, ABHD15, 
TP53I13, GIT1, ANKRD13B, CORO6, SSH2, 
EFCAB5, NSRP1, SLC6A4, BLMH, TMIGD1, CPD, 
GOSR1, TBC1D29, LRRC37BP1, SH3GL1P2, 
SUZ12P1, CRLF3, ATAD5, TEFM, ADAP2, 
DPRXP4, RNF135, NF1 
       99   
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Category Term Count 
EASE  
p-value 
Genes Fold Enrichment 
BIOCARTA 
h_raccPathway 
Ion Channels and Their Functional Role in Vascular 
Endothelium 
5 0.0498 GNAS, GNGT1, NOS3, KCNQ4, SGCB 3.27 
KEGG 
hsa04742 
Taste transduction 26 0.0000 
GNAS, ADCY4, ADCY8, GNG13, PLCB2, TAS1R3, TAS2R1, TAS2R10, TAS2R13, 
TAS2R14, TAS2R19, TAS2R20, TAS2R3, TAS2R31, TAS2R38, TAS2R4, TAS2R41, 
TAS2R42, TAS2R43, TAS2R46, TAS2R5, TAS2R50, TAS2R60, TAS2R7, TAS2R8, 
TAS2R9 
3.06 
BIOCARTA 
h_hesPathway 
Segmentation Clock 7 0.0199 LFNG, NOTCH1, NOTCH2,  DVL1,  HES7,  HEY2,  RBPJ 2.94 
BIOCARTA 
h_il1rPathway 
Signal transduction through IL1R 12 0.0052 
ECSIT, IL1RAP, IL1R1, IL1A, IL6, JUN, MAP2K3, MAP2K6, MAP3K14, MAP3K7, 
NFKBIA, TGFB1 
2.44 
BIOCARTA 
h_nthiPathway 
NFkB activation by Nontypeable Hemophilus influenzae 9 0.0370 
SMAD3, MAP2K3,  MAP2K6,  MAP3K14,  MAP3K7,  NFKBIA,  TGFBR1,  TGFBR2,  
RELA 
2.21 
KEGG 
hsa05020 
Prion diseases 12 0.0195 FYN, NOTCH1, C1QA, C1QB, C1QC, C7, C8A, C8B, C8G, HSPA5, IL1A, IL6 2.10 
KEGG 
hsa04512 
ECM-receptor interaction 28 0.0002 
CD44, AGRN, COL1A2, COL3A1, COL4A1, COL4A2, COL5A1, COL5A2, COL6A1, 
COL6A2, COL6A3, COL11A1, GP1BA, ITGA1, ITGA11, ITGA2, ITGA9, ITGB5, 
LAMA1, LAMA3, LAMA4, LAMA5, LAMB1, LAMB4, RELN, SV2A, TNC, TNR 
2.04 
BIOCARTA 
h_keratinocytePathway 
Keratinocyte Differentiation 12 0.0434 
CEBPA,  TRAF2,  EGFR,  HOXA7,  JUN,  MAP2K3, MAP2K4, MAP2K6, MAP2K7, 
MAP3K14, NFKBIA, PRKCA 
1.86 
KEGG 
hsa05212 
Pancreatic cancer 20 0.0191 
BAD, BCL2L1, SMAD3, ACVR1B, CDK6, CDKN2A, EGFR, RALBP1, PIK3CG, 
RALGDS, RAC2, RAC3, TGFB1, TGFB3, TGFBR1, TGFBR2, BRAF, RALB, RELA, 
VEGFB 
1.70 
KEGG 
hsa05222 
Small cell lung cancer 23 0.0134 
BCL2L1, MAX, TRAF2, COL4A1, COL4A2, CDK6, CDKN1B, CDKN2B, FHIT, ITGA2, 
LAMA1, LAMA3, LAMA4, LAMA5, LAMB1, LAMB4, NFKBIA, PTENP1, PIK3CG, RARB, 
RXRA, RXRG, RELA 
1.68 
KEGG 
hsa04360 
Axon guidance 34 0.0042 
EPHA1, EPHA2, EPHA3, EPHA6, EPHA8, EPHB2, EPHB6, FYN, SRGAP3, EFNA2, 
EFNA5, FES, GNAI2, MET, NFATC2, NFATC4, PAK1, PAK4, PAK6, PLXNA2, 
PLXNB1, PPP3R2, RAC2, RAC3, ROBO1, ROBO2, SEMA3A, SEMA3E, SEMA3F, 
SEMA4D, SEMA5A, SEMA6A, SLIT2, SLIT3 
1.61 
KEGG 
hsa04520 
Adherens junction 20 0.0372 
BAIAP2,  FYN,  SMAD3,  WASF2,  WASL,  ACVR1B,  CTNNB1,  EGFR,  INSR,  MET,  
MAP3K7,  PTPN1,  PTPRF,  RAC2,  RAC3,  MLLT4,  SNAI2,  SSX2IP,  TGFBR1,  
TGFBR2 
1.59 
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Category Term Count 
EASE  
p-value 
Genes Fold Enrichment 
KEGG 
hsa04510 
Focal adhesion 52 0.0005 
BAD, FYN, RAPGEF1, ARHGAP5, SHC3, CTNNB1, CAV3, COL1A2, COL3A1, 
COL4A1, COL4A2, COL5A1, COL5A2, COL6A1, COL6A2, COL6A3, COL11A1, EGFR, 
HGF, ITGA1, ITGA11, ITGA2, ITGA9, ITGB5, JUN, LAMA1, LAMA3, LAMA4, LAMA5, 
LAMB1, LAMB4, MET, MYL12A, MYL12B, PAK1, PAK4, PAK6, PARVA, PTENP1, 
PIK3CG, PDGFB, PRKCA, RAC2, RAC3, RELN, TLN2, TNC, TNR, CRK, BRAF, 
VEGFB, VAV2 
1.58 
BIOCARTA 
h_mapkPathway 
MAPKinase Signaling Pathway 21 0.0379 
CEBPA,  MKNK1,  MAX,  TRAF2,  JUN,  MAPK7,  MAP2K3,  MAP2K4,  MAP2K6,  
MAP2K7,  MAP3K11,  MAP3K14,  MAP3K2,  MAP3K6,  MAP3K7,  MAP4K2,  NFKBIA,  
PAK1,  TGFB1,  TGFBR1,  BRAF 
1.55 
KEGG 
hsa04010 
MAPK signaling pathway 62 0.0027 
ECSIT, MKNK1, MAX, RASGRP1, TRAF2, ACVR1B, ARRB1, CACNA1D, CACNA1E, 
CACNA1I, CACNA2D3, CACNG1, CACNG4, CACNG5, DUSP7, MECOM, EGFR, 
FGF10, FGF20, GADD45A, GNA12, GNG12, FGF7, CACNA1C, IL1R1, IL1A, JUND, 
JUN, MAPK7, MAP2K3, MAP2K4, MAP2K6, MAP2K7, MAP3K11, MAP3K14, MAP3K2, 
MAP3K6, MAP3K7, TAB2, MAP4K2, NTRK2, NTF3, NFATC2, NFATC4, NR4A1, 
PAK1, PLA2G2C, PLA2G4E, PDGFB, PRKCA, PPP3R2, RAC2, RAC3, STK3, TGFB1, 
TGFB3, TGFBR1, TGFBR2, CRK, MOS, BRAF, RELA 
1.42 
KEGG 
hsa05200 
Pathways in cancer 72 0.0053 
BAD, BCL2L1, CEBPA, GLI3, MAX, SMAD3, TRAF2, TFG, ACVR1B, APC2, ARNT2, 
AXIN2, CTNNB1, COL4A1, COL4A2, CDK6, CDKN1B, CDKN2A, CDKN2B, DAPK1, 
DVL1, MECOM, EGLN2, EGLN3, EGFR, FGF10, FGF20, HGF, RALBP1, FGF7, 
ITGA2, IL6, JUN, LAMA1, LAMA3, LAMA4, LAMA5, LAMB1, LAMB4, MMP1, MET, 
MITF, MLH1, NFKBIA, PTCH1, PTENP1, PIK3CG, PDGFB, PRKCA, RALGDS, RAC2, 
RAC3, RET, RARB, RXRA, RXRG, RUNX1T1, KIT, SHH, TGFB1, TGFB3, TGFBR1, 
TGFBR2, TPR, CRK, BRAF, RALB, RELA, VEGFB, WNT2, WNT16, WNT5A 
1.34 
KEGG 
hsa04080 
Neuroactive ligand-receptor interaction 53 0.0478 
HTR1F, MAS1, ADORA2A, ADRA2C, BDKRB1, BDKRB2, CALCR, CHRM2, C3AR1, 
CRHR1, DRD5, GRIN1, GRIN2B, GRIN3A, GRIK1, GRIK2, GRIK3, GRM1, GRM3, 
GRM5, GRM7, GRM8, HRH1, HRH2, HCRTR1, ADORA2B, LEPR, LTB4R, LTB4R2, 
LPAR2, LPAR3, MC2R, MC5R, NPBWR2, NTSR1, OPRL1, OPRD1, OXTR, PTH1R, 
PRLR, PTGDR, PTGER2, PTGER3, PRSS1, PRSS2, P2RY13, P2RY14, SSTR1, 
SSTR3, S1PR3, THRB, TRHR, TSPO 
1.27 
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Pathway ID Term 
Gene 
Count 
Fisher 
p-value 
EASE  
p-value 
Genes 
Fold 
Enrichment 
BIOCARTA 
h_rbPathway 
RB Tumor Suppressor/Checkpoint 
Signaling in response to DNA damage 
7 3.10E-04 2.43E-03 
CHEK1, RASGRF1, CDK1, MYT1, NPAT, 
RB1, TP53 
4.34 
KEGG 
hsa04020 
Calcium signaling pathway 38 2.10E+03 3.82E-03 
HTR7, ATP2A1, ATP2B4, ATP2A3, 
PTK2B, ADCY9, ADRA1A, ADRB3, 
AVPR1B, CACNA1S, CACNA1H, 
CALML3, CALML5, CHRM5, F2R, 
CYSLTR2, DRD1, EDNRB, GRIN2A, 
GRIN2D, GRM1, ITPKA, MYLK3, PDE1A, 
PLCG2, PHKB, PHKG1, PRKCG, 
PPP3CB, PPP3CC, P2RX1, P2RX5, 
RYR2, SLC8A2, TACR3, ERBB4, VDAC1, 
VDAC3 
1.58 
BIOCARTA 
h_amiPathway 
Acute Myocardial Infarction 7 6.00E-04 4.01E-03 F2, F2R, F7, F10, AHSP, FGA, PLG 4.01 
BIOCARTA 
h_ctbp1Pathway 
SUMOylation as a mechanism to 
modulate CtBP-dependent gene 
responses 
5 7.00E-04 7.79E-03 CTBP1, SUMO1, SAE1, CDH1, ZEB1 5.32 
KEGG 
hsa00640 
Propanoate metabolism 11 2.40E-03 7.84E-03 
HIBCH, ABAT, ACAT1, ACAT2, ACACA, 
ALDH2, ALDH7A1, LDHA, LDHAL6A, 
LDHC, SUCLA2 
2.52 
BIOCARTA 
h_cdc25Pathway 
cdc25 and chk1 Regulatory Pathway in 
response to DNA damage 
5 1.70E-03 1.40E-02 CHEK1, RASGRF1, CDK1, MYT1, NPAT 4.65 
BIOCARTA 
h_intrinsicPathway 
Intrinsic Prothrombin Activation 
Pathway 
7 4.20E-03 1.82E-02 F2, F2R, F10, F11, CYP4V2, FGA, KLKB1 3.07 
BIOCARTA 
h_caspasePathway 
Caspase Cascade in Apoptosis 8 9.90E-03 3.19E-02 
APAF1, CASP10, CASP3, CASP4, 
CASP7, CASP8, LMNB1, PRF1 
2.48 
KEGG 
hsa04610 
Complement and coagulation cascades 16 2.10E-02 4.15E-02 
F2, F2R, F7, F10, F11, CR1, CR2, 
C4BPA, C4BPB, C5AR1, FGA, FGB, 
FGG, KLKB1, PLG, SERPINF2 
1.70 
BIOCARTA 
h_fasPathway 
FAS signaling pathway ( CD95 ) 9 1.70E-02 4.49E-02 
CFLAR, FAS, CASP10, CASP3, CASP7, 
CASP8, LMNB1, PTPN13, RB1 
2.16 
BIOCARTA 
h_extrinsicPathway 
Extrinsic Prothrombin Activation 
Pathway 
5 9.70E-03 4.76E-02 F2, F2R, F7, F10, FGA 3.38 
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 Region Cytoband 
Length 
(Mb) 
Freq. in , 
NOS (%) 
Freq. in 
Others (%) 
Difference p-value q-bound Count Genes 
Chr 1 
 17,236,783-17,280,446 p36.13 0.04 56.25 16.22 40.03 0.0064 0.41 1 CROCC 
 33,570,565-33,600,936 p35.1 0.03 56.25 10.81 45.44 0.0010 0.37 1 ADC 
 34,489,528-34,777,012 p35.1 - p34.3 0.29 56.25 16.22 40.03 0.0064 0.41 1 CSMD2 
 54,724,167-54,779,132 p32.3 0.05 50.00 8.11 41.89 0.0014 0.37 1 SSBP3 
 59,228,562-59,247,642 p32.1 0.02 75.00 29.73 45.27 0.0056 0.41 1 JUN 
 63,085,146-63,097,309 p31.3 0.01 50.00 8.11 41.89 0.0014 0.37 1 DOCK7 
Chr 3,  
 63,310,435-63,415,348 p14.2 0.1 50.00 8.11 41.89 0.0014 0.37 1 SYNPR 
 85,152,448-86,003,801 p12.1 0.69 50.00 5.41 44.59 0.0005 0.35 1 CADM2 
 86,880,017-87,076,959 p12.1 0.2 68.75 13.51 55.24 0.0001 0.33 1 VGLL3 
 87,727,265-88,074,845 p11.2 - p11.1 0.35 56.25 8.11 48.14 0.0004 0.33 1 HTR1F 
 89,441,269-89,908,861 p11.1 0.47 50.00 5.41 44.59 0.0005 0.35 1 EPHA3 
Chr 7 
 15,302,504-15,335,686 p21.2 0.03 62.50 18.92 43.58 0.0034 0.41 1 AGMO 
 15,964,268-16,510,513 p21.2 - p21.1 0.55 56.25 16.22 40.03 0.0064 0.41 2 ISPD, SOSTDC1 
 17,985,333-18,169,473 p21.1 0.18 62.50 18.92 43.58 0.0034 0.41 1 PRPS1L1 
 18,349,312-19,091,057 p21.1 0.12 68.75 24.32 44.43 0.0045 0.41 1 HDAC9 
 19,808,883-20,020,725 p21.1 0.21 62.50 18.92 43.58 0.0034 0.41 1 TMEM196 
 20,390,109-20,400,245 p21.1 0.01 62.50 21.62 40.88 0.0098 0.44 1 ITGB8 
 22,696,520-22,969,146 p15.3 0.27 62.50 18.92 43.58 0.0034 0.41 3 GPNMB, MALSU1, IGF2BP3 
 23,301,525-23,362,857 p15.3 0.06 56.25 16.22 40.03 0.0064 0.41 3 IL6, TOMM7, SNORD93 
 24,593,062-24,738,029 p15.3 0.14 62.50 16.22 46.28 0.0023 0.40 2 MPP6, DFNA5 
 25,241,387-25,274,221 p15.3 0.03 68.75 21.62 47.13 0.0017 0.37 1 NPVF 
 26,387,705-26,400,185 p15.2 0.01 56.25 16.22 40.03 0.0064 0.41 1 SNX10 
 27,792,941-27,803,481 p15.2 0.01 56.25 13.51 42.74 0.0023 0.40 1 TAX1BP1 
 30,417,431-30,561,717 p14.3 0.14 56.25 16.22 40.03 0.0064 0.41 2 NOD1, GGCT 
 116,680,093-116,921,396 q31.2 0.24 50.00 8.11 41.89 0.0014 0.37 2 ST7, WNT2 
 135,033,284-135,102,970 q33 0.07 62.50 21.62 40.88 0.0098 0.44 1 CNOT4 
Chr 9 
 77,295,023-77,307,482 q21.13 0.01 56.25 10.81 45.44 0.0010 0.37 1 RORB 
 100,186,536-100,230,335 q22.33 0.04 50.00 8.11 41.89 0.0014 0.37 1 TDRD7 
Chr 11 
 101,384,809-101,437,354 q22.1 0.05 43.75 0.00 43.75 0.0001 0.33 1 TRPC6 
 102,169,359-102,234,053 q22.2 0.06 43.75 2.70 41.05 0.0005 0.35 2 BIRC3, BIRC2 
 102,393,563-102,740,197 q22.2 0.35 43.75 0.00 43.75 0.0001 0.33 9 
MMP7, MMP20, MMP27, MMP8, MMP10, MMP1, 
WTAPP1, MMP3, MMP12 
 102,822,550-103,076,857 q22.2 - q22.3 0.25 43.75 0.00 43.75 0.0001 0.33 3 MMP13, DCUN1D5, DYNC2H1 
Chr 20 
 31,009,725-31,128,856 q11.21 0.12 56.25 16.22 40.03 0.0064 0.41 1 ASXL1 
 31,866,250-31,890,835 q11.21 0.02 56.25 16.22 40.03 0.0064 0.41 1 BFIFB1 
         53  
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 Region Cytoband Length (Mb) 
Freq. in NOS 
(%) 
Freq. in 
Others (%) 
Difference p-value q-bound Count Genes 
Chr 1 
 213,443,234-213,697,129 q32.3 0.25 43.75 2.70 41.05 0.0005 0.38 1 RPSKC1 
 213,980,880-214,338,265 q32.3 0.36 43.75 2.70 41.05 0.0005 0.38 1 PROX1 
 215,302,569-215,751,141 q41 0.45 43.75 2.70 41.05 0.0005 0.38 2 KCNK2, KCTD3 
 216,043,174-216,684,943 q41 0.64 43.75 2.70 41.05 0.0005 0.38 2 USH2A, ESRRG 
 216,731,644-217,224,745 q41 0.49 43.75 2.70 41.05 0.0005 0.38 1 ESRRG 
 234,357,539-234,437,898 q42.2 0.08 50.00 5.41 44.59 0.0005 0.38 1 SLC35F3 
 242,489,058-242,528,211 q43 0.39 43.75 2.70 41.05 0.0005 0.38 1 PLD5 
 245,514,462-245,689,504 q44 0.18 50.00 5.41 44.59 0.0005 0.38 1 KIF26B 
Chr 13 
  70,404,055-70,857,794 q21.33 0.21 75.00 32.43 42.57 0.0066 0.47 2 KLHL1, ATXN8OS 
 19,296,544-19,550,188 q11 - q12.11 0.25 75.00 29.73 45.27 0.0056 0.47 1 ANKRD20A9P 
 24,831,951-24,864,286 q12.12 0.03 68.75 27.03 41.72 0.0064 0.47 1 SPATA13 
 26,218,732-26,263,107 q12.13 0.04 81.25 32.43 48.82 0.0021 0.43 1 ATP8A2 
 37,588,232-37,598,673 q13.3 0.01 68.75 27.03 41.72 0.0064 0.47 1 SUPT20H 
 58,178,513-58,211,706 q21.1 0.03 81.25 37.84 43.41 0.0063 0.47 1 PCDH17 
 67,442,419-67,451,208 q21.32 0.01 75.00 32.43 42.57 0.0066 0.47 1 PCDH9 
 74,152,253-74,320,849 q22.1 0.17 81.25 32.43 48.82 0.0021 0.43 1 KLF12 
 92,058,034-92,596,337 q31.3 0.05 68.75 24.32 44.43 0.0045 0.47 1 GPC5 
 96,808,522-97,090,785 q32.1 0.28 68.75 24.32 44.43 0.0045 0.47 1 HS6ST3 
Chr 15  83,773,547-83,780,826 q25.2 0.01 43.75 2.70 41.05 0.0005 0.38 1 TM6SF1 
Chr 16  6,127,389-6,503,206 p13.3 0.38 50.00 8.11 41.89 0.0014 0.42 1 RBFOX1 
Chr 17 
 26,726,585-27,042,613 q11.2 0.31 50.00 5.41 44.59 0.0005 0.38 14 
SARM1, SLC46A1, SLC13A2, 
FOXN1, UNC119, PIGS, ALDOC, 
SPAG5, SGK494, KIAA0100, 
SDF2, SUPT6H, PROCA1, RAB34 
 27,203,586-27,211,735 q11.2 0.01 56.25 8.11 48.14 0.0004 0.38 1 FLOT2 
 27,862,668-27,880,882 q11.2 0.02 62.50 13.51 48.99 0.0006 0.42 1 TAOK1 
 28,458,050-28,525,378 q11.2 0.07 56.25 13.51 42.74 0.0023 0.43 2 NSRP1, SLC6A4 
 29,464,657-29,476,900 q11.2 0.01 56.25 16.22 40.03 0.0064 0.47 1 NF1 
 8,574,964-8,676,013 p13.1 0.1 56.25 16.22 40.03 0.0064 0.47 2 CCDC42, SPDYE4 
Chr 21  47,760,929-47,790,354 q22.3 0.03 56.25 10.81 45.44 0.0010 0.42 1 PCNT 
         45  
 
